nct_id,start_date.x,primary_completion_date.x,study_type.x,brief_title.x,overall_status.x,phase.x,source.x,why_stopped.x,pubmed_links,ctg_links,Abstract,Registry,Total_pubs,country,Has_Results,Number_of_updates,intervention,vaccine_trial_flag
NCT04292899,3/6/2020,4/9/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/32706859,https://clinicaltrials.gov/ct2/show/NCT04292899,3,0,3,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,20,Remdesivir|Standard of Care,0
NCT04351152,5/5/2020,3/31/2021,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"Active, not recruiting",Phase 3,"Humanigen, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34863332,https://clinicaltrials.gov/ct2/show/NCT04351152,3,0,3,United States|Brazil,0,11,Lenzilumab|Standard of Care,0
NCT04355767,8/11/2020,3/29/2021,Interventional,Convalescent Plasma in Outpatients With COVID-19,Completed,Phase 3,Stanford University,NA,https://pubmed.ncbi.nlm.nih.gov/34407339,https://clinicaltrials.gov/ct2/show/NCT04355767,1,1,2,United States,1,14,Convalescent Plasma|Saline,0
NCT04492475,8/5/2020,12/21/2020,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/34672949,https://clinicaltrials.gov/ct2/show/NCT04492475,2,0,2,"United States|Japan|Korea, Republic of|Mexico|Singapore",1,31,Interferon beta-1a|Placebo|Remdesivir,0
NCT04328467,4/6/2020,7/13/2020,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://pubmed.ncbi.nlm.nih.gov/33204764,https://clinicaltrials.gov/ct2/show/NCT04328467,2,1,3,United States,1,7,Hydroxychloroquine|Placebo,0
NCT04308668,3/17/2020,5/20/2020,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://pubmed.ncbi.nlm.nih.gov/33204764,https://clinicaltrials.gov/ct2/show/NCT04308668,3,3,6,United States|Canada,1,14,Hydroxychloroquine|Placebo,0
NCT04410328,10/21/2020,3/15/2021,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,https://pubmed.ncbi.nlm.nih.gov/31282542,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,United States,0,4,Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Standard of care,0
NCT04354428,4/16/2020,12/31/2020,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Phase 2/Phase 3,University of Washington,NA,https://pubmed.ncbi.nlm.nih.gov/33681731,https://clinicaltrials.gov/ct2/show/NCT04354428,1,0,1,United States,0,7,Ascorbic Acid|Hydroxychloroquine Sulfate|Azithromycin|Folic Acid|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra],0
NCT04332107,5/22/2020,3/16/2021,Interventional,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Terminated,Phase 3,"University of California, San Francisco",Futility,https://pubmed.ncbi.nlm.nih.gov/34269813,https://clinicaltrials.gov/ct2/show/NCT04332107,1,0,1,United States,1,13,Azithromycin|Placebos,0
NCT04328961,3/31/2020,9/24/2020,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,https://pubmed.ncbi.nlm.nih.gov/33284679,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,United States,1,7,Hydroxychloroquine Sulfate|Ascorbic Acid,0
NCT04322682,3/23/2020,1/21/2021,Interventional,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Terminated,Phase 3,Montreal Heart Institute,"Due to several considerations (logistical, human and budgetary), the study was stopped early.",https://pubmed.ncbi.nlm.nih.gov/34051877,https://clinicaltrials.gov/ct2/show/NCT04322682,1,0,1,United States|Brazil|Canada|Greece|South Africa|Spain,1,14,Colchicine|Placebo oral tablet,0
NCT04546581,10/8/2020,5/21/2021,Interventional,Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC),Completed,Phase 3,University of Minnesota,NA,https://pubmed.ncbi.nlm.nih.gov/33715160,https://clinicaltrials.gov/ct2/show/NCT04546581,1,0,1,United States|Denmark|Greece|Japan|Nigeria|Spain|United Kingdom,0,9,Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Placebo|Remdesivir,0
NCT04292730,3/15/2020,4/29/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/32821939,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,20,Remdesivir|Standard of Care,0
NCT04332991,4/2/2020,6/19/2020,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33165621,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,United States,1,9,Hydroxychloroquine|Placebo,0
NCT04320615,4/3/2020,6/24/2020,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://pubmed.ncbi.nlm.nih.gov/33631066,https://clinicaltrials.gov/ct2/show/NCT04320615,1,0,1,United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain|United Kingdom,1,12,Tocilizumab (TCZ)|Placebo,0
NCT04501978,8/4/2020,7/31/2022,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/33356051,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,United States|Argentina|Denmark|Georgia|Greece|India|Mexico|Mozambique|Nigeria|Poland|Singapore|Spain|Switzerland|Uganda|United Kingdom,0,57,LY3819253|Placebo|Remdesivir|VIR-7831|BRII-196/BRII-198|AZD7442|MP0420|PF-07304814,0
NCT04401579,5/8/2020,7/31/2020,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/33306283,https://clinicaltrials.gov/ct2/show/NCT04401579,1,0,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,16,Placebo|Remdesivir|Baricitinib,0
NCT04372186,5/14/2020,8/18/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Phase 3,"Genentech, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/33332779,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,1,15,Placebo|Tocilizumab,0
NCT04356937,4/20/2020,7/13/2020,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33085857,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,United States,1,7,Tocilizumab|Placebos,0
NCT04280705,2/21/2020,5/21/2020,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04280705,1,0,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,24,Placebo|Remdesivir,0
NCT04401293,4/26/2020,5/14/2021,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Completed,Phase 3,Northwell Health,NA,https://pubmed.ncbi.nlm.nih.gov/34617959,https://clinicaltrials.gov/ct2/show/NCT04401293,2,0,2,United States,1,8,Enoxaparin|Prophylactic/Intermediate Dose Enoxaparin,0
NCT04649151,12/9/2020,6/30/2022,Interventional,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","Active, not recruiting",Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34379915,https://clinicaltrials.gov/ct2/show/NCT04649151,1,0,1,United States,0,9,mRNA-1273|Placebo,1
NCT04796896,3/15/2021,6/12/2023,Interventional,A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,Recruiting,Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34870630,https://clinicaltrials.gov/ct2/show/NCT04796896,1,0,1,United States|Canada,0,18,mRNA-1273|Placebo,1
NCT04421027,6/12/2020,2/12/2021,Interventional,A Study of Baricitinib (LY3009104) in Participants With COVID-19,Completed,Phase 3,Eli Lilly and Company,NA,https://pubmed.ncbi.nlm.nih.gov/34480861,https://clinicaltrials.gov/ct2/show/NCT04421027,1,0,1,"United States|Argentina|Brazil|Germany|India|Italy|Japan|Korea, Republic of|Mexico|Puerto Rico|Russian Federation|Spain|United Kingdom",0,26,Baricitinib|Placebo,0
NCT04470427,7/27/2020,10/27/2022,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34401888,https://clinicaltrials.gov/ct2/show/NCT04470427,3,0,3,United States,0,18,mRNA-1273|Placebo,1
NCT04505774,9/4/2020,9/30/2022,Interventional,Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE,Recruiting,Phase 4,University of Pittsburgh,NA,https://pubmed.ncbi.nlm.nih.gov/34351721,https://clinicaltrials.gov/ct2/show/NCT04505774,1,0,1,United States|Brazil|Italy|Spain,0,6,theraputic heparin|prophylactic heparin|P2Y12|Crizanlizumab Injection|SGLT2 inhibitor,1
NCT04372589,5/20/2020,5/17/2021,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),Completed,Phase 2/Phase 3,University of Manitoba,NA,https://pubmed.ncbi.nlm.nih.gov/34351722,https://clinicaltrials.gov/ct2/show/NCT04372589,2,0,2,United States|Brazil|Canada|Mexico,0,6,Heparin,1
NCT04340557,3/27/2020,6/13/2020,Interventional,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Completed,Phase 4,Sharp HealthCare,NA,https://pubmed.ncbi.nlm.nih.gov/33977506,https://clinicaltrials.gov/ct2/show/NCT04340557,1,0,1,United States,1,4,Losartan,0
NCT04516746,8/28/2020,3/5/2021,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,https://pubmed.ncbi.nlm.nih.gov/34587382,https://clinicaltrials.gov/ct2/show/NCT04516746,1,0,1,United States|Chile|Peru,0,9,AZD1222|Placebo,1
NCT04368728,4/29/2020,5/15/2023,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://pubmed.ncbi.nlm.nih.gov/34525277,https://clinicaltrials.gov/ct2/show/NCT04368728,6,0,6,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,35,BNT162b1|BNT162b2|Placebo|BNT162b2SA,1
NCT04348656,3/14/2020,3/5/2021,Interventional,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),Terminated,Phase 3,McMaster University,Study was terminated after the planned interim analysis as the pre-defined futility threshold was met,https://pubmed.ncbi.nlm.nih.gov/34504336,https://clinicaltrials.gov/ct2/show/NCT04348656,2,0,2,United States|Brazil|Canada,0,14,Convalescent plasma,0
NCT04816643,3/24/2021,5/5/2026,Interventional,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://pubmed.ncbi.nlm.nih.gov/34752019,https://clinicaltrials.gov/ct2/show/NCT04816643,1,0,1,United States|Finland|Poland|Spain,0,10,Biological/Vaccine: BNT162b2 10mcg|BNT162b2 20mcg|BNT162b2 30mcg|Placebo|Biological/Vaccine: BNT162b2 3mcg,1
NCT04498273,9/7/2020,8/5/2021,Interventional,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Terminated,Phase 3,University of Pittsburgh,an event rate lower than anticipated,https://pubmed.ncbi.nlm.nih.gov/34633405,https://clinicaltrials.gov/ct2/show/NCT04498273,1,0,1,United States,0,6,Apixaban 2.5 MG|Apixaban 5MG|Aspirin|Placebo,0
NCT04362176,4/24/2020,7/6/2021,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Completed,Phase 3,Vanderbilt University Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/33688640,https://clinicaltrials.gov/ct2/show/NCT04362176,2,0,2,United States,0,9,pathogen reduced SARS-CoV-2 convalescent plasma|Placebo,0
NCT04369469,5/11/2020,2/8/2021,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,Terminated,Phase 3,Alexion Pharmaceuticals,Met futility bar at interim analysis.,https://pubmed.ncbi.nlm.nih.gov/33826106,https://clinicaltrials.gov/ct2/show/NCT04369469,3,0,3,United States|France|Japan|Spain|United Kingdom,0,10,Ravulizumab|Best Supportive Care,0
NCT04360824,5/6/2020,4/16/2021,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,United States,0,4,Intermediate dose thromboprophylaxis|Standard of Care thromboprophylaxis,0
NCT04358549,4/17/2020,9/30/2020,Interventional,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,Completed,Phase 2,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34888401,https://clinicaltrials.gov/ct2/show/NCT04358549,1,0,1,United States,0,13,Favipiravir + Standard of Care|Standard of Care,0
NCT04472611,10/30/2020,10/30/2021,Interventional,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Recruiting,Phase 3,Yale University,NA,https://pubmed.ncbi.nlm.nih.gov/34461322,https://clinicaltrials.gov/ct2/show/NCT04472611,1,0,1,United States,0,2,Standard of Care (SOC) and Colchicine+Rosuvastatin,0
NCT04364737,4/17/2020,3/29/2021,Interventional,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://pubmed.ncbi.nlm.nih.gov/34901997,https://clinicaltrials.gov/ct2/show/NCT04364737,1,0,1,United States,0,13,Convalescent Plasma|Saline solution,0
NCT04435184,7/9/2020,11/28/2020,Interventional,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,Phase 2,Johns Hopkins University,NA,https://pubmed.ncbi.nlm.nih.gov/34904132,https://clinicaltrials.gov/ct2/show/NCT04435184,2,0,2,United States,1,6,Crizanlizumab|0.9% saline,0
NCT04452318,7/13/2020,10/4/2021,Interventional,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,Completed,Phase 3,Regeneron Pharmaceuticals,NA,https://pubmed.ncbi.nlm.nih.gov/34159343,https://clinicaltrials.gov/ct2/show/NCT04452318,3,0,3,"United States|Moldova, Republic of|Romania",0,17,REGN10933 + REGN10987|Placebo,0
NCT04505722,9/7/2020,1/22/2021,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://pubmed.ncbi.nlm.nih.gov/34824596,https://clinicaltrials.gov/ct2/show/NCT04505722,2,0,2,United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru|South Africa,0,20,Ad26.COV2.S|Placebo,0
NCT04400890,9/12/2020,3/1/2021,Interventional,"Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19",Terminated,Phase 2,Mount Carmel Health System,Feasibility,https://pubmed.ncbi.nlm.nih.gov/34545357,https://clinicaltrials.gov/ct2/show/NCT04400890,1,0,1,United States,0,8,Resveratrol|Vitamin D3,0
NCT04329832,3/30/2020,12/18/2020,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/33166179,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,United States,0,3,Hydroxychloroquine|Azithromycin,0
NCT04427501,6/17/2020,2/16/2021,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"Active, not recruiting",Phase 2/Phase 3,Eli Lilly and Company,NA,https://pubmed.ncbi.nlm.nih.gov/34260849,https://clinicaltrials.gov/ct2/show/NCT04427501,3,0,3,United States|Puerto Rico,0,47,LY3819253|LY3832479|Placebo,0
NCT04329923,4/9/2020,11/11/2020,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis,https://pubmed.ncbi.nlm.nih.gov/33001138,https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,United States,1,7,Hydroxychloroquine Sulfate 400 mg twice a day|Hydroxychloroquine Sulfate 600 mg twice a day|Hydroxychloroquine Sulfate 600 mg once a day|Placebo oral tablet,0
NCT04497987,8/2/2020,1/16/2021,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,Completed,Phase 3,Eli Lilly and Company,NA,https://pubmed.ncbi.nlm.nih.gov/34081073,https://clinicaltrials.gov/ct2/show/NCT04497987,1,0,1,United States,0,21,LY3819253|Placebo|LY3832479,0
NCT04331795,4/4/2020,6/5/2020,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Phase 2,University of Chicago,NA,https://pubmed.ncbi.nlm.nih.gov/33210302,https://clinicaltrials.gov/ct2/show/NCT04331795,0,1,1,United States,0,10,Tocilizumab|Tocilizumab,0
NCT04495816,7/15/2020,12/31/2021,Interventional,COVID-19 Anosmia Study,"Active, not recruiting",Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://pubmed.ncbi.nlm.nih.gov/33225989,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,United States,0,4,Omega-3 Fatty Acid Supplement|Placebo/Control,0
NCT04865029,7/22/2021,5/31/2022,Interventional,Estradiol and Progesterone in Hospitalized COVID-19 Patients,Recruiting,Phase 2,Tulane University,NA,https://pubmed.ncbi.nlm.nih.gov/34848523,https://clinicaltrials.gov/ct2/show/NCT04865029,1,0,1,United States,0,4,Placebo injection and placebo pill|Estradiol Cypionate 5 MG/ML|Progesterone 200 MG Oral Capsule,0
NCT04611802,12/27/2020,6/30/2023,Interventional,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2","Active, not recruiting",Phase 3,Novavax,NA,https://pubmed.ncbi.nlm.nih.gov/34910859,https://clinicaltrials.gov/ct2/show/NCT04611802,1,0,1,United States|Mexico|Puerto Rico,0,17,SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Placebo (Initial Vaccination Period)|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|Placebo (Crossover Vaccination period),1
NCT04425629,6/16/2020,12/29/2021,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 3,Regeneron Pharmaceuticals,NA,https://pubmed.ncbi.nlm.nih.gov/34587383,https://clinicaltrials.gov/ct2/show/NCT04425629,2,0,2,United States|Chile|Mexico|Romania,0,21,casirivimab+imdevimab combination therapy,0
NCT04315298,3/18/2020,7/24/2020,Interventional,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://pubmed.ncbi.nlm.nih.gov/34496013,https://clinicaltrials.gov/ct2/show/NCT04315298,1,0,1,United States,1,10,Sarilumab|Placebo,0
NCT04377711,6/8/2020,1/5/2021,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Completed,Phase 3,Covis Pharma S.Ã .r.l.,NA,https://pubmed.ncbi.nlm.nih.gov/34807241,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,United States,0,7,Ciclesonide|Placebo,0
NCT04545060,8/27/2020,4/8/2021,Interventional,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,Completed,Phase 2/Phase 3,"Vir Biotechnology, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34706189,https://clinicaltrials.gov/ct2/show/NCT04545060,1,0,1,United States|Austria|Brazil|Canada|Peru|Spain|United Kingdom,0,16,VIR-7831|Placebo,0
NCT04889209,5/28/2021,12/1/2022,Interventional,Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,Recruiting,Phase 1/Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/34671773,https://clinicaltrials.gov/ct2/show/NCT04889209,1,0,1,United States,0,18,Ad26.COV2.S|BNT162b2|mRNA-1273|mRNA-1273.211,1
NCT04311177,4/9/2020,2/1/2021,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://pubmed.ncbi.nlm.nih.gov/34195577,https://clinicaltrials.gov/ct2/show/NCT04311177,1,1,2,United States,0,12,Losartan|Placebo,0
NCT04362813,4/30/2020,9/16/2020,Interventional,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,Completed,Phase 3,Novartis,NA,https://pubmed.ncbi.nlm.nih.gov/34367680,https://clinicaltrials.gov/ct2/show/NCT04362813,2,0,2,United States|France|Italy|Russian Federation|Spain|United Kingdom,1,19,Canakinumab|Placebo,0
NCT04374149,4/30/2020,9/30/2020,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,Completed,Phase 2,Prisma Health-Upstate,NA,https://pubmed.ncbi.nlm.nih.gov/33190086,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,United States,1,4,Therapeutic Plasma Exchange|Ruxolitinib,0
NCT04312009,4/13/2020,2/1/2021,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,United States,0,15,Losartan|Placebo,0
NCT04575597,10/19/2020,5/5/2022,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),"Active, not recruiting",Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://pubmed.ncbi.nlm.nih.gov/34914868,https://clinicaltrials.gov/ct2/show/NCT04575597,1,0,1,United States|Argentina|Brazil|Canada|Chile|Colombia|Egypt|France|Germany|Guatemala|Israel|Italy|Japan|Mexico|Philippines|Poland|Russian Federation|South Africa|Spain|Sweden|Taiwan|Ukraine|United Kingdom,0,47,Molnupiravir|Placebo,0
NCT04501952,9/18/2020,5/6/2021,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,Terminated,Phase 3,Gilead Sciences,The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.,https://pubmed.ncbi.nlm.nih.gov/34937145,https://clinicaltrials.gov/ct2/show/NCT04501952,1,0,1,United States|Denmark|Spain|United Kingdom,1,14,RDV|Placebo to Match RDV,0
NCT04402970,6/19/2020,12/31/2020,Interventional,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,Phase 3,University of Missouri-Columbia,NA,https://pubmed.ncbi.nlm.nih.gov/34745093,https://clinicaltrials.gov/ct2/show/NCT04402970,1,0,1,United States,1,6,Dornase Alfa Inhalation Solution,0
NCT04350593,4/22/2020,3/31/2021,Interventional,Dapagliflozin in Respiratory Failure in Patients With COVID-19,Completed,Phase 3,Saint Luke's Health System,NA,https://pubmed.ncbi.nlm.nih.gov/34302745,https://clinicaltrials.gov/ct2/show/NCT04350593,1,0,1,United States|Argentina|Brazil|Canada|India|Mexico|United Kingdom,0,6,Dapagliflozin 10 MG|Placebo,0
NCT04389840,6/3/2020,5/20/2021,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Terminated,Phase 2/Phase 3,Chimerix,Limited enrollment,https://pubmed.ncbi.nlm.nih.gov/33108622,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,United States,0,12,Dociparstat sodium|Placebo,0
NCT04323800,6/10/2020,12/31/2022,Interventional,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Active, not recruiting",Phase 2,Johns Hopkins University,NA,https://pubmed.ncbi.nlm.nih.gov/34931202,https://clinicaltrials.gov/ct2/show/NCT04323800,1,0,1,United States,0,21,Anti- SARS-CoV-2 Plasma|SARS-CoV-2 non-immune Plasma,0
NCT04343261,4/10/2020,7/23/2020,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,https://pubmed.ncbi.nlm.nih.gov/32951151,https://clinicaltrials.gov/ct2/show/NCT04343261,1,2,3,United States,1,9,Convalescent Plasma,0
NCT04359810,4/21/2020,12/30/2020,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Completed,Phase 2,Columbia University,NA,https://pubmed.ncbi.nlm.nih.gov/33974559,https://clinicaltrials.gov/ct2/show/NCT04359810,2,0,2,United States|Brazil,0,5,Convalescent Plasma (anti-SARS-CoV-2 plasma)|Non-convalescent Plasma (control plasma),0
NCT04344535,4/8/2020,1/1/2021,Interventional,Convalescent Plasma vs. Standard Plasma for COVID-19,Terminated,Phase 1/Phase 2,Stony Brook University,Insufficient eligible and consenting patients,https://pubmed.ncbi.nlm.nih.gov/33870923,https://clinicaltrials.gov/ct2/show/NCT04344535,1,0,1,United States,1,5,Convalescent Plasma|Standard Donor Plasma,0
NCT04434131,4/28/2020,4/28/2021,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,https://pubmed.ncbi.nlm.nih.gov/32779705,https://clinicaltrials.gov/ct2/show/NCT04434131,1,0,1,United States,0,3,Convalescent Plasma,0
NCT04328480,4/17/2020,4/25/2021,Interventional,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Completed,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://pubmed.ncbi.nlm.nih.gov/34964849,https://clinicaltrials.gov/ct2/show/NCT04328480,1,0,1,Argentina,0,6,Colchicine|Local standard of care,0
NCT04359095,8/18/2020,3/20/2021,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Completed,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,https://pubmed.ncbi.nlm.nih.gov/34957385,https://clinicaltrials.gov/ct2/show/NCT04359095,1,17,18,Colombia,0,5,Emtricitabine/tenofovir|Colchicine Pill|Rosuvastatin|Standard treatment,0
NCT04315948,3/22/2020,3/31/2023,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,Recruiting,Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://pubmed.ncbi.nlm.nih.gov/34534511,https://clinicaltrials.gov/ct2/show/NCT04315948,3,3,6,Austria|Belgium|France|Luxembourg|Norway|Portugal,0,18,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine|Standard of care|AZD7442|Placebo,0
NCT04330638,4/3/2020,12/18/2020,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,Completed,Phase 3,"University Hospital, Ghent",NA,https://pubmed.ncbi.nlm.nih.gov/34756178,https://clinicaltrials.gov/ct2/show/NCT04330638,3,0,3,Belgium,0,8,Usual Care|Anakinra|Siltuximab|Tocilizumab,0
NCT04350320,4/30/2020,10/20/2020,Interventional,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Completed,Phase 3,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://pubmed.ncbi.nlm.nih.gov/34658014,https://clinicaltrials.gov/ct2/show/NCT04350320,2,0,2,Spain,0,3,Colchicine Tablets|Standard therapy for COVID-19 according to the stablished hospital protocols.,0
NCT04652648,5/27/2020,10/31/2020,Interventional,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Phase 4,Bryn Mawr Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34037911,https://clinicaltrials.gov/ct2/show/NCT04652648,2,0,2,United States,0,0,Hydroxychloroquine,0
NCT04342728,4/8/2020,12/30/2020,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Completed,Not Applicable,The Cleveland Clinic,NA,https://pubmed.ncbi.nlm.nih.gov/34291813,https://clinicaltrials.gov/ct2/show/NCT04342728,2,0,2,United States,0,6,Ascorbic Acid|Zinc Gluconate|Ascorbic Acid and Zinc Gluconate|Standard of Care,0
NCT04355936,5/19/2020,11/2/2020,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,https://pubmed.ncbi.nlm.nih.gov/34189447,https://clinicaltrials.gov/ct2/show/NCT04355936,2,0,2,Argentina,0,8,Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,0
NCT04331834,4/3/2020,6/25/2020,Interventional,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Completed,Phase 3,Barcelona Institute for Global Health,NA,https://pubmed.ncbi.nlm.nih.gov/34781981,https://clinicaltrials.gov/ct2/show/NCT04331834,2,0,2,Spain,0,3,Hydroxychloroquine|Placebos,0
NCT04523831,6/1/2020,8/22/2020,Interventional,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Phase 3,Dhaka Medical College,NA,https://pubmed.ncbi.nlm.nih.gov/33983065,https://clinicaltrials.gov/ct2/show/NCT04523831,1,0,1,Bangladesh,1,5,Ivermectin and Doxycycline|Standard of care,0
NCT04420247,4/16/2020,8/20/2020,Interventional,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Phase 3,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,https://pubmed.ncbi.nlm.nih.gov/33907251,https://clinicaltrials.gov/ct2/show/NCT04420247,1,0,1,Brazil,0,3,Chloroquine|Hydroxychloroquine|standard care,0
NCT04325893,4/1/2020,6/18/2020,Interventional,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Phase 3,"University Hospital, Angers",decrease in number of eligible patients,https://pubmed.ncbi.nlm.nih.gov/33813110,https://clinicaltrials.gov/ct2/show/NCT04325893,1,0,1,France|Monaco,0,4,Hydroxychloroquine|Placebo,0
NCT04329611,4/13/2020,7/20/2020,Interventional,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Phase 3,University of Calgary,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.",https://pubmed.ncbi.nlm.nih.gov/34145052,https://clinicaltrials.gov/ct2/show/NCT04329611,1,0,1,Canada,0,8,Hydroxychloroquine,0
NCT04348305,4/17/2020,9/10/2020,Interventional,Hydrocortisone for COVID-19 and Severe Hypoxia,Completed,Phase 3,Scandinavian Critical Care Trials Group,NA,https://pubmed.ncbi.nlm.nih.gov/34138478,https://clinicaltrials.gov/ct2/show/NCT04348305,1,0,1,Denmark,0,14,Hydrocortisone|Sodium Chloride 9mg/mL,0
NCT04304053,3/18/2020,6/15/2020,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://pubmed.ncbi.nlm.nih.gov/33289973,https://clinicaltrials.gov/ct2/show/NCT04304053,1,0,1,Spain,0,9,Treatment and prophylaxis|Standard Public Health measures,0
NCT04381962,6/3/2020,1/29/2021,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Completed,Phase 3,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/34252378,https://clinicaltrials.gov/ct2/show/NCT04381962,2,0,2,United Kingdom,0,3,Azithromycin Capsule,0
NCT04381936,3/19/2020,11/30/2022,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/33394942,https://clinicaltrials.gov/ct2/show/NCT04381936,3,2,5,Ghana|India|Indonesia|Nepal|South Africa|Sri Lanka|United Kingdom|Vietnam,0,12,Lopinavir-Ritonavir|Corticosteroid|Hydroxychloroquine|Azithromycin|Convalescent plasma|Tocilizumab|Immunoglobulin|Synthetic neutralising antibodies|Aspirin|Colchicine|Baricitinib|Anakinra|Dimethyl fumarate|High Dose Corticosteroid|Empagliflozin,0
NCT04436276,7/15/2020,2/2/2024,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://pubmed.ncbi.nlm.nih.gov/33083026,https://clinicaltrials.gov/ct2/show/NCT04436276,4,0,4,United States|Belgium,0,16,Ad26.COV2.S|Placebo,0
NCT04970719,7/10/2021,12/31/2021,Interventional,Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus,Recruiting,Phase 3,"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders",NA,https://pubmed.ncbi.nlm.nih.gov/33990684,https://clinicaltrials.gov/ct2/show/NCT04970719,0,15,15,Bangladesh,0,4,Baricitinib|Dexamethasone|Remdesivir,0
NCT04403100,6/3/2020,2/1/2021,Interventional,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Phase 3,Cardresearch,NA,https://pubmed.ncbi.nlm.nih.gov/33885775,https://clinicaltrials.gov/ct2/show/NCT04403100,1,0,1,Brazil,0,3,Hydroxychloroquine Sulfate Tablets|Lopinavir/ Ritonavir Oral Tablet|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Placebo,0
NCT04634409,10/29/2020,7/27/2021,Interventional,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Completed,Phase 2,Eli Lilly and Company,NA,https://pubmed.ncbi.nlm.nih.gov/34374951,https://clinicaltrials.gov/ct2/show/NCT04634409,1,0,1,United States|Argentina|Puerto Rico,0,21,LY3819253|LY3832479|Placebo|VIR-7831|LY3853113,0
NCT04333420,3/31/2020,9/30/2021,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,https://pubmed.ncbi.nlm.nih.gov/33015643,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,Belgium|Brazil|France|Germany|Mexico|Netherlands|Peru|Russian Federation|South Africa,0,15,SOC + IFX-1|SOC + Placebo,0
NCT04244591,1/26/2020,4/13/2020,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,China,0,6,methylprednisolone therapy|Standard care,0
NCT04529525,8/19/2020,2/22/2021,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Completed,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,https://pubmed.ncbi.nlm.nih.gov/34215210,https://clinicaltrials.gov/ct2/show/NCT04529525,2,11,13,Argentina,0,6,Ivermectin|Placebo,0
NCT04447534,6/23/2020,10/1/2030,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,https://pubmed.ncbi.nlm.nih.gov/33247380,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,Egypt,0,3,Chloroquine|zinc,0
NCT04327505,6/3/2020,4/30/2022,Interventional,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Karolinska Institutet,NA,https://pubmed.ncbi.nlm.nih.gov/34226219,https://clinicaltrials.gov/ct2/show/NCT04327505,1,0,1,Germany|Sweden,0,8,Hyperbaric oxygen,0
NCT04405843,7/14/2020,12/21/2020,Interventional,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),Completed,Phase 2/Phase 3,Centro de Estudios en InfectogÃ­a Pediatrica,NA,https://pubmed.ncbi.nlm.nih.gov/33662102,https://clinicaltrials.gov/ct2/show/NCT04405843,1,0,1,Colombia,0,8,Ivermectin Oral Product|Placebo,0
NCT04322123,4/1/2020,8/30/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,https://pubmed.ncbi.nlm.nih.gov/32706953,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,Brazil,0,7,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,0
NCT04316377,3/25/2020,5/25/2020,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,https://pubmed.ncbi.nlm.nih.gov/33082342,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,Norway,0,3,Hydroxychloroquine Sulfate,0
NCT04321278,3/28/2020,6/14/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://pubmed.ncbi.nlm.nih.gov/32896292,https://clinicaltrials.gov/ct2/show/NCT04321278,1,0,1,Brazil,0,6,Hydroxychloroquine + azithromycin|Hydroxychloroquine,0
NCT04403685,5/8/2020,7/8/2020,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,https://pubmed.ncbi.nlm.nih.gov/33472855,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,Brazil,0,3,Tocilizumab,0
NCT04327206,3/30/2020,11/20/2021,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,"Active, not recruiting",Phase 3,Murdoch Childrens Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/32934758,https://clinicaltrials.gov/ct2/show/NCT04327206,2,0,2,Australia|Brazil|Netherlands|Spain|United Kingdom,0,14,BCG Vaccine|0.9%NaCl,1
NCT04261517,2/6/2020,2/25/2020,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,https://pubmed.ncbi.nlm.nih.gov/32391667,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,China,0,3,Hydroxychloroquine,0
NCT04364802,4/29/2020,4/30/2022,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,https://pubmed.ncbi.nlm.nih.gov/32936949,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,United States,0,3,Povidone-Iodine Nasal Spray and Gargle|Povidone-Iodine Nasal Spray and Gargle|Povidone-Iodine Nasal Spray and Gargle,0
NCT04326920,3/24/2020,9/28/2020,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Completed,Phase 4,"University Hospital, Ghent",NA,https://pubmed.ncbi.nlm.nih.gov/32559419,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,Belgium,0,5,Sargramostim|Control,0
NCT04257656,2/6/2020,3/30/2020,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be enrolled at present.",https://pubmed.ncbi.nlm.nih.gov/32423584,https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,China,0,3,Remdesivir|Remdesivir placebo,0
NCT04411446,8/11/2020,7/28/2021,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Completed,Phase 4,Vitamin D Study Group,NA,https://pubmed.ncbi.nlm.nih.gov/32422305,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,Argentina,0,5,Vitamin D|Placebo,0
NCT04283461,3/16/2020,11/22/2022,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://pubmed.ncbi.nlm.nih.gov/34642699,https://clinicaltrials.gov/ct2/show/NCT04283461,4,0,4,United States,0,36,mRNA-1273,1
NCT04509973,8/27/2020,6/17/2021,Interventional,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Phase 3,Scandinavian Critical Care Trials Group,NA,https://pubmed.ncbi.nlm.nih.gov/34673895,https://clinicaltrials.gov/ct2/show/NCT04509973,3,0,3,India|Denmark|Sweden|Switzerland,0,3,Dexamethasone,0
NCT04368988,5/25/2020,5/21/2022,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,https://pubmed.ncbi.nlm.nih.gov/34597298,https://clinicaltrials.gov/ct2/show/NCT04368988,4,0,4,United States|Australia,0,8,"SARS-CoV-2 rS - Phase 1|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Normal saline solution (NSS), Placebo - Phase 1|Normal saline solution (NSS), Placebo - Phase 2|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2",1
NCT04425538,6/1/2020,1/22/2021,Interventional,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,Phase 2,Tufts Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/34100026,https://clinicaltrials.gov/ct2/show/NCT04425538,0,2,2,United States,1,4,Infliximab,0
NCT04394377,6/21/2020,3/26/2021,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Completed,Phase 4,Brazilian Clinical Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/34097856,https://clinicaltrials.gov/ct2/show/NCT04394377,2,0,2,Brazil,0,9,Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Group 2: control group with enoxaparin 40mg/d,0
NCT04486508,7/30/2020,4/4/2021,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Completed,Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,https://pubmed.ncbi.nlm.nih.gov/33734299,https://clinicaltrials.gov/ct2/show/NCT04486508,1,1,2,"Iran, Islamic Republic of",0,9,intermediate dose Enoxaparin/ unfractionated heparin|standard prophylactic dose Enoxaparin/ unfractionated heparin|Atorvastatin 20mg|Matched placebo,0
NCT04331899,4/25/2020,8/14/2020,Interventional,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,Completed,Phase 2,Stanford University,NA,https://pubmed.ncbi.nlm.nih.gov/33785743,https://clinicaltrials.gov/ct2/show/NCT04331899,1,1,2,United States,1,8,Peginterferon Lambda-1a|Placebo,0
NCT04579393,10/8/2020,3/30/2021,Interventional,Fostamatinib for Hospitalized Adults With COVID-19,Completed,Phase 2,National Institutes of Health Clinical Center (CC),NA,https://pubmed.ncbi.nlm.nih.gov/33367731,https://clinicaltrials.gov/ct2/show/NCT04579393,1,0,1,United States,0,22,Placebo|fostamatinib,0
NCT04351295,4/20/2020,9/28/2020,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Completed,Phase 2/Phase 3,Tanta University,NA,https://pubmed.ncbi.nlm.nih.gov/33492523,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,Egypt,0,5,Favipiravir|Chloroquine,0
NCT04342663,4/10/2020,8/20/2020,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,https://pubmed.ncbi.nlm.nih.gov/33180097,https://clinicaltrials.gov/ct2/show/NCT04342663,1,0,1,United States,1,7,Fluvoxamine|Placebo,0
NCT04327401,4/13/2020,7/22/2020,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial results, which was accepted by the CoDEX Steering Committee.",https://pubmed.ncbi.nlm.nih.gov/32876695,https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,Brazil,0,5,Dexamethasone,0
NCT04325061,4/3/2020,6/19/2020,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,https://pubmed.ncbi.nlm.nih.gov/32043986,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,Spain,0,8,Dexamethasone,0
NCT04754698,2/9/2021,12/30/2021,Interventional,COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS,"Active, not recruiting",Phase 4,University of Sao Paulo General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34954325,https://clinicaltrials.gov/ct2/show/NCT04754698,6,0,6,Brazil,0,7,CoronaVac,0
NCT04582344,9/14/2020,2/15/2022,Interventional,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Active, not recruiting",Phase 3,Health Institutes of Turkey,NA,https://pubmed.ncbi.nlm.nih.gov/34246358,https://clinicaltrials.gov/ct2/show/NCT04582344,2,0,2,Turkey,0,3,CoronaVac|Placebo,1
NCT04356495,7/29/2020,1/29/2022,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,https://pubmed.ncbi.nlm.nih.gov/33050924,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,France,0,7,Vitamins|Telmisartan|Ciclesonide|interferon Î²-1b,0
NCT04405570,6/16/2020,2/21/2021,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://pubmed.ncbi.nlm.nih.gov/34100024,https://clinicaltrials.gov/ct2/show/NCT04405570,2,0,2,United States,0,18,EIDD-2801|Placebo (PBO),0
NCT04405076,5/29/2020,10/26/2021,Interventional,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older",Completed,Phase 2,"ModernaTX, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34526698,https://clinicaltrials.gov/ct2/show/NCT04405076,2,0,2,United States,0,8,Biological: mRNA-1273|Placebo|mRNA-1273.351,1
NCT04326426,4/13/2020,8/1/2020,Interventional,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Phase 3,Vanda Pharmaceuticals,NA,https://pubmed.ncbi.nlm.nih.gov/34353696,https://clinicaltrials.gov/ct2/show/NCT04326426,1,0,1,United States,0,2,Tradipitant|Placebo,0
NCT04306393,3/21/2020,12/21/2021,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33783269,https://clinicaltrials.gov/ct2/show/NCT04306393,2,0,2,United States|Sweden,0,8,Nitric Oxide Gas,0
NCT04344041,4/15/2020,1/14/2021,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,Phase 3,"University Hospital, Angers",NA,https://pubmed.ncbi.nlm.nih.gov/33371905,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,France,0,5,"cholecalciferol 200,000 IU|cholecalciferol 50,000 IU",0
NCT04405739,6/16/2020,12/16/2021,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://pubmed.ncbi.nlm.nih.gov/33273742,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,United States,0,18,EIDD-2801|Placebo,0
NCT04397757,5/13/2020,2/6/2021,Interventional,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,Completed,Phase 1,University of Pennsylvania,NA,https://pubmed.ncbi.nlm.nih.gov/34788233,https://clinicaltrials.gov/ct2/show/NCT04397757,1,0,1,United States,0,8,COVID-19 Convalescent Plasma,0
NCT04412057,6/9/2020,12/2/2020,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Completed,Phase 2,Cerecor Inc,NA,https://pubmed.ncbi.nlm.nih.gov/34871182,https://clinicaltrials.gov/ct2/show/NCT04412057,2,0,2,United States,0,6,CERC-002|Placebo,0
NCT04357730,5/14/2020,3/21/2021,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,"Active, not recruiting",Phase 2,Denver Health and Hospital Authority,NA,https://pubmed.ncbi.nlm.nih.gov/34592318,https://clinicaltrials.gov/ct2/show/NCT04357730,2,0,2,United States,0,11,Alteplase 50 MG [Activase]|Alteplase 50 MG [Activase],0
NCT04537208,9/3/2020,11/19/2021,Interventional,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Completed,Phase 1/Phase 2,Sanofi,NA,https://pubmed.ncbi.nlm.nih.gov/33887209,https://clinicaltrials.gov/ct2/show/NCT04537208,1,0,1,United States,0,6,SARS-CoV-2 vaccine formulation 1 with adjuvant 1|SARS-CoV-2 vaccine formulation 1 with adjuvant 2|SARS-CoV-2 vaccine formulation 2 with adjuvant 1|SARS-CoV-2 vaccine formulation 2 with adjuvant 2|SARS-CoV-2 vaccine formulation 2 without adjuvant|Placebo (0.9% normal saline),1
NCT04485130,5/1/2021,12/31/2021,Interventional,DISulfiram for COvid-19 (DISCO) Trial,Recruiting,Phase 2,"University of California, San Francisco",NA,https://pubmed.ncbi.nlm.nih.gov/32364011,https://clinicaltrials.gov/ct2/show/NCT04485130,0,6,6,United States,0,6,Disulfiram|Placebo,0
NCT04374526,5/27/2020,5/26/2021,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Completed,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://pubmed.ncbi.nlm.nih.gov/33092632,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,Italy,0,3,COVID-19 Convalescent Plasma,0
NCT04533347,2/19/2021,1/31/2022,Interventional,Tafenoquine in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,60 Degrees Pharmaceuticals LLC,NA,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04533347,0,7,7,United States,0,3,Tafenoquine Oral Tablet|Placebo,0
NCT04555096,9/9/2020,5/28/2021,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Terminated,Phase 2,"Galera Therapeutics, Inc.",Participants are no longer receiving intervention,https://pubmed.ncbi.nlm.nih.gov/33050459,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,United States,0,5,GC4419|Placebo,0
NCT04426201,12/20/2020,12/30/2021,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),Recruiting,Phase 2,Revimmune,NA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04426201,0,4,4,United States,0,4,CYT107|Placebo,0
NCT04345614,4/8/2020,6/28/2021,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Completed,Phase 2,"CalciMedica, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/32795330,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,United States,0,19,Auxora|Placebo,0
NCT04606784,10/28/2020,3/18/2021,Interventional,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,"Active, not recruiting",Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://pubmed.ncbi.nlm.nih.gov/34775578,https://clinicaltrials.gov/ct2/show/NCT04606784,1,0,1,United States,0,2,Ampion|Standard of Care,0
NCT04345523,4/3/2020,2/5/2021,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Completed,Phase 2,Puerta de Hierro University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34473652,https://clinicaltrials.gov/ct2/show/NCT04345523,2,0,2,Spain,0,3,Blood and derivatives.|Standard of Care,0
NCT04321616,3/28/2020,8/31/2020,Interventional,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Phase 2/Phase 3,Oslo University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34251903,https://clinicaltrials.gov/ct2/show/NCT04321616,1,0,1,Norway,0,2,Hydroxychloroquine|Remdesivir|(Standard of Care) SoC,0
NCT04350684,4/15/2020,4/22/2020,Interventional,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/34273635,https://clinicaltrials.gov/ct2/show/NCT04350684,1,0,1,"Iran, Islamic Republic of",0,1,Umifenovir|Interferon-Î² 1a|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine|Standards of Care,0
NCT04381884,5/18/2020,9/29/2020,Interventional,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Phase 2,Laboratorio Elea Phoenix S.A.,NA,https://pubmed.ncbi.nlm.nih.gov/34189446,https://clinicaltrials.gov/ct2/show/NCT04381884,1,0,1,Argentina,0,7,IVERMECTIN (IVER PÂ®) arm will receive IVM 600 Âµg / kg once daily plus standard care. CONTROL arm will receive standard care.,0
NCT04779047,10/1/2020,3/10/2021,Interventional,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,Recruiting,Phase 4,October 6 University,NA,https://pubmed.ncbi.nlm.nih.gov/34764044,https://clinicaltrials.gov/ct2/show/NCT04779047,1,0,1,Egypt,0,2,Remdesivir|Hydroxychloroquine|Tocilizumab|Lopinavir/ Ritonavir|Ivermectin,0
NCT04596839,9/4/2020,4/30/2021,Interventional,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Completed,Phase 2,Beximco Pharmaceuticals Ltd.,NA,https://pubmed.ncbi.nlm.nih.gov/34350582,https://clinicaltrials.gov/ct2/show/NCT04596839,1,0,1,Bangladesh,0,5,Remdesivir|Standard of Care,0
NCT04649515,12/4/2020,8/31/2021,Interventional,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Recruiting,Phase 3,Tychan Pte Ltd.,NA,https://pubmed.ncbi.nlm.nih.gov/34473343,https://clinicaltrials.gov/ct2/show/NCT04649515,1,0,1,Singapore,0,1,TY027|TY027|0.9% saline,0
NCT04420741,6/15/2020,2/23/2021,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Completed,Phase 2,"Rigshospitalet, Denmark",NA,https://pubmed.ncbi.nlm.nih.gov/34813414,https://clinicaltrials.gov/ct2/show/NCT04420741,2,1,3,Denmark,0,8,Iloprost|Isotonic saline,0
NCT04333368,4/6/2020,11/2/2020,Interventional,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Phase 1/Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://pubmed.ncbi.nlm.nih.gov/34774107,https://clinicaltrials.gov/ct2/show/NCT04333368,1,0,1,France,0,5,Umbilical cord Wharton's jelly-derived human|NaCl 0.9%,0
NCT04364022,4/23/2020,3/24/2021,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Completed,Phase 3,"University Hospital, Geneva",NA,https://pubmed.ncbi.nlm.nih.gov/34778734,https://clinicaltrials.gov/ct2/show/NCT04364022,2,0,2,Brazil|Switzerland,0,2,Lopinavir/ritonavir,0
NCT04526990,9/15/2020,12/30/2021,Interventional,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Phase 3,CanSino Biologics Inc.,NA,https://pubmed.ncbi.nlm.nih.gov/34953526,https://clinicaltrials.gov/ct2/show/NCT04526990,1,0,1,Argentina|Chile|Mexico|Pakistan|Russian Federation,0,11,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Placebo,1
NCT04480593,6/2/2020,8/30/2020,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://pubmed.ncbi.nlm.nih.gov/32313880,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,Brazil,0,1,Brazilian Green Propolis Extract (EPP-AF)|Standard care,0
NCT04444674,6/24/2020,12/31/2020,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/34416193,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,South Africa,0,4,ChAdOx1 nCoV-19|Normal saline 0.9%,1
NCT04343768,4/9/2020,4/27/2020,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/33850184,https://clinicaltrials.gov/ct2/show/NCT04343768,2,0,2,"Iran, Islamic Republic of",0,3,Hydroxychloroquine|Lopinavir / Ritonavir|Interferon Beta-1A|Interferon Beta-1B,0
NCT04429854,5/2/2020,4/30/2021,Interventional,Donated Antibodies Working Against nCoV,Completed,Phase 2,Universitaire Ziekenhuizen Leuven,NA,https://pubmed.ncbi.nlm.nih.gov/33246499,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,Belgium,0,4,Convalescent Plasma|Standard of care,0
NCT04449380,11/2/2020,3/30/2021,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Terminated,Phase 2,IRCCS San Raffaele,Futility,https://pubmed.ncbi.nlm.nih.gov/33225960,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,Italy,0,5,Interferon-ÃŸ-1a|Standard of Care (SOC),0
NCT04397718,7/6/2020,6/8/2021,Interventional,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Completed,Phase 2,VA Office of Research and Development,NA,https://pubmed.ncbi.nlm.nih.gov/34225789,https://clinicaltrials.gov/ct2/show/NCT04397718,1,0,1,United States,0,12,Degarelix|Saline,0
NCT04400838,5/28/2020,12/31/2021,Interventional,Investigating a Vaccine Against COVID-19,"Active, not recruiting",Phase 2/Phase 3,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/34480858,https://clinicaltrials.gov/ct2/show/NCT04400838,5,0,5,United Kingdom,0,12,ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose MenACWY vaccine min. 4 weeks apart|Two dose MenACWY vaccine|ChAdOx1 nCoV-19 (qPCR)|ChAdOx1 nCoV-19 (Abs 260)|MenACWY vaccine|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL,1
NCT04706416,11/14/2020,1/15/2021,Interventional,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Completed,Phase 1,Quantinosis.ai LLC,NA,https://pubmed.ncbi.nlm.nih.gov/34306677,https://clinicaltrials.gov/ct2/show/NCT04706416,1,0,1,United States,1,1,N-acetyl glucosamine (NAG)|Control,0
NCT04516811,9/21/2020,12/30/2021,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,https://pubmed.ncbi.nlm.nih.gov/32190290,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,South Africa,0,2,COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Standard of care (SOC) plus placebo,0
NCT04510207,7/16/2020,6/16/2021,Interventional,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Phase 3,China National Biotec Group Company Limited,NA,https://pubmed.ncbi.nlm.nih.gov/34037666,https://clinicaltrials.gov/ct2/show/NCT04510207,1,0,1,Bahrain|Egypt|Jordan|United Arab Emirates,0,7,Inactivated SARS-CoV-2 Vaccine (Vero cell)|Inactivated SARS-CoV-2 Vaccine (Vero cell)|Placebo,1
NCT04317092,3/19/2020,12/19/2021,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,https://pubmed.ncbi.nlm.nih.gov/33043164,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,Italy,0,4,Tocilizumab Injection,0
NCT04326790,4/3/2020,4/27/2020,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Terminated,Phase 2,National and Kapodistrian University of Athens,Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece,https://pubmed.ncbi.nlm.nih.gov/32579195,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,Greece,0,5,Colchicine|Standard treatment,0
NCT04322396,4/6/2020,2/2/2021,Interventional,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Terminated,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",Recommended by the DSMB,https://pubmed.ncbi.nlm.nih.gov/33081817,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,Denmark,1,7,Azithromycin|Hydroxychloroquine|Placebo oral tablet|Placebo oral tablet,0
NCT04390022,7/31/2020,9/17/2020,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://pubmed.ncbi.nlm.nih.gov/33495752,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,Spain,1,6,Ivermectin|Placebo,0
NCT04252885,1/28/2020,4/30/2020,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32838353,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,China,0,1,Lopinavir and Ritonavir Tablets|Arbidol,0
NCT04336410,4/3/2020,1/31/2022,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,https://pubmed.ncbi.nlm.nih.gov/33392485,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,United States,0,13,INO-4800|CELLECTRAÂ® 2000,1
NCT04451174,6/23/2020,1/30/2021,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Terminated,Phase 3,University of Chile,Corticosteroid use approval,https://pubmed.ncbi.nlm.nih.gov/33499887,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,Chile,0,4,Prednisone,0
NCT04516941,1/21/2021,12/31/2022,Interventional,CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,Recruiting,Phase 3,"University Hospital Inselspital, Berne",NA,https://pubmed.ncbi.nlm.nih.gov/32302438,https://clinicaltrials.gov/ct2/show/NCT04516941,0,4,4,Belgium|Italy|Spain|Switzerland,0,1,Edoxaban Tablets|Colchicine Tablets,0
NCT04343729,4/18/2020,6/16/2020,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://pubmed.ncbi.nlm.nih.gov/34917633,https://clinicaltrials.gov/ct2/show/NCT04343729,2,0,2,Brazil,0,8,Methylprednisolone Sodium Succinate|Placebo solution,0
NCT04662684,10/16/2020,8/10/2021,Interventional,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,"Active, not recruiting",Phase 3,Science Valley Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/34921756,https://clinicaltrials.gov/ct2/show/NCT04662684,1,0,1,Brazil,0,1,Rivaroxaban 10 MG,0
NCT04583995,11/28/2020,1/14/2022,Interventional,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","Active, not recruiting",Phase 3,Novavax,NA,https://pubmed.ncbi.nlm.nih.gov/34800364,https://clinicaltrials.gov/ct2/show/NCT04583995,1,0,1,United Kingdom,0,4,SARS-CoV-2 rS/Matrix M1-Adjuvant|Placebo|Licensed seasonal influenza vaccine,1
NCT04435795,9/14/2020,6/8/2021,Interventional,Inhaled Ciclesonide for Outpatients With COVID19,Terminated,Phase 2/Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,could not meet target enrolment,https://pubmed.ncbi.nlm.nih.gov/34728476,https://clinicaltrials.gov/ct2/show/NCT04435795,1,0,1,Canada,0,3,Normal Saline intranasal and placebo inhaler|Ciclesonide|Ciclesonide nasal,0
NCT04651790,11/27/2020,1/31/2022,Interventional,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults",Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://pubmed.ncbi.nlm.nih.gov/34659237,https://clinicaltrials.gov/ct2/show/NCT04651790,1,0,1,Chile,0,2,SARS-CoV-2 inactivated vaccine,1
NCT04362085,5/11/2020,5/10/2021,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Completed,Phase 3,Unity Health Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/34268513,https://clinicaltrials.gov/ct2/show/NCT04362085,3,0,3,Canada,0,5,Therapeutic Anticoagulation,0
NCT04467918,7/6/2020,11/16/2021,Interventional,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://pubmed.ncbi.nlm.nih.gov/34619044,https://clinicaltrials.gov/ct2/show/NCT04467918,1,0,1,Brazil,0,6,Cannabidiol|PLACEBO,0
NCT04635241,6/1/2020,11/1/2021,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://pubmed.ncbi.nlm.nih.gov/33377218,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,Argentina|Egypt,0,2,Unfractionated heparin,0
NCT04504877,6/16/2020,11/16/2020,Interventional,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Completed,Phase 2/Phase 3,University of Sao Paulo,NA,https://pubmed.ncbi.nlm.nih.gov/34387679,https://clinicaltrials.gov/ct2/show/NCT04504877,1,0,1,Brazil,0,4,Cannabidiol,0
NCT04469114,9/16/2020,1/9/2021,Interventional,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://pubmed.ncbi.nlm.nih.gov/34133856,https://clinicaltrials.gov/ct2/show/NCT04469114,1,0,1,Brazil,0,6,Tofacitinib 10 mg|Placebo,0
NCT04416399,7/16/2020,1/12/2021,Interventional,STerOids in COVID-19 Study,Terminated,Phase 2,University of Oxford,Independent statistical review advice,https://pubmed.ncbi.nlm.nih.gov/33844996,https://clinicaltrials.gov/ct2/show/NCT04416399,1,0,1,United Kingdom,0,4,Budesonide dry powder inhaler,0
NCT04790786,3/10/2021,2/28/2022,Interventional,"UPMC OPTIMISE-C19 Trial, a COVID-19 Study",Recruiting,Phase 3,University of Pittsburgh,NA,https://pubmed.ncbi.nlm.nih.gov/34034784,https://clinicaltrials.gov/ct2/show/NCT04790786,1,0,1,United States,0,3,Lilly Bamlanivimab|Regeneron Casirivimab + Imdevimab|Lilly Bamlanivimab + Etesevimab|Sotrovimab,0
NCT04327388,3/28/2020,7/31/2020,Interventional,Sarilumab COVID-19,Completed,Phase 3,Sanofi,NA,https://pubmed.ncbi.nlm.nih.gov/33676590,https://clinicaltrials.gov/ct2/show/NCT04327388,1,0,1,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,1,19,Sarilumab SAR153191|Placebo,0
NCT04836780,6/10/2021,3/30/2022,Interventional,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia,Recruiting,Phase 3,Hospital Universitario Infanta Leonor,NA,https://pubmed.ncbi.nlm.nih.gov/32678530,https://clinicaltrials.gov/ct2/show/NCT04836780,0,8,8,Spain,0,1,Dexamethasone,0
NCT04530396,9/7/2020,5/1/2021,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://pubmed.ncbi.nlm.nih.gov/33545094,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,Russian Federation,0,8,Gam-COVID-Vac|placebo,1
NCT04328493,4/7/2020,9/10/2020,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Completed,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,https://pubmed.ncbi.nlm.nih.gov/33110944,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,Vietnam,0,4,Chloroquine phosphate,0
NCT04323527,3/23/2020,5/7/2020,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://pubmed.ncbi.nlm.nih.gov/32330277,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,Brazil,0,5,Chloroquine diphosphate,0
NCT04588480,10/21/2020,11/25/2021,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults",Completed,Phase 1/Phase 2,BioNTech SE,NA,https://pubmed.ncbi.nlm.nih.gov/34907170,https://clinicaltrials.gov/ct2/show/NCT04588480,1,0,1,Japan,0,7,BNT162b2|Placebo,1
NCT04568031,8/23/2020,11/22/2021,Interventional,Study of AZD1222 for the Prevention of COVID-19 in Japan,Completed,Phase 1/Phase 2,AstraZeneca,NA,https://pubmed.ncbi.nlm.nih.gov/34688944,https://clinicaltrials.gov/ct2/show/NCT04568031,1,0,1,Japan,0,7,AZD1222|0.9% (w/v) saline,1
NCT04535167,9/9/2020,6/7/2021,Interventional,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.",Completed,Phase 1,Pfizer,NA,https://pubmed.ncbi.nlm.nih.gov/34541899,https://clinicaltrials.gov/ct2/show/NCT04535167,1,0,1,United States|Belgium|Brazil|Spain,0,9,PF-07304814|Placebo,0
NCT04603794,10/1/2020,11/30/2020,Interventional,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Phase 4,Ohio State University,NA,https://pubmed.ncbi.nlm.nih.gov/34561086,https://clinicaltrials.gov/ct2/show/NCT04603794,1,0,1,United States,0,0,0.5% Povidone Iodine|0.12% Chlorhexidine Gluconate Mouth Rinse|1% Hydrogen Peroxide|0.9% Normal Saline,0
NCT04353596,4/20/2020,2/16/2021,Interventional,Stopping ACE-inhibitors in COVID-19,Completed,Phase 4,Medical University Innsbruck,NA,https://pubmed.ncbi.nlm.nih.gov/34126053,https://clinicaltrials.gov/ct2/show/NCT04353596,1,0,1,Austria|Germany,0,3,"ACE inhibitor, angiotensin receptor blocker",0
NCT04338009,3/31/2020,8/20/2020,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Completed,Not Applicable,University of Pennsylvania,NA,https://pubmed.ncbi.nlm.nih.gov/33422263,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,United States,1,3,Discontinuation of ARB/ACEI|Continuation of ARB/ACEI,0
NCT04641481,11/16/2020,1/8/2021,Interventional,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"Active, not recruiting",Phase 3,Bharat Biotech International Limited,NA,https://pubmed.ncbi.nlm.nih.gov/34774196,https://clinicaltrials.gov/ct2/show/NCT04641481,1,0,1,India,0,3,BBV152|Placebo,1
NCT04652102,12/14/2020,4/16/2021,Interventional,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,"Active, not recruiting",Phase 2/Phase 3,CureVac AG,NA,https://pubmed.ncbi.nlm.nih.gov/34826381,https://clinicaltrials.gov/ct2/show/NCT04652102,1,0,1,Argentina|Belgium|Colombia|Dominican Republic|Germany|Mexico|Netherlands|Panama|Peru|Spain,0,7,CVnCoV|Placebo,1
NCT04350580,4/11/2020,11/20/2020,Interventional,Polyvalent Immunoglobulin in COVID-19 Related ARds,Completed,Phase 3,Centre Hospitalier St Anne,NA,https://pubmed.ncbi.nlm.nih.gov/34774185,https://clinicaltrials.gov/ct2/show/NCT04350580,2,0,2,France,0,5,Human immunoglobulin|Placebo,0
NCT04397562,4/29/2020,7/3/2020,Interventional,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Phase 3,Biocad,NA,https://pubmed.ncbi.nlm.nih.gov/34586459,https://clinicaltrials.gov/ct2/show/NCT04397562,1,0,1,Russian Federation,0,5,Levilimab|Placebo,0
NCT04716569,1/20/2021,2/20/2021,Interventional,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,Recruiting,Phase 2/Phase 3,South Valley University,NA,https://pubmed.ncbi.nlm.nih.gov/34163159,https://clinicaltrials.gov/ct2/show/NCT04716569,1,0,1,Egypt,0,7,intranasal ivermectin spray,0
NCT04494984,7/27/2020,11/23/2020,Interventional,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",Completed,Phase 2/Phase 3,Inmunova S.A.,NA,https://pubmed.ncbi.nlm.nih.gov/34013969,https://clinicaltrials.gov/ct2/show/NCT04494984,2,0,2,Argentina,0,4,INM005|Placebo,0
NCT04393818,5/5/2020,8/24/2020,Interventional,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Phase 3,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,https://pubmed.ncbi.nlm.nih.gov/33909587,https://clinicaltrials.gov/ct2/show/NCT04393818,2,0,2,Spain,0,4,Intervention App,0
NCT04484493,8/8/2020,10/25/2020,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,https://pubmed.ncbi.nlm.nih.gov/33429174,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,Egypt,0,5,mometasone furoate nasal spray,0
NCT04472728,6/16/2020,12/31/2021,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,https://pubmed.ncbi.nlm.nih.gov/33430924,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,United States|Belgium|Brazil|France|Puerto Rico,0,7,BIO101|Placebo,0
NCT04578158,9/29/2020,3/28/2021,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Completed,Phase 3,Liaquat University of Medical & Health Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/33179911,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,Pakistan,0,9,Standard COVID-19 care|Quercetin Phytosome,0
NCT04433910,8/30/2020,1/21/2021,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Completed,Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,https://pubmed.ncbi.nlm.nih.gov/34464358,https://clinicaltrials.gov/ct2/show/NCT04433910,2,0,2,Germany,0,4,Convalesscent Plasma,0
NCT04347681,4/18/2020,11/1/2020,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Completed,Phase 2,King Fahad Specialist Hospital Dammam,NA,https://pubmed.ncbi.nlm.nih.gov/33519339,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,Saudi Arabia,0,4,convalescent plasma from recovered COVID 19 donor,0
NCT04482647,6/17/2020,7/1/2021,Interventional,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Phase 1,M.D. Anderson Cancer Center,NA,https://pubmed.ncbi.nlm.nih.gov/33835830,https://clinicaltrials.gov/ct2/show/NCT04482647,1,0,1,United States,0,4,Media Intervention|Meditation Therapy|Quality-of-Life Assessment|Questionnaire Administration|Yoga,0
NCT04375098,5/4/2020,8/17/2020,Interventional,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Phase 2,Pontificia Universidad Catolica de Chile,NA,https://pubmed.ncbi.nlm.nih.gov/33657114,https://clinicaltrials.gov/ct2/show/NCT04375098,1,0,1,Chile,0,3,COVID-19 convalescent plasma,0
NCT04721457,1/3/2021,3/28/2021,Interventional,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,Completed,Phase 4,King Abdulaziz University,NA,https://pubmed.ncbi.nlm.nih.gov/33215159,https://clinicaltrials.gov/ct2/show/NCT04721457,0,16,16,Saudi Arabia,0,2,Distilled Water|1% Povidone Iodine (PVP-I)|1.5% Hydrogen Peroxide (H2O2)|0.075% Cetylpyridinium Chloride (CPC)|0.1% Sodium Hypochlorite,0
NCT04356482,5/20/2020,11/30/2020,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04356482,0,5,5,Mexico,0,3,convalescent plasma,0
NCT04816682,3/17/2021,6/30/2021,Interventional,Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes,Recruiting,Phase 4,F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica,NA,https://pubmed.ncbi.nlm.nih.gov/32517353,https://clinicaltrials.gov/ct2/show/NCT04816682,0,1,1,Slovakia,0,1,Silymarin,0
NCT04442178,9/15/2020,10/30/2021,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,United States,0,2,CYT107|Placebo,0
NCT04344587,4/23/2020,5/7/2021,Interventional,Awake Prone Position for Early Hypoxemia in COVID-19,Completed,Not Applicable,Boston University,NA,https://pubmed.ncbi.nlm.nih.gov/33647225,https://clinicaltrials.gov/ct2/show/NCT04344587,1,0,1,United States|Spain,0,14,Self-prone position recommendation|Usual care,0
NCT04431466,7/1/2020,12/1/2020,Interventional,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Terminated,Phase 2,Universidade Federal de Sao Carlos,"Preliminary data from a pilot study suggest that the administration of ivermectin in patients with SARS-CoV-2 is safe, reducing symptoms and viral load. The antiviral effects of ivermectin appear to depend on the dose administered.",https://pubmed.ncbi.nlm.nih.gov/33723507,https://clinicaltrials.gov/ct2/show/NCT04431466,1,0,1,Brazil,0,2,Ivermectin|Standard of Care,0
NCT04434248,4/23/2020,7/31/2020,Interventional,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2/Phase 3,Chromis LLC,NA,https://pubmed.ncbi.nlm.nih.gov/32770240,https://clinicaltrials.gov/ct2/show/NCT04434248,1,0,1,Russian Federation,0,0,Favipiravir|Standard of Care,0
NCT04446429,10/21/2020,12/24/2020,Interventional,Anti-Androgen Treatment for COVID-19,Completed,Not Applicable,"Applied Biology, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34350193,https://clinicaltrials.gov/ct2/show/NCT04446429,1,0,1,Brazil,1,9,Proxalutamide|Standard of Care,0
NCT04392973,5/21/2020,1/26/2021,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Completed,Not Applicable,King Abdullah International Medical Research Center,NA,https://pubmed.ncbi.nlm.nih.gov/34319552,https://clinicaltrials.gov/ct2/show/NCT04392973,2,0,2,Saudi Arabia,0,3,Favipiravir and Hydroxychloroquine,0
NCT04356534,4/19/2020,6/15/2020,Interventional,Convalescent Plasma Trial in COVID -19 Patients,Completed,Not Applicable,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://pubmed.ncbi.nlm.nih.gov/33976287,https://clinicaltrials.gov/ct2/show/NCT04356534,1,0,1,Bahrain,0,4,plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Routine care for COVID-19 patients,0
NCT04340349,2/1/2021,5/30/2021,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,https://pubmed.ncbi.nlm.nih.gov/33558079,https://clinicaltrials.gov/ct2/show/NCT04340349,1,16,17,Mexico,0,4,Hydroxychloroquine Sulfate|Bromhexine 8 MG,0
NCT04783311,2/23/2021,3/31/2022,Interventional,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults",Recruiting,Phase 1/Phase 2,"EuBiologics Co.,Ltd",NA,https://pubmed.ncbi.nlm.nih.gov/34050027,https://clinicaltrials.gov/ct2/show/NCT04783311,1,0,1,"Korea, Republic of",0,1,EuCorVac-19|Normal Saline,1
NCT04477954,7/6/2020,11/6/2020,Interventional,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Terminated,Phase 2,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,"Investigators and Ethic Committee endorsed early suspension of the protocol because of superiority and safety. For the interim analysys, the statistical methodology presented by Pocock was followed.",https://pubmed.ncbi.nlm.nih.gov/34907003,https://clinicaltrials.gov/ct2/show/NCT04477954,1,0,1,Argentina,0,2,Hyperbaric Oxygen,0
NCT04352608,4/16/2020,7/10/2020,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://pubmed.ncbi.nlm.nih.gov/34890537,https://clinicaltrials.gov/ct2/show/NCT04352608,2,0,2,China,0,4,Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of placebo at the emergency vaccination schedule|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of placebo at the routine vaccination schedule|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of placebo at the emergency vaccination schedule|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of placebo at the routine vaccination schedule,1
NCT04367168,5/27/2020,4/27/2021,Interventional,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://pubmed.ncbi.nlm.nih.gov/34755269,https://clinicaltrials.gov/ct2/show/NCT04367168,1,0,1,Mexico,0,2,Colchicine|Placebo oral tablet,0
NCT04634903,11/19/2020,3/15/2021,Interventional,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Completed,Not Applicable,Stony Brook University,NA,https://pubmed.ncbi.nlm.nih.gov/34887544,https://clinicaltrials.gov/ct2/show/NCT04634903,1,0,1,United States,1,4,Supportive Therapy SSI|Behavioral Activation SSI|Growth Mindset SSI,0
NCT04362059,6/18/2020,7/27/2021,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,Not Applicable,University Hospital Southampton NHS Foundation Trust,NA,https://pubmed.ncbi.nlm.nih.gov/33302976,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,United Kingdom,0,3,COVSurf Drug Delivery System|Standard of Care,0
NCT04644328,11/12/2020,2/11/2021,Interventional,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,Completed,Not Applicable,"National Bureau of Economic Research, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34413518,https://clinicaltrials.gov/ct2/show/NCT04644328,1,1,2,United States,1,5,Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday,0
NCT04325906,4/2/2020,1/26/2021,Interventional,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Completed,Not Applicable,Rush University Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/34535158,https://clinicaltrials.gov/ct2/show/NCT04325906,1,0,1,United States,0,6,high flow nasal cannula (HFNC)|Prone positioning (PP),0
NCT04359290,7/1/2020,12/31/2020,Interventional,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,Completed,Phase 2,Philipps University Marburg Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/34385593,https://clinicaltrials.gov/ct2/show/NCT04359290,1,0,1,Germany,0,6,Ruxolitinib administration,0
NCT04416334,8/19/2020,12/25/2021,Interventional,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Phase 3,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://pubmed.ncbi.nlm.nih.gov/34488841,https://clinicaltrials.gov/ct2/show/NCT04416334,1,0,1,Spain,0,4,Colchicine plus symptomatic treatment (paracetamol)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations),0
NCT05049213,9/20/2021,9/30/2023,Interventional,Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19,Recruiting,Phase 4,National Taiwan University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34044151,https://clinicaltrials.gov/ct2/show/NCT05049213,0,2,2,Taiwan,0,1,Carrageenan nasal spray and 1% PVP- mouthwash and gargle,0
NCT04530617,10/5/2020,6/10/2021,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Terminated,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Results from the interim analysis,https://pubmed.ncbi.nlm.nih.gov/32298251,https://clinicaltrials.gov/ct2/show/NCT04530617,0,25,25,Mexico,0,5,Camostat Mesilate|Artemisia Annua Leaf,0
NCT04521322,7/24/2020,10/30/2020,Interventional,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Phase 4,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://pubmed.ncbi.nlm.nih.gov/34629893,https://clinicaltrials.gov/ct2/show/NCT04521322,1,0,1,Argentina,0,1,Iota-Carrageenan,0
NCT04341415,4/9/2020,11/20/2020,Interventional,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Terminated,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,Inclusion stopped at 50% after interim analysis: primary efficacy endpoint not significant,https://pubmed.ncbi.nlm.nih.gov/34408665,https://clinicaltrials.gov/ct2/show/NCT04341415,1,0,1,France,0,3,Auricular neuromodulation|Control,0
NCT04385043,5/1/2020,10/15/2020,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://pubmed.ncbi.nlm.nih.gov/32129478,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,Italy,0,0,plasma hyperimmune|standard therapy,0
NCT04572399,10/30/2020,12/28/2020,Interventional,UVA Light Device to Treat COVID-19,Completed,Not Applicable,Cedars-Sinai Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/34173969,https://clinicaltrials.gov/ct2/show/NCT04572399,1,0,1,United States,0,4,UV Light Treatment,0
NCT04373135,5/8/2020,2/28/2021,Interventional,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",Not Applicable,"University of California, Los Angeles",NA,https://pubmed.ncbi.nlm.nih.gov/34013254,https://clinicaltrials.gov/ct2/show/NCT04373135,2,0,2,United States,0,3,Brief educational video,0
NCT04557046,6/26/2020,11/30/2021,Interventional,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,Not Applicable,LumiraDx UK Limited,NA,https://pubmed.ncbi.nlm.nih.gov/33629225,https://clinicaltrials.gov/ct2/show/NCT04557046,1,0,1,United States,0,3,Nasal Swab|Nasopharyngeal swab|Throat swab|Fingerstick|Saliva specimen,0
NCT04393246,7/3/2020,2/15/2022,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://pubmed.ncbi.nlm.nih.gov/32736592,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,United Kingdom,0,4,EDP1815|Dapagliflozin|Ambrisentan|Standard of care,0
NCT04502056,8/7/2020,9/6/2020,Interventional,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,Not Applicable,"National Bureau of Economic Research, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/34259846,https://clinicaltrials.gov/ct2/show/NCT04502056,1,0,1,United States,1,3,Acknowledgement Racial Injustice AMA|African American Sender Acknowledgement|African American Sender in Informational Videos.|Racial Inequality Highlighted|AMA Acknowledgement Drug Pricing|White Sender in Acknowledgement|White Sender in Informational Videos|No Racial Inequality Highlighting|Placebo videos,0
NCT04459247,6/15/2020,3/30/2021,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19",Completed,Not Applicable,Postgraduate Institute of Medical Education and Research,NA,https://pubmed.ncbi.nlm.nih.gov/34029377,https://clinicaltrials.gov/ct2/show/NCT04459247,2,0,2,India,0,3,Vit D,0
NCT04321096,4/4/2020,1/31/2022,Interventional,The Impact of Camostat Mesilate on COVID-19 Infection,Recruiting,Phase 1/Phase 2,University of Aarhus,NA,https://pubmed.ncbi.nlm.nih.gov/33903855,https://clinicaltrials.gov/ct2/show/NCT04321096,1,0,1,Denmark|Sweden,0,5,Camostat Mesilate|Placebo oral tablet,0
NCT04407507,7/1/2020,1/29/2021,Interventional,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",Completed,Phase 2,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,NA,https://pubmed.ncbi.nlm.nih.gov/32135219,https://clinicaltrials.gov/ct2/show/NCT04407507,0,5,5,Mexico,1,1,Ivermectin|Placebo,0
NCT04355364,4/21/2020,12/21/2021,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://pubmed.ncbi.nlm.nih.gov/32560746,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,France,0,8,Dornase Alfa Inhalation Solution [Pulmozyme]|standard procedure,0
NCT04484207,7/6/2020,10/20/2020,Interventional,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,Not Applicable,"Research Foundation for Mental Hygiene, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/33734539,https://clinicaltrials.gov/ct2/show/NCT04484207,1,0,1,United States,1,4,A short video intervention|A vignette intervention,0
NCT04730323,5/12/2020,6/12/2020,Interventional,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://pubmed.ncbi.nlm.nih.gov/33585031,https://clinicaltrials.gov/ct2/show/NCT04730323,1,0,1,Pakistan,0,0,Tocilizumab,0
NCT04329533,4/13/2020,11/1/2020,Interventional,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,Not Applicable,University of Arizona,NA,https://pubmed.ncbi.nlm.nih.gov/33957663,https://clinicaltrials.gov/ct2/show/NCT04329533,1,0,1,United States,0,8,"""Calm"" is a mindfulness meditation mobile app",0
NCT04371419,5/13/2020,5/24/2020,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,Not Applicable,"National Bureau of Economic Research, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/33347320,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,United States,1,4,Messaging,0
NCT04501965,6/1/2020,8/30/2020,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://pubmed.ncbi.nlm.nih.gov/31936284,https://clinicaltrials.gov/ct2/show/NCT04501965,0,15,15,Guinea,0,1,Hydroxychloroquine/Azithromycine|Quinquina-Stevia/Azythromycin|4Plants/Azythromycin,0
NCT04380818,6/5/2020,9/4/2021,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,Not Applicable,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,https://pubmed.ncbi.nlm.nih.gov/32613089,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,Spain,0,3,Low-dose radiotherapy|Hydroxychloroquine Sulfate|Ritonavir/lopinavir|Tocilizumab Injection [Actemra]|Azithromycin|Corticosteroid|Low molecular weight heparin|Oxygen supply,0
NCT04350723,6/10/2020,7/17/2021,Interventional,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Completed,Not Applicable,St. Joseph's Healthcare Hamilton,NA,https://pubmed.ncbi.nlm.nih.gov/33555780,https://clinicaltrials.gov/ct2/show/NCT04350723,1,0,1,United States|Canada|Kuwait|Saudi Arabia,0,3,Awake Proning,0
NCT04346355,3/31/2020,6/6/2020,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,https://pubmed.ncbi.nlm.nih.gov/33080005,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,Italy,0,2,Tocilizumab,0
NCT04331808,3/30/2020,3/31/2021,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://pubmed.ncbi.nlm.nih.gov/33080017,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,France,0,2,Tocilizumab,0
NCT04315480,3/12/2020,4/9/2020,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,https://pubmed.ncbi.nlm.nih.gov/33307107,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,Italy,0,2,Tocilizumab,0
NCT04324606,4/23/2020,10/31/2021,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/33335322,https://clinicaltrials.gov/ct2/show/NCT04324606,3,0,3,United Kingdom,0,14,ChAdOx1 nCoV-19|MenACWY|ChAdOx1 nCoV-19 full boost|ChAdOx1 nCoV-19 half boost|MenACWY boost|Paracetamol|ChAdOx1 nCoV-19 0.5mL boost|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT),1
NCT04647695,11/20/2020,7/31/2021,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,Hong Kong,0,2,Interferon beta-1b|Remdesivir,0
NCT04339816,5/13/2020,11/4/2020,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,https://pubmed.ncbi.nlm.nih.gov/32641163,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,Czechia,0,3,Azithromycin|Hydroxychloroquine|Placebo,0
NCT04445324,8/25/2020,8/25/2020,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",Not Applicable,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,https://pubmed.ncbi.nlm.nih.gov/33259326,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,Canada,0,4,"Transitional Online Peer Support Group (n=20)|Control Group (pharmacotherapy and/or psychotherapy, n=10)",0
NCT04341493,4/6/2020,8/30/2020,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Terminated,Phase 4,Materno-Perinatal Hospital of the State of Mexico,Concerns about safety of Hydroxychloroquine,https://pubmed.ncbi.nlm.nih.gov/32513231,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,Mexico,0,3,Nitazoxanide 500 MG|Hydroxychloroquine,0
NCT04477655,5/3/2020,1/26/2021,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Completed,Not Applicable,Hospital Civil de Guadalajara,NA,https://pubmed.ncbi.nlm.nih.gov/33225990,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,Mexico,0,3,Awake prone positioning|Standard oxygen therapy,0
NCT04445467,7/30/2020,11/30/2021,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,"Active, not recruiting",Phase 2,Bayside Health,NA,https://pubmed.ncbi.nlm.nih.gov/33050947,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,Australia,0,3,Favipiravir,0
NCT04373291,5/18/2020,7/31/2021,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Completed,Phase 3,Bandim Health Project,NA,https://pubmed.ncbi.nlm.nih.gov/32943115,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,Denmark,0,6,BCG-Denmark|Saline,1
NCT04369378,8/19/2020,4/28/2021,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Completed,Not Applicable,Lake Erie College of Osteopathic Medicine,NA,https://pubmed.ncbi.nlm.nih.gov/33298117,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,United States,0,3,Meditation app usage,0
NCT04353674,4/28/2020,12/31/2021,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,Not Applicable,Lawson Health Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04353674,0,13,13,Canada,0,6,Control group|SLEDD with a L-MOD,0
NCT04828668,4/2/2021,12/30/2021,Interventional,Study to Evaluate Benefits & Safety of Endourage Formula Câ„¢ Oral Drops in People With Post-Acute COVID-19 Syndrome.,"Active, not recruiting",Not Applicable,"Endourage, LLC",NA,https://pubmed.ncbi.nlm.nih.gov/28861491,https://clinicaltrials.gov/ct2/show/NCT04828668,0,6,6,United States,0,4,Targeted Wellness Formula Câ„¢ Sublingual Drops - 1200mg - 30 mL (Formula C),0
NCT04784481,9/20/2020,12/20/2020,Interventional,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://pubmed.ncbi.nlm.nih.gov/32251768,https://clinicaltrials.gov/ct2/show/NCT04784481,0,1,1,Argentina,0,2,Ivermectin,0
NCT04341389,4/12/2020,1/31/2021,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://pubmed.ncbi.nlm.nih.gov/32702299,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,China,0,3,Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Placebo,1
NCT04700163,1/11/2021,3/31/2022,Interventional,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,"Active, not recruiting",Phase 1,Rockefeller University,NA,https://pubmed.ncbi.nlm.nih.gov/32555388,https://clinicaltrials.gov/ct2/show/NCT04700163,0,1,1,United States,0,4,C144-LS and C-135-LS,0
NCT04338958,4/22/2020,7/15/2021,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Completed,Phase 2,University of Jena,NA,https://pubmed.ncbi.nlm.nih.gov/32518419,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,Germany,0,5,Ruxolitinib,0
NCT04276688,2/10/2020,3/30/2020,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,https://pubmed.ncbi.nlm.nih.gov/32401715,https://clinicaltrials.gov/ct2/show/NCT04276688,1,0,1,Hong Kong,0,2,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,0
NCT04486001,12/15/2020,1/15/2022,Interventional,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Recruiting,Phase 1,"Sorrento Therapeutics, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/32423449,https://clinicaltrials.gov/ct2/show/NCT04486001,0,1,1,United States,0,4,PSC-04,0
NCT04973488,7/25/2020,1/10/2021,Interventional,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Completed,Phase 2/Phase 3,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",NA,https://pubmed.ncbi.nlm.nih.gov/34934447,https://clinicaltrials.gov/ct2/show/NCT04973488,1,0,1,Romania,0,0,Therapeutic plasma exchange,0
NCT04727424,1/19/2021,2/1/2022,Interventional,Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms,Recruiting,Phase 3,Cardresearch,NA,https://pubmed.ncbi.nlm.nih.gov/34717820,https://clinicaltrials.gov/ct2/show/NCT04727424,1,0,1,Brazil,0,2,Fluvoxamine Maleate 100 MG [Luvox]|Doxazosin 2 Mg Oral Tablet|Ivermectin 06 mg Oral Tablet|Placebo|Peginterferon Lambda-1a|Peginterferon Beta-1A Prefilled Syringe,0
NCT04401202,5/21/2020,12/31/2020,Interventional,Nigella Sativa in COVID-19,Completed,Phase 2,King Abdulaziz University,NA,https://pubmed.ncbi.nlm.nih.gov/34407441,https://clinicaltrials.gov/ct2/show/NCT04401202,2,0,2,Saudi Arabia,1,3,Nigella sativa oil,0
NCT04330586,4/1/2020,3/31/2021,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Completed,Phase 2,Korea University Guro Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34441840,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,"Korea, Republic of",0,3,Ciclesonide Metered Dose Inhaler [Alvesco],0
NCT04453384,9/1/2020,12/31/2021,Interventional,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,"Active, not recruiting",Phase 2,Nantes University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34181475,https://clinicaltrials.gov/ct2/show/NCT04453384,2,0,2,France|Martinique|RÃ©union,0,3,XAV-19|Placebo,0
NCT04341038,4/1/2020,6/1/2020,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,https://pubmed.ncbi.nlm.nih.gov/34195214,https://clinicaltrials.gov/ct2/show/NCT04341038,2,0,2,Spain,0,0,Tacrolimus|Methylprednisolone,0
NCT04492514,5/20/2020,5/31/2021,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Phase 2,University of Cincinnati,NA,https://pubmed.ncbi.nlm.nih.gov/33754144,https://clinicaltrials.gov/ct2/show/NCT04492514,1,0,1,United States,0,0,Mavrilimumab|Placebo,0
NCT04533399,8/17/2020,11/30/2021,Interventional,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Phase 2,Novavax,NA,https://pubmed.ncbi.nlm.nih.gov/33951374,https://clinicaltrials.gov/ct2/show/NCT04533399,1,0,1,South Africa,0,3,Placebo|SARS-CoV-2 rS/Matrix-M1 Adjuvant,1
NCT04354259,5/13/2020,12/15/2021,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://pubmed.ncbi.nlm.nih.gov/33556319,https://clinicaltrials.gov/ct2/show/NCT04354259,1,0,1,Brazil|Canada,0,4,Peginterferon Lambda-1A|placebo,0
NCT04357366,4/15/2020,4/15/2022,Interventional,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://pubmed.ncbi.nlm.nih.gov/33682678,https://clinicaltrials.gov/ct2/show/NCT04357366,1,0,1,Greece,0,6,Anakinra,0
NCT04663555,2/2/2021,3/31/2022,Interventional,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Recruiting,Phase 4,Brno University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33648568,https://clinicaltrials.gov/ct2/show/NCT04663555,1,0,1,Czechia,0,3,Dexamethasone,0
NCT04273321,2/14/2020,4/15/2020,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,Not Applicable,Beijing Chao Yang Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33486496,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,China,0,4,Methylprednisolone,0
NCT04385095,3/16/2020,2/17/2021,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,"Active, not recruiting",Phase 2,Synairgen Research Ltd.,NA,https://pubmed.ncbi.nlm.nih.gov/33189161,https://clinicaltrials.gov/ct2/show/NCT04385095,1,0,1,United Kingdom,0,3,SNG001|Placebo,0
NCT04394416,6/2/2020,6/1/2022,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,https://pubmed.ncbi.nlm.nih.gov/33115543,https://clinicaltrials.gov/ct2/show/NCT04394416,1,0,1,United States,0,2,Imatinib|Placebo oral tablet,0
NCT04466670,7/11/2020,12/30/2021,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 2,University of Sao Paulo General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/29264361,https://clinicaltrials.gov/ct2/show/NCT04466670,0,25,25,Brazil,0,1,acetylsalicylic acid|Unfractionated heparin nebulized,0
NCT04400799,6/15/2020,3/14/2022,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,https://pubmed.ncbi.nlm.nih.gov/32907635,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,Germany|Switzerland,0,5,Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml,0
NCT04436471,6/17/2020,8/3/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://pubmed.ncbi.nlm.nih.gov/32896291,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,Russian Federation,0,3,Gam-COVID-Vac,1
NCT04627467,3/28/2020,7/9/2020,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Completed,Phase 2,Fundacion Clinica Valle del Lili,NA,https://pubmed.ncbi.nlm.nih.gov/32150618,https://clinicaltrials.gov/ct2/show/NCT04627467,0,16,16,Colombia,0,2,Chloroquine,0
NCT04344951,4/6/2020,11/30/2020,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Terminated,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,No clinical efficacy against SARS-CoV-2 recorded,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04344951,0,2,2,Greece,0,2,UNIKINON (Chloroquine phosphate) 200mg tablets,0
NCT04361474,5/18/2020,11/24/2020,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Completed,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://pubmed.ncbi.nlm.nih.gov/32690074,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,France,0,6,Budesonide Nasal|Physiological serum,0
NCT04282902,2/4/2020,4/30/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/31762329,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,China,0,0,pirfenidone,0
NCT04352400,6/4/2021,12/31/2021,Interventional,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Recruiting,Phase 2/Phase 3,University Hospital Padova,NA,https://pubmed.ncbi.nlm.nih.gov/32187464,https://clinicaltrials.gov/ct2/show/NCT04352400,0,7,7,Italy,0,1,Nafamostat Mesilate|Placebo,0
NCT04288102,3/5/2020,5/12/2020,Interventional,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Phase 2,Beijing 302 Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34963099,https://clinicaltrials.gov/ct2/show/NCT04288102,2,0,2,China,0,5,UC-MSCs|Saline containing 1% Human serum albuminï¼ˆsolution without UC-MSCsï¼‰,0
NCT04885907,5/25/2021,7/30/2021,Interventional,Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients,"Active, not recruiting",Phase 4,"University Health Network, Toronto",NA,https://pubmed.ncbi.nlm.nih.gov/34807716,https://clinicaltrials.gov/ct2/show/NCT04885907,1,0,1,Canada,0,2,mRNA-1273 vaccine|Normal Saline Placebo,1
NCT04780152,10/31/2021,8/31/2022,Interventional,TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic,Recruiting,Phase 2/Phase 3,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,NA,https://pubmed.ncbi.nlm.nih.gov/25309825,https://clinicaltrials.gov/ct2/show/NCT04780152,0,57,57,Mexico,0,2,Transcranial Direct Current Stimulation|Placebo-simulation of transcranial direct current stimulation|Fluoxetine Tablets,0
NCT04361942,5/1/2020,11/30/2021,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,https://pubmed.ncbi.nlm.nih.gov/32257537,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,Spain,0,3,Mesenchymal Stromal Cells|Placebo,0
NCT04328441,3/25/2020,3/31/2021,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,https://pubmed.ncbi.nlm.nih.gov/32503602,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,Netherlands,0,4,BCG Vaccine|Placebo,1
NCT04685512,11/18/2020,4/1/2021,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Completed,Phase 2/Phase 3,"University Hospital, Caen",NA,https://pubmed.ncbi.nlm.nih.gov/34222849,https://clinicaltrials.gov/ct2/show/NCT04685512,1,0,1,France,0,1,tenofovir disoproxil and emtricitabine,0
NCT04860739,4/24/2021,5/20/2021,Interventional,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"Active, not recruiting",Phase 2,Spanish Clinical Research Network - SCReN,NA,https://pubmed.ncbi.nlm.nih.gov/34181880,https://clinicaltrials.gov/ct2/show/NCT04860739,1,0,1,Spain,0,3,COMIRNATY,1
NCT04319731,3/20/2020,3/20/2021,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,https://pubmed.ncbi.nlm.nih.gov/33482902,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,United States,0,1,Human Amniotic Fluid,0
NCT04432103,8/8/2020,1/29/2021,Interventional,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,Terminated,Phase 3,Centro Medico ABC,There is new evidence that the Convalescent plasma is not useful for severe and critical COVID-19 Pneumonia,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04432103,0,26,26,Mexico,0,2,Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients,0
NCT04252274,1/30/2020,8/31/2020,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,https://pubmed.ncbi.nlm.nih.gov/32671131,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,China,0,2,Darunavir and Cobicistat,0
NCT04610541,10/12/2020,10/30/2021,Interventional,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Phase 3,University of Pecs,NA,https://pubmed.ncbi.nlm.nih.gov/32224310,https://clinicaltrials.gov/ct2/show/NCT04610541,0,6,6,Hungary,0,1,Remdesivir-HU,0
NCT04730856,2/1/2021,6/1/2021,Interventional,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Recruiting,Phase 3,Hospital Universitario Infanta Leonor,NA,https://pubmed.ncbi.nlm.nih.gov/31986264,https://clinicaltrials.gov/ct2/show/NCT04730856,0,1,1,Spain,0,2,Tinzaparin,0
NCT04352751,5/1/2020,4/30/2021,Interventional,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,Not Applicable,Hilton Pharma,NA,https://pubmed.ncbi.nlm.nih.gov/34579646,https://clinicaltrials.gov/ct2/show/NCT04352751,1,0,1,Pakistan,0,4,convalescent plasma,0
NCT04551547,10/31/2020,4/30/2021,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Enrolling by invitation,Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://pubmed.ncbi.nlm.nih.gov/34197764,https://clinicaltrials.gov/ct2/show/NCT04551547,1,0,1,China,0,4,"Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Two doses of placebo at the schedule of day 0,28",1
NCT04695652,12/30/2020,6/2/2021,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,https://pubmed.ncbi.nlm.nih.gov/34655522,https://clinicaltrials.gov/ct2/show/NCT04695652,1,0,1,Taiwan|Vietnam,0,8,MVC-COV1901(S protein with adjuvant)|MVC-COV1901(Saline),1
NCT04408209,4/23/2020,8/30/2021,Interventional,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,Not Applicable,National and Kapodistrian University of Athens,NA,https://pubmed.ncbi.nlm.nih.gov/33920489,https://clinicaltrials.gov/ct2/show/NCT04408209,1,0,1,Greece,0,4,Convalescent Plasma,0
NCT04398004,5/6/2020,11/30/2020,Interventional,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://pubmed.ncbi.nlm.nih.gov/34363189,https://clinicaltrials.gov/ct2/show/NCT04398004,1,0,1,Greece,0,3,Clarithromycin,0
NCT04569188,5/15/2020,8/15/2020,Interventional,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Phase 2,Azienda Socio Sanitaria Territoriale di Mantova,NA,https://pubmed.ncbi.nlm.nih.gov/33585799,https://clinicaltrials.gov/ct2/show/NCT04569188,1,0,1,Italy,0,1,Convalescent plasma,0
NCT04530357,9/19/2020,11/25/2020,Interventional,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine",Completed,Phase 1/Phase 2,Research Institute for Biological Safety Problems,NA,https://pubmed.ncbi.nlm.nih.gov/34414368,https://clinicaltrials.gov/ct2/show/NCT04530357,1,0,1,Kazakhstan,0,10,QazCovid-inÂ® - COVID-19 inactivated vaccine|Placebo,1
NCT04412018,6/4/2020,11/6/2020,Interventional,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Completed,Phase 2,Canadian Medical and Surgical Knowledge Translation Research Group,NA,https://pubmed.ncbi.nlm.nih.gov/34462732,https://clinicaltrials.gov/ct2/show/NCT04412018,1,0,1,Canada,0,4,Icosapent ethyl,0
NCT04383535,5/15/2020,9/27/2020,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,Not Applicable,Hospital Italiano de Buenos Aires,NA,https://pubmed.ncbi.nlm.nih.gov/33232588,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,Argentina,0,4,Convalescent SARS COVID-19 plasma|Placebo,0
NCT04479163,6/4/2020,10/25/2020,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,Not Applicable,Fundacion Infant,NA,https://pubmed.ncbi.nlm.nih.gov/33406353,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,Argentina,0,3,Convalescent Plasma|Placebo,0
NCT04627584,12/29/2020,5/31/2021,Interventional,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,Recruiting,Phase 2,"Mabwell (Shanghai) Bioscience Co., Ltd.",NA,https://pubmed.ncbi.nlm.nih.gov/34346827,https://clinicaltrials.gov/ct2/show/NCT04627584,1,0,1,China,0,3,MW33 injection|MW33 injection placebo,0
NCT04521309,6/19/2020,1/26/2021,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Completed,Phase 1/Phase 2,Dow University of Health Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/34109306,https://clinicaltrials.gov/ct2/show/NCT04521309,3,0,3,Pakistan,0,4,SARS-CoV-2 antibody based IVIG therapy,0
NCT04383574,5/22/2020,12/28/2021,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://pubmed.ncbi.nlm.nih.gov/33548194,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,China,0,5,"Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Two doses of placebo at the schedule of day 0,28|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28",1
NCT04471519,7/15/2020,7/31/2020,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,https://pubmed.ncbi.nlm.nih.gov/33705727,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,India,0,4,BBV152A - Phase I|BBV152B - Phase I|BBV152C - Phase I|Placebo - Phase I|BBV152A - Phase II|BBV152B - Phase II,1
NCT04517162,8/19/2020,2/19/2021,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://pubmed.ncbi.nlm.nih.gov/32089354,https://clinicaltrials.gov/ct2/show/NCT04517162,0,23,23,Mexico,0,3,Collagen-Polyvinylpyrrolidone,0
NCT04393727,5/1/2020,9/30/2020,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana",Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,Italy,0,2,CONVALESCENT PLASMA,0
NCT04382755,5/22/2020,12/29/2020,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,Completed,Phase 2,"University Hospital, Ghent",NA,https://pubmed.ncbi.nlm.nih.gov/33213529,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,Belgium,0,4,ZilucoplanÂ®|Placebo,0
NCT04494724,7/13/2020,12/31/2020,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04494724,0,7,7,United States,0,0,Clazakizumab|Placebo,0
NCT04473170,4/4/2020,5/20/2020,Interventional,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Phase 1/Phase 2,Abu Dhabi Stem Cells Center,NA,https://pubmed.ncbi.nlm.nih.gov/34849303,https://clinicaltrials.gov/ct2/show/NCT04473170,2,0,2,United Arab Emirates,0,0,Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|COVID-19 standard care,0
NCT04681430,1/8/2021,11/30/2021,Interventional,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,Phase 2,"Heinrich-Heine University, Duesseldorf",NA,https://pubmed.ncbi.nlm.nih.gov/34001215,https://clinicaltrials.gov/ct2/show/NCT04681430,1,0,1,Germany,0,4,Camostat Mesilate|Placebo for Camostat Mesilate|Convalescent plasma|Standard of Care (SoC),0
NCT04581954,10/2/2020,12/1/2021,Interventional,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Phase 1/Phase 2,Imperial College London,NA,https://pubmed.ncbi.nlm.nih.gov/33845867,https://clinicaltrials.gov/ct2/show/NCT04581954,1,0,1,United Kingdom,0,3,Ruxolitinib|Fostamatinib|Standard of care,0
NCT04449718,6/1/2020,10/7/2020,Interventional,Vitamin D Supplementation in Patients With COVID-19,Completed,Not Applicable,University of Sao Paulo,NA,https://pubmed.ncbi.nlm.nih.gov/34852148,https://clinicaltrials.gov/ct2/show/NCT04449718,2,0,2,Brazil,0,1,Vitamin D|Placebo,0
NCT04412538,5/15/2020,9/30/2020,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/33165503,https://clinicaltrials.gov/ct2/show/NCT04412538,2,0,2,China,0,1,Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Placebo on a 0- and 28-day schedule|Placebo on a 0- and 14-day schedule,1
NCT04459286,10/9/2020,5/2/2021,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Completed,Phase 2,Obafemi Awolowo University,NA,https://pubmed.ncbi.nlm.nih.gov/33397457,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,Nigeria,0,4,Nitazoxanide and atazanavir/ritonavir|Standard of Care,0
NCT04713111,5/4/2020,11/30/2020,Interventional,Stress and Recovery in Frontline COVID-19 Workers,Completed,Not Applicable,4YouandMe,NA,https://pubmed.ncbi.nlm.nih.gov/34726607,https://clinicaltrials.gov/ct2/show/NCT04713111,1,0,1,United States,0,1,Lifestyle (Meditation)|Lifestyle (Exercise),0
NCT04460703,7/3/2020,7/8/2020,Interventional,"COVID-19 Vaccine Messaging, Part 1",Completed,Not Applicable,Yale University,NA,https://pubmed.ncbi.nlm.nih.gov/34774363,https://clinicaltrials.gov/ct2/show/NCT04460703,1,0,1,United States,0,2,Control message|Baseline message|Personal freedom message|Economic freedom message|Self-interest message|Community interest message|Economic benefit message|Guilt message|Embarrassment message|Anger message|Trust in science message|Not bravery message,1
NCT04936997,6/7/2021,2/1/2022,Interventional,Immune Response to the COVID-19 Vaccine,"Active, not recruiting",Early Phase 1,University of Arizona,NA,https://pubmed.ncbi.nlm.nih.gov/34594036,https://clinicaltrials.gov/ct2/show/NCT04936997,1,0,1,United States,0,2,SARS-COV2 Pfizer Vaccine,1
NCT04557241,1/14/2020,1/14/2021,Interventional,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,Not Applicable,Indiana University,NA,https://pubmed.ncbi.nlm.nih.gov/34581678,https://clinicaltrials.gov/ct2/show/NCT04557241,2,0,2,United States,0,1,Brief informational infographic|Placebo control (non-behavioral infographic),0
NCT05017805,8/15/2021,12/15/2022,Interventional,COVID-19 Vaccines in Patients With Chronic Liver Disease,Recruiting,Not Applicable,Beijing 302 Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33577086,https://clinicaltrials.gov/ct2/show/NCT05017805,0,2,2,China,0,1,COVID-19 Vaccines,1
NCT04565509,11/20/2020,6/30/2022,Interventional,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,Not Applicable,Washington University School of Medicine,NA,https://pubmed.ncbi.nlm.nih.gov/34465306,https://clinicaltrials.gov/ct2/show/NCT04565509,2,0,2,United States,0,2,General Communication Message|Focused/Targeted Message|Best Message Alone|Best Message + Augmented Message or Implementation Strategy,0
NCT04620798,9/14/2020,11/11/2020,Interventional,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Completed,Not Applicable,Indiana University,NA,https://pubmed.ncbi.nlm.nih.gov/34418958,https://clinicaltrials.gov/ct2/show/NCT04620798,1,0,1,United States,0,1,Immediate vs. delayed provision of antibody test results,0
NCT04357808,4/13/2020,11/30/2020,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Completed,Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,https://pubmed.ncbi.nlm.nih.gov/32907638,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,Spain,0,3,Sarilumab|Standar of care,0
NCT04365127,4/27/2020,8/20/2020,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Completed,Phase 1,Cedars-Sinai Medical Center,NA,https://pubmed.ncbi.nlm.nih.gov/33621601,https://clinicaltrials.gov/ct2/show/NCT04365127,1,0,1,United States,0,2,Progesterone 100 MG,0
NCT04368923,3/15/2020,6/21/2020,Interventional,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",Not Applicable,Cairo University,NA,https://pubmed.ncbi.nlm.nih.gov/33819166,https://clinicaltrials.gov/ct2/show/NCT04368923,1,0,1,Egypt,0,1,Oxygen Therapy|Physical Therapy,0
NCT04349592,4/14/2020,8/14/2020,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,Not Applicable,Hamad Medical Corporation,NA,https://pubmed.ncbi.nlm.nih.gov/33251500,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,Qatar,0,2,Hydroxychloroquine|Azithromycin|Placebo Tablet|Placebo capsules,0
NCT04366089,3/26/2020,10/30/2020,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,https://pubmed.ncbi.nlm.nih.gov/32228825,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,Italy,0,0,"Oxygen-ozone therapy, probiotic supplementation and Standard of care|SivoMixx (200 billion)|Azithromycin|hydroxychloroquine",0
NCT04661410,12/1/2020,12/1/2021,Interventional,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,Not Applicable,Drexel University,NA,https://pubmed.ncbi.nlm.nih.gov/33908655,https://clinicaltrials.gov/ct2/show/NCT04661410,1,0,1,United States,0,1,Reward Re-Training|Supportive Therapy,0
NCT04464408,7/23/2020,8/4/2021,Interventional,Favipiravir Therapy in Adults With Mild COVID-19,Completed,Phase 2/Phase 3,King Abdullah International Medical Research Center,NA,https://pubmed.ncbi.nlm.nih.gov/33853806,https://clinicaltrials.gov/ct2/show/NCT04464408,1,0,1,Saudi Arabia,0,5,Favipiravir|Placebo,0
NCT04390464,5/8/2020,5/7/2021,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,https://pubmed.ncbi.nlm.nih.gov/32641154,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,United Kingdom,0,1,Ravulizumab|Baricitinib|Standard of care,0
NCT04321174,4/17/2020,8/27/2021,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,"Active, not recruiting",Phase 3,Unity Health Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/33752741,https://clinicaltrials.gov/ct2/show/NCT04321174,1,0,1,Canada,0,2,Lopinavir/ritonavir,0
NCT04499677,9/24/2020,12/1/2021,Interventional,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Completed,Phase 2,"University College, London",NA,https://pubmed.ncbi.nlm.nih.gov/33685502,https://clinicaltrials.gov/ct2/show/NCT04499677,1,0,1,United Kingdom,0,4,Favipiravir|Lopinavir/ Ritonavir|Favipiravir Placebo|Lopinavir/ Ritonavir Placebo,0
NCT04251871,1/22/2020,1/22/2021,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,Not Applicable,Beijing 302 Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,China,0,1,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",0
NCT04609865,11/4/2020,12/31/2021,Interventional,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://pubmed.ncbi.nlm.nih.gov/33573681,https://clinicaltrials.gov/ct2/show/NCT04609865,1,0,1,France,0,2,Lidocaine 2%|Control,0
NCT04363827,5/14/2020,6/30/2021,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://pubmed.ncbi.nlm.nih.gov/32736597,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,Italy,0,3,Hydroxychloroquine,0
NCT04338698,4/22/2020,9/1/2020,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://pubmed.ncbi.nlm.nih.gov/32771032,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,Pakistan,0,2,Hydroxychloroquine|Oseltamivir|Azithromycin,0
NCT04392323,5/13/2020,10/1/2020,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Completed,Not Applicable,Northwell Health,NA,https://pubmed.ncbi.nlm.nih.gov/32292899,https://clinicaltrials.gov/ct2/show/NCT04392323,0,10,10,United States,0,1,COVID-19 PCR and Serology,0
NCT04384380,4/1/2020,5/31/2020,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,Not Applicable,Taoyuan General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,Taiwan,0,1,Hydroxychloroquine Sulfate 200 MG [Plaquenil],0
NCT04410562,5/13/2020,5/13/2021,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,https://pubmed.ncbi.nlm.nih.gov/32616063,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,Spain,0,2,Hydroxychloroquine|Placebo,0
NCT04395807,6/3/2020,4/12/2021,Interventional,Helmet CPAP Versus HFNC in COVID-19,Terminated,Not Applicable,Lund University,"Few eligible patients at study start
Patients received HFNC prior to intermediate care ward admission
NIV was locally considered a step-up therapy to HFNC
Full-face masks replaced the Helmet interface as local NIV standard",https://pubmed.ncbi.nlm.nih.gov/33272319,https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,Sweden,0,2,Helmet CPAP|HFNC,0
NCT04568356,4/24/2020,6/12/2020,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,Not Applicable,"E25Bio, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/32542934,https://clinicaltrials.gov/ct2/show/NCT04568356,0,16,16,United States,0,1,Direct Antigen Tests for COVID-19,0
NCT04374786,5/15/2020,9/1/2020,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,Not Applicable,University of Arizona,NA,https://pubmed.ncbi.nlm.nih.gov/32039812,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,United States,0,2,Calm Meditation App,0
NCT04360980,3/20/2020,9/1/2021,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/32503620,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,"Iran, Islamic Republic of",0,3,Colchicine Tablets,0
NCT04313127,3/16/2020,1/20/2021,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,Completed,Phase 1,CanSino Biologics Inc.,NA,https://pubmed.ncbi.nlm.nih.gov/32450106,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,China,0,5,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),1
NCT04707742,6/15/2020,9/18/2021,Interventional,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Completed,Not Applicable,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,https://pubmed.ncbi.nlm.nih.gov/34937855,https://clinicaltrials.gov/ct2/show/NCT04707742,1,0,1,Spain,0,1,Distilled Water|BetadineÂ© bucal 100 mg/ml|OximenÂ® 3%|Clorhexidine Dental PHBÂ©|Vitis Xtra ForteÂ©,0
NCT04348409,5/25/2020,7/31/2020,Interventional,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,Not Applicable,Azidus Brasil,NA,https://pubmed.ncbi.nlm.nih.gov/34222847,https://clinicaltrials.gov/ct2/show/NCT04348409,1,0,1,Brazil,0,2,Nitazoxanide Tablets|Placebo,0
NCT04623021,9/25/2020,12/12/2020,Interventional,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Completed,Phase 2,Chong Kun Dang Pharmaceutical,NA,https://pubmed.ncbi.nlm.nih.gov/34723164,https://clinicaltrials.gov/ct2/show/NCT04623021,1,0,1,Russian Federation,0,1,Nafamostat Mesilate,0
NCT04382768,5/1/2020,1/31/2021,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,Not Applicable,QuÃ­mica Luar SRL,NA,https://pubmed.ncbi.nlm.nih.gov/34460083,https://clinicaltrials.gov/ct2/show/NCT04382768,1,3,4,Argentina,0,3,Inhaled Hypertonic ibuprofen,0
NCT04394117,6/19/2020,11/2/2021,Interventional,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,"Active, not recruiting",Phase 4,The George Institute,NA,https://pubmed.ncbi.nlm.nih.gov/34454580,https://clinicaltrials.gov/ct2/show/NCT04394117,1,0,1,Australia|India,0,5,Angiotensin Receptor Blockers|Placebo,0
NCT04746183,7/3/2020,11/18/2021,Interventional,AGILE (Early Phase Platform Trial for COVID-19),Recruiting,Phase 1/Phase 2,University of Liverpool,NA,https://pubmed.ncbi.nlm.nih.gov/34311777,https://clinicaltrials.gov/ct2/show/NCT04746183,1,0,1,South Africa|United Kingdom,0,3,CST-2: EIDD-2801|CST-2: Placebo|Nitazoxanide|VIR-7832|VIR-7831|CST-5: Placebo,0
NCT04438980,5/15/2020,3/12/2021,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Completed,Phase 3,Fundacion Miguel Servet,NA,https://pubmed.ncbi.nlm.nih.gov/33430891,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,Spain,0,2,Methylprednisolone|Placebo,0
NCT04753476,6/8/2020,2/1/2022,Interventional,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,Recruiting,Phase 2,Stem Cell and Cancer Research Indonesia,NA,https://pubmed.ncbi.nlm.nih.gov/33274176,https://clinicaltrials.gov/ct2/show/NCT04753476,0,2,2,Indonesia,0,2,Injection of Secretome-MSCs|Standard treatment of Covid-19,0
NCT04441424,4/3/2020,6/1/2020,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,Not Applicable,Alkarkh Health Directorate-Baghdad,NA,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,Iraq,0,1,Convalescent plasma|Hydroxychloroquin with Azithromycin,0
NCT04483375,7/24/2020,11/17/2020,Interventional,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Completed,Phase 1,Sinocelltech Ltd.,NA,https://pubmed.ncbi.nlm.nih.gov/34491805,https://clinicaltrials.gov/ct2/show/NCT04483375,1,0,1,China,0,4,SCTA01|Placebo,0
NCT04528641,8/10/2020,5/19/2021,Interventional,GRAd-COV2 Vaccine Against COVID-19,Completed,Phase 1,ReiThera Srl,NA,https://pubmed.ncbi.nlm.nih.gov/33895322,https://clinicaltrials.gov/ct2/show/NCT04528641,1,0,1,Italy,0,3,GRAd-COV2,1
NCT04450004,7/10/2020,9/20/2021,Interventional,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Phase 1,Medicago,NA,https://pubmed.ncbi.nlm.nih.gov/34007070,https://clinicaltrials.gov/ct2/show/NCT04450004,1,0,1,Canada,0,3,Intramuscular Vaccine,1
NCT04335786,4/17/2020,5/25/2021,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Terminated,Phase 4,Radboud University,Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.,https://pubmed.ncbi.nlm.nih.gov/32512291,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,Netherlands,0,7,Valsartan (Diovan)|Placebo oral tablet,0
NCT04830943,8/1/2020,2/28/2021,Interventional,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,Completed,Phase 4,Assiut University,NA,https://pubmed.ncbi.nlm.nih.gov/32253535,https://clinicaltrials.gov/ct2/show/NCT04830943,0,1,1,Egypt,0,0,Cerebrolysin,0
NCT04479202,2/8/2020,4/18/2020,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,https://pubmed.ncbi.nlm.nih.gov/32213556,https://clinicaltrials.gov/ct2/show/NCT04479202,0,2,2,China,0,0,Berberine|Montmorrillonite,0
NCT04604327,10/26/2020,5/31/2021,Interventional,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Phase 3,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://pubmed.ncbi.nlm.nih.gov/34638151,https://clinicaltrials.gov/ct2/show/NCT04604327,1,0,1,Spain,0,0,Bemiparin sodium,0
NCT04578210,9/4/2020,1/31/2021,Interventional,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Phase 1/Phase 2,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://pubmed.ncbi.nlm.nih.gov/34775592,https://clinicaltrials.gov/ct2/show/NCT04578210,3,0,3,Spain,0,1,T memory cells and NK cells,0
NCT04805125,4/19/2021,7/31/2022,Interventional,Immunocompromised Swiss Cohorts Based Trial Platform,"Active, not recruiting",Phase 3,"University Hospital, Basel, Switzerland",NA,https://pubmed.ncbi.nlm.nih.gov/34674742,https://clinicaltrials.gov/ct2/show/NCT04805125,1,0,1,Switzerland,0,3,"Moderna COVID-19 Vaccine, mRNA-1273 (100 Î¼g)|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 Âµg)( ComirnatyÂ®)",1
NCT04420806,3/14/2020,7/30/2020,Interventional,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,Not Applicable,University of Erlangen-NÃ¼rnberg Medical School,NA,https://pubmed.ncbi.nlm.nih.gov/33712920,https://clinicaltrials.gov/ct2/show/NCT04420806,1,0,1,Germany,0,3,HIT-exercise|Sham intervention,0
NCT04487210,10/7/2020,6/1/2021,Interventional,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"Active, not recruiting",Phase 1,Medigen Vaccine Biologics Corp.,NA,https://pubmed.ncbi.nlm.nih.gov/34222848,https://clinicaltrials.gov/ct2/show/NCT04487210,1,0,1,Taiwan,0,6,MVC-COV1901,0
NCT04445194,6/22/2020,10/22/2020,Interventional,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://pubmed.ncbi.nlm.nih.gov/33773111,https://clinicaltrials.gov/ct2/show/NCT04445194,1,0,1,China,0,3,Recombinant new coronavirus vaccine (CHO cell) low-dose group|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Recombinant new coronavirus vaccine (CHO cells) placebo group,1
NCT04598581,11/2/2020,4/9/2021,Interventional,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Completed,Not Applicable,"University Hospital, Basel, Switzerland",NA,https://pubmed.ncbi.nlm.nih.gov/33677049,https://clinicaltrials.gov/ct2/show/NCT04598581,1,1,2,Switzerland,0,4,Low Dose Radiation Therapy (LD-RT)|Sham irradiation,0
NCT04931238,1/20/2021,12/31/2021,Interventional,Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,Peking Union Medical College Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33215063,https://clinicaltrials.gov/ct2/show/NCT04931238,0,1,1,China,0,1,JS016,0
NCT04497389,10/28/2020,9/15/2021,Interventional,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Phase 1/Phase 2,University of Utah,NA,https://pubmed.ncbi.nlm.nih.gov/33574155,https://clinicaltrials.gov/ct2/show/NCT04497389,1,0,1,United States,0,2,Human Amniotic Fluid,0
NCT04275414,2/15/2020,4/5/2020,Interventional,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Phase 2,Qilu Hospital of Shandong University,NA,https://pubmed.ncbi.nlm.nih.gov/33547300,https://clinicaltrials.gov/ct2/show/NCT04275414,1,0,1,China|Italy,0,2,Bevacizumab Injection,0
NCT04705753,4/1/2020,10/15/2020,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,https://pubmed.ncbi.nlm.nih.gov/33390932,https://clinicaltrials.gov/ct2/show/NCT04705753,0,3,3,Greece,0,0,Cretan IAMA,0
NCT04395105,5/21/2020,4/5/2021,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Terminated,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,Low rate of recruitment,https://pubmed.ncbi.nlm.nih.gov/32843098,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,Argentina,0,4,High-Dose Dexamethasone,0
NCT05132972,1/17/2021,11/30/2021,Interventional,Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients,Recruiting,Phase 2/Phase 3,"Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia",NA,https://pubmed.ncbi.nlm.nih.gov/32756149,https://clinicaltrials.gov/ct2/show/NCT05132972,0,5,5,Indonesia,0,0,Normoxic Allogenic UCMSC|Normal saline solution,0
NCT04716556,7/16/2020,1/14/2021,Interventional,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,Completed,Not Applicable,Istituto Superiore di SanitÃ ,NA,https://pubmed.ncbi.nlm.nih.gov/34842924,https://clinicaltrials.gov/ct2/show/NCT04716556,1,0,1,Italy,0,2,Convalescent plasma,0
NCT04542941,6/16/2020,12/31/2020,Interventional,Assessment of Safety and Efficacy of CCP,Completed,Not Applicable,Makerere University,NA,https://pubmed.ncbi.nlm.nih.gov/34376401,https://clinicaltrials.gov/ct2/show/NCT04542941,1,0,1,Uganda,0,1,COVID Convalescent Plasma,0
NCT04407208,5/1/2020,6/22/2020,Interventional,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Phase 1,Biofarma,NA,https://pubmed.ncbi.nlm.nih.gov/34104878,https://clinicaltrials.gov/ct2/show/NCT04407208,1,0,1,Indonesia,0,2,Convalescent plasma,0
NCT04348513,5/29/2020,4/19/2021,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Terminated,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Due to specific inclusion criteria no more subjects could be enrolled.,https://pubmed.ncbi.nlm.nih.gov/34151781,https://clinicaltrials.gov/ct2/show/NCT04348513,2,0,2,Greece,0,2,T3 solution for injection|Placebo,0
NCT04497324,9/21/2020,4/17/2021,Interventional,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,Completed,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://pubmed.ncbi.nlm.nih.gov/34001174,https://clinicaltrials.gov/ct2/show/NCT04497324,1,0,1,Peru,0,4,Convalescent plasma,0
NCT05043324,2/20/2020,2/20/2022,Interventional,"Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","Active, not recruiting",Phase 2,"Trieu, Nguyen Thi, M.D.",NA,https://pubmed.ncbi.nlm.nih.gov/32947424,https://clinicaltrials.gov/ct2/show/NCT05043324,0,11,11,Vietnam,0,2,AntiCov-220 (1)|AntiCov-220 (2),0
NCT04742738,1/20/2021,7/30/2021,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"SK Bioscience Co., Ltd.",NA,https://pubmed.ncbi.nlm.nih.gov/33873199,https://clinicaltrials.gov/ct2/show/NCT04742738,1,0,1,"Korea, Republic of",0,2,GBP510 adjuvanted with Alum (RBD 10Î¼g/dose) - Stage 1|Normal saline (0.9% sodium chloride solution) - Stage 1|GBP510 adjuvanted with Alum (RBD 25Î¼g/dose) - Stage 1|Normal saline (0.9% sodium chloride solution) - Stage 1|GBP510 adjuvanted with Alum (RBD 10Î¼g/dose) - Stage 2|GBP510 adjuvanted with Alum (RBD 25Î¼g/dose)- Stage 2|Normal saline (0.9% sodium chloride solution)- Stage 2,1
NCT04403477,5/20/2020,7/20/2020,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://pubmed.ncbi.nlm.nih.gov/33106167,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,Bangladesh,0,0,Convalescent plasma,0
NCT04366050,5/11/2020,5/31/2021,Interventional,Ramipril for the Treatment of COVID-19,Recruiting,Phase 2,"University of California, San Diego",NA,https://pubmed.ncbi.nlm.nih.gov/33631357,https://clinicaltrials.gov/ct2/show/NCT04366050,1,0,1,United States,0,2,Ramipril 2.5 MG Oral Capsule|Placebo oral capsule,0
NCT04321421,3/17/2020,4/28/2020,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,Not Applicable,Foundation IRCCS San Matteo Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32648959,https://clinicaltrials.gov/ct2/show/NCT04321421,2,0,2,Italy,0,2,hyperimmune plasma,0
NCT04348929,4/16/2020,8/16/2023,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,Not Applicable,"Central Hospital, Nancy, France",NA,https://pubmed.ncbi.nlm.nih.gov/33303470,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,France,0,4,Self-administered questionnaires,0
NCT04333550,4/30/2020,9/30/2020,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/29619244,https://clinicaltrials.gov/ct2/show/NCT04333550,0,16,16,"Iran, Islamic Republic of",0,2,Deferoxamine,0
NCT04927169,3/1/2021,12/30/2021,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort),Recruiting,Phase 2,Revimmune,NA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04927169,0,4,4,Brazil,0,1,Interleukin-7|PLACEBO,0
NCT04407689,6/8/2020,7/30/2021,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,France,0,2,Interleukin-7|Placebo,0
NCT04610567,10/27/2020,3/15/2021,Interventional,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Phase 1/Phase 2,University of Sao Paulo General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32653469,https://clinicaltrials.gov/ct2/show/NCT04610567,0,3,3,Brazil,0,2,Methotrexate-LDE phase 1|Methotrexate-LDE phase 2|Placebo-LDE phase 2,0
NCT04473053,7/3/2020,12/31/2022,Interventional,DEFINE - Evaluating Therapies for COVID-19,"Active, not recruiting",Phase 1/Phase 2,University of Edinburgh,NA,https://pubmed.ncbi.nlm.nih.gov/34911721,https://clinicaltrials.gov/ct2/show/NCT04473053,1,0,1,United Kingdom,0,2,Nafamostat Mesilate|TD139|Standard care,0
NCT04358939,4/27/2020,2/21/2021,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Completed,Not Applicable,"University Hospital, Tours",NA,https://pubmed.ncbi.nlm.nih.gov/34425070,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,France,0,8,Prone decubitus,0
NCT04373200,5/25/2020,9/25/2022,Interventional,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,Not Applicable,Rennes University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34715884,https://clinicaltrials.gov/ct2/show/NCT04373200,1,0,1,France,0,5,Blood samples collection|Saliva collection,0
NCT04609462,8/11/2020,1/13/2021,Interventional,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Completed,Not Applicable,Fundacion Clinica Valle del Lili,NA,https://pubmed.ncbi.nlm.nih.gov/34874419,https://clinicaltrials.gov/ct2/show/NCT04609462,1,0,1,Colombia,0,4,Conventional oxygen therapy|High flow nasal cannula,0
NCT04872075,5/26/2021,6/13/2021,Interventional,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,https://pubmed.ncbi.nlm.nih.gov/34843662,https://clinicaltrials.gov/ct2/show/NCT04872075,1,0,1,France,0,5,Concert|Rapid nasopharyngeal antigen test for Sars-Cov-2|Saliva Sample,0
NCT04715438,1/8/2021,6/4/2021,Interventional,Vaccination Against COVID-19 in Cancer,"Active, not recruiting",Not Applicable,University Medical Center Groningen,NA,https://pubmed.ncbi.nlm.nih.gov/34767759,https://clinicaltrials.gov/ct2/show/NCT04715438,1,0,1,Netherlands,0,4,mRNA-1273 SARS-CoV-2 vaccine from Moderna,1
NCT04530435,10/6/2020,3/29/2021,Interventional,PEP Flute-selfcare in COVID-19,"Active, not recruiting",Not Applicable,Bispebjerg Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34819329,https://clinicaltrials.gov/ct2/show/NCT04530435,2,0,2,Denmark,0,4,PEP flute,0
NCT04394182,4/21/2020,12/31/2020,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,Not Applicable,Fundacion GenesisCare,NA,https://pubmed.ncbi.nlm.nih.gov/33502567,https://clinicaltrials.gov/ct2/show/NCT04394182,1,9,10,Spain,0,0,Ultra-Low-dose radiotherapy|ventilatory support with oxygen therapy|Lopinavir/ritonavir|Hydroxychloroquine|Azithromycin|Piperacillin/tazobactam|Low molecular weight heparin|Corticosteroid injection|Tocilizumab,0
NCT04472585,11/14/2020,8/15/2021,Interventional,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://pubmed.ncbi.nlm.nih.gov/34488858,https://clinicaltrials.gov/ct2/show/NCT04472585,1,0,1,Pakistan,0,2,Ivermectin Injectable Solution|Injectable Placebo|Zinc|Placebo empty capsule|Oral Ivermectin,0
NCT04558476,9/1/2020,9/1/2022,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,https://pubmed.ncbi.nlm.nih.gov/33287790,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,Belgium,0,1,Convalescent Plasma|Standard of Care,0
NCT04622891,4/1/2020,7/30/2020,Interventional,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,Not Applicable,South Valley University,NA,https://pubmed.ncbi.nlm.nih.gov/34381155,https://clinicaltrials.gov/ct2/show/NCT04622891,1,0,1,Egypt,0,0,Clarithromycin 500mg|Azithromycin|Placebo,0
NCT04589104,5/26/2020,8/17/2020,Interventional,Expressive Writing for COVID-19 Resilience,Completed,Not Applicable,Duke University,NA,https://pubmed.ncbi.nlm.nih.gov/34332289,https://clinicaltrials.gov/ct2/show/NCT04589104,1,0,1,United States,0,0,Expressive writing,0
NCT04400279,6/1/2020,11/28/2020,Interventional,The COVID-19 Pandemic and Exercise Study,Completed,Not Applicable,University of British Columbia,NA,https://pubmed.ncbi.nlm.nih.gov/34580067,https://clinicaltrials.gov/ct2/show/NCT04400279,1,0,1,Canada,0,4,Yoga group|High Intensity Interval Training group|Combination,0
NCT04637906,11/18/2020,4/18/2021,Interventional,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),Recruiting,Not Applicable,"University of Campania ""Luigi Vanvitelli""",NA,https://pubmed.ncbi.nlm.nih.gov/34522871,https://clinicaltrials.gov/ct2/show/NCT04637906,1,0,1,Italy,0,4,BioargininaÂ®,0
NCT04347941,7/11/2020,1/26/2021,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Terminated,Not Applicable,University College Hospital Galway,"Enrollment for trial was terminated on January 26, 2021 after a third interim analysis demonstrated that a pre-defined statistical criteria for efficacy were met as part of meta-trial study of awake prone positioning.",https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04347941,0,1,1,Ireland,1,3,Prone Positioning|Standard of care.,0
NCT04495933,7/13/2020,11/6/2021,Interventional,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","Active, not recruiting",Phase 1,The University of Queensland,NA,https://pubmed.ncbi.nlm.nih.gov/33887208,https://clinicaltrials.gov/ct2/show/NCT04495933,1,0,1,Australia,0,3,MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Placebo,1
NCT04668625,11/30/2020,12/20/2020,Interventional,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Completed,Not Applicable,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://pubmed.ncbi.nlm.nih.gov/34051886,https://clinicaltrials.gov/ct2/show/NCT04668625,1,0,1,Spain,0,4,Participate in a massive musical event,0
NCT04889274,5/10/2021,8/1/2021,Interventional,Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19),Recruiting,Phase 1,Queen Mary University of London,NA,https://pubmed.ncbi.nlm.nih.gov/33035428,https://clinicaltrials.gov/ct2/show/NCT04889274,0,3,3,United Kingdom,0,0,COVID-19 vaccine|Concentrate beetroot Juice|Nitrate-deplete beetroot juice,1
NCT04455815,9/25/2020,12/31/2021,Interventional,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive.,"Active, not recruiting",Phase 2,Cancer Research UK,NA,https://pubmed.ncbi.nlm.nih.gov/34412682,https://clinicaltrials.gov/ct2/show/NCT04455815,1,0,1,United Kingdom,0,7,Camostat,0
NCT04366141,5/1/2020,2/1/2021,Interventional,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Completed,Not Applicable,University of British Columbia,NA,https://pubmed.ncbi.nlm.nih.gov/33973161,https://clinicaltrials.gov/ct2/show/NCT04366141,1,0,1,Canada,0,3,COVID-19 barrier box,0
NCT04445935,6/28/2020,9/28/2020,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,https://pubmed.ncbi.nlm.nih.gov/32895056,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,Qatar,0,0,Bivalirudin Injection|Standard treatment,0
NCT04343053,4/8/2020,6/9/2020,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,Recruiting,Not Applicable,University Hospital of Ferrara,NA,https://pubmed.ncbi.nlm.nih.gov/33270471,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,Italy,0,3,SARS-Cov-2 infection,0
NCT04386694,5/18/2020,9/17/2020,Interventional,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,Not Applicable,University of Nove de Julho,NA,https://pubmed.ncbi.nlm.nih.gov/34335043,https://clinicaltrials.gov/ct2/show/NCT04386694,1,0,1,Brazil,0,6,Active PBMT/sMF|Placebo PBMT/sMF,0
NCT04635943,8/29/2020,4/30/2021,Interventional,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Completed,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://pubmed.ncbi.nlm.nih.gov/33836826,https://clinicaltrials.gov/ct2/show/NCT04635943,1,0,1,Peru,0,2,Ivermectin|Placebo,0
NCT04324528,3/27/2020,1/27/2021,Interventional,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,Not Applicable,University Hospital Freiburg,NA,https://pubmed.ncbi.nlm.nih.gov/34000236,https://clinicaltrials.gov/ct2/show/NCT04324528,1,0,1,Germany,0,3,vv-ECMO + cytokine adsorption (Cytosorb adsorber)|vv-ECMO only (no cytokine adsorption),0
NCT04335279,4/9/2020,6/3/2020,Interventional,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,Not Applicable,Lady Davis Institute,NA,https://pubmed.ncbi.nlm.nih.gov/33899008,https://clinicaltrials.gov/ct2/show/NCT04335279,1,0,1,Canada,0,7,SPIN-CHAT Program,0
NCT04399252,6/24/2020,7/8/2021,Interventional,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Completed,Not Applicable,Duke University,NA,https://pubmed.ncbi.nlm.nih.gov/33952552,https://clinicaltrials.gov/ct2/show/NCT04399252,1,0,1,United States,0,4,Lactobaciltus rhamnosus GG|Lactobaciltus rhamnosus GG Placebo,0
NCT04341922,5/9/2020,8/20/2020,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",Not Applicable,Karolinska Institutet,NA,https://pubmed.ncbi.nlm.nih.gov/33212440,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,Sweden,0,5,Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic,0
NCT04413968,6/2/2020,7/2/2020,Interventional,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,https://pubmed.ncbi.nlm.nih.gov/33571450,https://clinicaltrials.gov/ct2/show/NCT04413968,1,0,1,France,0,3,Rapid detection test|Nasopharyngeal swab|Stool collection,0
NCT04517422,8/19/2020,2/2/2021,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,Not Applicable,"AB Biotics, SA",NA,https://pubmed.ncbi.nlm.nih.gov/32787470,https://clinicaltrials.gov/ct2/show/NCT04517422,0,5,5,Mexico,0,7,Probiotics|Placebo,0
NCT04410016,5/25/2020,7/31/2020,Interventional,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Completed,Not Applicable,University of Nottingham,NA,https://pubmed.ncbi.nlm.nih.gov/33807306,https://clinicaltrials.gov/ct2/show/NCT04410016,0,2,2,United Kingdom,0,3,Staff Wellbeing Centres,0
NCT04318431,4/14/2020,5/12/2020,Interventional,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,Not Applicable,Centre Hospitalier Intercommunal Creteil,NA,https://pubmed.ncbi.nlm.nih.gov/33665371,https://clinicaltrials.gov/ct2/show/NCT04318431,1,0,1,France,0,7,Data collection and rhinopharyngeal swab,0
NCT04405908,6/19/2020,10/16/2020,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,https://pubmed.ncbi.nlm.nih.gov/33524311,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,Australia,0,4,SCB-2019|SCB-2019 with AS03 adjuvant|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant,1
NCT04341142,4/9/2020,4/9/2023,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,https://pubmed.ncbi.nlm.nih.gov/33234651,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,France,0,5,Serological tests will be applied on patients blood sampling,0
NCT04351906,5/3/2020,5/31/2022,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Not Applicable,University of Giessen,NA,https://pubmed.ncbi.nlm.nih.gov/33304914,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,Germany,0,7,ECCO2R,0
NCT04468893,5/20/2020,7/31/2021,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Completed,Not Applicable,Universidad Internacional de Valencia,NA,https://pubmed.ncbi.nlm.nih.gov/33196449,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,Mexico,0,3,Online Intervention Mental Health COVID-19,0
NCT04672291,7/21/2021,12/31/2022,Interventional,Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults,Recruiting,Phase 1,"Oncovir, Inc.",NA,https://pubmed.ncbi.nlm.nih.gov/32998157,https://clinicaltrials.gov/ct2/show/NCT04672291,0,34,34,Canada,0,6,Poly-ICLC (HiltonolÂ®) or Placebo|Poly-ICLC (HiltonolÂ®) or Placebo,1
NCT04627519,12/9/2020,5/19/2021,Interventional,Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,"Active, not recruiting",Not Applicable,Universitas Padjadjaran,NA,https://pubmed.ncbi.nlm.nih.gov/28090211,https://clinicaltrials.gov/ct2/show/NCT04627519,0,13,13,Indonesia,0,4,Rhea Health ToneÂ®,0
NCT04424953,6/1/2020,9/25/2020,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,Not Applicable,Singapore General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/30505605,https://clinicaltrials.gov/ct2/show/NCT04424953,0,14,14,Singapore,0,3,McGrath videolaryngoscope|Direct laryngoscope,0
NCT04338568,4/16/2020,11/30/2020,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,Not Applicable,Hasselt University,NA,https://pubmed.ncbi.nlm.nih.gov/31346914,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,Belgium,0,3,Lung ultrasound,0
NCT04352959,4/27/2020,12/11/2020,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,Not Applicable,Claude Bernard University,NA,https://pubmed.ncbi.nlm.nih.gov/32936948,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,France,0,4,mouthrinse with bÃªta-cyclodextrin and citrox|mouthrinse without bÃªta-cyclodextrin and citrox,0
NCT04368676,6/25/2020,6/30/2022,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic,"Active, not recruiting",Early Phase 1,Lawson Health Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/32627860,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,Canada,0,3,Sudarshan Kriya Yoga (SKY)|Health Enhancement Program,0
NCT04264533,2/14/2020,3/2/2020,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19 patients decreased with the control of the epidemic so that we had to stop our trial before reaching the predefined sample size.",https://pubmed.ncbi.nlm.nih.gov/32641343,https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,China,0,2,VC|Sterile Water for Injection,0
NCT04392713,4/15/2020,7/31/2020,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,Not Applicable,"Combined Military Hospital, Pakistan",NA,https://pubmed.ncbi.nlm.nih.gov/32293834,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,Pakistan,0,0,Ivermectin 6 MG Oral Tablet (2 tablets),0
NCT04437719,6/29/2020,6/28/2021,Interventional,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","Active, not recruiting",Not Applicable,Groupe Hospitalier Paris Saint Joseph,NA,https://pubmed.ncbi.nlm.nih.gov/32007143,https://clinicaltrials.gov/ct2/show/NCT04437719,0,1,1,France,0,3,Obvio-19 app,0
NCT04615429,9/15/2020,1/31/2022,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33407777,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,Spain,0,3,Mesenchymal stromal cells|Placebo,0
NCT04364893,4/9/2020,10/1/2020,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,Not Applicable,D'Or Institute for Research and Education,NA,https://pubmed.ncbi.nlm.nih.gov/33464336,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,Brazil,0,2,Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors,0
NCT04990544,7/31/2021,12/31/2021,Interventional,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),Recruiting,Phase 2,"Shanghai Zerun Biotechnology Co.,Ltd",NA,https://pubmed.ncbi.nlm.nih.gov/34750014,https://clinicaltrials.gov/ct2/show/NCT04990544,1,0,1,China,0,0,202-CoV low adjuvant dose|202-CoV low antigen dose|202-CoV standard dose|Placebo,1
NCT04405544,5/22/2020,7/22/2020,Interventional,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,Not Applicable,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,https://pubmed.ncbi.nlm.nih.gov/34768339,https://clinicaltrials.gov/ct2/show/NCT04405544,1,0,1,Russian Federation,0,2,CT-scan|EEG|EP|Pulse oximetry|Blood tests,0
NCT04412343,5/23/2020,10/5/2020,Interventional,The Seniors COvid-19 Pandemic and Exercise Study,Completed,Not Applicable,University of British Columbia,NA,https://pubmed.ncbi.nlm.nih.gov/34328433,https://clinicaltrials.gov/ct2/show/NCT04412343,1,0,1,Canada,0,2,Virtual Group Intervention|Personal Exercise Intervention,0
NCT04767087,3/5/2021,2/15/2022,Interventional,Honey and Nigella Sativa in COVID-19 Prophylaxis,Recruiting,Phase 2/Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://pubmed.ncbi.nlm.nih.gov/34526081,https://clinicaltrials.gov/ct2/show/NCT04767087,1,0,1,Pakistan,0,1,Honey|Nigella sativa seed|Placebo,0
NCT04552379,12/1/2020,5/31/2021,Interventional,The Containing Coronavirus Disease 19 (COVID-19) Trial,Completed,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://pubmed.ncbi.nlm.nih.gov/34388972,https://clinicaltrials.gov/ct2/show/NCT04552379,1,0,1,Chile,0,2,Peginterferon beta-1a,0
NCT04343963,4/4/2020,9/30/2020,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://pubmed.ncbi.nlm.nih.gov/33066761,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,Mexico,0,2,Pyridostigmine Bromide|Placebo,0
NCT04600440,4/25/2020,12/31/2021,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Not Applicable,Skane University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/34863304,https://clinicaltrials.gov/ct2/show/NCT04600440,1,0,1,Sweden,0,0,Convalescent plasma,0
NCT04860284,9/18/2020,2/9/2021,Interventional,Hydroxychloroquine for Treatment of Non-Severe COVID-19,"Active, not recruiting",Phase 2,Makerere University,NA,https://pubmed.ncbi.nlm.nih.gov/34872511,https://clinicaltrials.gov/ct2/show/NCT04860284,1,0,1,Uganda,0,0,Hydroxychloroquine tablets,0
NCT04516759,8/12/2020,4/25/2021,Interventional,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Completed,Phase 2,St George Street Capital,NA,https://pubmed.ncbi.nlm.nih.gov/34853102,https://clinicaltrials.gov/ct2/show/NCT04516759,1,0,1,Czechia|Romania|United Kingdom,0,15,AZD1656|Placebo,0
NCT04445246,5/23/2020,5/31/2021,Interventional,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Phase 2,Hamad Medical Corporation,NA,https://pubmed.ncbi.nlm.nih.gov/34529182,https://clinicaltrials.gov/ct2/show/NCT04445246,1,0,1,Qatar,0,0,Inhaled ILOPROST,0
NCT04647604,6/23/2020,4/30/2021,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33505321,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,Sweden,0,0,OmegavenÂ®|Sodium chloride,0
NCT04414631,8/6/2020,9/15/2021,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Terminated,Phase 2,"University Hospital, Basel, Switzerland",Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.,https://pubmed.ncbi.nlm.nih.gov/33397449,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,Brazil|Mexico|Switzerland,0,7,Conestat alfa,0
NCT04568707,10/23/2020,10/15/2022,Interventional,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,https://pubmed.ncbi.nlm.nih.gov/34341142,https://clinicaltrials.gov/ct2/show/NCT04568707,1,0,1,France,0,1,blood sample,0
NCT04751474,2/1/2021,3/1/2021,Interventional,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction",Completed,Not Applicable,Saglik Bilimleri Universitesi,NA,https://pubmed.ncbi.nlm.nih.gov/34895798,https://clinicaltrials.gov/ct2/show/NCT04751474,1,0,1,Turkey,0,1,Motivational messages,0
NCT04359264,4/20/2020,5/29/2020,Interventional,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",Not Applicable,Unity Health Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/34924360,https://clinicaltrials.gov/ct2/show/NCT04359264,1,0,1,Canada,0,2,Cash transfer,0
NCT04394169,5/25/2020,10/15/2021,Interventional,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Completed,Not Applicable,Hospital Clinic of Barcelona,NA,https://pubmed.ncbi.nlm.nih.gov/34866276,https://clinicaltrials.gov/ct2/show/NCT04394169,2,0,2,Spain,0,2,Intervention program,0
NCT04552366,9/29/2020,12/31/2020,Interventional,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Phase 1,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://pubmed.ncbi.nlm.nih.gov/34324836,https://clinicaltrials.gov/ct2/show/NCT04552366,1,0,1,China,0,2,Ad5-nCoV,1
NCT04870723,3/1/2021,8/31/2021,Interventional,#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support,Recruiting,Not Applicable,University of Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/34726610,https://clinicaltrials.gov/ct2/show/NCT04870723,1,0,1,Canada|India|Thailand,0,1,eHealth for Covid-19 prevention and support,0
NCT04453475,7/1/2020,12/31/2021,Interventional,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,Not Applicable,Jacobs University Bremen gGmbH,NA,https://pubmed.ncbi.nlm.nih.gov/34544173,https://clinicaltrials.gov/ct2/show/NCT04453475,1,4,5,Germany,0,2,Training session adressing information and health literacy,0
NCT05001542,5/31/2021,8/30/2021,Interventional,Digital Interventions for Detection and Reduction of Moral Distress,Completed,Not Applicable,Unity Health Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/34871178,https://clinicaltrials.gov/ct2/show/NCT05001542,1,0,1,Canada,0,1,Educational moral injury video,0
NCT05104346,3/31/2019,3/31/2021,Interventional,Presentation and Outcomes of Acute Appendicitis During COVID Pandemic,Completed,Not Applicable,Mansoura University,NA,https://pubmed.ncbi.nlm.nih.gov/34700020,https://clinicaltrials.gov/ct2/show/NCT05104346,0,6,6,Egypt,0,1,appendectomy,0
NCT04874766,5/28/2021,7/15/2021,Interventional,The Effects of Wearing a Face Mask During Exercise in Youth Hockey Players During COVID-19,Completed,Not Applicable,University of Saskatchewan,NA,https://pubmed.ncbi.nlm.nih.gov/34682512,https://clinicaltrials.gov/ct2/show/NCT04874766,1,0,1,Canada,0,2,Wingate exercise test and on-ice testing while wearing a face mask|Wingate exercise test and on-ice testing while wearing a sham face mask,0
NCT04399005,5/25/2020,6/5/2020,Interventional,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,Not Applicable,The First Affiliated Hospital of Zhejiang Chinese Medical University,NA,https://pubmed.ncbi.nlm.nih.gov/34676191,https://clinicaltrials.gov/ct2/show/NCT04399005,1,0,1,China,0,1,after-each-case room disinfection|daily room disinfection,0
NCT04338841,4/9/2020,6/17/2020,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,Not Applicable,"University Hospital, Angers",NA,https://pubmed.ncbi.nlm.nih.gov/34004154,https://clinicaltrials.gov/ct2/show/NCT04338841,2,0,2,Belgium|France|Monaco,0,2,HOME-CoV rule implementation,0
NCT04895267,7/3/2020,9/3/2021,Interventional,Low-field Thoracic Magnetic Stimulation Increases Peripheral Oxygen Saturation Levels in COVID-19 Patients,Enrolling by invitation,Not Applicable,Hospital Univeristario Benemerita Universidad Autonoma de Puebla,NA,https://pubmed.ncbi.nlm.nih.gov/34622862,https://clinicaltrials.gov/ct2/show/NCT04895267,1,0,1,Mexico,0,2,Low-field thoracic magnetic stimulation (LF-ThMS),0
NCT04798677,10/29/2020,7/31/2021,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,Not Applicable,AB Biotek,NA,https://pubmed.ncbi.nlm.nih.gov/32223047,https://clinicaltrials.gov/ct2/show/NCT04798677,0,17,17,Spain,0,2,ABBC1 Immunoessential|Placebo,1
NCT04379453,4/27/2020,4/27/2020,Interventional,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,Not Applicable,Hospital Israelita Albert Einstein,NA,https://pubmed.ncbi.nlm.nih.gov/33834847,https://clinicaltrials.gov/ct2/show/NCT04379453,1,0,1,Brazil,0,1,Robot Assisted Percutaneous Cardiovascular Intervention,0
NCT04572360,10/1/2020,12/31/2022,Interventional,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Recruiting,Not Applicable,Hong Kong Baptist University,NA,https://pubmed.ncbi.nlm.nih.gov/33970864,https://clinicaltrials.gov/ct2/show/NCT04572360,1,0,1,Hong Kong,0,1,Cardiorespiratory Exercise|Modified Bai He Gu Jin Tang,0
NCT04666233,3/16/2021,3/23/2021,Interventional,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Completed,Not Applicable,University Hospital Padova,NA,https://pubmed.ncbi.nlm.nih.gov/34489350,https://clinicaltrials.gov/ct2/show/NCT04666233,1,2,3,Italy,0,2,Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection,0
NCT04385108,3/4/2020,12/31/2021,Interventional,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,Not Applicable,"University Hospital, Toulouse",NA,https://pubmed.ncbi.nlm.nih.gov/34051147,https://clinicaltrials.gov/ct2/show/NCT04385108,1,0,1,France,0,2,Blood collection on admission and longitudinally|Blood collection on their first consultation and 10 to 14 days later,0
NCT04929691,11/13/2020,12/31/2021,Interventional,The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19,Recruiting,Not Applicable,New York University,NA,https://pubmed.ncbi.nlm.nih.gov/34446110,https://clinicaltrials.gov/ct2/show/NCT04929691,1,0,1,Nigeria,0,1,CPAP helmet|Standard of care non-helmet based CPAP ventilation,0
NCT04699227,4/23/2020,4/30/2023,Interventional,Can RIC Prevent Deterioration to Critical Care in Covid19,Recruiting,Not Applicable,University College London Hospitals,NA,https://pubmed.ncbi.nlm.nih.gov/34169381,https://clinicaltrials.gov/ct2/show/NCT04699227,1,0,1,United Kingdom,0,1,Cuff application with inflation|Sham inflation,0
NCT04370288,4/19/2020,9/20/2020,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,https://pubmed.ncbi.nlm.nih.gov/34019535,https://clinicaltrials.gov/ct2/show/NCT04370288,2,0,2,"Iran, Islamic Republic of",0,1,"MCN (Methylene blue, vitamin C, N-acetyl cysteine)",0
NCT04885517,2/1/2021,8/1/2021,Interventional,"Breathing Effort in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus",Recruiting,Not Applicable,San Luigi Gonzaga Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33140181,https://clinicaltrials.gov/ct2/show/NCT04885517,0,6,6,Italy,0,1,Esophageal catheter,0
NCT04486482,1/12/2021,3/30/2021,Interventional,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Completed,Not Applicable,Kaleido Biosciences,NA,https://pubmed.ncbi.nlm.nih.gov/33810796,https://clinicaltrials.gov/ct2/show/NCT04486482,1,0,1,United States,0,2,KB109 + Self Supportive Care (SSC)|Self Supportive Care (SSC) Alone,0
NCT04678843,2/9/2021,7/31/2021,Interventional,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond,"Active, not recruiting",Early Phase 1,McMaster University,NA,https://pubmed.ncbi.nlm.nih.gov/33832543,https://clinicaltrials.gov/ct2/show/NCT04678843,1,0,1,Canada,0,2,Virtual Family-Based Treatment,0
NCT04337541,4/2/2020,6/2/2020,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,Not Applicable,"Rigshospitalet, Denmark",NA,https://pubmed.ncbi.nlm.nih.gov/33205991,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,Denmark,0,1,Surgical facial mask,0
NCT04385017,5/11/2020,6/30/2022,Interventional,Role of Inflammasomes in COVID-19 Disease,Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,https://pubmed.ncbi.nlm.nih.gov/33683342,https://clinicaltrials.gov/ct2/show/NCT04385017,1,0,1,France,0,1,COVID-19 patients,0
NCT04507867,9/7/2020,4/10/2021,Interventional,Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,Not Applicable,Anahuac University,NA,https://pubmed.ncbi.nlm.nih.gov/31708357,https://clinicaltrials.gov/ct2/show/NCT04507867,0,21,21,Mexico,1,1,Nutritional support system (NSS)|Conventional nutritional support designed by hospital nutritionists,0
NCT04476667,6/15/2020,5/1/2021,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Completed,Not Applicable,Queen's University,NA,https://pubmed.ncbi.nlm.nih.gov/33290245,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,Canada,0,2,e-Psychotherapy,0
NCT04998253,10/1/2020,11/30/2020,Interventional,Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2,Completed,Early Phase 1,Unidad Temporal COVID-19 en Centro Citibanamex,NA,https://pubmed.ncbi.nlm.nih.gov/32728965,https://clinicaltrials.gov/ct2/show/NCT04998253,0,36,36,Mexico,0,1,Effects in oxygenation and hypoxic pulmonary vasoconstriction,0
NCT04488484,7/1/2020,12/31/2021,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",Not Applicable,Groupe Hospitalier Paris Saint Joseph,NA,https://pubmed.ncbi.nlm.nih.gov/32356910,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,France,0,2,Serology test follow-up,0
NCT04557605,9/14/2020,10/15/2020,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,Not Applicable,University of Saskatchewan,NA,https://pubmed.ncbi.nlm.nih.gov/33153145,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,Canada,0,1,Progressive cycling exercise test to exhaustion,0
NCT04487964,1/1/2020,12/1/2020,Interventional,Complementary Intervention for COVID-19,Recruiting,Not Applicable,Egyptian Biomedical Research Network,NA,https://pubmed.ncbi.nlm.nih.gov/33192504,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,Egypt,0,1,Licorice extract,0
NCT04522492,8/11/2020,3/1/2021,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",Not Applicable,Hospital de Clinicas de Porto Alegre,NA,https://pubmed.ncbi.nlm.nih.gov/32401873,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,Brazil,0,2,Internet-based Cognitive Behavioral Therapy|Quality of life promotion,0
NCT04362358,7/20/2020,9/1/2021,Interventional,Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,Completed,Not Applicable,"University Hospital, Strasbourg, France",NA,https://pubmed.ncbi.nlm.nih.gov/33087178,https://clinicaltrials.gov/ct2/show/NCT04362358,1,0,1,France,0,2,Online cognitive behavioral therapy (CBT)|Online bibliotherapy programme,0
NCT04482634,9/1/2020,8/31/2022,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,Not Applicable,KoÃ§ University,NA,https://pubmed.ncbi.nlm.nih.gov/30958989,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,Turkey,0,1,Remote controlled exercise|Home exercise,0
NCT04890665,7/16/2021,6/20/2022,Interventional,Online Multi-component Psychological Intervention for Healthcare Workers During COVID-19 Pandemic,Recruiting,Not Applicable,Universidad Internacional de Valencia,NA,https://pubmed.ncbi.nlm.nih.gov/32226353,https://clinicaltrials.gov/ct2/show/NCT04890665,0,7,7,Mexico,0,1,Online psychological intervention for healthcare workers,0
NCT05012267,3/25/2021,10/27/2021,Interventional,Duration of Prone Position in the Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).,Completed,Not Applicable,Hospital Universitario 12 de Octubre,NA,https://pubmed.ncbi.nlm.nih.gov/32449068,https://clinicaltrials.gov/ct2/show/NCT05012267,0,5,5,Spain,0,2,16-hour PP,0
NCT04360837,5/6/2020,6/1/2021,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,Not Applicable,Szeged University,NA,https://pubmed.ncbi.nlm.nih.gov/32250385,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,Hungary,0,2,alveolar recruitment,0
NCT04632043,11/18/2020,5/1/2021,Interventional,Early Versus Delayed Intubation of Patients With COVID-19,Recruiting,Not Applicable,Evangelismos Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32645311,https://clinicaltrials.gov/ct2/show/NCT04632043,0,3,3,Greece,0,1,Endotracheal intubation,0
NCT04813575,8/1/2021,4/1/2022,Interventional,COVID-19 Pathophysiology of Long Term Implications,Enrolling by invitation,Not Applicable,King Faisal Specialist Hospital & Research Center,NA,https://pubmed.ncbi.nlm.nih.gov/32534945,https://clinicaltrials.gov/ct2/show/NCT04813575,0,2,2,Saudi Arabia,0,1,Cryo lung biopsies,0
NCT04393636,6/5/2020,12/31/2022,Interventional,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,Not Applicable,Academisch Ziekenhuis Maastricht,NA,https://pubmed.ncbi.nlm.nih.gov/31986261,https://clinicaltrials.gov/ct2/show/NCT04393636,0,13,13,Netherlands,0,1,Digital cardiac Counseling,0
NCT04487990,6/29/2020,3/31/2021,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,"Active, not recruiting",Not Applicable,University of Sao Paulo General Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33176886,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,Brazil,0,1,unfractionated Heparin,0
NCT04357860,4/28/2020,3/9/2021,Interventional,Clinical Trial of Sarilumab in Adults With COVID-19,Completed,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://pubmed.ncbi.nlm.nih.gov/33191263,https://clinicaltrials.gov/ct2/show/NCT04357860,1,0,1,Spain,0,2,Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment,0
NCT04593641,9/4/2020,10/22/2020,Interventional,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Phase 1,Celltrion,NA,https://pubmed.ncbi.nlm.nih.gov/34551869,https://clinicaltrials.gov/ct2/show/NCT04593641,1,0,1,"Korea, Republic of",0,0,CT-P59,0
NCT04336254,5/6/2020,11/30/2021,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,https://pubmed.ncbi.nlm.nih.gov/32532356,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,China,0,1,allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous saline injection (Placebo),0
NCT04514705,8/11/2020,12/31/2021,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,Not Applicable,Universidade Metodista de Piracicaba,NA,https://pubmed.ncbi.nlm.nih.gov/32737507,https://clinicaltrials.gov/ct2/show/NCT04514705,0,4,4,Brazil,0,0,Exercise,0
NCT04475601,7/15/2020,3/24/2021,Interventional,Enzalutamide Treatment in COVID-19,Terminated,Phase 2,VÃ¤sterbotten County Council,"By sponsor, based on DSMB recommendations",https://pubmed.ncbi.nlm.nih.gov/33726804,https://clinicaltrials.gov/ct2/show/NCT04475601,1,0,1,Sweden,0,1,Enzalutamide Pill,0
NCT04473261,7/14/2020,8/15/2021,Interventional,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://pubmed.ncbi.nlm.nih.gov/33568226,https://clinicaltrials.gov/ct2/show/NCT04473261,1,0,1,Pakistan,0,2,Iodine Complex|Iodine Complex|Placebo|Idoine Complex,0
NCT04378738,5/1/2020,5/7/2020,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,Not Applicable,Acibadem University,NA,https://pubmed.ncbi.nlm.nih.gov/32250280,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,Turkey,0,0,survey,0
NCT04677270,8/31/2020,11/30/2020,Interventional,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,Not Applicable,Karolinska Institutet,NA,https://pubmed.ncbi.nlm.nih.gov/34559670,https://clinicaltrials.gov/ct2/show/NCT04677270,1,0,1,Sweden,0,0,Digital problem solving tool,0
NCT04631367,2/1/2021,8/20/2021,Interventional,mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda,Completed,Not Applicable,University of Toronto,NA,https://pubmed.ncbi.nlm.nih.gov/34810193,https://clinicaltrials.gov/ct2/show/NCT04631367,1,0,1,Canada,0,3,Kukaa Salama: mHealth intervention|Face Mask + Soap,0
NCT04518514,4/20/2020,10/31/2020,Interventional,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,Not Applicable,RWTH Aachen University,NA,https://pubmed.ncbi.nlm.nih.gov/34669644,https://clinicaltrials.gov/ct2/show/NCT04518514,1,0,1,Germany,0,0,TAPE-Software,0
NCT04535778,11/16/2020,7/1/2021,Interventional,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,King's College London,NA,https://pubmed.ncbi.nlm.nih.gov/34697123,https://clinicaltrials.gov/ct2/show/NCT04535778,1,0,1,United Kingdom,0,3,COMPASS|Standard charity resources,0
NCT04595097,3/1/2021,11/30/2021,Interventional,Inspiratory Muscle Training in COVID-19 Patients,Recruiting,Not Applicable,Escola Superior de Ciencias da Saude,NA,https://pubmed.ncbi.nlm.nih.gov/34551948,https://clinicaltrials.gov/ct2/show/NCT04595097,1,0,1,Brazil,0,4,inspiratory muscle traiing,0
NCT04477668,2/8/2021,9/30/2021,Interventional,Helmet Non-Invasive Ventilation for COVID-19 Patients,Recruiting,Not Applicable,King Abdullah International Medical Research Center,NA,https://pubmed.ncbi.nlm.nih.gov/34446500,https://clinicaltrials.gov/ct2/show/NCT04477668,1,0,1,Saudi Arabia,0,6,Helmet non-invasive ventilation,0
NCT04569825,8/1/2020,9/30/2020,Interventional,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Early Phase 1,University Of Anbar,NA,https://pubmed.ncbi.nlm.nih.gov/33839489,https://clinicaltrials.gov/ct2/show/NCT04569825,1,0,1,Iraq,0,0,Ophtamesone,0
NCT04852770,4/23/2021,9/30/2021,Interventional,"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics",Recruiting,Not Applicable,FundaÃ§Ã£o Bahiana de Infectologia,NA,https://pubmed.ncbi.nlm.nih.gov/31769377,https://clinicaltrials.gov/ct2/show/NCT04852770,0,14,14,Brazil,0,0,Trial-Based Cognitive Therapy|Mindfulness-Based Health Promotion|Positive psychotherapy,0
NCT04359251,3/5/2020,3/25/2020,Interventional,Different PEEP Settings of COVID-19 Induced ARDS,Completed,Not Applicable,"Southeast University, China",NA,https://pubmed.ncbi.nlm.nih.gov/34355001,https://clinicaltrials.gov/ct2/show/NCT04359251,1,0,1,China,0,0,Gas exchanges at different PEEP|lung mechanics at different PEEP|Hemodynamics changes at different PEEP,0
NCT04441918,6/5/2020,12/11/2020,Interventional,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://pubmed.ncbi.nlm.nih.gov/33972256,https://clinicaltrials.gov/ct2/show/NCT04441918,1,0,1,China,0,0,JS016 (anti-SARS-CoV-2 monoclonal antibody),0
NCT04616989,11/1/2020,1/30/2021,Interventional,Mental Health in Communities Affected by COVID-19 in Uganda,Completed,Not Applicable,Makerere University,NA,https://pubmed.ncbi.nlm.nih.gov/34256810,https://clinicaltrials.gov/ct2/show/NCT04616989,1,0,1,Uganda,0,3,Psycho-education|Comparator,0
NCT04719234,6/15/2020,12/1/2020,Interventional,Lung Ultrasonography in COVID-19 Pneumonia,Completed,Not Applicable,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33638057,https://clinicaltrials.gov/ct2/show/NCT04719234,1,0,1,Turkey,0,0,lung ultrasonography,0
NCT04454606,5/1/2020,5/15/2020,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,Not Applicable,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32461699,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,Thailand,0,0,Fit test|Filtration Test,0
NCT04715607,1/22/2021,5/30/2021,Interventional,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens",Completed,Not Applicable,"Rigshospitalet, Denmark",NA,https://pubmed.ncbi.nlm.nih.gov/33832565,https://clinicaltrials.gov/ct2/show/NCT04715607,1,0,1,Denmark,0,4,Sequence of testing.,0
NCT04568525,7/1/2020,7/25/2020,Interventional,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,Not Applicable,Kyrgyz State Medical Academy,NA,https://pubmed.ncbi.nlm.nih.gov/33562419,https://clinicaltrials.gov/ct2/show/NCT04568525,1,0,1,Kyrgyzstan,0,0,Passive Microwave Radiometry,0
NCT04537858,6/18/2020,8/20/2020,Interventional,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",Not Applicable,University of Sao Paulo,NA,https://pubmed.ncbi.nlm.nih.gov/33716889,https://clinicaltrials.gov/ct2/show/NCT04537858,1,0,1,Brazil,0,0,Virtual reality therapy first|Conventional therapy first,0
NCT04380909,5/6/2020,7/29/2021,Interventional,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Completed,Not Applicable,University of Bern,NA,https://pubmed.ncbi.nlm.nih.gov/33648555,https://clinicaltrials.gov/ct2/show/NCT04380909,1,0,1,Switzerland,0,3,Internet-based self-help|Internet-based self-help after 3 weeks,0
NCT04841681,6/7/2020,8/25/2020,Interventional,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Completed,Not Applicable,Indonesia University,NA,https://pubmed.ncbi.nlm.nih.gov/32406348,https://clinicaltrials.gov/ct2/show/NCT04841681,0,6,6,Indonesia,0,0,Video-based Psychotherapy,0
NCT04555005,3/10/2020,4/26/2020,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,Not Applicable,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://pubmed.ncbi.nlm.nih.gov/33329103,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,Spain,0,0,Mindfulness based intervention,0
NCT04430608,5/25/2020,4/25/2021,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,Not Applicable,Nordsjaellands Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33239100,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,Denmark,0,0,Dexcom G6,0
NCT04438070,4/10/2020,6/30/2020,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,Not Applicable,St. Joseph's Healthcare Hamilton,NA,https://pubmed.ncbi.nlm.nih.gov/33225995,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,Canada,0,0,COVID-19 Swab,0
NCT04642326,6/26/2020,7/1/2020,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",Not Applicable,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,https://pubmed.ncbi.nlm.nih.gov/31930543,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,Turkey,0,0,Test Group: experimental - UVC Therapy applied,0
NCT05172102,12/20/2021,5/20/2022,Interventional,Quality of Life and Lung Function on Post Covid-19 Patient,Recruiting,Not Applicable,Qassim University,NA,https://pubmed.ncbi.nlm.nih.gov/31499605,https://clinicaltrials.gov/ct2/show/NCT05172102,0,3,3,Saudi Arabia,0,0,"breathing exercise, Aerobic exercises",0
NCT04786483,11/1/2020,1/30/2021,Interventional,The Effect of Laughter Therapy on Students in the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Zonguldak Bulent Ecevit University,NA,https://pubmed.ncbi.nlm.nih.gov/32377489,https://clinicaltrials.gov/ct2/show/NCT04786483,0,1,1,Turkey,0,0,Laughter Theraphy,0
NCT04333589,4/1/2020,6/1/2020,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,Not Applicable,Peking University First Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32503657,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,China,0,2,Favipiravir,0
NCT05080920,10/28/2020,9/30/2022,Interventional,RosmalipÂ® for Cancer Infections Prevention,Enrolling by invitation,Not Applicable,FundaciÃ³n InvestigaciÃ³n E InnovaciÃ³n BiomÃ©dica Hospital Universitario Infanta Sofia-Henares,NA,https://pubmed.ncbi.nlm.nih.gov/31450563,https://clinicaltrials.gov/ct2/show/NCT05080920,0,5,5,Spain,0,0,RosmalipÂ®|Placebo,0
NCT04549337,9/25/2020,5/1/2021,Interventional,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,Not Applicable,"Rigshospitalet, Denmark",NA,https://pubmed.ncbi.nlm.nih.gov/34794987,https://clinicaltrials.gov/ct2/show/NCT04549337,1,0,1,Denmark,0,2,Exercise training,0
NCT04425616,6/4/2020,11/30/2021,Interventional,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,Not Applicable,University Hospital Southampton NHS Foundation Trust,NA,https://pubmed.ncbi.nlm.nih.gov/34446487,https://clinicaltrials.gov/ct2/show/NCT04425616,1,0,1,United Kingdom,0,1,Exercise|Psychological and Behaviour Change Support|Nutrition,0
NCT04549376,7/1/2020,10/20/2020,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,https://pubmed.ncbi.nlm.nih.gov/33397432,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,Bangladesh,0,0,Povidone-Iodine 0.4% NI|Povidone-Iodine 0.5% NI|Povidone-Iodine 0.6% NI|Povidone-Iodine 0.5% NS|Povidone-Iodine 0.6% NS|Placebo comparator: DW-NI|Placebo comparator: DW-NS,0
NCT04349618,4/15/2020,4/15/2023,Interventional,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,https://pubmed.ncbi.nlm.nih.gov/34635128,https://clinicaltrials.gov/ct2/show/NCT04349618,1,0,1,France,0,2,PROTECTIVE VENTILATION|ULTRAPROTECTIVE VENTILATION,0
NCT04663594,12/4/2020,2/10/2021,Interventional,Online Culture for Mental Health in People Aged 16-24,Completed,Not Applicable,University of Oxford,NA,https://pubmed.ncbi.nlm.nih.gov/34294126,https://clinicaltrials.gov/ct2/show/NCT04663594,1,0,1,United Kingdom,0,2,WofB|Ashmolean Website,0
NCT04403646,6/12/2020,10/20/2020,Interventional,Tannin Specific Natural Extract for COVID-19 Infection,Terminated,Not Applicable,Hospital de Clinicas JosÃ© de San MartÃ­n,low rate of covid patients,https://pubmed.ncbi.nlm.nih.gov/33910614,https://clinicaltrials.gov/ct2/show/NCT04403646,1,0,1,Argentina,0,1,ARBOX|PLACEBO,0
NCT04813770,4/6/2021,4/26/2021,Interventional,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,Not Applicable,University of Glasgow,NA,https://pubmed.ncbi.nlm.nih.gov/33926540,https://clinicaltrials.gov/ct2/show/NCT04813770,1,0,1,United Kingdom,0,1,Theory-based messages|General messages,1
NCT04786080,5/19/2021,10/30/2021,Interventional,Supporting Parents & Kids Through Lockdown Experiences (SPARKLE).,"Active, not recruiting",Not Applicable,King's College London,NA,https://pubmed.ncbi.nlm.nih.gov/33838678,https://clinicaltrials.gov/ct2/show/NCT04786080,1,0,1,United Kingdom,0,2,Parent Positive,0
NCT04391140,5/13/2020,12/31/2020,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,Not Applicable,Hospital Universitari Vall d'Hebron Research Institute,NA,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,Spain,0,2,Prone position,0
NCT04455360,10/1/2020,9/20/2021,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Completed,Not Applicable,University Hospital Southampton NHS Foundation Trust,NA,https://pubmed.ncbi.nlm.nih.gov/33203440,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,United Kingdom,0,2,Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol,0
NCT04321928,4/1/2020,4/21/2021,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,Not Applicable,University of Pecs,NA,https://pubmed.ncbi.nlm.nih.gov/32993779,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,Hungary,0,2,Personalized health education|General health education,0
NCT04399317,5/28/2020,7/31/2020,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,Not Applicable,Hamad Medical Corporation,NA,https://pubmed.ncbi.nlm.nih.gov/32917259,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,Qatar,0,1,Flow controlled ventilation (Evone-ventilator),0
NCT04368156,4/20/2020,2/23/2021,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",Not Applicable,Hospital ClÃ­nico Universitario de Valencia,NA,https://pubmed.ncbi.nlm.nih.gov/32586395,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,Spain,0,1,gammaCoreÂ® (Vagus nerve stimulation),0
NCT04334265,4/1/2020,6/1/2020,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,Not Applicable,Peking University First Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/32513299,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,China,0,1,Anluohuaxian,0
NCT04428099,1/13/2020,1/12/2022,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,Not Applicable,University of the Balearic Islands,NA,https://pubmed.ncbi.nlm.nih.gov/33157937,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,Spain,0,0,Lifestyle change promotion program|Mindfullness based cognitive program|Written Information,0
NCT04366882,4/14/2020,12/31/2020,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,Not Applicable,Jessa Hospital,NA,https://pubmed.ncbi.nlm.nih.gov/33175911,https://clinicaltrials.gov/ct2/show/NCT04366882,2,0,2,Belgium,0,0,NA,0
NCT04506268,9/9/2020,10/30/2020,Interventional,COVID-19 SAFE Enrollment,Completed,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,6,Opt-out Recruitment Email|Opt-in Recruitment Email,0
NCT04505592,9/25/2020,10/31/2021,Interventional,Tenecteplase in Patients With COVID-19,Enrolling by invitation,Phase 2,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States,0,5,Tenecteplase|Placebo,0
NCT04502667,7/15/2020,2/28/2021,Interventional,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,0,Cholecalciferol,0
NCT04508075,8/10/2020,1/9/2021,Interventional,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",Completed,Phase 3,PT Bio Farma,NA,NA,NA,NA,NA,NA,Indonesia,0,3,SARS-CoV-2 vaccine (inactivated)|Placebo,1
NCT04502342,6/1/2020,8/30/2020,Interventional,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,NA,NA,NA,NA,NA,Guinea,0,1,Hydroxycloroquine and Azythromycine|Cospherunate/Azythromycine|Cospherunate/Phytomedicine/Azythromycien,0
NCT04505761,8/1/2020,2/1/2021,Interventional,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Completed,Not Applicable,Radboud University,NA,NA,NA,NA,NA,NA,Netherlands,0,2,Virtual Reality,0
NCT04558125,9/8/2020,7/10/2021,Interventional,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,Terminated,Phase 4,Cedars-Sinai Medical Center,Identification of eligible patients was slower than anticipated.,NA,NA,NA,NA,NA,United States,1,4,TNKase|Placebo|Enoxaparin,0
NCT04500366,8/26/2020,10/31/2021,Interventional,GERAS Frailty Rehabilitation at Home During COVID-19,"Active, not recruiting",Not Applicable,McMaster University,NA,NA,NA,NA,NA,NA,Canada,0,2,Socialization|Virtual Group Exercise|Nutrition Consult and Protein Supplementation|Medication Review,0
NCT04501783,5/20/2020,7/29/2020,Interventional,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,R-Pharm,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Favipiravir|Standard of care (SOC)|standard concomitant therapy,0
NCT04502472,6/6/2020,12/31/2021,Interventional,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Phase 2/Phase 3,Inova Health Care Services,NA,NA,NA,NA,NA,NA,United States,0,3,Convalescent plasma transfusion,0
NCT04502433,1/6/2021,1/31/2022,Interventional,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Recruiting,Phase 2,Chiesi Farmaceutici S.p.A.,NA,NA,NA,NA,NA,NA,United States|Italy|United Kingdom,0,2,CUROSURFÂ® (poractant alfa),0
NCT04500067,5/7/2020,9/15/2020,Interventional,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Phase 3,Biopharma Plasma LLC,NA,NA,NA,NA,NA,NA,Ukraine,0,1,IVIG,0
NCT04499391,12/4/2020,7/31/2022,Interventional,COVID-19 Project ECHO in Nursing Homes,Recruiting,Not Applicable,Milton S. Hershey Medical Center,NA,NA,NA,NA,NA,NA,United States,0,5,Project ECHO,0
NCT04501445,9/14/2020,4/8/2021,Interventional,Psychological Symptoms and Families of COVID-19 Patients,Completed,Not Applicable,Rush University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,4,Written Summary of Rounds,0
NCT04500418,8/25/2020,9/30/2021,Interventional,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Phase 2,"Charite University, Berlin, Germany",NA,NA,NA,NA,NA,NA,Germany,0,2,Cenicriviroc (CVC)|Placebo,0
NCT04497623,7/28/2020,8/13/2020,Interventional,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,Not Applicable,FundaciÃ³n Neumologica Colombiana,NA,NA,NA,NA,NA,NA,Colombia,0,1,Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours,0
NCT04499313,8/2/2020,11/15/2020,Interventional,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Phase 3,Chattogram General Hospital,NA,NA,NA,NA,NA,NA,Bangladesh,0,4,Dexamethasone|Methylprednisolone,0
NCT04501458,8/10/2020,6/10/2022,Interventional,Western Kenya Integrated COVID-19 Response,"Active, not recruiting",Not Applicable,Surgical Systems Research Group,NA,NA,NA,NA,NA,NA,Kenya,0,4,"Training of youth, community health assistants and community health workers.|Training clinicians in basic critical care and the management of severe COVID-19 cases",0
NCT04500132,5/28/2020,8/31/2021,Interventional,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,EC-18|Placebo EC-18,0
NCT04497298,8/10/2020,5/12/2021,Interventional,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,Completed,Phase 1,Institut Pasteur,NA,NA,NA,NA,NA,NA,Belgium|France,0,7,Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Placebo,1
NCT04381988,5/7/2020,4/21/2021,Interventional,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Terminated,Phase 2,Memorial Sloan Kettering Cancer Center,The study was terminated based results of other studies and use of the new vaccine.,NA,NA,NA,NA,NA,United States,1,3,Hydroxychloroquine|Placebo|Radiation therapy,0
NCT04498442,5/22/2020,10/22/2020,Interventional,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,Not Applicable,Beth Israel Deaconess Medical Center,NA,NA,NA,NA,NA,NA,United States,0,4,Simha Kriya|Reading a Book,0
NCT04496245,8/24/2020,6/30/2021,Interventional,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,"Active, not recruiting",Phase 3,The University of Queensland,NA,NA,NA,NA,NA,NA,Australia,0,3,Broncho-VaxomÂ®,0
NCT04498936,7/15/2020,10/30/2020,Interventional,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Phase 4,Assiut University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Sofosbuvir and Ledipasvir|Nitazoxanide,0
NCT04497649,7/1/2020,4/1/2021,Interventional,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,2,Sofosbuvir|Daclatasvir,0
NCT04495543,12/1/2020,8/31/2021,Interventional,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Recruiting,Not Applicable,Unity Health Toronto,NA,NA,NA,NA,NA,NA,Canada,0,1,Brief Skills for Safer Living,0
NCT04497454,5/8/2020,7/1/2021,Interventional,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,Not Applicable,University of Sao Paulo General Hospital,NA,NA,NA,NA,NA,NA,Brazil,0,0,EIT-Group|ARDSNet,0
NCT04497272,8/7/2020,8/7/2021,Interventional,Assesment of the Metabolomic Signature in COVID-19 Patients,"Active, not recruiting",Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,2,COVID-19 patients,0
NCT04494867,8/19/2020,12/31/2020,Interventional,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,Not Applicable,Sharp HealthCare,NA,NA,NA,NA,NA,NA,United States,0,3,Core Warming|Standard of Care,0
NCT04495803,9/1/2020,8/1/2022,Interventional,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Recruiting,Not Applicable,St. Joseph's Healthcare Hamilton,NA,NA,NA,NA,NA,NA,Canada,0,1,Cognitive Behavioural Group Therapy for Perinatal Anxiety,0
NCT04495101,7/29/2020,4/26/2021,Interventional,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,Completed,Phase 2,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,Spain,0,6,Prolastin|Standard Medical Treatment,0
NCT04495842,10/1/2020,12/31/2021,Interventional,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,Not Applicable,Franklin School of Integrative Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,2,Essential Oil Blend|Control Blend,0
NCT04494646,9/8/2020,1/8/2021,Interventional,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Completed,Phase 2,NYU Langone Health,NA,NA,NA,NA,NA,NA,United States,0,6,Bardoxolone Methyl|Placebo,0
NCT04489446,8/19/2020,4/30/2021,Interventional,Sildenafil in COVID-19,Completed,Phase 1/Phase 2,Universidad Nacional Andres Bello,NA,NA,NA,NA,NA,NA,Chile,0,5,Sildenafil|Placebo,0
NCT04494204,8/7/2020,12/1/2020,Interventional,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Completed,Phase 2/Phase 3,Nutrin GmbH,NA,NA,NA,NA,NA,NA,India,0,4,Immunofree tablets and Reginmune capsule,0
NCT04494399,7/29/2020,7/1/2022,Interventional,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Phase 2,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Interferon beta-1b|Ribavirin,0
NCT04494386,7/23/2020,10/30/2021,Interventional,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Phase 1/Phase 2,"Restem, LLC.",NA,NA,NA,NA,NA,NA,United States,0,3,Umbilical Cord Lining Stem Cells (ULSC)|Placebo (carrier control),0
NCT04492358,10/22/2020,10/31/2021,Interventional,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Phase 2/Phase 3,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,NA,NA,NA,NA,NA,Spain,0,1,Prednisone tablet|Colchicine|standard of care,0
NCT04493359,7/25/2020,9/28/2021,Interventional,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Terminated,Phase 2/Phase 3,University of Sao Paulo,Dificulteis in enrolling patients,NA,NA,NA,NA,NA,Brazil,0,2,Renin-angiotensin system inhibitors,0
NCT04489628,8/1/2020,6/1/2021,Interventional,Tele-health Enabled Clinical Trial for COVID-19,Terminated,Phase 1/Phase 2,University Hospitals Cleveland Medical Center,Unable to overcome hurdles to study recruitment,NA,NA,NA,NA,NA,United States,0,3,Vitamin D3 or Placebo|Doctella telehealth monitoring,0
NCT04490200,3/1/2021,12/30/2021,Interventional,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Recruiting,Not Applicable,University of Brasilia,NA,NA,NA,NA,NA,NA,Brazil,0,2,VESTA respirator|Conventional N95 respirator,0
NCT04490473,7/24/2020,3/24/2021,Interventional,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,Not Applicable,Eskisehir Osmangazi University,NA,NA,NA,NA,NA,NA,Turkey,0,1,survey work,0
NCT04492410,7/21/2020,5/12/2021,Interventional,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),"Active, not recruiting",Not Applicable,Centre Antoine Lacassagne,NA,NA,NA,NA,NA,NA,France,0,2,rapid serological test,0
NCT04492228,9/1/2020,12/31/2020,Interventional,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,Not Applicable,Ospedale Policlinico San Martino,NA,NA,NA,NA,NA,NA,Italy,0,1,Ketogenic diet,0
NCT04492254,9/15/2020,7/31/2021,Interventional,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,Recruiting,Phase 3,Thrombosis Research Institute,NA,NA,NA,NA,NA,NA,Australia|Belgium|South Africa,0,1,Enoxaparin,0
NCT04490278,9/29/2020,6/30/2021,Interventional,CoV-PICS: A Virtual Post-ICU Clinic,Completed,Not Applicable,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,5,Medical Record Review - Inpatient Treatment|Online Questionnaires,0
NCT04487691,12/8/2020,6/1/2021,Interventional,Nebulized PL for Post-COVID-19 Syndrome,"Active, not recruiting",Not Applicable,"Regenexx, LLC",NA,NA,NA,NA,NA,NA,United States,0,3,Nebulized Platelet Lysate|Nebulized Sterile Saline,0
NCT04492501,4/1/2020,7/20/2020,Interventional,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,Not Applicable,UNICEF,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Therapeutic Plasma exchange|Convalescent Plasma|Tocilizumab|Remdesivir|Mesenchymal stem cell therapy,0
NCT04490824,10/1/2020,3/30/2021,Interventional,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,Not Applicable,Institute of Progressive Medicine,NA,NA,NA,NA,NA,NA,United States,0,4,KELEA Excellerated Water|Water Without an Elevated Level of KELEA,0
NCT04492527,7/28/2020,4/30/2021,Interventional,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Completed,Not Applicable,University of British Columbia,NA,NA,NA,NA,NA,NA,Canada,0,3,Telehealth coaching sessions,0
NCT04490850,7/15/2020,12/15/2021,Interventional,COVID-19 Seroprevalence Study in French Guiana,Recruiting,Not Applicable,Institut Pasteur,NA,NA,NA,NA,NA,NA,French Guiana,0,1,Blood sample,0
NCT04488796,9/7/2020,12/16/2020,Interventional,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Completed,Not Applicable,"Western University, Canada",NA,NA,NA,NA,NA,NA,Canada,0,5,Assigned Strategies: Opt-in|Assigned Strategies: Active Choice|Assigned Strategies: Enhanced Active Choice|Choice of Assignment: Opt-in|Choice of Assignment: Active Choice|Choice of Assignment: Enhanced Active Choice,0
NCT04488081,7/31/2020,7/24/2022,Interventional,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Phase 2,QuantumLeap Healthcare Collaborative,NA,NA,NA,NA,NA,NA,United States,0,6,Remdesivir|Pulmozyme|IC14|Celecoxib Famotidine|Narsoplimab|Aviptadil Acetate|Cyclosporine,0
NCT04483960,7/28/2020,12/31/2021,Interventional,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,Recruiting,Phase 3,University of Melbourne,NA,NA,NA,NA,NA,NA,Australia,0,3,Nafamostat Mesilate|Hyperimmune Globulin|Enoxaparin|Dalteparin|Tinzaparin,0
NCT04485169,4/1/2020,7/31/2020,Interventional,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,Not Applicable,UNICEF,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Therapeutic Plasma Exchange,0
NCT04486313,8/13/2020,2/8/2021,Interventional,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Completed,Phase 3,Romark Laboratories L.C.,NA,NA,NA,NA,NA,NA,United States,0,5,Nitazoxanide|Placebo|Vitamin Super B-Complex,0
NCT04487574,7/25/2020,10/29/2020,Interventional,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Phase 3,RSV Therapeutics LLC,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,XC221|Placebo,0
NCT04487639,7/10/2020,7/31/2021,Interventional,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,Not Applicable,"University Hospital, Clermont-Ferrand",NA,NA,NA,NA,NA,NA,France,0,0,"SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics",0
NCT04487886,11/18/2020,2/28/2022,Interventional,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Recruiting,Phase 2,Emory University,NA,NA,NA,NA,NA,NA,United States,0,2,Duvelisib|Placebo,0
NCT04483752,6/8/2020,12/24/2021,Interventional,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,Not Applicable,Centre Chirurgical Marie Lannelongue,NA,NA,NA,NA,NA,NA,France,0,1,CHEST CT SCAN,0
NCT04487444,9/10/2020,3/31/2022,Interventional,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Phase 2,Rhode Island Hospital,NA,NA,NA,NA,NA,NA,United States,0,4,Thymalfasin,0
NCT04487171,7/21/2020,7/31/2021,Interventional,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,0,NA,0
NCT04483830,6/5/2020,8/6/2020,Interventional,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Phase 2/Phase 3,Clinedem,NA,NA,NA,NA,NA,NA,Mexico,0,2,Sulodexide|Placebo,0
NCT04481685,7/20/2020,2/25/2021,Interventional,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",Completed,Phase 2,University of Kansas Medical Center,NA,NA,NA,NA,NA,NA,United States,0,4,ATI-450|Placebo,0
NCT04482387,7/24/2020,7/1/2021,Interventional,DigiVis: Self-testing Vision App for Telephone Consultations,Recruiting,Not Applicable,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,DigiVis visual acuity app,0
NCT04483271,10/2/2020,12/15/2020,Interventional,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,Not Applicable,Applied Science Private University,NA,NA,NA,NA,NA,NA,Jordan,0,1,300 mg of omega3-FA,0
NCT04483635,2/8/2021,5/4/2021,Interventional,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Terminated,Phase 3,St. Justine's Hospital,"A premature discontinuation was recommended by the Data Safety Monitoring Board and agreed upon by the principal investigator, because the significantly lower recruitment than planned, in the context of mass vaccination of the target population.",NA,NA,NA,NA,NA,Canada,0,3,Placebo|Vitamin D,0
NCT04480957,8/4/2020,1/29/2021,Interventional,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Completed,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,Singapore,0,2,ARCT-021 Dose 1|ARCT-021 Dose 2|ARCT-021 Dose 3|ARCT-021 Dose 4|ARCT-021 Dose Regimen 1|ARCT-021 Dose Regimen 2|Placebo,1
NCT04482621,9/14/2020,2/28/2022,Interventional,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Phase 2,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,4,Decitabine|Placebo Saline,0
NCT04477993,8/14/2020,3/29/2021,Interventional,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Terminated,Phase 2/Phase 3,University of Sao Paulo General Hospital,Low accrual,NA,NA,NA,NA,NA,Brazil,0,1,Janus Kinase Inhibitor (ruxolitinib)|Placebo,0
NCT04480112,6/2/2020,6/11/2021,Interventional,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Completed,Not Applicable,Boston University,NA,NA,NA,NA,NA,NA,United States,0,5,Technology based social interactions|No research related technology based social interactions,0
NCT04479540,5/26/2020,2/26/2022,Interventional,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,2,Angiography scanner,0
NCT04482673,7/31/2020,12/31/2021,Interventional,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Phase 4,Medical University of South Carolina,NA,NA,NA,NA,NA,NA,United States,0,1,Daily Vitamin D3|Daily placebo|Bolus vitamin D3|Bolus placebo,0
NCT04476992,7/24/2020,7/17/2021,Interventional,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Phase 1/Phase 2,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,NA,NA,NA,NA,NA,Russian Federation,0,4,Nitric Oxide-Sessions|Nitric Oxide-Continuous and Sessions,0
NCT04478019,7/7/2020,4/30/2022,Interventional,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Early Phase 1,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,4,10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,0
NCT04477083,7/15/2020,8/15/2020,Interventional,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",Not Applicable,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,0,inhalable hydroxychloroquine (HCQ)|supportive and symptomatic treatment,0
NCT04472559,6/16/2021,10/1/2021,Interventional,Acupressure for COVID-19 Related Quality of Life and Stress,Recruiting,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,4,Self-acupressure,0
NCT04476979,7/16/2020,6/30/2021,Interventional,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,French Guiana,0,2,Tocilizumab|Dexamethasone,0
NCT04475913,7/11/2018,7/11/2020,Interventional,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,Completed,Not Applicable,October University for Modern Sciences and Arts,NA,NA,NA,NA,NA,NA,Egypt,0,1,DIG Axial|DIG Tilted|CIG Axial|CIG Tilted,0
NCT04470544,7/28/2020,9/15/2022,Interventional,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Phase 2,Academic and Community Cancer Research United,NA,NA,NA,NA,NA,NA,United States,0,3,Camostat Mesilate|Standard of Care,0
NCT04475120,4/15/2020,7/2/2020,Interventional,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Phase 2/Phase 3,University of Rome Tor Vergata,NA,NA,NA,NA,NA,NA,Italy,0,2,liposomal lactoferrin|SOC therapy,0
NCT04473274,5/21/2020,11/1/2020,Interventional,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Phase 4,Samaritan Health Services,NA,NA,NA,NA,NA,NA,United States,0,2,Pioglitazone,0
NCT04470869,6/12/2020,10/12/2021,Interventional,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,"Active, not recruiting",Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,1,Phone call,0
NCT04473248,6/28/2020,8/30/2020,Interventional,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,Not Applicable,Spartan Bioscience Inc.,NA,NA,NA,NA,NA,NA,Canada,0,1,Spartan COVID-19 System,0
NCT04470258,6/25/2020,8/30/2020,Interventional,Elmo Respiratory Support Project - COVID-19,Completed,Not Applicable,Escola de SaÃºde PÃºblica do CearÃ¡,NA,NA,NA,NA,NA,NA,Brazil,0,2,ELMO PROJECT AT COVID-19: STUDY IN HUMANS|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY,0
NCT04468646,6/15/2020,7/15/2020,Interventional,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Phase 3,University of Health Sciences Lahore,NA,NA,NA,NA,NA,NA,Pakistan,0,0,NK-1R antagonist,0
NCT04468139,6/20/2020,7/20/2020,Interventional,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Phase 4,"Ministry of Health, Saudi Arabia",NA,NA,NA,NA,NA,NA,Saudi Arabia,0,0,Quercetin|bromelain|Zinc|Vitamin C,0
NCT04466540,5/12/2020,7/28/2021,Interventional,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,NA,NA,NA,NA,NA,Brazil,0,2,Hydroxychloroquine|Placebo,0
NCT04466098,7/30/2020,12/1/2021,Interventional,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Active, not recruiting",Phase 2,"Masonic Cancer Center, University of Minnesota",NA,NA,NA,NA,NA,NA,United States,0,3,Mesenchymal stromal cells|Placebo,0
NCT04464395,7/1/2020,3/1/2021,Interventional,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Completed,Phase 1,"Corvus Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United States,0,6,CPI-006|Standard of Care,0
NCT04466683,8/28/2020,12/31/2021,Interventional,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,NA,NA,NA,NA,NA,United States|Colombia,0,2,Low dose radiation 35 cGy|High dose radiation 100 cGy,0
NCT04467840,8/21/2020,7/18/2021,Interventional,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Completed,Phase 2/Phase 3,RedHill Biopharma Limited,NA,NA,NA,NA,NA,NA,United States|Brazil|Colombia|Israel|Italy|Mexico|Peru|Poland|Russian Federation|United Kingdom,0,47,Opaganib|Placebo,0
NCT04463602,7/25/2020,1/25/2021,Interventional,Desidustat in the Management of COVID-19 Patients,Completed,Phase 2,Cadila Healthcare Limited,NA,NA,NA,NA,NA,NA,Mexico,0,7,Desidustat|Standard of Care,0
NCT04463472,6/29/2020,9/28/2020,Interventional,Study of COVID-19 DNA Vaccine (AG0301-COVID19),Completed,Phase 1/Phase 2,"AnGes, Inc.",NA,NA,NA,NA,NA,NA,Japan,0,6,AG0301-COVID19|AG0301-COVID19,1
NCT04468009,6/25/2020,1/19/2021,Interventional,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Completed,Phase 2,Hospital de Infecciosas Francisco Javier Muniz,NA,NA,NA,NA,NA,NA,Argentina,0,5,Convalescent plasma,0
NCT04461925,5/2/2020,5/2/2021,Interventional,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Phase 1/Phase 2,Institute of Cell Therapy,NA,NA,NA,NA,NA,NA,Ukraine,0,0,Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Antibiotics|Hormones|Anticoagulant Therapy|Ðžxygen therapy,0
NCT04465604,2/1/2021,11/1/2021,Interventional,Hypertonic Saline for COVID-19 Symptoms,Recruiting,Not Applicable,King Faisal Specialist Hospital & Research Center,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,1,NA,0
NCT04460443,8/1/2020,8/1/2021,Interventional,Sofosbuvir in Treatment of COVID 19,Recruiting,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,2,sofosbuvir|Sofosbuvir ledipsavir|Daclatasvir,0
NCT04460690,7/13/2020,3/31/2021,Interventional,"Rapid, Onsite COVID-19 Detection",Completed,Not Applicable,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,6,Rapid Onsite COVID-19 Detection,0
NCT04459455,8/19/2020,10/15/2020,Interventional,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,Not Applicable,Stony Brook University,NA,NA,NA,NA,NA,NA,United States,0,2,Contain COVID Anxiety SSI|Remain COVID Free SSI,0
NCT04462757,5/28/2020,8/31/2020,Interventional,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Terminated,Phase 2,University of Manchester,Lack of patients in the trial population from which to recruit and lack of funding,NA,NA,NA,NA,NA,United Kingdom,0,4,Anakinra 100Mg/0.67Ml Inj Syringe,0
NCT04459962,6/29/2020,1/7/2021,Interventional,Covid-19 Breath Test,Completed,Not Applicable,Ancon Technologies Ltd,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Breath Test & Cheek Swab,0
NCT04457609,7/31/2020,8/31/2020,Interventional,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Phase 1,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Oseltamivir|Azithromycin|Umbilical Cord Mesenchymal Stem Cells,0
NCT04459325,6/1/2020,7/20/2020,Interventional,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Phase 3,AO GENERIUM,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,TigeraseÂ® and best available care|Best available care,0
NCT04457726,7/1/2020,3/31/2021,Interventional,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Phase 1/Phase 2,KK Women's and Children's Hospital,NA,NA,NA,NA,NA,NA,Singapore,0,1,SARS-CoV-2 Specific T Cells,0
NCT04458519,7/16/2020,5/27/2021,Interventional,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Completed,Not Applicable,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,NA,NA,NA,NA,NA,Canada,0,4,Probiorinse|Saline solution,0
NCT04458298,8/11/2020,6/2/2022,Interventional,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"Active, not recruiting",Phase 2,"Orpheris, Inc.",NA,NA,NA,NA,NA,NA,United States,0,6,OP-101|Placebo,0
NCT04456452,7/27/2020,9/8/2020,Interventional,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,Phase 1,Ampio Pharmaceuticals. Inc.,NA,NA,NA,NA,NA,NA,United States,0,5,Ampion|Standard of Care,0
NCT04456413,11/6/2020,11/30/2021,Interventional,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Phase 2,Hackensack Meridian Health,NA,NA,NA,NA,NA,NA,United States,0,3,Convalescent Plasma|Best Supportive Care,0
NCT04453774,11/1/2020,2/28/2022,Interventional,At Home Monitoring for Patients With Covid19,Recruiting,Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,3,Covidfree@home,0
NCT04456361,4/16/2020,10/15/2020,Interventional,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Early Phase 1,Instituto de Medicina Regenerativa,NA,NA,NA,NA,NA,NA,Mexico,0,1,Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords,0
NCT04456062,8/4/2020,7/20/2021,Interventional,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Sunnybrook Health Sciences Centre,NA,NA,NA,NA,NA,NA,Canada,0,3,Caring Contacts,0
NCT04455308,7/21/2020,10/19/2020,Interventional,COVID-19 and Chilblains,Completed,Not Applicable,Rennes University Hospital,NA,NA,NA,NA,NA,NA,France,0,2,Biological sample collection,0
NCT04480138,8/11/2020,7/31/2021,Interventional,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),"Active, not recruiting",Phase 2,Cadila Healthcare Limited,NA,NA,NA,NA,NA,NA,Mexico,0,5,Pegylated Interferon-Î±2b|Standard of Care,0
NCT04481633,9/9/2020,3/31/2022,Interventional,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,3,COVID 19 serology|COVID 19 Self-Questionnaire,0
NCT04476680,9/1/2020,4/28/2021,Interventional,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Recruiting,Not Applicable,Royal Centre for Defence Medicine,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Vitamin D,0
NCT04478539,6/1/2020,6/1/2021,Interventional,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,Not Applicable,Zan Mitrev Clinic,NA,NA,NA,NA,NA,NA,North Macedonia,0,0,Extracorporeal blood purification using the oXirisÂ® (AN69ST) hemofilter,0
NCT04474340,5/21/2020,9/30/2020,Interventional,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Phase 1,"Ministry of Health, Kuwait",NA,NA,NA,NA,NA,NA,Kuwait,0,1,COVID-19 Convalscent Plasma,0
NCT04476888,4/26/2020,9/15/2020,Interventional,Convalescent Plasma Treatment in COVID-19,Completed,Not Applicable,Aga Khan University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Convalescent Plasma (CP)|Drugs and supportive care,0
NCT04475991,7/13/2021,10/31/2021,Interventional,Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults,Recruiting,Phase 2,Hospital General de MÃ©xico Dr. Eduardo Liceaga,NA,NA,NA,NA,NA,NA,Mexico,0,14,Maraviroc + Currently used therapy|Curently used therapy for COVID-19 non-critical patients|Favipiravir + Currently used therapy|Maraviroc+Favipiravir+CT,0
NCT04475107,7/9/2020,3/25/2021,Interventional,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Completed,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,7,Pyronaridine-Artesunate|Placebo,0
NCT04473898,6/19/2020,10/19/2020,Interventional,Telerehabilitation After Coronavirus,Completed,Not Applicable,KTO Karatay University,NA,NA,NA,NA,NA,NA,Turkey,0,2,Aerobic Exercise Training|Patient Education|Respiratory Exercise Training,0
NCT04475562,4/6/2020,5/6/2020,Interventional,Can the Electronic Nose Smell COVID-19?,Completed,Not Applicable,Maastricht University Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,0,Aeonose,0
NCT04476953,8/3/2020,1/31/2022,Interventional,COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Phase 2,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,3,Placebo|Fisetin,0
NCT04476745,10/5/2020,12/15/2020,Interventional,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,Not Applicable,Applied Science Private University,NA,NA,NA,NA,NA,NA,Jordan,0,2,Vitamin D3,0
NCT04475575,4/6/2020,6/30/2020,Interventional,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,Not Applicable,Maastricht University Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,0,Aeonose,0
NCT04475302,7/1/2020,12/30/2021,Interventional,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,"Active, not recruiting",Phase 3,"Tuberculosis Research Centre, India",NA,NA,NA,NA,NA,NA,India,0,4,BCG vaccine (Freeze-dried),1
NCT04474483,11/6/2020,12/31/2021,Interventional,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Phase 2,State University of New York at Buffalo,NA,NA,NA,NA,NA,NA,United States,0,3,Melatonin|Placebo (Methylcellulose) capsule,0
NCT04470531,7/12/2020,10/12/2020,Interventional,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,NA,NA,NA,NA,NA,Bangladesh,0,1,oral co-trimoxazole,0
NCT04469621,7/17/2020,10/23/2020,Interventional,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Phase 1,Sanofi,NA,NA,NA,NA,NA,NA,Argentina|Brazil|Chile|Mexico|Russian Federation,0,9,SAR443122|Placebo,0
NCT04473690,12/30/2020,5/31/2022,Interventional,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,"Kentucky BioProcessing, Inc.",NA,NA,NA,NA,NA,NA,United States|Canada,0,18,Low Dose of KBP-COVID-19|High Dose of KBP-COVID-19|Placebo,1
NCT04471636,9/18/2020,11/30/2021,Interventional,Telemedicine in Outpatient Covid-19 Patients,Recruiting,Not Applicable,Ludwig-Maximilians - University of Munich,NA,NA,NA,NA,NA,NA,Germany,0,2,Withings ScanWatch,0
NCT04470999,4/15/2020,9/30/2021,Interventional,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,Not Applicable,Seraph Research Institute,NA,NA,NA,NA,NA,NA,United States,0,3,Leukapheresis,0
NCT04470739,5/30/2020,9/30/2020,Interventional,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,chest x-ray,0
NCT04466241,11/27/2020,3/26/2021,Interventional,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Phase 2/Phase 3,"ANRS, Emerging Infectious Diseases",NA,NA,NA,NA,NA,NA,CÃ´te D'Ivoire,0,3,Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Telmisartan 40Mg Oral Tablet|Atorvastatin 20 Mg Oral Tablet,0
NCT04470609,7/10/2020,11/30/2020,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,Enrolling by invitation,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,NA,NA,NA,NA,NA,China,0,0,Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Placebo on a 0- and 28-day schedule,1
NCT04466085,7/12/2020,10/22/2020,Interventional,Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,2,Recombinant new coronavirus vaccine (CHO cell) low-dose group|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Recombinant new coronavirus vaccine (CHO cells) placebo group,1
NCT04469491,9/20/2020,9/30/2021,Interventional,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Recruiting,Phase 2,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,5,inhaled type I interferon|WFI water nebulization,0
NCT04465513,8/31/2020,10/4/2021,Interventional,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,Completed,Not Applicable,Hofseth Biocare ASA,NA,NA,NA,NA,NA,NA,Brazil|Canada|Hungary|Mexico|Serbia,0,3,Best Standard of Care + CARDIO|Best Standard of Care,0
NCT04466280,7/15/2020,11/15/2020,Interventional,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,Not Applicable,Baqiyatallah Medical Sciences University,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,0,Hydroxychloroquine|Mucodentol|Personal protective equipment,0
NCT04468971,9/29/2020,9/30/2021,Interventional,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,"Active, not recruiting",Phase 1,"Cellenkos, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,CK0802|Placebo,0
NCT04465695,7/14/2020,6/30/2021,Interventional,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Phase 2,The University of Hong Kong,NA,NA,NA,NA,NA,NA,China,0,3,Interferon beta-1b|Clofazimine,0
NCT04466605,3/30/2020,6/30/2020,Interventional,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,India,0,0,Tele-yoga therapy|Primary care,0
NCT04464486,4/21/2020,7/30/2021,Interventional,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,Not Applicable,University of Utah,NA,NA,NA,NA,NA,NA,United States,0,1,SCH Intervention,0
NCT04463264,6/26/2020,11/15/2020,Interventional,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Phase 2/Phase 3,Laboratorios Roemmers S.A.I.C.F.,NA,NA,NA,NA,NA,NA,Argentina,0,4,Nitazoxanide|Placebo,0
NCT04463849,6/30/2020,10/31/2021,Interventional,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,Not Applicable,University of Milan,NA,NA,NA,NA,NA,NA,Italy,0,2,Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection,0
NCT04461379,7/21/2020,1/1/2021,Interventional,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Phase 3,Hospital Universitario Dr. Jose E. Gonzalez,NA,NA,NA,NA,NA,NA,Mexico,0,3,BCG vaccine|Placebo,1
NCT04463433,2/1/2020,12/31/2021,Interventional,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,Not Applicable,Beijing Normal University,NA,NA,NA,NA,NA,NA,China,0,0,Cognitive and behavioral intervention.|Problem-solving and relationship improvement intervention.,0
NCT04462627,4/14/2020,12/31/2021,Interventional,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,Not Applicable,Brugmann University Hospital,NA,NA,NA,NA,NA,NA,Belgium,0,1,Blood group determination|Antibody titration|Probiotic,0
NCT04463420,8/15/2020,11/15/2020,Interventional,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,Not Applicable,Baqiyatallah Medical Sciences University,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,2,PHR160 Spray|Placebo|Standard treatment,0
NCT04458246,7/31/2020,12/31/2020,Interventional,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Exercise training group,0
NCT04460651,8/14/2020,8/30/2021,Interventional,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,Completed,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,NA,NA,NA,NA,NA,Argentina,0,4,Icosapent ethyl (IPE)|Placebo,0
NCT04458948,3/24/2020,3/24/2021,Interventional,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Phase 2,University of New Mexico,NA,NA,NA,NA,NA,NA,United States,0,0,Hydroxychloroquine|Azithromycin,0
NCT04459676,7/31/2020,4/30/2021,Interventional,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Angion Biomedica Corp,NA,NA,NA,NA,NA,NA,Brazil,0,4,Standard of Care (SOC) + ANG-3777|Standard Of Care (SOC) + Placebo,0
NCT04461340,8/15/2020,10/30/2020,Interventional,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Phase 2,Alexandria University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Sirolimus,0
NCT04460183,7/29/2020,1/27/2021,Interventional,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,4,"RESP301, a Nitric Oxide generating solution|Standard of Care",0
NCT04460534,5/7/2020,5/12/2021,Interventional,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Completed,Not Applicable,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,NA,NA,NA,NA,NA,France,0,1,diagnostic,0
NCT04460027,6/22/2020,11/30/2020,Interventional,W-SUDs for COVID-19,Completed,Phase 1,"Woebot Labs, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,Woebot Substance Use Disorder,0
NCT04459520,7/23/2020,7/28/2020,Interventional,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,2,Positive COVID Test Result - Hypothetical Scenario|Negative COVID Test Result - Hypothetical Scenario|Unavailable COVID Test Result - Hypothetical Scenario,0
NCT04457388,3/25/2020,6/15/2020,Interventional,Tele-Yoga Therapy for Chronic Pain,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Tele-Yoga Therapy,0
NCT04457349,7/25/2020,12/29/2020,Interventional,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,Not Applicable,Alexandria University,NA,NA,NA,NA,NA,NA,Egypt,0,4,Therapeutic Plasma Exchange (TPE),0
NCT04456595,7/21/2020,12/17/2020,Interventional,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Active, not recruiting",Phase 3,Butantan Institute,NA,NA,NA,NA,NA,NA,Brazil,0,4,Adsorbed COVID-19 (inactivated) Vaccine|Placebo,1
NCT04453514,7/21/2020,6/19/2021,Interventional,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Completed,Not Applicable,National University of Natural Medicine,NA,NA,NA,NA,NA,NA,United States,0,2,Trauma-informed yoga video recording,0
NCT04452669,9/15/2020,6/29/2021,Interventional,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Completed,Phase 2,Aerogen Pharma Limited,NA,NA,NA,NA,NA,NA,United States,0,4,VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),0
NCT04453657,2/4/2021,9/30/2022,Interventional,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,Not Applicable,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,9,FamilyChildCare (provisional name of app),0
NCT04451291,9/25/2020,9/25/2021,Interventional,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,"Active, not recruiting",Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,4,Decidual Stromal Cells (DSC),0
NCT04453852,6/30/2020,2/1/2021,Interventional,Monovalent Recombinant COVID19 Vaccine,Completed,Phase 1,Vaxine Pty Ltd,NA,NA,NA,NA,NA,NA,Australia,0,2,COVID19 vaccine|Saline,1
NCT04452565,10/15/2020,12/31/2020,Interventional,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Phase 2/Phase 3,"NeuroActiva, Inc.",NA,NA,NA,NA,NA,NA,United States,0,4,Drug: NA-831|NA-831 and Atazanavir|NA-831and Dexamethasone|Atazanavir and Dexamethasone,0
NCT04452773,7/14/2020,9/30/2020,Interventional,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,Not Applicable,Reig Jofre Group,NA,NA,NA,NA,NA,NA,Spain,0,2,Manremyc|Placebo,0
NCT04451889,8/1/2020,7/1/2021,Interventional,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,Not Applicable,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,NA,NA,NA,NA,NA,Russian Federation,0,1,miniprobe Alveoflex,0
NCT04447781,7/15/2020,2/22/2022,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Phase 1/Phase 2,International Vaccine Institute,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,INO-4800|CELLECTRAÂ® 2000|Saline-sodium citrate (SSC) buffer,1
NCT04447404,9/21/2020,3/4/2021,Interventional,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",Terminated,Phase 2,Durect,low enrollment,NA,NA,NA,NA,NA,United States,0,3,DUR-928|Placebo,0
NCT04447235,7/23/2020,12/31/2020,Interventional,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Phase 2,Instituto do Cancer do Estado de SÃ£o Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,1,Placebo|Ivermectin|Losartan,0
NCT04448769,6/26/2020,7/24/2020,Interventional,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,Not Applicable,"Central Hospital, Nancy, France",NA,NA,NA,NA,NA,NA,France,0,3,Anti-SARS-CoV-2 IgT seropositivity,0
NCT04447469,7/27/2020,12/31/2021,Interventional,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Phase 2/Phase 3,"Kiniksa Pharmaceuticals, Ltd.",NA,NA,NA,NA,NA,NA,United States|Brazil|Chile|Peru|South Africa,0,6,mavrilimumab|Placebo,0
NCT04448756,7/29/2020,8/16/2021,Interventional,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),Completed,Phase 2,EMD Serono,NA,NA,NA,NA,NA,NA,Brazil|Philippines|United States,0,14,M5049|M5049|Placebo,0
NCT04446377,7/15/2020,3/31/2021,Interventional,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Phase 2,"AI Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,2,Apilimod Dimesylate Capsule|Placebo,0
NCT04446104,5/13/2020,8/31/2020,Interventional,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Phase 3,"National University Hospital, Singapore",NA,NA,NA,NA,NA,NA,Singapore,0,2,Hydroxychloroquine Sulfate Tablets|Ivermectin 3mg Tab|Zinc|Povidone-Iodine|Vitamin C,0
NCT04445311,5/31/2020,7/30/2020,Interventional,Ivermectin in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Zagazig University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Ivermectin,0
NCT04445454,6/12/2020,9/30/2022,Interventional,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Phase 1/Phase 2,University of Liege,NA,NA,NA,NA,NA,NA,Belgium,0,1,Mesenchymal stromal cells,0
NCT04445376,7/3/2020,9/10/2020,Interventional,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,Not Applicable,Government College University Faisalabad,NA,NA,NA,NA,NA,NA,Pakistan,0,6,Physical Exercises,0
NCT04445285,4/28/2020,11/30/2021,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,NA,NA,NA,NA,NA,United States,0,3,Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|0.9%sodium chloride,0
NCT04445597,5/7/2020,12/31/2022,Interventional,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,Not Applicable,Universitaire Ziekenhuizen Leuven,NA,NA,NA,NA,NA,NA,Belgium,0,1,Sampling of tissue,0
NCT04442048,6/25/2020,12/31/2021,Interventional,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"Active, not recruiting",Phase 3,Canadian Cancer Trials Group,NA,NA,NA,NA,NA,NA,Canada,0,12,IMM-101|Observation,0
NCT04445272,5/22/2020,12/23/2020,Interventional,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Completed,Phase 2,Fundacion SEIMC-GESIDA,NA,NA,NA,NA,NA,NA,Spain,0,2,Tocilizumab,0
NCT04445220,11/19/2020,3/31/2022,Interventional,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Phase 1/Phase 2,"Sentien Biotechnologies, Inc.",NA,NA,NA,NA,NA,NA,United States,0,6,SBI-101,0
NCT04448119,10/16/2020,11/30/2021,Interventional,Control of COVID-19 Outbreaks in Long Term Care,"Active, not recruiting",Phase 2,Appili Therapeutics Inc.,NA,NA,NA,NA,NA,NA,Canada,0,3,Favipiravir|Favipiravir Placebo,0
NCT04442958,5/15/2020,6/15/2020,Interventional,Effectiveness of Convalescent Immune Plasma Therapy,Completed,Not Applicable,Bagcilar Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,1,Convalescent Immune Plasma,0
NCT04439825,7/20/2020,9/3/2020,Interventional,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Completed,Phase 1,DeNova Research,NA,NA,NA,NA,NA,NA,United States,0,3,Botulinum Neurotoxin|Placebo,0
NCT04443881,5/8/2020,3/31/2021,Interventional,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Completed,Phase 2/Phase 3,Fundacion Miguel Servet,NA,NA,NA,NA,NA,NA,Spain,0,1,Anakinra 149 MG/ML Prefilled Syringe [Kineret],0
NCT04442191,5/5/2020,5/5/2021,Interventional,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Phase 2,University of Illinois at Chicago,NA,NA,NA,NA,NA,NA,United States,0,0,Convalescent plasma|Placebo,0
NCT04441684,4/17/2020,5/7/2020,Interventional,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Completed,Not Applicable,"University Hospital, Strasbourg, France",NA,NA,NA,NA,NA,NA,France,0,1,Blood sample for serological test,0
NCT04444596,6/17/2020,3/31/2021,Interventional,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,Not Applicable,Medical University Innsbruck,NA,NA,NA,NA,NA,NA,Austria,0,0,Conjunctival swab and nasopharyngeal swab,0
NCT04441385,6/26/2020,11/30/2020,Interventional,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Phase 2,Hospital Universitario Infanta Leonor,NA,NA,NA,NA,NA,NA,Spain,0,1,Maraviroc 300 mg|Standard care therapy,0
NCT04444271,5/1/2020,8/30/2020,Interventional,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Phase 2,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",NA,NA,NA,NA,NA,NA,Pakistan,0,3,Mesenchymal stem cells|Placebo,0
NCT04439006,10/23/2020,12/31/2021,Interventional,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,4,Best Practice|Ibrutinib,0
NCT04441632,6/15/2020,7/26/2020,Interventional,Effect of Positive Attitudes on Behavior and Wellness,Completed,Not Applicable,Cedars-Sinai Medical Center,NA,NA,NA,NA,NA,NA,United States,0,1,Positive feedback,0
NCT04442152,6/30/2020,8/31/2020,Interventional,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,Not Applicable,"Promundo, United States",NA,NA,NA,NA,NA,NA,Rwanda,0,0,MenCare+/Bandebereho fathers'/couples' group education,0
NCT04438057,8/12/2020,8/12/2020,Interventional,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Phase 2,Metro Infectious Disease Consultants,NA,NA,NA,NA,NA,NA,United States,0,2,CCP,0
NCT04435717,5/4/2020,11/4/2020,Interventional,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Terminated,Phase 2,Hospital Universitario Ramon y Cajal,Futility,NA,NA,NA,NA,NA,Spain,0,1,Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses),0
NCT04431180,6/13/2020,6/13/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,Not Applicable,Guangzhou Blood Center,NA,NA,NA,NA,NA,NA,China,0,0,blood donation SMS,0
NCT04435353,3/22/2020,12/31/2020,Interventional,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,Not Applicable,Astana Medical University,NA,NA,NA,NA,NA,NA,Kazakhstan,0,0,VibroLUNG,0
NCT04435522,10/1/2020,12/31/2020,Interventional,Maraviroc in Patients With Moderate and Severe COVID-19,Completed,Phase 1,Rhode Island Hospital,NA,NA,NA,NA,NA,NA,United States,0,3,Maraviroc,0
NCT04432298,6/20/2020,3/22/2021,Interventional,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease",Terminated,Phase 2,FibroGen,The study was terminated by Sponsor due to low enrollment.,NA,NA,NA,NA,NA,United States,0,3,Pamrevlumab|Placebo,0
NCT04429594,7/28/2020,7/15/2025,Interventional,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,2,blood sampling,0
NCT04432987,5/25/2020,8/25/2020,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Pulmozyme,0
NCT04432805,6/15/2020,6/15/2021,Interventional,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,0,Performing of lung ultrasound,0
NCT04431856,5/15/2020,11/17/2020,Interventional,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,Not Applicable,University of Miami,NA,NA,NA,NA,NA,NA,United States,0,3,Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|SHG,0
NCT04431297,3/22/2021,5/14/2021,Interventional,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,Completed,Not Applicable,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States,0,4,Mindfulness Rounds,0
NCT04428021,6/15/2020,3/31/2021,Interventional,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Active, not recruiting",Phase 2,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,NA,NA,NA,NA,NA,Italy,0,2,Standard Therapy Protocol (STP)|STP + Standard Plasma (SP)|STP + COVID-19 Convalescent Plasma (CP),0
NCT04429724,7/6/2020,3/16/2021,Interventional,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",Not Applicable,Tourcoing Hospital,NA,NA,NA,NA,NA,NA,France,0,3,Diagnostic test Covid-19,0
NCT04443673,8/20/2020,2/28/2021,Interventional,Glycine Supplement for Severe COVID-19,Recruiting,Not Applicable,Instituto Nacional de Enfermedades Respiratorias,NA,NA,NA,NA,NA,NA,Mexico,0,2,Glycine,0
NCT04442230,10/10/2020,2/15/2021,Interventional,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Terminated,Phase 2,"Altimmune, Inc.",Enrollment,NA,NA,NA,NA,NA,United States,0,6,NasoVAX|Placebo,0
NCT04439045,6/24/2020,9/2/2021,Interventional,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"Active, not recruiting",Phase 3,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,4,VPM1002|Placebo,0
NCT04438694,6/1/2020,5/31/2021,Interventional,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Phase 1/Phase 2,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Convalescent Plasma|Standard of Care,0
NCT04438850,7/31/2020,6/8/2021,Interventional,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Terminated,Phase 2,IRCCS Sacro Cuore Don Calabria di Negrar,Incidence has dramatically dropped and there is lack of eligible patients,NA,NA,NA,NA,NA,Italy,0,5,Ivermectin|Placebo,0
NCT04435587,7/13/2020,6/30/2021,Interventional,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Recruiting,Phase 4,Mahidol University,NA,NA,NA,NA,NA,NA,Thailand,0,2,Combined ART/hydroxychloroquine|Ivermectin Pill,0
NCT04435275,1/2/2021,3/31/2021,Interventional,Virtual Assistant for COVID-19 PPE,Recruiting,Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,1,"Virtual Assistant first, then Human Coach|Human Coach first, then Virtual Assistant",0
NCT04437875,6/17/2020,8/3/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,NA,NA,NA,NA,NA,Russian Federation,0,3,Gam-COVID-Vac Lyo,1
NCT04433546,7/15/2020,12/2/2020,Interventional,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Phase 2,PhaseBio Pharmaceuticals Inc.,Company no longer pursing indication,NA,NA,NA,NA,NA,United States,0,7,Pemziviptadil (PB1046)|Low Dose (10 mg) Control,0
NCT04437823,6/1/2020,5/31/2021,Interventional,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Phase 2,Jinnah Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Intravenous Infusions of Stem Cells,0
NCT04429555,1/11/2021,6/30/2022,Interventional,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",Recruiting,Phase 2,MediciNova,NA,NA,NA,NA,NA,NA,United States,0,6,Ibudilast|Placebo,0
NCT04432324,6/2/2020,3/3/2021,Interventional,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,Spain,0,4,Intravenous Immune Globulin|Standard Medical Treatment,0
NCT04432051,5/26/2020,8/8/2020,Interventional,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,Not Applicable,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,2,mechanical ventilator settings and position,0
NCT04433949,6/12/2020,5/30/2022,Interventional,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Phase 3,Emory University,NA,NA,NA,NA,NA,NA,United States,0,1,Best Practice|Low Dose Radiation Therapy,0
NCT04428008,1/12/2021,8/31/2021,Interventional,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,Phase 2,Inova Health System,NA,NA,NA,NA,NA,NA,United States,0,6,Thymalfasin,0
NCT04429529,6/9/2020,11/19/2020,Interventional,"Safety of TY027, a Treatment for COVID-19, in Humans",Completed,Phase 1,Tychan Pte Ltd.,NA,NA,NA,NA,NA,NA,Singapore,0,2,TY027|0.9% Saline,0
NCT04429867,5/7/2020,12/7/2020,Interventional,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Phase 4,WellStar Health System,NA,NA,NA,NA,NA,NA,United States,0,1,Hydroxychloroquine|Placebo,0
NCT04424797,7/13/2020,7/31/2022,Interventional,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,Not Applicable,Poudre Valley Health System,NA,NA,NA,NA,NA,NA,United States,0,2,Prone Positioning|Supine Positioning,0
NCT04429711,5/12/2020,9/30/2020,Interventional,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,Not Applicable,Sheba Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,1,Ivermectin Oral Product,0
NCT04429334,9/23/2020,6/30/2023,Interventional,Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support and Features of Systemic Inflammation.,Recruiting,Phase 2/Phase 3,Inotrem,NA,NA,NA,NA,NA,NA,Belgium|France,0,3,nangibotide|placebo,0
NCT04429828,6/13/2020,9/30/2020,Interventional,COVID-19 Psychological Wellbeing for Healthcare Students,Completed,Not Applicable,University of Nottingham,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,COVID-19 e-package: Psychological wellbeing for healthcare workers,0
NCT04427137,6/9/2020,11/9/2021,Interventional,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Centre for Addiction and Mental Health,NA,NA,NA,NA,NA,NA,Canada,0,2,"MagPro X100 Stimulator, B70 Fluid-Cooled Coil",0
NCT04427566,7/23/2020,12/31/2021,Interventional,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,6,Radiation therapy,0
NCT04427098,5/22/2020,10/30/2020,Interventional,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Phase 2,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,NA,NA,NA,NA,NA,Italy,0,1,Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin,0
NCT04425707,6/9/2020,7/1/2020,Interventional,Ivermectin In Treatment of COVID 19 Patients,Recruiting,Not Applicable,"Ministry of Health and Population, Egypt",NA,NA,NA,NA,NA,NA,Egypt,0,0,Ivermectin,0
NCT04426305,5/21/2020,6/20/2020,Interventional,Community Health Workers Against COVID19,Completed,Not Applicable,University Ghent,NA,NA,NA,NA,NA,NA,Belgium,0,1,community health worker support|care as usual,0
NCT04423289,3/31/2020,5/4/2020,Interventional,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,Not Applicable,Hospital Universitari Vall d'Hebron Research Institute,NA,NA,NA,NA,NA,NA,Spain,0,0,Farmalarm,0
NCT04426318,6/14/2020,1/12/2021,Interventional,COVID-19 and the Healthy Minds Program for Educators,Completed,Not Applicable,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,4,Healthy Minds Program Foundations Training,0
NCT04426006,6/1/2020,1/1/2022,Interventional,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Institut BergoniÃ©,NA,NA,NA,NA,NA,NA,France,0,2,PRO-SERO-COV,0
NCT04425317,9/10/2020,7/6/2021,Interventional,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,Not Applicable,CRG UZ Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,2,Blood sample,0
NCT04425252,8/1/2020,12/29/2020,Interventional,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Completed,Phase 1/Phase 2,"Clear Creek Bio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,9,Brequinar|Standard of Care,0
NCT04425005,5/10/2020,12/7/2020,Interventional,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Completed,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,1,Home-based exercise,0
NCT04424212,6/10/2020,6/30/2021,Interventional,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",Not Applicable,Linkoeping University,NA,NA,NA,NA,NA,NA,Sweden,0,2,Intervention group CoronaCope,0
NCT04424082,6/9/2020,6/25/2020,Interventional,External Dead Space in Ventilated COVID-19 Patients,Completed,Not Applicable,Karolinska Institutet,NA,NA,NA,NA,NA,NA,Sweden,0,4,Removal of dead space filter,0
NCT04427254,6/26/2020,1/31/2023,Interventional,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Recruiting,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,NA,NA,NA,NA,France,0,2,"Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",0
NCT04423991,3/10/2020,6/4/2020,Interventional,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,Not Applicable,Dascena,NA,NA,NA,NA,NA,NA,United States,0,0,COViage,0
NCT04424901,5/3/2020,5/1/2022,Interventional,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Phase 2,UConn Health,NA,NA,NA,NA,NA,NA,United States,0,2,Dipyridamole,0
NCT04417257,6/29/2020,7/15/2021,Interventional,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Completed,Phase 2,Laurent Pharmaceuticals Inc.,NA,NA,NA,NA,NA,NA,United States|Canada,0,19,LAU-7b|Placebo oral capsule,0
NCT04419025,9/23/2020,5/14/2021,Interventional,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Completed,Phase 2,Cambridge Health Alliance,NA,NA,NA,NA,NA,NA,United States,0,6,N-acetylcysteine,0
NCT04422509,10/30/2020,2/25/2021,Interventional,Lanadelumab for Treatment of COVID-19 Disease,Completed,Phase 1/Phase 2,Radboud University,NA,NA,NA,NA,NA,NA,Netherlands,0,4,lanadelumab|regular care,0
NCT04420260,3/18/2021,6/23/2021,Interventional,Primary Prevention of Infection by COVID-19 in Workers,Completed,Not Applicable,Unidad de InvestigaciÃ³n GenÃ©tica Molecular,NA,NA,NA,NA,NA,NA,Colombia,0,1,Group A: oropharygeal spray and immunostimulant emulsion|Group D:Placebo oropharyngeal spray + Placebo taken PO,0
NCT04421508,7/12/2020,12/28/2020,Interventional,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,Terminated,Phase 3,Bellerophon,Futility,NA,NA,NA,NA,NA,United States,0,12,INOpulse|Placebo,0
NCT04420676,9/24/2020,12/31/2021,Interventional,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,Not Applicable,Medical University of Graz,NA,NA,NA,NA,NA,NA,Austria,0,2,Omnibiotic AAD|Placebo,0
NCT04419623,7/9/2020,9/22/2020,Interventional,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Completed,Phase 1,"Telios Pharma, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,TL-895,0
NCT04420299,6/4/2020,3/31/2021,Interventional,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,NA,NA,NA,NA,NA,Spain,0,1,Bemiparin|Bemiparin,0
NCT04418505,9/2/2020,7/30/2021,Interventional,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,"Active, not recruiting",Not Applicable,Vielight Inc.,NA,NA,NA,NA,NA,NA,United States|Canada,0,6,Vielight RX Plus,0
NCT04420338,6/5/2020,12/15/2020,Interventional,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,2,Blood sample|Serum tube collection,0
NCT04418206,6/1/2020,12/1/2020,Interventional,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,1,patients COVID 19,0
NCT04421391,6/8/2020,11/1/2020,Interventional,QuadraMune(TM) for Prevention of COVID-19,Recruiting,Not Applicable,Therapeutic Solutions International,NA,NA,NA,NA,NA,NA,United States,0,0,QuadraMune(TM),0
NCT04419610,10/9/2020,5/12/2021,Interventional,RAS and Coagulopathy in COVID19,Completed,Early Phase 1,Imperial College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,10,TRV027|sodium chloride 0.9%,0
NCT04422353,5/1/2020,6/30/2021,Interventional,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,Not Applicable,Federal University of Rio Grande do Sul,NA,NA,NA,NA,NA,NA,Brazil,0,2,Video Dance classes|Unsupervised physical activities,0
NCT04416360,5/5/2020,7/31/2020,Interventional,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,0,Interview by psychologists,0
NCT04421612,4/2/2020,1/1/2021,Interventional,COVID-19 - No Health Without Mental Health,Completed,Not Applicable,Haukeland University Hospital,NA,NA,NA,NA,NA,NA,Norway,0,4,Co-mestring (co-coping),0
NCT04420390,5/1/2020,7/31/2020,Interventional,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,Not Applicable,"Hospital San Carlos, Madrid",NA,NA,NA,NA,NA,NA,Spain,0,0,Radiotherapy,0
NCT04420182,8/17/2020,6/30/2021,Interventional,COVID-19 Virtual Care at Home,Recruiting,Not Applicable,Lawson Health Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,4,Virtual Care at Home,0
NCT04421625,6/15/2020,6/15/2022,Interventional,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,Not Applicable,Institut Cancerologie de l'Ouest,NA,NA,NA,NA,NA,NA,France,0,2,Diagnostic test for SARS-Cov2 for patients and health staff,0
NCT04417335,4/16/2020,5/31/2021,Interventional,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Phase 4,Radboud University,NA,NA,NA,NA,NA,NA,Netherlands,0,0,BCG vaccine|Placebo,1
NCT04421664,3/25/2020,8/17/2020,Interventional,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,NA,NA,NA,NA,NA,United States|Canada,0,1,Placebo oral tablet|Hydroxychloroquine,0
NCT04416308,5/29/2020,7/10/2020,Interventional,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Completed,Not Applicable,Rennes University Hospital,NA,NA,NA,NA,NA,NA,France,0,2,NG test|Blood test|Self-questionnary,0
NCT04412668,6/12/2020,12/21/2020,Interventional,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,Completed,Phase 2,"aTyr Pharma, Inc.",NA,NA,NA,NA,NA,NA,United States|Puerto Rico,0,9,ATYR1923 1 mg/kg|ATYR1923 3 mg/kg|Placebo,0
NCT04414618,7/2/2020,11/26/2020,Interventional,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,Completed,Phase 2,RedHill Biopharma Limited,NA,NA,NA,NA,NA,NA,United States|Israel,0,17,Opaganib|Placebo,0
NCT04413006,5/25/2020,12/31/2020,Interventional,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,Not Applicable,University of Manitoba,NA,NA,NA,NA,NA,NA,Canada,0,0,Self-Compassion for Chronic Pain Virtual Group Treatment Program,0
NCT04416919,5/20/2020,6/1/2020,Interventional,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,"Active, not recruiting",Not Applicable,University of Oklahoma,NA,NA,NA,NA,NA,NA,United States,0,2,Assembled mask,0
NCT04417270,6/12/2020,11/30/2020,Interventional,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,Not Applicable,Northwell Health,NA,NA,NA,NA,NA,NA,United States,0,4,Freestyle Libre 14 day CGM system|Accuchek Inform II platform,0
NCT04413864,4/24/2020,10/24/2022,Interventional,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration,0
NCT04416139,5/1/2020,4/30/2021,Interventional,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,NA,NA,NA,NA,Mexico,0,0,Infusion IV of Mesenchymal Stem cells,0
NCT04416113,8/5/2021,12/31/2021,Interventional,Photodynamic Therapy for the Treatment of COVID-19,"Active, not recruiting",Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,2,photobiomodulation and photodynamic therapy,0
NCT04412239,4/20/2020,12/20/2020,Interventional,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,Not Applicable,Health Science Center of Xi'an Jiaotong University,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Patient-centred advice on Telephone Consultation in TB Patients:,0
NCT04320953,3/16/2020,3/26/2020,Interventional,Non-contact Endoscopy at Covid-19 Outbreak,Completed,Not Applicable,Changhai Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Non-contact MCE system,0
NCT04412330,5/1/2020,5/5/2021,Interventional,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Completed,Not Applicable,University of Kentucky,NA,NA,NA,NA,NA,NA,United States,0,3,ICU Recovery + Physical Therapy,0
NCT04414293,10/1/2020,7/31/2021,Interventional,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Recruiting,Not Applicable,Hospital Provincial de Castellon,NA,NA,NA,NA,NA,NA,Spain,0,3,Lung Low Dose Radiation,0
NCT04414124,8/2/2020,2/2/2021,Interventional,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,Completed,Not Applicable,Kaleido Biosciences,NA,NA,NA,NA,NA,NA,United States,0,3,KB109 + Self Supportive Care (SSC)|Self Supportive Care (SSC) Alone,0
NCT04414371,5/20/2020,12/31/2020,Interventional,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,Not Applicable,"Rutgers, The State University of New Jersey",NA,NA,NA,NA,NA,NA,United States,0,0,Yoga,0
NCT04410692,5/15/2020,5/16/2020,Interventional,Can the Prediction Market Improve Predictions of COVID-19?,Completed,Not Applicable,"National University, Singapore",NA,NA,NA,NA,NA,NA,Singapore,0,1,Prediction Market,0
NCT04412785,6/30/2020,10/31/2021,Interventional,Cyclosporine in Patients With Moderate COVID-19,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,3,Cyclosporine,0
NCT04414267,5/26/2020,4/28/2021,Interventional,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,Completed,Phase 4,Hellenic Institute for the Study of Sepsis,NA,NA,NA,NA,NA,NA,Greece,0,4,BCG vaccine|Placebo,1
NCT04416048,11/30/2020,12/31/2021,Interventional,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Recruiting,Phase 2,"Charite University, Berlin, Germany",NA,NA,NA,NA,NA,NA,Germany,0,4,Rivaroxaban|Standard Of Care (SOC),0
NCT04415060,6/15/2020,6/15/2023,Interventional,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Phase 3,Sunnybrook Health Sciences Centre,NA,NA,NA,NA,NA,NA,Canada,0,5,Isoflurane Inhalant Product|Sevoflurane inhalant product,0
NCT04412772,6/12/2020,12/31/2021,Interventional,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Phase 3,Queen's Medical Center,NA,NA,NA,NA,NA,NA,United States,0,1,Tocilizumab|Placebo,0
NCT04412356,6/6/2020,6/1/2021,Interventional,Timing of Tracheotomy in Covid-19 Patients,Completed,Not Applicable,"Sahlgrenska University Hospital, Sweden",NA,NA,NA,NA,NA,NA,Sweden,0,6,Tracheotomy,0
NCT04412291,6/11/2020,3/31/2021,Interventional,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Phase 2,Karolinska University Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,3,Anakinra Prefilled Syringe|Tocilizumab Prefilled Syringe|Standard-of-care treatment,0
NCT04411680,8/18/2020,3/2/2021,Interventional,Study of Sargramostim in Patients With COVID-19,Completed,Phase 2,"Partner Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,15,Sargramostim|Standard of care,0
NCT04410536,6/15/2020,12/31/2021,Interventional,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,NA,NA,NA,NA,NA,Italy,0,1,Symptomatic drugs|Bridge therapy|Mindfulness program,0
NCT04409496,6/2/2020,1/22/2021,Interventional,Chat-based Support for Preventing Smoking Relapse,Completed,Not Applicable,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,4,Chat-based instant messaging support|SMS message support|Self-help booklet,0
NCT04409509,7/1/2020,1/12/2021,Interventional,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,CSL Behring,NA,NA,NA,NA,NA,NA,United States,0,11,"Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Placebo",0
NCT04408066,4/30/2020,4/30/2022,Interventional,COVID-19: A POC Test Under Research & Evaluation,Recruiting,Not Applicable,LumiraDx UK Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Sample Collection/Performance Evaluation (A)|Sample Collection/Performance Evaluation (B),0
NCT04409925,12/25/2020,4/30/2021,Interventional,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Recruiting,Phase 1,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,Canada,0,7,rhDNase I,0
NCT04408157,5/20/2020,10/1/2021,Interventional,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,King's College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,5,Self-management booklet (SWitCh: Stay well during COVID-19),0
NCT04408287,9/15/2020,12/28/2021,Interventional,Improving Activity Engagement Among Persons With SCI During COVID-19,Recruiting,Not Applicable,Lawson Health Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,3,WebEx Physical Activity Program,0
NCT04409821,5/29/2020,2/28/2022,Interventional,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,Recruiting,Not Applicable,"Rigshospitalet, Denmark",NA,NA,NA,NA,NA,NA,Denmark,0,1,Tele-delivered psychological intervention,0
NCT04406389,10/13/2020,6/30/2022,Interventional,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Phase 4,Weill Medical College of Cornell University,NA,NA,NA,NA,NA,NA,United States,0,5,Argatroban|Enoxaparin sodium|Unfractionated heparin|Fondapariniux,0
NCT04411433,5/8/2020,12/31/2020,Interventional,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,"Ministry of Health, Turkey",NA,NA,NA,NA,NA,NA,Turkey,0,1,Favipiravir (3200 mg + 1200 mg)|Favipiravir (3600 mg + 1600 mg)|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Hydroxychloroquine|Hydroxychloroquine combined with Azithromycin,0
NCT04410458,5/31/2020,5/31/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,Not Applicable,Guangzhou Blood Center,NA,NA,NA,NA,NA,NA,China,0,0,blood donation SMS,0
NCT04408027,6/1/2020,6/1/2022,Interventional,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Recruiting,Not Applicable,The Hospital for Sick Children,NA,NA,NA,NA,NA,NA,Canada,0,2,Virtual-Care Cognitive Behavioural Therapy,0
NCT04409873,3/31/2021,2/28/2022,Interventional,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,Phase 2,"University of California, San Francisco",NA,NA,NA,NA,NA,NA,United States,0,8,Distilled water|Oral-B Mouth Sore mouthwash|Crest Pro-Health Multi-Protection mouthwash|CloSYS Ultra Sensitive Rinse mouthwash|Listerine Zero Mouthwash Product,0
NCT04409262,6/16/2020,2/1/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,NA,NA,NA,NA,NA,United States|Brazil|Russian Federation|Spain,0,9,Remdesivir|Tocilizumab|Placebo,0
NCT04407390,6/1/2020,5/1/2021,Interventional,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Phase 2,University of Copenhagen,NA,NA,NA,NA,NA,NA,Denmark,0,1,Nicotinamide riboside|Placebo,0
NCT04409327,7/11/2020,12/27/2020,Interventional,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Terminated,Phase 2,Restorbio Inc.,Insufficient accrual rate,NA,NA,NA,NA,NA,United States,0,6,RTB101|Placebo,0
NCT04410510,9/30/2020,6/30/2021,Interventional,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Phase 2/Phase 3,Hospital Universitario San Ignacio,NA,NA,NA,NA,NA,NA,Colombia,0,4,P2Et (Caesalpinia spinosa extract)|Placebo,0
NCT04410354,6/16/2020,12/1/2020,Interventional,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Phase 2,"ViralClear Pharmaceuticals, Inc.",Failure to meet primary endpoint,NA,NA,NA,NA,NA,United States,0,6,Merimepodib|Matching Placebo|Remdesivir,0
NCT04408131,5/28/2020,1/27/2021,Interventional,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,0,Blood sample|Blood sample,0
NCT04409522,5/12/2020,6/5/2020,Interventional,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,Not Applicable,Baqiyatallah Medical Sciences University,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,0,Melatonin|The usual treatment,0
NCT04408456,3/1/2020,7/31/2020,Interventional,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Phase 3,Postgraduate Institute of Medical Education and Research,NA,NA,NA,NA,NA,NA,India,0,2,HCQ|Standard therapy,0
NCT04408040,7/14/2020,9/14/2021,Interventional,Use of Convalescent Plasma for COVID-19,Terminated,Phase 2,"Northside Hospital, Inc.",New information regarding use of plasma in covid + patients,NA,NA,NA,NA,NA,United States,0,5,Convalescent Plasma,0
NCT04405999,5/14/2020,8/9/2020,Interventional,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,NA,NA,NA,NA,NA,Russian Federation,0,1,Bromhexine Hydrochloride,0
NCT04404361,5/22/2020,9/21/2021,Interventional,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,Terminated,Phase 3,CTI BioPharma,decision to close enrollment early,NA,NA,NA,NA,NA,United States,0,9,Pacritinib|Placebo,0
NCT04406246,5/21/2020,12/31/2020,Interventional,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Completed,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,NA,NA,NA,NA,NA,Mexico,0,1,Nitazoxanide 500Mg Oral Tablet,0
NCT04405986,5/19/2020,3/10/2021,Interventional,Exploring Brain Damages After COVID-19 Infection,Completed,Not Applicable,"University Hospital, Bordeaux",NA,NA,NA,NA,NA,NA,France,0,3,Auditory Evoked Potentials (AEP)|Blink and Masseter Inhibitory Reflex,0
NCT04406181,5/18/2020,12/31/2020,Interventional,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,1,HADS|a survey,0
NCT04405310,5/20/2020,11/20/2020,Interventional,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Completed,Phase 2,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,NA,NA,NA,NA,NA,Mexico,0,2,Convalescent Plasma of patients with COVID-19|placebo (hartmann plus albumine),0
NCT04407182,5/4/2020,8/1/2020,Interventional,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Completed,Phase 2,Catalysis SL,NA,NA,NA,NA,NA,NA,Ecuador,0,4,Viusid and Asbrip,0
NCT04406493,4/28/2020,4/28/2021,Interventional,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,Not Applicable,Hillel Yaffe Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Lung impedance technique,0
NCT04407130,6/16/2020,10/30/2020,Interventional,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Completed,Phase 2,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,NA,NA,NA,NA,NA,Bangladesh,0,5,Ivermectin + Doxycycline + Placebo|Ivermectin + Placebo|Placebo,0
NCT04405102,9/16/2020,1/1/2023,Interventional,COVID-19 Ozanimod Intervention Study,Recruiting,Phase 2,"Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University Laval",NA,NA,NA,NA,NA,NA,Canada,0,3,Ozanimod|Standard of care,0
NCT04402957,10/14/2020,5/31/2021,Interventional,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Active, not recruiting",Phase 2,Arch Biopartners Inc.,NA,NA,NA,NA,NA,NA,United States|Canada|Turkey,0,7,LSALT peptide|Placebo,0
NCT04404218,8/4/2020,12/31/2021,Interventional,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Recruiting,Phase 2,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Brazil|Canada,0,2,AÃ§aÃ­ palm berry extract - natural product|Placebo,0
NCT04403555,6/1/2020,10/31/2020,Interventional,Ivermectin as a Novel Therapy in COVID-19 Treatment,Completed,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,6,Ivermectin,0
NCT04402879,11/10/2020,12/1/2021,Interventional,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,Not Applicable,University of Calgary,NA,NA,NA,NA,NA,NA,Canada,0,5,Prone Positioning (PP),0
NCT04401423,2/10/2021,6/10/2021,Interventional,TXA127 for the Treatment of Severe COVID-19,Completed,Phase 2,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,3,TXA127|Placebo,0
NCT04402918,5/17/2020,5/19/2020,Interventional,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Completed,Not Applicable,Centre Hospitalier Universitaire de Besancon,NA,NA,NA,NA,NA,NA,France,0,2,biological samples day of delivery,0
NCT04400929,6/2/2020,6/30/2021,Interventional,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Phase 2,Singapore General Hospital,NA,NA,NA,NA,NA,NA,Singapore,0,1,Sargramostim|Normal Saline 0.9%,0
NCT04403269,5/5/2020,5/5/2021,Interventional,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Phase 2,Versailles Hospital,NA,NA,NA,NA,NA,NA,France,0,0,IgIV,0
NCT04402060,5/28/2020,2/19/2021,Interventional,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Completed,Phase 1/Phase 2,"Apellis Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United States|Brazil,0,4,APL-9|Vehicle Control,0
NCT04404426,11/4/2020,3/25/2021,Interventional,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Completed,Not Applicable,Rennes University Hospital,NA,NA,NA,NA,NA,NA,France,0,4,L-citrulline|Placebo,0
NCT04401150,8/14/2020,11/30/2021,Interventional,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Phase 3,UniversitÃ© de Sherbrooke,NA,NA,NA,NA,NA,NA,Canada,0,4,Vitamin C|Control,0
NCT04401475,11/25/2020,4/30/2021,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,Phase 2,Edesa Biotech Inc.,NA,NA,NA,NA,NA,NA,United States|Canada|Colombia,0,5,SOC plus 15mg/kg EB05 IV|SOC plus Placebo IV,0
NCT04402866,6/24/2020,4/21/2021,Interventional,TD-0903 for ALI Associated With COVID-19,Completed,Phase 2,Theravance Biopharma,NA,NA,NA,NA,NA,NA,"United States|Brazil|Finland|Moldova, Republic of|Romania|Ukraine|United Kingdom",0,11,TD-0903|Placebo,0
NCT04402203,5/31/2020,7/31/2020,Interventional,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Phase 2/Phase 3,Bangladesh Medical Research Council (BMRC),NA,NA,NA,NA,NA,NA,Bangladesh,0,0,Favipiravir|Only Standard Treatment,0
NCT04402840,4/24/2020,12/31/2021,Interventional,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,Not Applicable,West Virginia University,NA,NA,NA,NA,NA,NA,United States,0,1,Stellate Ganglion Block,0
NCT04402983,5/27/2020,12/1/2020,Interventional,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,Not Applicable,Istanbul Medipol University Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,2,Physiotherapy,0
NCT04400032,5/15/2020,4/22/2021,Interventional,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Completed,Phase 1/Phase 2,Ottawa Hospital Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,3,Mesenchymal Stromal Cells,0
NCT04399109,5/20/2020,5/19/2021,Interventional,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,Not Applicable,"Prince of Wales Hospital, Sydney",NA,NA,NA,NA,NA,NA,Australia,0,0,TCC-COVID mHealth solution,0
NCT04401046,5/20/2020,11/26/2020,Interventional,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Completed,Not Applicable,Institut Paoli-Calmettes,NA,NA,NA,NA,NA,NA,France,0,3,Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later,0
NCT04399681,5/10/2020,8/10/2020,Interventional,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,Bedside lung ultrasound,0
NCT04398277,5/1/2020,4/30/2021,Interventional,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,Not Applicable,Kent State University,NA,NA,NA,NA,NA,NA,United States,0,0,Daily Coping Toolkit,0
NCT04399746,3/15/2020,5/20/2020,Interventional,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,Not Applicable,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,NA,NA,NA,NA,NA,Mexico,0,0,Ivermectin|Azithromycin|Cholecalciferol,0
NCT04397692,6/13/2020,9/30/2020,Interventional,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,Not Applicable,Beyond Air Inc.,NA,NA,NA,NA,NA,NA,United States,0,2,Nitric Oxide delivered via LungFitâ„¢ system,0
NCT04397666,5/15/2020,12/15/2020,Interventional,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,"Active, not recruiting",Not Applicable,Versailles Hospital,NA,NA,NA,NA,NA,NA,France,0,2,conjunctival RT PCR,0
NCT04345419,6/16/2020,12/1/2020,Interventional,Remdesivir Efficacy in Coronavirus Disease,Completed,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,6,Remdesivir|Standard of care treatment,0
NCT04394455,6/30/2020,11/30/2020,Interventional,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,Not Applicable,Universidad Nacional Autonoma de Honduras,NA,NA,NA,NA,NA,NA,Honduras,0,2,Brief cognitive behavioral therapy|Crisis intervention therapy,0
NCT04394013,8/26/2020,12/31/2020,Interventional,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,Not Applicable,Monash University Malaysia,NA,NA,NA,NA,NA,NA,Malaysia,0,2,Mindfulness intervention|Non-Mindfulness intervention,0
NCT04393415,5/25/2020,8/25/2020,Interventional,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,Not Applicable,Aljazeera Hospital,NA,NA,NA,NA,NA,NA,Egypt,0,2,stem cells,0
NCT04397705,10/12/2020,4/30/2021,Interventional,Remote Monitoring of Cancer Patients With Suspected Covid-19,Recruiting,Phase 1,The Christie NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Patient Status Engine,0
NCT04397614,7/22/2020,12/31/2021,Interventional,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Recruiting,Not Applicable,University of Oklahoma,NA,NA,NA,NA,NA,NA,United States,0,6,mHealth Assessments,0
NCT04394403,5/14/2020,12/31/2021,Interventional,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,Not Applicable,Hebrew University of Jerusalem,NA,NA,NA,NA,NA,NA,Israel,0,2,Internet-based guided self-help based on CBT principles,0
NCT04390594,8/13/2020,2/12/2021,Interventional,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Phase 3,Institut Pasteur de Dakar,NA,NA,NA,NA,NA,NA,Senegal,0,4,Nafamostat Mesilate,0
NCT04397510,6/1/2020,12/31/2021,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,NA,NA,NA,NA,NA,United States,0,7,Heparin|0.9% Sodium-chloride,0
NCT04394442,3/21/2020,8/31/2020,Interventional,Hydroxychloroquine in COVID-19 Patients,Recruiting,Phase 2,Zagazig University,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,0,Hydroxychloroquine,0
NCT04393961,4/5/2020,7/29/2020,Interventional,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,Not Applicable,ProofPilot,NA,NA,NA,NA,NA,NA,United States,0,0,Premier Biotech COVID-19 IgG/IgM Rapid test Cassette,0
NCT04392414,5/1/2020,7/10/2020,Interventional,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Phase 2,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,NA,NA,NA,NA,NA,Russian Federation,0,2,COVID-19 convalescent hyperimmune plasma|Non-convalescent fresh frozen plasma (Standard plasma),0
NCT04397796,8/3/2020,6/30/2021,Interventional,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,"Active, not recruiting",Phase 1,"ImmunityBio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,BM-Allo.MSC|Placebo,0
NCT04395911,9/10/2020,7/5/2021,Interventional,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Completed,Not Applicable,SeaStar Medical,NA,NA,NA,NA,NA,NA,United States,0,7,SCD,0
NCT04395430,9/18/2020,4/30/2022,Interventional,A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,"Active, not recruiting",Not Applicable,KK Women's and Children's Hospital,NA,NA,NA,NA,NA,NA,Singapore,0,3,Usual Care|online KKH Sports Singapore Program with Usual Care,0
NCT04391829,8/31/2020,8/31/2021,Interventional,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,1,Ejaculated semen sample,0
NCT04390516,3/24/2020,5/4/2020,Interventional,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,Not Applicable,Dascena,NA,NA,NA,NA,NA,NA,United States,0,3,COViage,0
NCT04391179,5/31/2020,2/22/2021,Interventional,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,Phase 2,University of Michigan,NA,NA,NA,NA,NA,NA,United States,0,7,Dipyridamole 100 Milligram(mg)|Placebo oral tablet,0
NCT04393077,5/10/2020,5/15/2020,Interventional,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,Not Applicable,Istanbul Saglik Bilimleri University,NA,NA,NA,NA,NA,NA,Turkey,0,2,Emotional Freedom Technique,0
NCT04389450,10/1/2020,5/17/2021,Interventional,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","Active, not recruiting",Phase 2,Pluristem Ltd.,NA,NA,NA,NA,NA,NA,United States,0,9,PLX-PAD|Placebo,0
NCT04390503,3/12/2021,4/30/2022,Interventional,Convalescent Plasma for Early Treatment of COVID-19,Recruiting,Phase 2,Columbia University,NA,NA,NA,NA,NA,NA,Brazil,0,2,Convalescent Plasma (anti-SARS-CoV-2 plasma)|Control (albumin 5%),0
NCT04390152,1/13/2020,12/31/2021,Interventional,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Recruiting,Phase 1/Phase 2,BioXcellerator,NA,NA,NA,NA,NA,NA,Colombia,0,3,"Wharton's jelly derived Mesenchymal stem cells.|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)",0
NCT04388514,4/8/2020,10/8/2020,Interventional,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,Not Applicable,Azienda Sanitaria-Universitaria Integrata di Udine,NA,NA,NA,NA,NA,NA,Italy,0,0,Medical Ozone procedure,0
NCT04389385,5/1/2020,9/30/2020,Interventional,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Phase 1,TC Erciyes University,NA,NA,NA,NA,NA,NA,Turkey,0,0,COVID-19 Specific T Cell derived exosomes (CSTC-Exo),0
NCT04390477,5/4/2020,3/21/2021,Interventional,Study to Evaluate the Effect of a Probiotic in COVID-19,Completed,Not Applicable,Bioithas SL,NA,NA,NA,NA,NA,NA,Spain,0,2,Probiotic,0
NCT04385849,7/22/2020,7/11/2022,Interventional,Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,"Active, not recruiting",Phase 1,"ImmunityBio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,4,N-803|Saline,0
NCT04385199,5/4/2020,8/1/2020,Interventional,Convalescent Plasma for Patients With COVID-19,Completed,Phase 2,Henry Ford Health System,NA,NA,NA,NA,NA,NA,United States,0,2,Convalescent plasma,0
NCT04386616,6/2/2020,1/8/2021,Interventional,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,Completed,Phase 2,"Genentech, Inc.",NA,NA,NA,NA,NA,NA,United States|Brazil|Mexico|Spain,0,20,MSTT1041A|MSTT1041A-matched Placebo|UTTR1147A|UTTR1147A-matched Placebo,0
NCT04386668,5/26/2020,7/12/2020,Interventional,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,Not Applicable,"University College, London",Interim analysis indicated adaptations to intervention may be required.,NA,NA,NA,NA,NA,United Kingdom,0,4,Let It Out (LIO)-C|Neutral writing control,0
NCT04384458,7/20/2020,9/10/2020,Interventional,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,Not Applicable,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,NA,NA,NA,NA,NA,NA,Brazil,0,3,Hydroxychloroquine|Ivermectin,0
NCT04384731,5/29/2020,5/29/2021,Interventional,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 2,Versailles Hospital,NA,NA,NA,NA,NA,NA,France,0,2,poractant alfa,0
NCT04385810,4/27/2020,7/29/2020,Interventional,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,NA,NA,NA,NA,France,0,1,Ophthalmologic exam,0
NCT04386798,7/25/2020,12/22/2020,Interventional,Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit,Recruiting,Not Applicable,Eskisehir Osmangazi University,NA,NA,NA,NA,NA,NA,Turkey,0,3,survey work,0
NCT04382131,6/23/2020,10/31/2020,Interventional,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,Not Applicable,University of Edinburgh,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,NaCl Solution,0
NCT04385836,6/1/2020,9/1/2020,Interventional,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Early Phase 1,"Ministry of Health, Saudi Arabia",NA,NA,NA,NA,NA,NA,Saudi Arabia,0,0,alpha one antitrypsin inhalation,0
NCT04382378,2/1/2021,9/30/2021,Interventional,Effects of NMES in Critically Ill Patients,Recruiting,Not Applicable,Escola Superior de Ciencias da Saude,NA,NA,NA,NA,NA,NA,Brazil,0,4,neuromuscular electrical stimulation,0
NCT04381052,5/18/2020,2/3/2021,Interventional,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,Phase 2,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,1,Clazakizumab|Placebo,0
NCT04382391,5/8/2020,7/21/2021,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",Not Applicable,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),NA,NA,NA,NA,NA,NA,United States,0,4,gammaCoreÂ® Sapphire (non-invasive vagus nerve stimulator)|Standard of care therapies,0
NCT04385901,5/19/2020,9/19/2020,Interventional,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,Not Applicable,University of Missouri-Columbia,NA,NA,NA,NA,NA,NA,United States,0,3,Therapy Intervention,0
NCT04380532,5/15/2020,5/15/2021,Interventional,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Phase 1/Phase 2,Immunitor LLC,NA,NA,NA,NA,NA,NA,Canada|Mongolia,0,1,V-SARS,1
NCT04395768,9/9/2020,9/30/2021,Interventional,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Phase 2,"National Institute of Integrative Medicine, Australia",NA,NA,NA,NA,NA,NA,Australia,0,1,Vitamin C|Hydroxychloroquine|Azithromycin|Zinc Citrate|Vitamin D3|Vitamin B12,0
NCT04397523,4/30/2020,5/10/2021,Interventional,Efficacy and Safety of COVID-19 Convalescent Plasma,Completed,Not Applicable,Institute for Transfusion Medicine of RNM,NA,NA,NA,NA,NA,NA,North Macedonia,0,3,anti-SARS-CoV-2 convalescent plasma,0
NCT04394793,6/13/2020,8/27/2020,Interventional,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",Not Applicable,"All India Institute of Medical Sciences, New Delhi",NA,NA,NA,NA,NA,NA,India,0,4,Low dose radiation therapy,0
NCT04395144,5/15/2020,3/15/2021,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Completed,Not Applicable,HÃ´pital de Verdun,NA,NA,NA,NA,NA,NA,Canada,0,3,Awake Prone Positioning|Standard care,0
NCT04392778,4/1/2020,11/1/2020,Interventional,Clinical Use of Stem Cells for the Treatment of Covid-19,Completed,Phase 1/Phase 2,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,NA,NA,NA,NA,NA,Turkey,0,1,MSC Treatment|Saline Control,0
NCT04393948,6/30/2020,10/31/2020,Interventional,Lung Irradiation for COVID-19 Pneumonia,Recruiting,Not Applicable,Brigham and Women's Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Phase 1|Phase 1|Phase 2|Phase 2|Phase 2,0
NCT04394039,6/1/2020,8/1/2020,Interventional,Post-Pandemic Perception of Public Space in Singapore,Completed,Not Applicable,"National University, Singapore",NA,NA,NA,NA,NA,NA,Singapore,0,1,Public space exposure,0
NCT04394208,8/16/2020,1/30/2021,Interventional,Silymarin in COVID-19 Pneumonia,Recruiting,Phase 3,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Silymarin|Placebo,0
NCT04393792,5/5/2020,3/31/2022,Interventional,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Phase 1,Hampshire Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Povidone-Iodine|Normal saline,0
NCT04392453,10/26/2020,12/31/2021,Interventional,Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,Recruiting,Not Applicable,Fondazione Don Carlo Gnocchi Onlus,NA,NA,NA,NA,NA,NA,Italy,0,1,Robotic therapy,0
NCT04393038,7/1/2020,3/5/2021,Interventional,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Terminated,Phase 2/Phase 3,Abivax S.A.,Interim analysis concludes that the study is futile,NA,NA,NA,NA,NA,Belgium|Brazil|France|Germany|Italy|Mexico|Spain|United Kingdom,0,3,ABX464|Placebo,0
NCT04391309,4/12/2021,11/30/2021,Interventional,COVID-19 and Anti-CD14 Treatment Trial,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,14,anti-CD14|Placebo|remdesivir,0
NCT04389333,3/26/2020,4/26/2020,Interventional,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,Not Applicable,Changhai Hospital,NA,NA,NA,NA,NA,NA,China,0,2,non-contact magnetically-controlled capsule endoscopy,0
NCT04392531,4/16/2020,3/31/2021,Interventional,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Completed,Phase 4,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,NA,NA,NA,NA,NA,Spain,0,3,Cyclosporine|Standard treatment,0
NCT04387292,9/7/2020,1/21/2021,Interventional,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Completed,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,NA,NA,NA,NA,France,0,3,Ophthalmologic exam,0
NCT04387409,5/25/2020,5/1/2021,Interventional,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,NA,NA,NA,NA,NA,Germany,0,3,VPM1002|Placebo,0
NCT04389944,3/31/2020,6/30/2020,Interventional,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,Not Applicable,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,NA,NA,Switzerland,0,2,convalescent plasma application to SARS-CoV-2 infected patients,0
NCT04391127,5/4/2020,11/6/2020,Interventional,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,NA,NA,NA,NA,NA,Mexico,0,4,Hydroxychloroquine|Ivermectin|Placebo,0
NCT04390412,5/4/2020,8/30/2020,Interventional,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Phase 1/Phase 2,Shahid Beheshti University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,2,Low Dose Radiotherapy,0
NCT04391712,4/30/2020,5/15/2020,Interventional,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Phase 2,Lowell General Hospital,NA,NA,NA,NA,NA,NA,United States,0,1,MLS Laser|Regular Inpatient Medical Care,0
NCT04388527,4/30/2020,1/25/2021,Interventional,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,Completed,Phase 1,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,6,COVID-19 Convalescent Plasma,0
NCT04390191,5/7/2020,2/18/2021,Interventional,Early CPAP in COVID-19 Confirmed or Suspected Patients,Terminated,Not Applicable,Icahn School of Medicine at Mount Sinai,Declining cases of COVID in New York due to vaccinations and new treatments for outpatient management,NA,NA,NA,NA,NA,United States,0,3,Continuous Positive Airway Pressure,0
NCT04390139,5/13/2020,10/31/2021,Interventional,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Phase 1/Phase 2,Banc de Sang i Teixits,NA,NA,NA,NA,NA,NA,Spain,0,1,XCEL-UMC-BETA|Placebo,0
NCT04389710,4/15/2020,11/3/2020,Interventional,Convalescent Plasma for the Treatment of COVID-19,Completed,Phase 2,Thomas Jefferson University,NA,NA,NA,NA,NA,NA,United States,0,2,Convalescent Plasma,0
NCT04388683,5/12/2020,11/23/2020,Interventional,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Terminated,Phase 2,Tufts Medical Center,Bellerophon requested study to be stopped.,NA,NA,NA,NA,NA,United States,0,3,Nitric Oxide,0
NCT04388410,8/25/2020,11/30/2020,Interventional,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,NA,NA,NA,NA,Mexico,0,2,convalescent plasma,0
NCT04386291,5/25/2020,4/19/2021,Interventional,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,"Active, not recruiting",Not Applicable,"Research Foundation for Mental Hygiene, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,Anxiety Reduction Training|Kundalini Yoga and Anxiety Reduction Training|Meditation and Anxiety Reduction Training,0
NCT04389372,3/15/2020,3/31/2021,Interventional,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,NA,NA,NA,NA,NA,Italy,0,1,Mindfulness,0
NCT04382547,5/11/2020,6/30/2021,Interventional,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Completed,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,NA,NA,NA,NA,NA,Belarus,0,2,Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Standard treatment according to the Clinical protocols,0
NCT04385940,3/19/2021,1/31/2023,Interventional,Vitamin D and COVID-19 Management,Recruiting,Phase 3,University of Alberta,NA,NA,NA,NA,NA,NA,Canada,0,2,"DdropsÂ® products, 50,000 IU, Oral|Vitamin D3",0
NCT04386239,1/1/2021,12/31/2021,Interventional,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,Early Phase 1,ASST Fatebenefratelli Sacco,NA,NA,NA,NA,NA,NA,Italy,0,2,Sarilumab Prefilled Syringe,0
NCT04382729,4/17/2020,7/31/2020,Interventional,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,Not Applicable,"University of Turin, Italy",NA,NA,NA,NA,NA,NA,Italy,0,0,Neuromuscular Electrical Stimulation|Physical Therapy Exercise,0
NCT04384549,5/20/2020,2/20/2021,Interventional,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,BCG GROUP|PLACEBO GROUP,1
NCT04382586,7/6/2020,2/1/2021,Interventional,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,Completed,Phase 2,BeiGene,NA,NA,NA,NA,NA,NA,United States,0,9,Zanubrutinib|Supportive Care|Placebo,0
NCT04381858,5/6/2020,11/26/2020,Interventional,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,NA,NA,NA,NA,NA,Mexico,0,2,Plasma from COVID-19 convalescent patient|Human immunoglobulin,0
NCT04386850,4/14/2020,11/15/2020,Interventional,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Phase 2/Phase 3,Tehran University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,Oral 25-Hydroxyvitamin D3,0
NCT04382846,5/8/2020,12/1/2030,Interventional,Novel Regimens in COVID-19 Treatment,Recruiting,Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Nitazoxanide,0
NCT04382560,5/2/2020,5/31/2020,Interventional,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,Not Applicable,University of Parma,NA,NA,NA,NA,NA,NA,Italy,0,2,Deep Breathing training|Compassion focused intervention,0
NCT04382092,3/23/2020,4/24/2020,Interventional,Co-infection Management in COVID-19 Critically Ill,Completed,Not Applicable,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,NA,NA,Belgium,0,0,FilmArray Pneumonia,0
NCT04384445,9/8/2020,6/30/2021,Interventional,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Phase 1/Phase 2,Organicell Regenerative Medicine,NA,NA,NA,NA,NA,NA,United States,0,7,Zofin|Placebo,0
NCT04384588,4/7/2020,4/6/2021,Interventional,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Phase 2/Phase 3,Fundacion Arturo Lopez Perez,NA,NA,NA,NA,NA,NA,Chile,0,0,Convalescent Plasma from COVID-19 donors,0
NCT04383002,9/2/2020,5/11/2021,Interventional,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),"Active, not recruiting",Phase 1,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,5,Nitric Oxide,0
NCT04382651,6/11/2020,1/6/2021,Interventional,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,Completed,Phase 2,Novartis,NA,NA,NA,NA,NA,NA,United States,0,16,MAS825|Matching placebo,0
NCT04382040,5/8/2020,11/5/2020,Interventional,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,Phase 2,MGC Pharmaceuticals d.o.o,NA,NA,NA,NA,NA,NA,India|Israel,0,7,ArtemiC|Placebo,0
NCT04381364,5/29/2020,12/1/2021,Interventional,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Phase 2,St Goran's Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,4,Ciclesonide Inhalation Aerosol,0
NCT04383613,5/15/2020,6/1/2021,Interventional,Prone Positioning for Patients on General Medical Wards With COVID19,"Active, not recruiting",Not Applicable,Unity Health Toronto,NA,NA,NA,NA,NA,NA,Canada,0,6,Prone positioning,0
NCT04381377,4/29/2020,4/30/2021,Interventional,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"Active, not recruiting",Phase 2/Phase 3,NPO Petrovax,NA,NA,NA,NA,NA,NA,Russian Federation|Slovakia,0,2,azoximer bromide|Placebo,0
NCT04380935,5/18/2020,10/31/2020,Interventional,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,1,Convalescent plasma|Standard of care,0
NCT04379037,6/27/2020,9/1/2020,Interventional,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Completed,Not Applicable,Nemechek Technologies,NA,NA,NA,NA,NA,NA,Argentina,0,2,Transcutaneous Auricular Vagus Nerve Stimulation,0
NCT04380519,4/23/2020,7/10/2020,Interventional,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Phase 2/Phase 3,R-Pharm,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,RPH-104 80 mg|Olokizumab 64 mg|Placebo,0
NCT04379661,5/7/2020,7/7/2020,Interventional,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,Not Applicable,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,2,Online support Group,0
NCT04381000,4/1/2020,5/29/2020,Interventional,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,Not Applicable,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,NA,NA,NA,NA,NA,Greece,0,2,Exercise Group,0
NCT04380402,6/25/2020,12/31/2021,Interventional,Atorvastatin as Adjunctive Therapy in COVID-19,Recruiting,Phase 2,Mount Auburn Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Atorvastatin,0
NCT04379076,5/14/2020,10/30/2021,Interventional,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Phase 2,Revimmune,NA,NA,NA,NA,NA,NA,United Kingdom,0,5,Interleukin-7|Placebos,0
NCT04376476,5/5/2020,6/5/2021,Interventional,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,1,Blood sample|Low or upper respiratory tract sample|Stool collection or fecal swab|Blood sample for whole genome sequencing|phone call,0
NCT04380376,4/30/2020,10/30/2020,Interventional,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Phase 2,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",NA,NA,NA,NA,NA,NA,Russian Federation,0,1,Melphalan|Standard of care,0
NCT04377620,5/24/2020,2/26/2021,Interventional,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Terminated,Phase 3,Incyte Corporation,Study terminated by sponsor,NA,NA,NA,NA,NA,United States|Russian Federation,0,10,Placebo|Ruxolitinib,0
NCT04377308,5/1/2020,4/20/2021,Interventional,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Phase 4,University of Toledo Health Science Campus,NA,NA,NA,NA,NA,NA,United States,0,0,Fluoxetine,0
NCT04380961,4/24/2020,4/9/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Completed,Phase 2,"Janssen Pharmaceutica N.V., Belgium",NA,NA,NA,NA,NA,NA,United States,0,16,Sirukumab|Placebo|Standard of Care (SOC),0
NCT04379531,4/25/2020,5/22/2020,Interventional,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,Not Applicable,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Low-dose Chest CT,0
NCT04377750,4/8/2020,4/29/2020,Interventional,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Phase 4,Hadassah Medical Organization,NA,NA,NA,NA,NA,NA,Israel,0,0,Tocilizumab,0
NCT04373096,12/7/2020,8/31/2021,Interventional,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Recruiting,Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,3,current IPAC-UHN PPE|modified IPAC-UHN PPE,0
NCT04379375,7/27/2020,9/30/2020,Interventional,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,Not Applicable,Medical College of Wisconsin,Slow enrollment rate,NA,NA,NA,NA,NA,United States,0,6,Nudge,0
NCT04376788,5/20/2020,7/1/2020,Interventional,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Phase 2,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,1,exchange blood transfusion from normal donor|plasma from convalescent patients with COVID-19|Methylene Blue 5 MG/ML,0
NCT04380701,4/23/2020,4/30/2023,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,NA,NA,NA,NA,NA,Germany,0,5,BNT162a1|BNT162b1|BNT162b2|BNT162c2,1
NCT04378803,5/13/2020,8/4/2020,Interventional,Mindfulness Training for Seniors,Completed,Not Applicable,University of Miami,NA,NA,NA,NA,NA,NA,United States,0,3,Mindfulness training (MT) Connect,0
NCT04379154,4/14/2020,4/30/2021,Interventional,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,3,Volatile Organic Compounds analysis,0
NCT04379271,6/11/2020,1/12/2021,Interventional,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Completed,Phase 2/Phase 3,Immunic AG,NA,NA,NA,NA,NA,NA,Bulgaria|Germany,0,3,IMU-838|Placebo,0
NCT04377789,3/20/2020,7/31/2020,Interventional,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,5,Quercetin Prophylaxis|Quercetin Treatment,0
NCT04376814,3/29/2020,4/5/2020,Interventional,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,Not Applicable,Baqiyatallah Medical Sciences University,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,2,Favipiravir|Hydroxychloroquine|Lopinavir / Ritonavir,0
NCT04377477,5/10/2020,8/10/2021,Interventional,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,Not Applicable,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,NA,NA,NA,NA,NA,NA,Italy,0,2,Single fraction whole lung radiotherapy,0
NCT04378712,1/21/2020,3/23/2020,Interventional,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,Not Applicable,Guangzhou Institute of Respiratory Disease,NA,NA,NA,NA,NA,NA,China,0,2,Hydrogen Oxygen Generator with Nebulizer|Standard-of-care,0
NCT04377165,5/6/2020,8/26/2020,Interventional,Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities,Terminated,Not Applicable,The University of Queensland,"Engagement issues, poor recruitment to study",NA,NA,NA,NA,NA,NA,0,3,Gamification|Newsfeed function,0
NCT04374942,4/30/2020,3/31/2021,Interventional,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Terminated,Phase 3,"University Health Network, Toronto","Due to unproven issues associated with hydroxychloroquine use and safety, further complicated by media and political misinformation which in effect rendered all global studies on HCQ to stop enrolling participants.",NA,NA,NA,NA,NA,Canada,0,2,Hydroxychloroquine|Placebo oral tablet,0
NCT04374591,8/1/2020,11/1/2020,Interventional,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",Not Applicable,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Sodium Bicarbonate,0
NCT04375124,4/25/2020,8/31/2020,Interventional,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,2,Biological/Vaccine: Angiotensin peptide (1-7) derived plasma,0
NCT04374487,5/9/2020,8/9/2021,Interventional,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Phase 2,Max Healthcare Insititute Limited,NA,NA,NA,NA,NA,NA,India,0,1,Convalescent Plasma|Standard Care Therapy,0
NCT04374032,5/1/2020,10/7/2020,Interventional,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,Completed,Phase 2/Phase 3,Bosnalijek D.D,NA,NA,NA,NA,NA,NA,Bosnia and Herzegovina,0,3,metenkefalin + tridecactide|The standard of care,0
NCT04372602,10/12/2020,11/30/2021,Interventional,Duvelisib to Combat COVID-19,Recruiting,Phase 2,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,7,Duvelisib|Peripheral blood draw|Placebo,0
NCT04374539,4/29/2020,5/5/2021,Interventional,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,NA,NA,NA,NA,NA,Spain,0,1,Plasma exchange|Standar medical treatmen,0
NCT04376840,5/28/2020,1/28/2022,Interventional,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,Not Applicable,CHU de Reims,NA,NA,NA,NA,NA,NA,France,0,1,Blood sample and data record,0
NCT04373824,4/25/2020,7/25/2020,Interventional,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,Not Applicable,Max Healthcare Insititute Limited,NA,NA,NA,NA,NA,NA,India,0,0,Ivermectin,0
NCT04375774,5/31/2020,5/31/2020,Interventional,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,Not Applicable,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,NA,NA,Belgium,0,0,FFP2|Facial mask|MFS,0
NCT04375202,4/18/2020,10/31/2022,Interventional,Colchicine in COVID-19: a Pilot Study,Recruiting,Phase 2,University Of Perugia,NA,NA,NA,NA,NA,NA,Italy,0,2,Colchicine 1 MG Oral Tablet,0
NCT04374565,5/5/2020,4/5/2021,Interventional,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Phase 2,University of Virginia,NA,NA,NA,NA,NA,NA,United States,0,5,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,0
NCT04374461,5/1/2020,5/31/2023,Interventional,A Study of N-acetylcysteine in Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,10,N-acetylcysteine|Peripheral Blood,0
NCT04375397,6/6/2020,5/10/2021,Interventional,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,Completed,Phase 2,AbbVie,NA,NA,NA,NA,NA,NA,United States,0,14,Ibrutinib|Placebo,0
NCT04374019,5/1/2020,5/31/2022,Interventional,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Phase 2,University of Kentucky,NA,NA,NA,NA,NA,NA,United States,0,4,Ivermectin|Camostat Mesilate|Artemesia annua|Artesunate,0
NCT04373382,7/27/2020,2/28/2022,Interventional,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,"Mount Sinai Hospital, Canada",NA,NA,NA,NA,NA,NA,Canada,0,3,Enriched Survey Feedback|Peer Resilience Champion,0
NCT04372979,9/14/2020,5/31/2021,Interventional,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,NA,NA,France,0,3,Transfusion of SARS-CoV-2 Convalescent Plasma.|Transfusion of standard Plasma.,0
NCT04376684,5/28/2020,7/15/2021,Interventional,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,Completed,Phase 2,GlaxoSmithKline,NA,NA,NA,NA,NA,NA,Poland|United States|Argentina|Belgium|Brazil|Canada|Chile|Colombia|France|India|Italy|Japan|Mexico|Netherlands|Peru|Russian Federation|South Africa|Spain|United Kingdom,0,25,Otilimab|Placebo 1|Placebo 2|Standard of care,0
NCT04376034,4/16/2020,3/30/2021,Interventional,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Phase 3,West Virginia University,NA,NA,NA,NA,NA,NA,United States,0,0,Convalescent Plasma 1 Unit|Convalescent Plasma 2 Units|Standard of Care,0
NCT04373161,3/20/2020,4/22/2020,Interventional,Home Pulse Oximeter Use in Patients With COVID-19,Completed,Not Applicable,Swedish Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Home Pulse Oximetry Monitoring,0
NCT04372680,4/22/2020,10/22/2021,Interventional,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,1,CTUS examination,0
NCT04366908,5/7/2020,12/30/2021,Interventional,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Recruiting,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,NA,NA,NA,NA,NA,Spain,0,3,BAT + Calcifediol|BAT,0
NCT04365439,7/20/2020,12/20/2020,Interventional,Convalescent Plasma for COVID-19,"Active, not recruiting",Not Applicable,"Ente Ospedaliero Cantonale, Bellinzona",NA,NA,NA,NA,NA,NA,Switzerland,0,1,Blood plasma,0
NCT04373044,5/1/2020,5/12/2021,Interventional,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Terminated,Phase 2,University of Southern California,The study was terminated after the release of results of ACTT-2 (NCT04401579).,NA,NA,NA,NA,NA,United States,0,5,Baricitinib|Hydroxychloroquine|Placebo Administration,0
NCT04368260,4/24/2020,7/31/2020,Interventional,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,Not Applicable,University of Virginia,NA,NA,NA,NA,NA,NA,United States,0,0,Control swab|Prototype swab,0
NCT04371029,4/28/2020,9/9/2020,Interventional,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Completed,Not Applicable,"University Hospital, Bordeaux",NA,NA,NA,NA,NA,NA,France,0,3,PSG,0
NCT04368845,5/11/2020,3/31/2021,Interventional,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,Not Applicable,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,NA,NA,NA,NA,NA,Greece,0,2,Telerehabilitation,0
NCT04367662,4/9/2020,5/14/2020,Interventional,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,Not Applicable,"University Hospital, Rouen",NA,NA,NA,NA,NA,NA,France,0,1,blood sampling,0
NCT04368377,4/6/2020,4/23/2020,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,NA,NA,NA,NA,NA,Italy,0,0,Tirofiban Injection|Clopidogrel|Acetylsalicylic acid|Fondaparinux,0
NCT04372693,9/1/2020,7/30/2021,Interventional,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,6,impliminting Online Distance Learning,0
NCT04371367,4/27/2020,3/30/2021,Interventional,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Completed,Phase 2,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,3,avdoralimab|Placebo,0
NCT04370236,10/21/2020,2/28/2021,Interventional,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Phase 2/Phase 3,"Inmune Bio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,INB03|Placebo,0
NCT04371393,4/30/2020,1/14/2021,Interventional,MSCs in COVID-19 ARDS,"Active, not recruiting",Phase 3,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States,0,18,Remestemcel-L|Placebo,0
NCT04371510,4/22/2020,10/22/2020,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,0,blood sample,0
NCT04370782,4/28/2020,9/30/2020,Interventional,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,NA,NA,NA,NA,NA,United States,0,2,Hydroxychloroquine|Azithromycin|Zinc Sulfate|Doxycycline,0
NCT04369742,4/15/2020,4/1/2021,Interventional,Treating COVID-19 With Hydroxychloroquine (TEACH),Terminated,Phase 2,NYU Langone Health,Investigator decision,NA,NA,NA,NA,NA,United States,0,4,Hydroxychloroquine (HCQ)|Pacebo: Calcium citrate,0
NCT04369456,4/22/2020,10/22/2020,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,1,blood sample,0
NCT04369365,4/27/2020,8/27/2020,Interventional,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Phase 2,Medical University of Vienna,NA,NA,NA,NA,NA,NA,Austria,0,1,Azithromycin 500 milligram (mg) oral Tablet|Placebo,0
NCT04369820,3/31/2020,9/30/2020,Interventional,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,1,draw blood,0
NCT04371978,10/1/2020,4/4/2021,Interventional,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Terminated,Phase 3,Rabin Medical Center,End of COVID-19 outbreak in Israel,NA,NA,NA,NA,NA,Israel,0,4,Linagliptin 5 MG,0
NCT04369066,4/28/2020,12/31/2021,Interventional,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","Active, not recruiting",Not Applicable,Institut Curie,NA,NA,NA,NA,NA,NA,France,0,6,Blood samples (collection of 5 mL of blood in a dry tube)|Nasopharyngeal swabs,0
NCT04372004,5/8/2020,5/31/2021,Interventional,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Phase 1,Texas Cardiac Arrhythmia Research Foundation,NA,NA,NA,NA,NA,NA,United States,0,2,diagnostic tests for COVID-19 infection,0
NCT04367636,4/30/2020,9/30/2021,Interventional,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,Recruiting,Not Applicable,University Ghent,NA,NA,NA,NA,NA,NA,Belgium,0,1,Behavioral: OCAT-sham|Behavioral: OCAT|psycho-education video,0
NCT04366960,5/14/2020,5/25/2021,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Completed,Phase 3,Niguarda Hospital,NA,NA,NA,NA,NA,NA,Italy,0,4,Enoxaparin,0
NCT04367831,5/2/2020,5/12/2021,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Completed,Phase 4,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,3,Enoxaparin Prophylactic Dose|Heparin Infusion|Heparin SC|Enoxaparin/Lovenox Intermediate Dose,0
NCT04371965,9/1/2020,10/23/2020,Interventional,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Phase 2,Poitiers University Hospital,NA,NA,NA,NA,NA,NA,France,0,3,Povidone-Iodine,0
NCT04368299,5/1/2020,12/17/2021,Interventional,Telemedicine for Follow-up of Systemic Lupus Erythematosus,"Active, not recruiting",Not Applicable,Chinese University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,2,Telemedicine|Standard care,0
NCT04369794,8/10/2020,6/30/2021,Interventional,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Phase 4,"University of Campinas, Brazil",NA,NA,NA,NA,NA,NA,Brazil,0,1,BCG|Placebo,1
NCT04365309,2/10/2020,4/30/2020,Interventional,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Phase 2/Phase 3,Xijing Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Aspirin 100mg,0
NCT04370886,4/30/2020,4/30/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,Not Applicable,Guangzhou Blood Center,NA,NA,NA,NA,NA,NA,China,0,2,blood donation SMS,0
NCT04371601,3/1/2020,12/31/2021,Interventional,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Early Phase 1,Fuzhou General Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Oseltamivir|hormones|oxygen therapy|mesenchymal stem cells,0
NCT04368000,4/29/2020,8/6/2020,Interventional,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,Not Applicable,University of Utah,Study was terminated due to lack of adherence to the protocol in the intervention arm.,NA,NA,NA,NA,NA,United States,0,3,Intermittent prone positioning instructions|Usual care positioning with no instructions,0
NCT04366297,1/12/2020,2/25/2020,Interventional,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,Not Applicable,Lazarski University,NA,NA,NA,NA,NA,NA,Poland,0,0,Intravenous access|Intraosseous access,0
NCT04367545,4/16/2020,5/17/2020,Interventional,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,Not Applicable,"University Hospital, Rouen",NA,NA,NA,NA,NA,NA,France,0,2,Saliva collection,0
NCT04367077,4/28/2020,1/31/2023,Interventional,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Phase 2/Phase 3,"Athersys, Inc",NA,NA,NA,NA,NA,NA,United States,0,7,MultiStem|Placebo,0
NCT04366245,4/23/2020,12/31/2021,Interventional,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,NA,NA,NA,NA,NA,Spain,0,4,Hyperimmune plasma|Standard of care for SARS-CoV-2 infection,0
NCT04366063,4/5/2020,6/6/2020,Interventional,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Royan Institute,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,Cell therapy protocol 1|Cell therapy protocol 2,0
NCT04365972,4/23/2020,4/30/2020,Interventional,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Completed,Not Applicable,Tel Aviv University,NA,NA,NA,NA,NA,NA,Israel,0,1,Attention Bias Modification (ABM),0
NCT04365608,3/20/2020,11/30/2020,Interventional,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Completed,Not Applicable,Lazarski University,NA,NA,NA,NA,NA,NA,Poland,0,2,Direct laryngoscopy|Vie Scope laryngoscopy,0
NCT04366947,4/14/2020,9/20/2020,Interventional,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Completed,Not Applicable,Lazarski University,NA,NA,NA,NA,NA,NA,Poland,0,1,NIOÂ® (Intraosseous access)|Standard of Care (Intravenous access),0
NCT04366232,8/19/2020,10/2/2020,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,NA,NA,NA,NA,NA,France,0,5,Anakinra alone (stages 2b/3)|Anakinra and Ruxolitinib (overcome stage 3)|Standard of care,0
NCT04366180,4/24/2020,6/30/2020,Interventional,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,Not Applicable,Biosearch S.A.,NA,NA,NA,NA,NA,NA,Spain,0,1,Probiotic|Control,0
NCT04365985,4/29/2020,4/1/2021,Interventional,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Terminated,Phase 2,William Beaumont Hospitals,"Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality",NA,NA,NA,NA,NA,United States,0,5,Naltrexone|Ketamine|Placebo,0
NCT04366323,4/27/2020,10/31/2021,Interventional,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,NA,NA,NA,NA,NA,Spain,0,2,ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,0
NCT04365738,3/11/2020,4/10/2020,Interventional,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,Not Applicable,Istanbul Bilgi University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Rehabilitation,0
NCT04366817,4/27/2020,8/31/2021,Interventional,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,"Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,psychological assessment,0
NCT04370262,4/7/2020,9/7/2020,Interventional,Multi-site Adaptive Trials for COVID-19,Completed,Phase 3,Northwell Health,NA,NA,NA,NA,NA,NA,United States,0,3,SOC + Intravenous Famotidine|SOC + Placebo,0
NCT04363606,5/27/2020,4/30/2022,Interventional,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,NA,NA,NA,NA,France,0,5,Questionnaires|blood test|Maximal effort test|actigraphy|Neuromuscular evaluation|stool analysis|food diary,0
NCT04363853,6/1/2020,6/1/2021,Interventional,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Phase 2,Instituto Nacional de Cancerologia de Mexico,NA,NA,NA,NA,NA,NA,Mexico,0,3,Tocilizumab,0
NCT04363593,5/4/2020,11/16/2020,Interventional,Serology COVID-19 From the Cornwall Hospital Union,Completed,Not Applicable,Centre Hospitalier de Cornouaille,NA,NA,NA,NA,NA,NA,France,0,2,Serological test|Serum test,0
NCT04363541,8/27/2020,4/30/2022,Interventional,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,Not Applicable,Instituto Nacional de Perinatologia,NA,NA,NA,NA,NA,NA,Mexico,0,2,Electric pad for human external pain therapy,0
NCT04363437,4/26/2020,5/31/2020,Interventional,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Phase 2,Maimonides Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Colchicine|Usual Care,0
NCT04364009,4/27/2020,10/20/2020,Interventional,Anakinra for COVID-19 Respiratory Symptoms,Terminated,Phase 3,"University Hospital, Tours",Efficiency and safety reasons,NA,NA,NA,NA,NA,France,0,5,Anakinra plus oSOC|oSOC,0
NCT04359875,4/30/2020,6/30/2020,Interventional,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Completed,Not Applicable,"University Hospital, Tours",NA,NA,NA,NA,NA,NA,France,0,1,Phone-call screening and management by a medical student/general practitioner tandem,0
NCT04364828,10/21/2020,4/30/2022,Interventional,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Recruiting,Not Applicable,University Hospital Tuebingen,NA,NA,NA,NA,NA,NA,Germany,0,3,Whole Genome Analysis|T-cell receptor (TCR) repertoire|SARS-CoV-2 viral composition,0
NCT04361448,4/20/2020,6/30/2020,Interventional,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Terminated,Not Applicable,Jessa Hospital,Insufficient sample number,NA,NA,NA,NA,NA,Belgium,0,1,samling of oropharynx and nasopharynx,0
NCT04362111,7/29/2020,1/31/2022,Interventional,Early Treatment of Cytokine Storm Syndrome in Covid-19,"Active, not recruiting",Phase 3,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,2,Anakinra|Normal saline,0
NCT04361214,5/5/2020,2/28/2021,Interventional,Leflunomide in Mild COVID-19 Patients,Recruiting,Phase 1,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,5,Leflunomide,0
NCT04361396,6/16/2020,12/31/2021,Interventional,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,Not Applicable,Centre Hospitalier RenÃ© Dubos,NA,NA,NA,NA,NA,NA,France,0,6,Collection of samples,0
NCT04365101,5/13/2020,12/30/2021,Interventional,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,"Active, not recruiting",Phase 1/Phase 2,Celularity Incorporated,NA,NA,NA,NA,NA,NA,United States,0,19,CYNK-001,0
NCT04361916,4/21/2020,6/30/2020,Interventional,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,Not Applicable,Mario Negri Institute for Pharmacological Research,interrupted early due to the drastic reduction in the number of cases,NA,NA,NA,NA,NA,Italy,0,2,home care monitoring,0
NCT04359953,4/25/2020,4/30/2022,Interventional,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,NA,NA,NA,NA,NA,France,0,2,Hydroxychloroquine|Azithromycin|Telmisartan,0
NCT04364594,3/26/2020,4/24/2020,Interventional,COVID-19 Search in Conjunctival Cells,Completed,Not Applicable,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,NA,NA,NA,NA,NA,Italy,0,2,conjunctival swab,0
NCT04359537,5/1/2020,8/25/2020,Interventional,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Phase 2,Shaheed Zulfiqar Ali Bhutto Medical University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Hydroxychloroquine Sulfate 200 MG|Placebo,0
NCT04362189,6/30/2020,10/31/2021,Interventional,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,NA,NA,NA,NA,NA,United States,0,8,HB-adMSC|Placebo,0
NCT04360551,7/1/2020,6/30/2021,Interventional,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Phase 2,University of Hawaii,NA,NA,NA,NA,NA,NA,United States,0,1,Telmisartan 40mg|Placebo,0
NCT04363346,5/14/2020,1/31/2022,Interventional,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,"Active, not recruiting",Phase 1,"Masonic Cancer Center, University of Minnesota",NA,NA,NA,NA,NA,NA,United States,0,3,FT516,0
NCT04363502,5/7/2020,5/31/2022,Interventional,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Phase 2,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,7,Clazakizumab|Placebo,0
NCT04363385,5/31/2020,5/31/2022,Interventional,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,Not Applicable,Centre Hospitalier Intercommunal Creteil,NA,NA,NA,NA,NA,NA,France,0,5,Biological test,0
NCT04361253,4/30/2020,4/1/2021,Interventional,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Terminated,Phase 3,Brigham and Women's Hospital,Futility,NA,NA,NA,NA,NA,United States,0,3,High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Standard Plasma (FFP),0
NCT04363749,4/27/2020,1/11/2021,Interventional,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,3,"hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint",0
NCT04363450,4/27/2020,3/31/2021,Interventional,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Phase 3,Louisiana State University Health Sciences Center in New Orleans,NA,NA,NA,NA,NA,NA,United States,0,2,Hydroxychloroquine|Placebo,0
NCT04360811,4/17/2020,4/30/2021,Interventional,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,0,COVID 19 diagnostic test by PCR,0
NCT04359862,4/16/2020,3/31/2021,Interventional,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Terminated,Phase 4,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,Low recruitment ratio,NA,NA,NA,NA,NA,Spain,0,4,Sevoflurane|Propofol,0
NCT04361526,4/17/2020,7/31/2020,Interventional,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,Not Applicable,Hospital Clinic of Barcelona,NA,NA,NA,NA,NA,NA,Spain,0,0,Cytokine Adsorption,0
NCT04363528,4/24/2020,12/30/2020,Interventional,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,"Active, not recruiting",Not Applicable,Versailles Hospital,NA,NA,NA,NA,NA,NA,France,0,2,Doppler Echo,0
NCT04362332,4/14/2020,6/8/2020,Interventional,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Phase 4,UMC Utrecht,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions",NA,NA,NA,NA,NA,Netherlands,0,1,Chloroquine Sulfate|Hydroxychloroquine|Standard supportive care,0
NCT04358926,4/30/2020,10/15/2020,Interventional,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,Not Applicable,Assaf-Harofeh Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,5,Hyperbaric oxygen therapy,0
NCT04361838,5/21/2020,4/30/2021,Interventional,The COVID-19 ICU PRAYER Study,Recruiting,Not Applicable,Kansas City Heart Rhythm Institute,NA,NA,NA,NA,NA,NA,United States,0,3,prayer,0
NCT04357782,4/16/2020,10/13/2020,Interventional,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Completed,Phase 1/Phase 2,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,NA,NA,NA,NA,NA,United States,0,4,L-ascorbic acid,0
NCT04359901,4/10/2020,4/30/2022,Interventional,Sarilumab for Patients With Moderate COVID-19 Disease,"Active, not recruiting",Phase 2,VA Boston Healthcare System,NA,NA,NA,NA,NA,NA,United States,0,6,SARILUMAB,0
NCT04358406,7/30/2020,5/1/2021,Interventional,Rhu-pGSN for Severe Covid-19 Pneumonia,"Active, not recruiting",Phase 2,BioAegis Therapeutics Inc.,NA,NA,NA,NA,NA,NA,Romania|Spain,0,4,Recombinant human plasma gelsolin (Rhu-pGSN)|Placebo,0
NCT04357340,4/2/2020,4/30/2020,Interventional,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,Not Applicable,Tehran University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,Pulmonary Physiotherapy Techniques,0
NCT04355234,5/4/2020,8/31/2021,Interventional,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,3,identify SARS-CoV-2 infection by serology|collection of biological samples,0
NCT04359680,5/13/2020,3/29/2021,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,NA,NA,NA,NA,NA,United States,0,5,Nitazoxanide|Placebo|Vitamin Super B-Complex,0
NCT04355351,5/5/2020,10/22/2021,Interventional,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,Not Applicable,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,NA,NA,France,0,3,blood sampling|additional blood tubes,0
NCT04358783,4/27/2020,5/1/2021,Interventional,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,Completed,Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,NA,NA,NA,NA,NA,NA,Mexico,0,3,Plasma|Best Available Therapy,0
NCT04355143,5/1/2020,9/8/2021,Interventional,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Active, not recruiting",Phase 2,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,4,Colchicine Tablets|Current care per UCLA treating physicians,0
NCT04358614,3/16/2020,4/5/2020,Interventional,Baricitinib Therapy in COVID-19,Completed,Phase 2/Phase 3,Hospital of Prato,NA,NA,NA,NA,NA,NA,Italy,0,0,Baricitinib 4 MG Oral Tablet,0
NCT04357327,4/16/2020,5/31/2020,Interventional,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,Not Applicable,UniversitÃ  degli Studi dell'Insubria,NA,NA,NA,NA,NA,NA,Italy,0,2,rapid salivary test,0
NCT04357106,4/13/2020,7/31/2020,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,NA,NA,NA,NA,NA,Mexico,0,0,Convalescent plasma,0
NCT04355533,7/29/2020,7/31/2022,Interventional,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,6,serology test|nasopharyngeal swab|rectal swab|saliva sample,0
NCT04354155,6/2/2020,6/4/2021,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Completed,Phase 2,Johns Hopkins All Children's Hospital,NA,NA,NA,NA,NA,NA,United States,0,3,Enoxaparin Prefilled Syringe [Lovenox],0
NCT04357990,9/4/2020,3/31/2021,Interventional,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,Not Applicable,Kerecis Ltd.,NA,NA,NA,NA,NA,NA,Iceland,0,2,Viruxal Oral and Nasal Spray|Placebo,0
NCT04355897,4/28/2020,7/31/2020,Interventional,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Early Phase 1,The Christ Hospital,NA,NA,NA,NA,NA,NA,United States,0,3,Convalescent COVID 19 Plasma,0
NCT04357444,10/23/2020,11/2/2020,Interventional,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,4,1: ILT101|2: Placebo Comparator,0
NCT04355637,4/21/2020,6/30/2021,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Completed,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,NA,NA,NA,NA,NA,Argentina|Spain,0,5,Inhaled budesonide,0
NCT04358809,6/30/2020,2/28/2021,Interventional,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,NA,NA,NA,NA,NA,India,0,1,Suspension of heat killed (autoclaved) Mycobacterium w|Placebo,0
NCT04355026,4/10/2020,6/30/2020,Interventional,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Phase 4,General and Teaching Hospital Celje,NA,NA,NA,NA,NA,NA,Slovenia,0,0,Bromhexine Oral Tablet and/or hydroxychloroquine tablet,0
NCT04358003,5/20/2020,12/31/2021,Interventional,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,Not Applicable,Marker Therapeutics AG,NA,NA,NA,NA,NA,NA,United States,0,9,Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra OptiaÂ® Apheresis System (Optia SPD Protocol),0
NCT04354610,4/27/2020,12/19/2020,Interventional,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Completed,Not Applicable,"Central Hospital, Nancy, France",NA,NA,NA,NA,NA,NA,France,0,6,Biological samples specific to research|Clinical examination|Telephone follow-up,0
NCT04356690,5/8/2020,12/31/2021,Interventional,Etoposide in Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Boston Medical Center,NA,NA,NA,NA,NA,NA,United States,0,6,Etoposide,0
NCT04355247,4/14/2020,7/31/2020,Interventional,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Phase 2,Auxilio Mutuo Cancer Center,NA,NA,NA,NA,NA,NA,Puerto Rico,0,0,MethylPREDNISolone 80 Mg/mL Injectable Suspension,0
NCT04355962,4/23/2020,6/25/2021,Interventional,Sevoflurane in COVID-19 ARDS (SevCov),Completed,Phase 3,University of Zurich,NA,NA,NA,NA,NA,NA,Switzerland,0,7,Sevoflurane|Intravenous drug,0
NCT04356833,4/22/2020,4/30/2021,Interventional,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Phase 2,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,2,nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV,0
NCT04351347,6/16/2020,12/1/2030,Interventional,The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,5,Ivermectin,0
NCT04353271,4/17/2020,7/8/2020,Interventional,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Phase 2/Phase 3,University of South Alabama,FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias,NA,NA,NA,NA,NA,United States,0,4,Hydroxychloroquine|Placebo,0
NCT04351542,3/6/2020,4/6/2020,Interventional,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Ayurveda|Usual Care,0
NCT04352348,3/31/2020,5/31/2022,Interventional,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,"Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,5,sweat samples (COVIDOG ancillary study)|blood samples|feces samples (COVI-BIOME ancillary study)|saliva samples|6 minutes walk test|Phone call|Urine samples,0
NCT04353518,6/30/2020,3/30/2021,Interventional,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,NA,NA,NA,NA,NA,India,0,2,Suspension of heat killed (autoclaved) Mycobacterium w|Placebo,0
NCT04352933,5/11/2020,10/31/2020,Interventional,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Hydroxychloroquine - Daily dosing|Hydroxychloroquine - Weekly Dosing|Matched Placebo Hydroxychloroquine,0
NCT04349241,4/18/2020,6/1/2020,Interventional,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Phase 3,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,2,favipiravir|Standard of care therapy,0
NCT04353336,3/23/2020,6/1/2020,Interventional,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,Phase 2/Phase 3,Tanta University,NA,NA,NA,NA,NA,NA,Egypt,0,6,Chloroquine or Hydroxychloroquine,0
NCT04351620,4/30/2020,6/30/2020,Interventional,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Phase 1,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,0,Hydroxychloroquine,0
NCT04351763,5/20/2020,5/25/2021,Interventional,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Completed,Phase 2/Phase 3,Nicolaus Copernicus University,NA,NA,NA,NA,NA,NA,Poland,0,1,Amiodarone|Verapamil,0
NCT04353284,6/9/2020,3/3/2021,Interventional,Camostat Mesylate in COVID-19 Outpatients,Completed,Phase 2,Yale University,NA,NA,NA,NA,NA,NA,United States,0,8,Camostat Mesilate|Placebo,0
NCT04347980,4/17/2020,8/7/2020,Interventional,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Terminated,Phase 3,Centre Chirurgical Marie Lannelongue,ANSM RECOMMANDATION,NA,NA,NA,NA,NA,France,0,2,Dexamethasone and Hydroxychloroquine|Hydroxychloroquine,0
NCT04347382,4/30/2020,8/30/2020,Interventional,Honey & Nigella Sativa Trial Against COVID-19,Completed,Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,NA,NA,NA,NA,NA,Pakistan,0,6,Honey|Nigella Sativa / Black Cumin|Placebos,0
NCT04349371,4/21/2020,1/7/2021,Interventional,Saved From COVID-19,Terminated,Phase 2,Columbia University,Low enrollment.,NA,NA,NA,NA,NA,United States,0,2,Chloroquine|Placebo oral tablet,0
NCT04351724,4/16/2020,12/1/2021,Interventional,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Phase 2/Phase 3,Medical University of Vienna,NA,NA,NA,NA,NA,NA,Austria,0,3,Chloroquine or Hydroxychloroquine|Lopinavir/Ritonavir|Best standard of care|Rivaroxaban|Thromboprophylaxis|Candesartan|non-RAS blocking antihypertensives|Remdesivir|Asunercept 400mg|Asunercept 100mg|Asunercept 25mg|Pentaglobin,0
NCT04347031,4/8/2020,11/1/2020,Interventional,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,Completed,Phase 2/Phase 3,Burnasyan Federal Medical Biophysical Center,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Mefloquine|Hydroxychloroquine|Mefloquine + azithromycin + / - tocilizumab|Hydroxychloroquine + azithromycin + / - tocilizumab,0
NCT04350281,4/9/2020,7/1/2020,Interventional,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Phase 2,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,2,Interferon Beta-1B|Hydroxychloroquine,0
NCT04350736,4/23/2020,6/24/2020,Interventional,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Phase 1,Theravance Biopharma,NA,NA,NA,NA,NA,NA,United Kingdom,0,5,Placebo|TD-0903,0
NCT04349631,4/22/2020,11/24/2020,Interventional,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,Completed,Phase 2,Hope Biosciences,NA,NA,NA,NA,NA,NA,United States,0,10,HB-adMSCs,0
NCT04351789,5/1/2020,4/30/2023,Interventional,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,Not Applicable,"Copenhagen University Hospital, Hvidovre",NA,NA,NA,NA,NA,NA,Denmark,0,1,Psychoeducational intervention,0
NCT04348370,4/20/2020,5/31/2022,Interventional,BCG Vaccine for Health Care Workers as Defense Against COVID 19,"Active, not recruiting",Phase 4,Texas A&M University,NA,NA,NA,NA,NA,NA,United States,0,6,BCG Vaccine|Placebo Vaccine,1
NCT04351191,4/15/2020,8/23/2020,Interventional,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual,NA,NA,NA,NA,NA,Pakistan,0,2,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,0
NCT04346589,4/15/2020,8/31/2020,Interventional,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,Not Applicable,A.O. Ospedale Papa Giovanni XXIII,NA,NA,NA,NA,NA,NA,Italy,0,3,Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,0
NCT04351581,5/18/2020,6/30/2022,Interventional,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19,Recruiting,Not Applicable,"University Hospital, Gentofte, Copenhagen",NA,NA,NA,NA,NA,NA,Denmark,0,5,Discontinuation of ACEi/ARB|Continuation of ACEi/ARB,0
NCT04345679,4/14/2020,6/1/2021,Interventional,Anti COVID-19 Convalescent Plasma Therapy,Recruiting,Early Phase 1,Orthosera Kft.,NA,NA,NA,NA,NA,NA,Hungary,0,3,anti-SARS-CoV-2 convalescent plasma,0
NCT04349410,4/11/2020,9/14/2020,Interventional,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,Phase 2/Phase 3,The Camelot Foundation,NA,NA,NA,NA,NA,NA,United States,0,8,"Hydroxychloroquine, Azithromycin|Hydroxychloroquine, Doxycycline|Hydroxychloroquine, Clindamycin|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Remdesivir|Tocilizumab|Methylprednisolone|Interferon-Alpha2B|Losartan|Convalescent Serum",0
NCT04345549,2/26/2020,3/30/2020,Interventional,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Individualised Ayurveda,0
NCT04350671,4/15/2020,4/20/2020,Interventional,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,Interferon Beta-1A|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine,0
NCT04347174,4/30/2020,8/10/2020,Interventional,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Completed,Not Applicable,Cadila Pharnmaceuticals,NA,NA,NA,NA,NA,NA,India,0,6,Suspension of heat killed (autoclaved) Mycobacterium w|Placebo,0
NCT04348435,5/14/2020,7/9/2021,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",Completed,Phase 2,Hope Biosciences,NA,NA,NA,NA,NA,NA,United States,0,9,HB-adMSCs|Placebos,0
NCT04346667,4/14/2020,8/23/2020,Interventional,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual.,NA,NA,NA,NA,NA,Pakistan,0,2,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,0
NCT04346017,3/20/2020,11/23/2020,Interventional,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Completed,Not Applicable,Brugmann University Hospital,NA,NA,NA,NA,NA,NA,Belgium,0,1,Cytokines dosage|Complement dosage,0
NCT04347915,5/6/2020,1/30/2021,Interventional,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Phase 2,Bukwang Pharmaceutical,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,4,Clevudine|Placebo,0
NCT04348695,4/12/2020,5/13/2020,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,NA,NA,NA,NA,NA,Spain,0,1,Ruxolitinib plus simvastatin|Standard of Care,0
NCT04346797,4/16/2020,9/30/2020,Interventional,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,Eculizumab,0
NCT04346420,4/9/2020,5/1/2020,Interventional,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,Not Applicable,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,NA,NA,Belgium,0,1,Standard interface|Double-Trunk Mask,0
NCT04348383,4/8/2020,4/15/2021,Interventional,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Phase 2,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,NA,NA,NA,NA,NA,Spain,0,4,Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Placebo 250 cc 24 hours continuous infusion for 15 days,0
NCT04345692,3/26/2020,8/31/2020,Interventional,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Phase 3,Queen's Medical Center,RECOVERY Trial results - no efficacy,NA,NA,NA,NA,NA,United States,0,2,Hydroxychloroquine,0
NCT04345601,2/12/2021,10/31/2022,Interventional,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Recruiting,Phase 1/Phase 2,Baylor College of Medicine,NA,NA,NA,NA,NA,NA,United States,0,9,Supportive Care|Mesenchymal Stromal Cells,0
NCT04347239,4/15/2020,8/24/2021,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,NA,NA,NA,NA,NA,United States,0,14,Placebos|Leronlimab (700mg),0
NCT04345848,4/28/2020,6/2/2021,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Terminated,Phase 3,"University Hospital, Geneva",Low recruitement,NA,NA,NA,NA,NA,Switzerland,0,5,Enoxaparin,0
NCT04346628,7/12/2020,4/16/2021,Interventional,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Completed,Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,7,Favipiravir|Placebo|Standard of care treatment,0
NCT04346147,5/7/2020,6/2/2021,Interventional,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,"Active, not recruiting",Phase 2,Hospital Universitario de Fuenlabrada,NA,NA,NA,NA,NA,NA,Spain,0,5,Imatinib tablets|Baricitinib Oral Tablet|Supportive tratment,0
NCT04346927,8/10/2020,10/10/2020,Interventional,Telerehabilitation for Patients Diagnosed With Coronavirus,Completed,Not Applicable,Istinye University,NA,NA,NA,NA,NA,NA,Turkey,0,2,Telerehabilitation|exercise brochure,0
NCT04346446,4/20/2020,5/30/2020,Interventional,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Phase 2,"Institute of Liver and Biliary Sciences, India",NA,NA,NA,NA,NA,NA,India,0,7,Convalescent Plasma Transfusion|Supportive Care|Random Donor Plasma,0
NCT04344210,4/17/2020,9/20/2020,Interventional,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,Not Applicable,Federal University of Rio Grande do Sul,NA,NA,NA,NA,NA,NA,Brazil,0,1,Tele-interventions related to diabetes management and mental well-being,0
NCT04343794,4/1/2020,12/31/2021,Interventional,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,Not Applicable,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,BIOVITALS,0
NCT04341584,4/8/2020,5/10/2020,Interventional,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Anakinra,0
NCT04345289,5/1/2020,6/15/2021,Interventional,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Phase 3,Hvidovre University Hospital,NA,NA,NA,NA,NA,NA,Denmark,0,2,Convalescent anti-SARS-CoV-2 plasma|Infusion placebo,0
NCT04344288,4/21/2020,8/18/2020,Interventional,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Phase 2,Hospices Civils de Lyon,Competent Authority's decision,NA,NA,NA,NA,NA,France,0,4,Prednisone|Control group,0
NCT04343976,6/22/2020,7/30/2021,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Terminated,Phase 2,Massachusetts General Hospital,"Unable to meet enrollment goal, lack of funding.",NA,NA,NA,NA,NA,United States,0,6,Pegylated interferon lambda,0
NCT04344080,4/1/2020,4/10/2021,Interventional,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Completed,Not Applicable,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,NA,NA,Germany,0,2,CytoSorb-Therapy,0
NCT04341675,4/24/2020,7/31/2020,Interventional,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,University of Cincinnati,NA,NA,NA,NA,NA,NA,United States,0,4,Sirolimus|Placebo,0
NCT04344730,4/10/2020,12/31/2021,Interventional,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,"Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Dexamethasone injection|placebo|conventional oxygen|CPAP|HFNO|mechanical ventilation,0
NCT04344184,12/18/2020,3/31/2022,Interventional,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Recruiting,Phase 2,Virginia Commonwealth University,NA,NA,NA,NA,NA,NA,United States,0,9,L-ascorbic acid|Placebo,0
NCT04342182,4/8/2020,7/1/2021,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,11,Convalescent plasma,0
NCT04341207,4/3/2020,4/30/2022,Interventional,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",NA,NA,NA,NA,NA,NA,France,0,0,Hydroxychloroquine|Azithromycin,0
NCT04344600,6/29/2020,9/24/2021,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Terminated,Phase 2,Johns Hopkins University,Single center study with low enrollment,NA,NA,NA,NA,NA,United States,0,6,Peginterferon lambda alfa-1a subcutaneous injection|Saline,0
NCT04345276,3/18/2020,4/15/2020,Interventional,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,Huoshenshan Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Danoprevir+Ritonavir,0
NCT04342650,4/8/2020,5/14/2020,Interventional,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,NA,NA,NA,NA,NA,Brazil,0,NA,Chloroquine Diphosphate|Placebo oral tablet,0
NCT04344015,4/13/2020,6/2/2020,Interventional,COVID-19 Plasma Collection,Completed,Not Applicable,Thomas Jefferson University,NA,NA,NA,NA,NA,NA,United States,0,3,Plasma Donation,0
NCT04343755,4/9/2020,4/30/2022,Interventional,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,NA,NA,NA,NA,NA,United States,0,6,Convalescent Plasma,0
NCT04342221,3/29/2020,2/26/2021,Interventional,Hydroxychloroquine for COVID-19,Terminated,Phase 3,University Hospital Tuebingen,Reduced acceptance of IMP,NA,NA,NA,NA,NA,Germany,0,3,Hydroxychloroquine Sulfate|Placebo,0
NCT04344444,4/13/2020,4/10/2021,Interventional,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Phase 3,LCMC Health,NA,NA,NA,NA,NA,NA,United States,0,1,Hydroxychloroquine|Azithromycin,0
NCT04342689,6/3/2020,3/1/2022,Interventional,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Phase 2/Phase 3,Yale University,NA,NA,NA,NA,NA,NA,United States,0,6,Dietary Supplement containing resistant starch|Placebo Starch,0
NCT04344379,4/17/2020,6/18/2020,Interventional,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Completed,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,4,hydroxychloroquine|azithromycin|hydroxychloroquine placebo,0
NCT04343651,4/1/2020,7/21/2020,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,Completed,Phase 2,"CytoDyn, Inc.",NA,NA,NA,NA,NA,NA,United States,0,8,Placebos|Leronlimab (700mg),0
NCT04341441,4/7/2020,12/15/2020,Interventional,Will Hydroxychloroquine Impede or Prevent COVID-19,Terminated,Phase 3,Henry Ford Health System,"Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.",NA,NA,NA,NA,NA,United States,0,5,Hydroxychloroquine - Daily Dosing|Hydroxychloroquine - Weekly Dosing|Placebo oral tablet|Monitoring Visit - Baseline|Monitoring Visit - Week 4|Monitoring Visit - Week 8|Weekly Assessment,0
NCT04342169,4/4/2020,6/1/2021,Interventional,University of Utah COVID-19 Hydrochloroquine Trial,"Active, not recruiting",Phase 2,University of Utah,NA,NA,NA,NA,NA,NA,United States,0,4,Hydroxychloroquine|Placebo oral tablet,0
NCT04343248,5/12/2020,6/30/2021,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,NA,NA,NA,NA,NA,United States,0,6,Nitazoxanide|Placebo|Vitamin Super B-Complex,0
NCT04344457,4/16/2020,6/20/2020,Interventional,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Phase 1/Phase 2,"Perseverance Research Center, LLC",NA,NA,NA,NA,NA,NA,United States,0,3,NA,0
NCT04344561,5/25/2020,5/1/2022,Interventional,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,Not Applicable,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,4,Postural Positioning,0
NCT04344431,4/14/2020,4/30/2022,Interventional,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Phase 2/Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,NA,NA,France,0,2,Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device),0
NCT04344106,4/1/2020,4/15/2020,Interventional,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,Not Applicable,Centre Hospitalier Intercommunal Aix-Pertuis,NA,NA,NA,NA,NA,NA,France,0,0,Prone positioning,0
NCT04339660,2/1/2020,6/30/2020,Interventional,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Phase 1/Phase 2,Puren Hospital Affiliated to Wuhan University of Science and Technology,NA,NA,NA,NA,NA,NA,China,0,0,UC-MSCs|Placebo,0
NCT04340544,4/22/2020,10/12/2020,Interventional,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Phase 2,University Hospital Tuebingen,"It appeared to be impossible for the study centres to recruit the targeted number of patients, due to reduced incidence and reduced acceptance to IMP",NA,NA,NA,NA,NA,Germany,0,2,Hydroxychloroquine|Placebo,0
NCT04340050,4/10/2020,12/23/2020,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,5,anti-SARS-CoV-2 convalescent plasma,0
NCT04339426,4/20/2020,7/31/2021,Interventional,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Phase 2,HonorHealth Research Institute,NA,NA,NA,NA,NA,NA,United States,0,5,Atovaquone/Azithromycin,0
NCT04337996,7/13/2020,1/13/2021,Interventional,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,Not Applicable,Tourcoing Hospital,NA,NA,NA,NA,NA,NA,France,0,3,COVID-19 diagnostic test,0
NCT04341727,4/4/2020,4/1/2021,Interventional,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",Terminated,Phase 3,Washington University School of Medicine,DSMB recommended study suspension slow accrual,NA,NA,NA,NA,NA,United States,0,2,Hydroxychloroquine Sulfate|Azithromycin|Chloroquine Sulfate,0
NCT04337918,5/8/2020,1/31/2021,Interventional,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Completed,Phase 2,Sanotize Research and Development corp.,NA,NA,NA,NA,NA,NA,Canada,0,7,NORS (Nitric Oxide Releasing Solution)|NORS (Nitric Oxide Releasing Solution),0
NCT04335097,4/22/2020,4/8/2022,Interventional,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,Not Applicable,Oslo University Hospital,NA,NA,NA,NA,NA,NA,Norway,0,4,Biosensors,0
NCT04336332,4/1/2020,6/30/2022,Interventional,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,"Active, not recruiting",Phase 2,"Rutgers, The State University of New Jersey",NA,NA,NA,NA,NA,NA,United States,0,5,Hydroxychloroquine Sulfate + Azithromycin|Hydroxychloroquine Sulfate,0
NCT04335305,4/9/2020,12/31/2020,Interventional,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Phase 2,MedSIR,NA,NA,NA,NA,NA,NA,Spain,0,8,Tocilizumab|Pembrolizumab (MK-3475),0
NCT04338828,4/18/2020,4/30/2021,Interventional,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Nitric Oxide Gas|Inhaled Supplemental Oxygen,0
NCT04334460,5/4/2020,11/11/2020,Interventional,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Phase 2,Blade Therapeutics,NA,NA,NA,NA,NA,NA,United States|Brazil,0,10,BLD-2660,0
NCT04333654,4/12/2020,5/26/2020,Interventional,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Phase 1,Sanofi,Rate of enrollment too slow to allow completion in a reasonable timeframe,NA,NA,NA,NA,NA,United States|Belgium|France|Netherlands,0,7,Hydroxychloroquine SAR321068|Placebo,0
NCT04339712,4/2/2020,12/1/2020,Interventional,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,NA,NA,NA,NA,NA,Greece,0,5,Anakinra|Tocilizumab,0
NCT04333914,4/15/2020,7/6/2021,Interventional,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,"Active, not recruiting",Phase 2,Centre Leon Berard,NA,NA,NA,NA,NA,NA,France,0,8,Autophagy inhibitor (GNS651)|Standard of care|Avdoralimab|Monalizumab,0
NCT04336904,3/25/2020,7/31/2020,Interventional,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Phase 3,ASST Fatebenefratelli Sacco,NA,NA,NA,NA,NA,NA,Italy,0,1,Favipiravir|Placebo,0
NCT04335201,5/20/2020,6/20/2021,Interventional,Defibrotide in COVID-19 Pneumonia,Recruiting,Phase 2,IRCCS San Raffaele,NA,NA,NA,NA,NA,NA,Italy,0,1,Defibrotide Injection,0
NCT04334434,7/30/2020,9/15/2020,Interventional,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Completed,Not Applicable,Istanbul University-Cerrahpasa,NA,NA,NA,NA,NA,NA,Turkey,0,4,Telerehabilitation,0
NCT04328285,4/14/2020,3/30/2022,Interventional,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Phase 3,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,NA,NA,NA,NA,France,0,8,Hydroxychloroquine|Placebo of Hydroxychloroquine|Lopinavir and ritonavir|Placebo of LPV/r Tablets,0
NCT04335123,4/4/2020,6/21/2020,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,NA,NA,NA,NA,NA,United States,0,5,Losartan,0
NCT04337008,4/3/2020,6/3/2020,Interventional,Renin Angiotensin System - CoronaVirus,Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,1,blood draw,0
NCT04336462,2/15/2020,2/21/2020,Interventional,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,Not Applicable,Shanghai Asclepius Meditec Inc.,NA,NA,NA,NA,NA,NA,China,0,0,oxyhydrogen|Oxygen,0
NCT04335851,4/6/2020,5/15/2020,Interventional,Video-Based Exercises and Well-Being During Social Isolation,Completed,Not Applicable,Biruni University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Video based aerobic exercise,0
NCT04332380,5/1/2020,7/28/2020,Interventional,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Phase 2,Universidad del Rosario,NA,NA,NA,NA,NA,NA,Colombia,0,2,Plasma,0
NCT04334928,4/15/2020,2/25/2021,Interventional,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Completed,Phase 3,Plan Nacional sobre el Sida (PNS),NA,NA,NA,NA,NA,NA,Spain,0,7,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Hydroxychloroquine,0
NCT04334629,5/26/2020,5/25/2021,Interventional,LIBERATE Trial in COVID-19,Recruiting,Phase 4,King's College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,4,Ibuprofen,0
NCT04335071,4/26/2020,9/27/2020,Interventional,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Phase 2,"University Hospital Inselspital, Berne","1.) Not possible to recruit the planned number of patients during the planned study period; 2.) ""Dexamethason"" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.",NA,NA,NA,NA,NA,Switzerland,0,4,Tocilizumab (TCZ)|Placebo,0
NCT04332094,4/2/2020,6/30/2021,Interventional,Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,NA,NA,NA,NA,Spain,0,4,Tocilizumab|Hydroxychloroquine|Azithromycin,0
NCT04331613,1/27/2020,12/31/2020,Interventional,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Phase 1/Phase 2,Chinese Academy of Sciences,NA,NA,NA,NA,NA,NA,China,0,0,CAStem,0
NCT04333407,4/3/2020,3/30/2021,Interventional,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,Not Applicable,Imperial College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Aspirin 75mg|Clopidogrel 75mg|Rivaroxaban 2.5 MG|Atorvastatin 40mg|Omeprazole 20mg,0
NCT04334850,4/20/2020,12/20/2020,Interventional,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Usual antibiotic treatment,0
NCT04334382,4/2/2020,12/31/2020,Interventional,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Phase 3,"Intermountain Health Care, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,Hydroxychloroquine|Azithromycin,0
NCT04333628,6/1/2020,9/1/2020,Interventional,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Phase 2/Phase 3,"HaEmek Medical Center, Israel",Teminated due to changes in treatment guidelines .,NA,NA,NA,NA,NA,Israel,0,3,chloroquine|standard care,0
NCT04333355,5/8/2020,8/20/2020,Interventional,Safety in Convalescent Plasma Transfusion to COVID-19,Terminated,Phase 1,Hospital San Jose Tec de Monterrey,Other clinical trails probed that the use of convalescent plasma for patients with COVID-19 is safe .,NA,NA,NA,NA,NA,Mexico,0,3,Convalescent Plasma,0
NCT04334044,9/1/2020,4/12/2021,Interventional,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Completed,Phase 1/Phase 2,Grupo Cooperativo de HemopatÃ­as Malignas,NA,NA,NA,NA,NA,NA,Mexico,0,3,Ruxolitinib Oral Tablet,0
NCT04334512,6/22/2020,6/30/2023,Interventional,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,NA,NA,NA,NA,NA,United States,0,7,Hydroxychloroquine|Azithromycin|Vitamin C|Vitamin D|Zinc,0
NCT04331470,4/4/2020,4/20/2020,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,2,Levamisole Pill + Budesonide+Formoterol inhaler|Lopinavir/Ritonavir + hydoxychloroquine,0
NCT04331665,5/21/2020,1/5/2021,Interventional,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,Terminated,Not Applicable,"University Health Network, Toronto","A Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. With this news, recruitment was stopped for this study.",NA,NA,NA,NA,NA,Canada,0,4,Ruxolitinib,0
NCT04331600,4/16/2020,12/17/2020,Interventional,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Completed,Phase 4,Wroclaw Medical University,NA,NA,NA,NA,NA,NA,Poland,0,2,Chloroquine phosphate|Telemedicine,0
NCT04332835,8/8/2020,10/31/2020,Interventional,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Phase 2/Phase 3,Universidad del Rosario,NA,NA,NA,NA,NA,NA,Colombia,0,4,Plasma|Standard Therapy,0
NCT04331054,4/13/2020,5/28/2021,Interventional,Protective Role of Inhaled Steroids for Covid-19 Infection,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,Insufficient recruitment,NA,NA,NA,NA,NA,France,0,5,2: Usual practice + SYMBICORT RAPIHALER|1: Usual practice,0
NCT04329650,4/15/2020,5/20/2020,Interventional,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,NA,NA,NA,NA,NA,Spain,0,3,Siltuximab|Methylprednisolone,0
NCT04330690,3/18/2020,3/18/2022,Interventional,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Phase 2,Sunnybrook Health Sciences Centre,NA,NA,NA,NA,NA,NA,Canada,0,35,Interferon beta-1a|Remdesivir,0
NCT04325867,3/31/2020,10/1/2020,Interventional,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,Not Applicable,Grigore T. Popa University of Medicine and Pharmacy,NA,NA,NA,NA,NA,NA,Romania,0,1,Tele-medicine platform,0
NCT04327349,3/28/2020,5/20/2020,Interventional,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,Not Applicable,Mazandaran University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,0,Convalescent Plasma,0
NCT04328129,3/23/2020,3/23/2022,Interventional,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,Not Applicable,Institut Pasteur,NA,NA,NA,NA,NA,NA,French Guiana|Guadeloupe|New Caledonia,0,3,Human biological samples,0
NCT04325633,4/24/2020,12/15/2020,Interventional,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,Stop inclusions for insufficient recruitment,NA,NA,NA,NA,NA,France,0,2,1: Naproxen|2: Standard of care,0
NCT04326452,3/27/2020,3/27/2021,Interventional,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,Not Applicable,TMC HealthCare,NA,NA,NA,NA,NA,NA,United States,0,2,bidirectional oxygenation mouthpiece,0
NCT04329195,4/9/2020,12/9/2020,Interventional,ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,insufficient recrutment,NA,NA,NA,NA,NA,France,0,4,1: discontinuation of RAS blocker therapy|2: continuation of RAS blocker therapy,0
NCT04326036,3/25/2020,11/1/2021,Interventional,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Early Phase 1,"Black Tie Medical, Inc.",NA,NA,NA,NA,NA,NA,United States,0,2,Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Centricyte 1000|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Liberase Enzyme (Roche)|Sterile Normal Saline for Intravenous Use,0
NCT04328012,4/6/2020,6/1/2021,Interventional,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19,Recruiting,Phase 2/Phase 3,Bassett Healthcare,NA,NA,NA,NA,NA,NA,United States,0,3,Losartan|Placebo,0
NCT04324996,2/21/2020,2/20/2022,Interventional,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,Phase 1/Phase 2,Chongqing Public Health Medical Center,NA,NA,NA,NA,NA,NA,China,0,1,"NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",0
NCT04322344,3/23/2020,6/30/2020,Interventional,Escin in Patients With Covid-19 Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,NA,NA,NA,NA,NA,Italy,0,2,Escin|standard therapy,0
NCT04324463,4/21/2020,11/30/2021,Interventional,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Phase 3,Population Health Research Institute,NA,NA,NA,NA,NA,NA,Brazil|Canada|Colombia|Ecuador|Egypt|India|Pakistan|Philippines|Russian Federation|Saudi Arabia|United Arab Emirates,0,6,Colchicine|Interferon-Beta|Aspirin|Rivaroxaban,0
NCT04324190,4/8/2020,6/30/2020,Interventional,DIgital Online SuPport for COVID-19 StrEss,Recruiting,Not Applicable,International Psychoanalytic University Berlin,NA,NA,NA,NA,NA,NA,Germany,0,3,Guided online support program|WHO recommendations (waiting condition),0
NCT04324021,4/2/2020,11/13/2020,Interventional,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Terminated,Phase 2/Phase 3,Swedish Orphan Biovitrum,"Standard of care evolved during the timeframe of the study and had critical impact on recruitment.

Early termination is not based on safety reasons but because of recruitment issues.

Patients ongoing will be completed. Planned LPLV 25Jan2021",NA,NA,NA,NA,NA,United States|Italy,0,8,Emapalumab|Anakinra,0
NCT04322773,4/5/2020,10/8/2020,Interventional,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Phase 2,Frederiksberg University Hospital,The study has been terminated due to changed clinical conditions and too few patients available,NA,NA,NA,NA,NA,Denmark,0,4,RoActemra iv|RoActemra sc|Kevzara sc|Standard medical care,0
NCT04322565,4/20/2020,12/20/2020,Interventional,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Phase 2,Azienda Ospedaliero-Universitaria di Parma,NA,NA,NA,NA,NA,NA,Italy,0,3,Colchicine,0
NCT04324489,3/6/2020,4/16/2020,Interventional,DAS181 for Severe COVID-19: Compassionate Use,Completed,Not Applicable,Renmin Hospital of Wuhan University,NA,NA,NA,NA,NA,NA,China,0,2,DAS181,0
NCT04323228,9/1/2020,12/1/2020,Interventional,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Phase 2/Phase 3,King Saud University,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,6,Oral supplement enriched in antioxidants|cellulose-containing placebo capsules,0
NCT04318444,3/29/2020,3/31/2021,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Phase 2/Phase 3,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,2,Hydroxychloroquine|Placebo oral tablet,0
NCT04324073,3/27/2020,3/27/2021,Interventional,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Phase 2/Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Sarilumab,0
NCT04321993,4/17/2020,2/28/2022,Interventional,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Phase 2,Nova Scotia Health Authority,NA,NA,NA,NA,NA,NA,Canada,0,6,Baricitinib (janus kinase inhibitor),0
NCT04323345,4/15/2020,12/15/2020,Interventional,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Phase 3,Misr University for Science and Technology,NA,NA,NA,NA,NA,NA,Egypt,0,1,Natural Honey|Standard Care,0
NCT04323514,3/13/2020,3/13/2021,Interventional,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,Not Applicable,University of Palermo,NA,NA,NA,NA,NA,NA,Italy,0,0,Vitamin C,0
NCT04319900,3/5/2020,4/30/2020,Interventional,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,Phase 2/Phase 3,Beijing Chao Yang Hospital,NA,NA,NA,NA,NA,NA,China,0,0,favipiravir tablets+chloroquine phosphatetablets tablets|Favipiravir tablets|Placebo,0
NCT04318015,4/14/2020,12/31/2020,Interventional,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,1,Hydroxychloroquine|Placebo oral tablet,0
NCT04319445,3/22/2020,8/31/2020,Interventional,Mindfulness During COVID-19,Completed,Not Applicable,Wake Forest University Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,6,Mindfulness session(s),0
NCT04320238,1/21/2020,5/31/2020,Interventional,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Phase 3,Shanghai Jiao Tong University School of Medicine,NA,NA,NA,NA,NA,NA,China,0,1,recombinant human interferon Alpha-1b|thymosin alpha 1,0
NCT04313023,6/9/2020,7/31/2021,Interventional,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Completed,Phase 2,"Pulmotect, Inc.",NA,NA,NA,NA,NA,NA,United States,0,15,PUL-042 Inhalation Solution|Placebo,0
NCT04312243,4/7/2020,4/7/2021,Interventional,NO Prevention of COVID-19 for Healthcare Providers,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,3,Inhaled nitric oxide gas,0
NCT04320056,4/20/2020,4/30/2021,Interventional,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,Not Applicable,Laval University,NA,NA,NA,NA,NA,NA,Canada,0,2,Standard administration of oxygen flow|Automated oxygen administration - FreeO2,0
NCT04315896,4/14/2020,7/1/2020,Interventional,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,2,Hydroxychloroquine|Placebo oral tablet,0
NCT04312997,6/16/2020,7/2/2021,Interventional,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Completed,Phase 2,"Pulmotect, Inc.",NA,NA,NA,NA,NA,NA,United States,0,17,PUL-042 Inhalation Solution|Placebo,0
NCT04310228,3/8/2020,5/31/2020,Interventional,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,Not Applicable,Peking University First Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Favipiravir Combined With Tocilizumab|Favipiravir|Tocilizumab,0
NCT04311697,5/15/2020,2/22/2021,Interventional,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Completed,Phase 2/Phase 3,"NeuroRx, Inc.",NA,NA,NA,NA,NA,NA,United States,0,21,Aviptadil by intravenous infusion + standard of care|Normal Saline Infusion + standard of care,0
NCT04313322,3/16/2020,6/30/2020,Interventional,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Phase 1,Stem Cells Arabia,NA,NA,NA,NA,NA,NA,Jordan,0,0,WJ-MSCs,0
NCT04304313,2/9/2020,3/1/2020,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Sildenafil citrate tablets,0
NCT04305457,3/21/2020,4/1/2021,Interventional,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,12,Nitric Oxide,0
NCT04307693,3/11/2020,4/30/2020,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,NA,NA,NA,NA,NA,"Korea, Republic of",0,2,Lopinavir/ritonavir|Hydroxychloroquine sulfate,0
NCT04306055,3/13/2020,3/13/2020,Interventional,Blood Donor Recruitment During Epidemic of COVID-19,Completed,Not Applicable,Guangzhou Blood Center,NA,NA,NA,NA,NA,NA,China,0,1,Questionnaire with precaution information|Experimental: Questionnaire without precaution information,0
NCT04303299,8/19/2020,8/28/2021,Interventional,Fight COVID-19 Trial,Completed,Phase 3,Rajavithi Hospital,NA,NA,NA,NA,NA,NA,Thailand,0,8,Oral,0
NCT04308317,3/5/2020,3/1/2021,Interventional,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Phase 4,Henan Provincial People's Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Tetrandrine,0
NCT04304690,3/16/2020,5/16/2021,Interventional,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,4,blood sample,0
NCT04305106,3/17/2020,6/30/2020,Interventional,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,Not Applicable,Qilu Hospital of Shandong University,NA,NA,NA,NA,NA,NA,China,0,2,Bevacizumab,0
NCT04299724,2/15/2020,7/31/2023,Interventional,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Phase 1,Shenzhen Geno-Immune Medical Institute,NA,NA,NA,NA,NA,NA,China,0,0,Pathogen-specific aAPC,1
NCT04303507,4/29/2020,12/31/2021,Interventional,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,Not Applicable,University of Oxford,NA,NA,NA,NA,NA,NA,Bangladesh|Benin|Ethiopia|Indonesia|Italy|Kenya|Lao People's Democratic Republic|Mali|Nepal|Niger|Pakistan|Thailand|United Kingdom|Zambia,0,8,Chloroquine or Hydroxychloroquine|Placebo,0
NCT04296643,4/1/2020,2/1/2021,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,Not Applicable,McMaster University,NA,NA,NA,NA,NA,NA,Canada|Israel,0,2,Medical Mask|N95 respirator,0
NCT04291729,2/17/2020,3/19/2020,Interventional,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,The Ninth Hospital of Nanchang,NA,NA,NA,NA,NA,NA,China,0,3,Ganovo+ritonavir+/-Interferon nebulization,0
NCT04279197,4/23/2020,12/31/2021,Interventional,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Phase 2,ShuGuang Hospital,NA,NA,NA,NA,NA,NA,China,0,2,Fuzheng Huayu Tablet|Vitamin C tablets|Placebo|respiratory function rehabilitation training,0
NCT04276896,3/24/2020,7/31/2023,Interventional,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Phase 1/Phase 2,Shenzhen Geno-Immune Medical Institute,NA,NA,NA,NA,NA,NA,China,0,2,Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,1
NCT04280224,2/15/2020,12/30/2021,Interventional,NK Cells Treatment for COVID-19,Recruiting,Phase 1,Xinxiang medical university,NA,NA,NA,NA,NA,NA,China,0,2,NK Cells,0
NCT04276987,2/15/2020,5/31/2020,Interventional,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Phase 1,Ruijin Hospital,NA,NA,NA,NA,NA,NA,China,0,3,MSCs-derived exosomes,0
NCT04275245,2/3/2020,3/9/2020,Interventional,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Completed,Phase 1/Phase 2,Tang-Du Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Meplazumab for Injection,0
NCT04269525,2/6/2020,12/1/2020,Interventional,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Phase 2,Zhongnan Hospital,NA,NA,NA,NA,NA,NA,China,0,3,UC-MSCs,0
NCT04273763,2/16/2020,5/10/2020,Interventional,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",Not Applicable,Second Affiliated Hospital of Wenzhou Medical University,NA,NA,NA,NA,NA,NA,China,0,4,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,0
NCT04263402,2/1/2020,6/1/2020,Interventional,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Phase 4,Tongji Hospital,NA,NA,NA,NA,NA,NA,China,0,3,Methylprednisolone|Methylprednisolone,0
NCT04261270,2/1/2020,5/1/2020,Interventional,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Phase 3,Tongji Hospital,NA,NA,NA,NA,NA,NA,China,0,2,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,0
NCT04252118,1/27/2020,12/31/2020,Interventional,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Phase 1,Beijing 302 Hospital,NA,NA,NA,NA,NA,NA,China,0,4,MSCs,0
NCT04260594,2/8/2020,3/12/2020,Interventional,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,Completed,Phase 4,Ruijin Hospital,NA,NA,NA,NA,NA,NA,China,0,2,Arbidol|basic treatment,0
NCT04255017,2/1/2020,6/1/2020,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,NA,NA,NA,NA,NA,China,0,3,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,0
NCT04254874,2/1/2020,6/1/2020,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,NA,NA,NA,NA,NA,China,0,3,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,0
NCT05075304,2/21/2020,4/14/2020,Interventional,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients",Completed,Phase 1,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,0,BDB-001 injection|BDB-001 injection|BDB-001 injection,0
NCT05075499,3/20/2021,12/31/2021,Interventional,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,Recruiting,Not Applicable,Sheba Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,COVID-19 vaccination,1
NCT04667247,12/3/2020,12/31/2021,Interventional,Mushroom-based Product for COVID-19,Recruiting,Phase 1/Phase 2,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,5,FoTv,0
NCT05004805,8/6/2021,10/25/2021,Interventional,COVID-19 Methylene Blue Antiviral Treatment,"Active, not recruiting",Phase 2,Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,Methylene Blue|Saline nasal spray,0
NCT04962022,7/20/2021,9/30/2021,Interventional,Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants,Completed,Phase 1,Pfizer,NA,NA,NA,NA,NA,NA,Belgium,0,3,PF-07321332/ritonavir|Itraconazole|PF-07321332/ritonavir,0
NCT05074368,7/6/2021,11/19/2021,Interventional,Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination,"Active, not recruiting",Not Applicable,National Taiwan University Hospital,NA,NA,NA,NA,NA,NA,Taiwan,0,0,ChAdOx1-nCov-19 (Astra-Zeneca)|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine,1
NCT05074979,10/20/2021,4/1/2022,Interventional,Telerehabilitation in COVID-19 Survivors,Recruiting,Not Applicable,BandÄ±rma Onyedi EylÃ¼l University,NA,NA,NA,NA,NA,NA,Turkey,0,0,telerehabilitation|home exercise program|informed program,0
NCT04521296,9/11/2020,12/17/2020,Interventional,Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo,"Active, not recruiting",Phase 2/Phase 3,Daewoong Pharmaceutical Co. LTD.,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,Part 1|Part 2,0
NCT04449588,7/23/2020,11/30/2021,Interventional,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Phase 2/Phase 3,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,NA,NA,NA,NA,NA,Bangladesh|China|India|Indonesia|Spain,0,3,BDB-001 Injection|Conventional treatment,0
NCT04542408,11/12/2020,2/28/2022,Interventional,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Phase 3,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,NA,NA,Germany,0,3,Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Low dose Low molecular weight heparin or Placebo,0
NCT04830033,4/28/2021,9/23/2021,Interventional,ENO Breathe vs Usual Care in COVID-19 Recovery,Completed,Not Applicable,Imperial College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,4,ENO Breathe group,0
NCT04980326,11/1/2021,8/31/2022,Interventional,A Scalable Psychological Intervention to Reduce Psychological Distress Among Healthcare Workers,Recruiting,Not Applicable,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,NA,NA,NA,NA,NA,Spain,0,2,Doing What Matters (DWM)|Problem Management Plus (PM+)|Psychological First Aid (PFA),0
NCT05143372,11/9/2021,6/1/2022,Interventional,Influence of Vibroacoustic Therapy Modes on the Course of Coronavirus Infection,Recruiting,Not Applicable,Astana Medical University,NA,NA,NA,NA,NA,NA,Kazakhstan,0,0,Vibrolung,0
NCT05118737,10/1/2021,4/30/2022,Interventional,Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.,Recruiting,Early Phase 1,Hamad Medical Corporation,NA,NA,NA,NA,NA,NA,Qatar,0,1,Colchicine,0
NCT04776317,3/25/2021,9/19/2022,Interventional,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,Recruiting,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,20,"ChAdV68-S|ChAdV68-S-TCE|SAM-LNP-S|SAM-LNP-S-TCE|Sodium Chloride, 0.9%",1
NCT04821674,3/15/2021,8/13/2021,Interventional,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,"Active, not recruiting",Phase 1/Phase 2,"Daiichi Sankyo, Inc.",NA,NA,NA,NA,NA,NA,Japan,0,3,DS-5670a|Placebo,1
NCT04628039,5/28/2021,12/31/2023,Interventional,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs",Recruiting,Not Applicable,VA Office of Research and Development,NA,NA,NA,NA,NA,NA,United States,0,6,Rehabilitation-focused program,0
NCT04707664,4/27/2021,12/31/2021,Interventional,Sargramostim Use in COVID-19 to Recover Patient Health,"Active, not recruiting",Phase 2,"Partner Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States|Argentina,0,25,Sargramostim|Placebo,0
NCT04649736,10/26/2020,6/19/2021,Interventional,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Completed,Not Applicable,Universidad Peruana Cayetano Heredia,NA,NA,NA,NA,NA,NA,Peru,0,2,Respiratory and psychological rehabilitation,0
NCT04600895,11/30/2020,10/20/2021,Interventional,The Prevent Severe COVID-19 (PRESECO) Study,Completed,Phase 3,Appili Therapeutics Inc.,NA,NA,NA,NA,NA,NA,United States|Brazil|Mexico,0,6,Favipiravir|Placebo,0
NCT04551898,12/2/2020,5/25/2021,Interventional,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,BeiGene,NA,NA,NA,NA,NA,NA,United States|Australia|Brazil|Mexico|South Africa,0,2,BGB-DXP593|Placebo,0
NCT04524507,8/27/2020,1/4/2021,Interventional,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,Completed,Phase 2,"University of North Carolina, Chapel Hill",NA,NA,NA,NA,NA,NA,United States,1,4,High-titer Convalescent COVID-19 Plasma (CCP1)|Standard-titer Convalescent COVID-19 plasma (CCP2),0
NCT04382924,8/5/2020,12/24/2020,Interventional,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,Phase 2/Phase 3,Algernon Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States|Australia|Philippines|Romania,1,8,NP-120 (Ifenprodil),0
NCT04384497,5/7/2020,6/1/2020,Interventional,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Completed,Phase 1/Phase 2,Karolinska University Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,2,SARS-CoV-2 convalescent plasma,0
NCT04335032,1/8/2021,11/30/2021,Interventional,EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2),Recruiting,Phase 3,S.L.A. Pharma AG,NA,NA,NA,NA,NA,NA,Spain|United Kingdom,0,4,Eicosapentaenoic acid gastro-resistant capsules|Placebo,0
NCT04961541,9/8/2021,3/31/2022,Interventional,Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,NA,NA,NA,NA,NA,Australia,0,7,ICC Vaccine|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant,1
NCT04957082,8/4/2021,6/1/2023,Interventional,Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake,Recruiting,Not Applicable,Michigan State University,NA,NA,NA,NA,NA,NA,United States,0,1,Culturally Targeted SARS-CoV-2 Communication|General SARS-CoV-2 Communication,0
NCT04615949,4/30/2021,3/31/2022,Interventional,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,Recruiting,Phase 2/Phase 3,Cardiol Therapeutics Inc.,NA,NA,NA,NA,NA,NA,United States|Brazil|Germany|Mexico,0,12,"Cannabidiol, pharmaceutically produced with < 5 ppm THC|Placebo",0
NCT04852978,4/29/2021,12/29/2021,Interventional,"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","Active, not recruiting",Phase 2,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,5,casirivimab+imdevimab|Moderna mRNA-1273 vaccine,1
NCT04493242,9/24/2020,5/1/2021,Interventional,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Completed,Phase 2,"Direct Biologics, LLC",NA,NA,NA,NA,NA,NA,United States,0,2,DB-001|Intravenous normal saline,0
NCT04355728,4/25/2020,10/31/2020,Interventional,Use of UC-MSCs for COVID-19 Patients,Completed,Phase 1/Phase 2,University of Miami,NA,NA,NA,NA,NA,NA,United States,1,9,Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Vehicle + Heparin along with best supportive care,0
NCT05091307,11/2/2021,1/6/2022,Interventional,A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults,Recruiting,Phase 3,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,United States|Belgium|Poland|Spain,0,2,Ad26.COV2.S|Placebo|Influenza Vaccine,1
NCT05114655,11/11/2021,12/31/2021,Interventional,Aromatherapy for Stress and Burnout Among Healthcare Providers,Recruiting,Not Applicable,Franklin School of Integrative Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,1,Herbaceous Essential Oil Blend|Citrus Essential Oil Blend|Inert Oil,0
NCT05077176,10/8/2021,9/29/2022,Interventional,Phase 3 Booster Vaccination Against COVID-19,Recruiting,Phase 3,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,3,CoronaVac|Turkovac,1
NCT05033847,9/12/2021,11/30/2023,Interventional,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,Phase 2,"National Vaccine and Serum Institute, China",NA,NA,NA,NA,NA,NA,United Arab Emirates,0,2,Recombinant COVID-19 Vaccine (CHO cell)|COVID-19 vaccine (Vero cells),1
NCT04894721,6/1/2021,9/30/2021,Interventional,Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC),Completed,Phase 2/Phase 3,"Ministry of Public Health, Argentina",NA,NA,NA,NA,NA,NA,Argentina,0,1,Ivermectin|Placebo,0
NCT05007275,10/10/2021,9/30/2022,Interventional,A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,Recruiting,Phase 1,Imperial College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,1x10^9 vp AZD1222|5x10^9 vp AZD1222|1x10^10 vp AZD1222,1
NCT04392232,5/5/2020,9/21/2021,Interventional,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Completed,Phase 2,TriHealth Inc.,NA,NA,NA,NA,NA,NA,United States,0,2,Convalescent Plasma,0
NCT04581863,11/30/2020,2/5/2021,Interventional,COVID-19 Watch + COVID-19 Pulse,"Active, not recruiting",Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,7,pulse oximeter|COVID Watch,0
NCT04515147,9/28/2020,2/18/2022,Interventional,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","Active, not recruiting",Phase 2,CureVac AG,NA,NA,NA,NA,NA,NA,Panama|Peru,0,11,CVnCoV 6 Î¼g|CVnCoV 12 Î¼g|Hepatitis A vaccine|Pneumococcal vaccine|CVnCoV 12Î¼g,1
NCT04343989,3/31/2020,2/3/2021,Interventional,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,Phase 2,NYU Langone Health,NA,NA,NA,NA,NA,NA,United States,0,6,Clazakizumab 25 mg|Clazakizumab 12.5 mg|Placebo,0
NCT05148845,11/10/2021,12/17/2021,Interventional,Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.,Recruiting,Phase 3,Wits Health Consortium (Pty) Ltd,NA,NA,NA,NA,NA,NA,South Africa,0,0,Booster vaccine,1
NCT05148962,9/16/2021,11/4/2022,Interventional,Study of GRT-R910 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Boost Vaccine in Healthy Volunteers,Recruiting,Phase 1,"Gritstone Oncology, Inc.",NA,NA,NA,NA,NA,NA,United Kingdom,0,0,GRT-R910 booster 113 days after prime|GRT-R910 booster 28 days after prime,1
NCT05148936,10/25/2020,6/30/2022,Interventional,Communities Fighting COVID-19!,Recruiting,Not Applicable,San Diego State University,NA,NA,NA,NA,NA,NA,United States,0,0,COVID-19 Testing Home-based (Aim 1)|COVID-19 Testing Mobile (Aim 1)|COVID-19 Testing Mobile Approach 1 (Aim 2)|COVID-19 Testing Mobile Approach 2 (Aim 2),0
NCT05057221,11/12/2021,11/30/2023,Interventional,"Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia",Recruiting,Phase 1/Phase 2,University of Michigan,NA,NA,NA,NA,NA,NA,United States,0,3,Uproleselan,0
NCT05047640,9/14/2021,4/30/2022,Interventional,COVID-19 3rd Dose Vaccine in Transplant Patients,Recruiting,Phase 3,University of Miami,NA,NA,NA,NA,NA,NA,United States,0,2,BNT162b2 vaccine|JNJ-78436735 Vaccine,1
NCT04992260,9/10/2021,5/25/2022,Interventional,"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents",Recruiting,Phase 3,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,Chile|Malaysia|Philippines|South Africa|Turkey,0,5,Inactivated COVID-19 Vaccine|Controlled vaccine,1
NCT04859517,4/23/2021,7/31/2022,Interventional,Evaluation of ADG20 for the Prevention of COVID-19,Recruiting,Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,"United States|Argentina|Czechia|Georgia|Germany|Moldova, Republic of|Poland|Romania|Ukraine",0,23,ADG20|Placebo,0
NCT04920942,5/31/2021,10/31/2021,Interventional,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients,Completed,Phase 3,"Clinical Research Centre, Malaysia",NA,NA,NA,NA,NA,NA,Malaysia,0,4,Ivermectin 0.4mg/kg/day for 5 days,0
NCT04913129,11/4/2021,12/31/2022,Interventional,The Burden of COVID-19 Survivorship,Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,4,Exercise Training,0
NCT04625972,12/2/2020,4/7/2021,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,NA,NA,NA,NA,NA,United States|United Kingdom,0,6,AZD7442|Placebo,0
NCT04830761,3/26/2021,4/1/2022,Interventional,Behavior Change in Context to Contain the Spread of COVID-19,Recruiting,Not Applicable,University of Bern,NA,NA,NA,NA,NA,NA,Switzerland,0,2,Motivation|Habit|Social,0
NCT04818801,6/18/2021,12/31/2021,Interventional,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","Active, not recruiting",Early Phase 1,"Jiangsu Rec-Biotechnology Co., Ltd.",NA,NA,NA,NA,NA,NA,New Zealand,0,4,Recombinant two-component COVID-19 vaccine (CHO cell)|Placebo,1
NCT04668209,1/1/2021,3/31/2022,Interventional,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,University of Arizona,NA,NA,NA,NA,NA,NA,United States,0,4,Silmitasertib,0
NCT04582201,9/21/2020,10/1/2022,Interventional,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Phase 1,Agenus Inc.,NA,NA,NA,NA,NA,NA,United States,0,7,agenT-797,0
NCT04508023,8/13/2020,2/22/2022,Interventional,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Phase 3,"Janssen Research & Development, LLC",NA,NA,NA,NA,NA,NA,United States,0,15,Rivaroxaban|Placebo|Standard of Care (SOC),0
NCT04469634,7/31/2020,12/31/2022,Interventional,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",Not Applicable,"Institute of Tropical Medicine, Belgium",NA,NA,NA,NA,NA,NA,Belgium,0,3,"Assessing antibody responses, neutralizing capacity and memory B-cell function",0
NCT05151614,4/1/2021,10/30/2021,Interventional,Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection,Completed,Phase 1,University of Baghdad,NA,NA,NA,NA,NA,NA,Iraq,0,0,Colchicine 0.5 MG,0
NCT05069610,12/15/2021,4/15/2022,Interventional,"Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19",Recruiting,Phase 1/Phase 2,Advagene Biopharma Co. Ltd.,NA,NA,NA,NA,NA,NA,Taiwan,0,2,AD17002|Placebo (Formulation buffer),0
NCT05150860,10/17/2021,7/30/2023,Interventional,Communities Fighting COVID Return to School,Recruiting,Not Applicable,San Diego State University,NA,NA,NA,NA,NA,NA,United States,0,0,At-home COVID-19 testing|Family-based model|Onsite COVID-19 testing,0
NCT04584684,12/18/2020,6/30/2022,Interventional,Mouth Rinses for Inactivation of COVID-19,"Active, not recruiting",Phase 2,"University of North Carolina, Chapel Hill",NA,NA,NA,NA,NA,NA,United States,0,4,Saline|1.5% w/v Hydrogen Peroxide|0.12% Chlorohexidine Gluconate|27% Ethanol plus essential oils|0.5% w/v Povidone-iodide|0.075% Cetylpyridinium Chloride,0
NCT04609423,11/10/2020,6/2/2021,Interventional,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Phase 4,Oslo University Hospital,NA,NA,NA,NA,NA,NA,Norway,0,4,Cod liver oil|Corn oil (placebo),0
NCT04847050,4/28/2021,1/1/2022,Interventional,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...",Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),NA,NA,NA,NA,NA,NA,United States,0,19,mRNA-1273,1
NCT04750759,2/3/2021,10/29/2021,Interventional,Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat,Terminated,Phase 2,CharitÃ© Research Organisation GmbH,sub-therapeutic plasma levels of active substance,NA,NA,NA,NA,NA,Germany,0,4,Niclosamide + Camostat|Placebo,0
NCT04715997,12/30/2020,7/30/2021,Interventional,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","Active, not recruiting",Phase 1/Phase 2,"Genexine, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,GX-19N|Placebo,1
NCT04527198,9/14/2020,12/31/2020,Interventional,Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Brainstem Responses Assessment Sedation Score (BRASS)|Electroencephalogram with EKG lead,0
NCT04526821,10/17/2020,2/10/2021,Interventional,Lactoferrin for Prevention of COVID-19 in Health Care Workers,Terminated,Phase 2,Universidad Peruana Cayetano Heredia,The study was interrupted due to the arrival and distribution of the vaccine to hospital workers in Peru,NA,NA,NA,NA,NA,Peru,0,2,Bovine Lactoferrin|Maltodextrin,0
NCT04516512,1/14/2021,7/8/2021,Interventional,Assessment of SARS-CoV-2 Seroprevalence in Detention,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,Blood draw,0
NCT04445389,6/17/2020,12/30/2021,Interventional,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","Active, not recruiting",Phase 1/Phase 2,"Genexine, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,3,GX-19|Saline,1
NCT04365257,5/13/2020,3/30/2022,Interventional,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Phase 2,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,5,Prazosin|Standard of care,0
NCT05152849,12/31/2021,5/31/2022,Interventional,"Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC",Recruiting,Phase 2,"Axcella Health, Inc",NA,NA,NA,NA,NA,NA,United Kingdom,0,0,AXA1125|Placebo,0
NCT05092698,5/1/2020,12/31/2021,Interventional,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,Recruiting,Not Applicable,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Vitamin D (cholecalciferol)|Herbal oil,0
NCT05124171,12/8/2021,12/31/2022,Interventional,Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,"BNT162b2|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK",1
NCT04785144,3/29/2021,8/31/2022,Interventional,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,22,mRNA-1273|mRNA-1273.351,1
NCT04803409,3/22/2021,12/15/2021,Interventional,UNITE Study (UCSD-SW) for COVID-19,"Active, not recruiting",Not Applicable,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,4,Splenic Ultrasound,0
NCT04638634,2/2/2021,6/9/2021,Interventional,"Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects",Terminated,Phase 1,CSL Behring,"For business reasons, not a safety issue",NA,NA,NA,NA,NA,Australia,0,8,CSL760,0
NCT04616846,8/4/2020,2/15/2022,Interventional,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,Not Applicable,Centre Antoine Lacassagne,NA,NA,NA,NA,NA,NA,France|Monaco,0,2,Peripheral venous ultrasound,0
NCT04331366,4/8/2020,8/31/2020,Interventional,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,Not Applicable,Emory University,NA,NA,NA,NA,NA,NA,NA,1,5,GO2 PEEP MOUTHPIECE,0
NCT04372017,5/14/2020,6/4/2021,Interventional,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,Terminated,Phase 3,Sanford Health,Unlikelihood of benefit based on other studies.,NA,NA,NA,NA,NA,United States,1,5,Hydroxychloroquine|Vitamin D,0
NCT05047770,10/7/2021,3/29/2022,Interventional,A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine,"Active, not recruiting",Phase 3,GlaxoSmithKline,NA,NA,NA,NA,NA,NA,United States,0,2,HZ/su|Flu D-QIV|mRNA-1273,1
NCT04924660,7/15/2021,5/31/2023,Interventional,Novel Experimental COVID-19 Therapies Affecting Host Response,Recruiting,Phase 2/Phase 3,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,6,TXA127|TRV027|Placebo|Fostamatinib|APN01,0
NCT04973449,6/27/2021,1/26/2022,Interventional,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","Active, not recruiting",Phase 2/Phase 3,AstraZeneca,NA,NA,NA,NA,NA,NA,Brazil|Poland|South Africa|United Kingdom,0,3,AZD1222|AZD2816,1
NCT04966013,6/17/2021,12/31/2021,Interventional,Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19,Recruiting,Not Applicable,KNOWBio Inc.,NA,NA,NA,NA,NA,NA,United States,0,3,RD-X19|Sham,0
NCT04960215,5/25/2021,12/31/2021,Interventional,Coenzyme Q10 as Treatment for Long Term COVID-19,Recruiting,Phase 2,University of Aarhus,NA,NA,NA,NA,NA,NA,Denmark,0,1,Coenzyme Q10|Placebo,0
NCT04749173,11/21/2020,6/18/2021,Interventional,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.",Completed,Phase 1,Daewoong Pharmaceutical Co. LTD.,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,4,"DWRX2003, 96mg|DWRX2003, 432mg|DWRX2003, 144mg|DWRX2003, 144mg",0
NCT04876274,7/14/2020,12/29/2020,Interventional,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic,Completed,Not Applicable,Taipei Medical University,NA,NA,NA,NA,NA,NA,Taiwan,1,4,TMU-LOVE,0
NCT04655586,12/10/2020,11/30/2021,Interventional,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","Active, not recruiting",Phase 2/Phase 3,"ARCA Biopharma, Inc.",NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil,0,11,rNAPc2|Heparin,0
NCT04501796,11/27/2020,3/31/2022,Interventional,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Phase 1,NeoImmuneTech,NA,NA,NA,NA,NA,NA,United States,0,4,Double-Blind NT-I7|Double-Blind Placebo,0
NCT04524598,7/20/2020,9/3/2021,Interventional,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,"Active, not recruiting",Not Applicable,"Limbix Health, Inc.",NA,NA,NA,NA,NA,NA,United States,1,7,Limbix Spark|Psychoeducation,0
NCT04366856,6/26/2020,9/23/2021,Interventional,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,1: Prone positioning|2: No instruction regarding positioning,0
NCT04441996,7/17/2020,3/18/2021,Interventional,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,Phase 4,Emory University,NA,NA,NA,NA,NA,NA,United States,0,4,Therapeutic plasma exchange (TPE)|Standard of care,0
NCT04326075,12/1/2020,6/30/2021,Interventional,Early CPAP in COVID-19 Patients With Respiratory Failure.,Recruiting,Not Applicable,Mario Negri Institute for Pharmacological Research,NA,NA,NA,NA,NA,NA,Italy,0,4,CPAP treatment,0
NCT05157178,6/20/2021,2/11/2022,Interventional,Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.,"Active, not recruiting",Phase 4,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),NA,NA,NA,NA,NA,NA,Brazil,0,0,Covid-19 (recombinante) vaccine,1
NCT05157139,11/1/2021,3/31/2022,Interventional,Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease,Recruiting,Phase 2/Phase 3,Alexandria University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Oral Capsule,0
NCT05157230,9/1/2021,12/15/2021,Interventional,Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination,Recruiting,Not Applicable,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,exercise,1
NCT05112913,7/27/2021,11/17/2021,Interventional,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years,"Active, not recruiting",Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1,1
NCT05156723,7/19/2021,8/30/2021,Interventional,"The Objectives of This Study Are Study the Immunogenicity, Safety and Tolerability of the Coronavirus Vaccine in Healthy Adult Volunteer Aged 18 to 60 Years.","Active, not recruiting",Phase 1/Phase 2,St. Petersburg Research Institute of Vaccines and Sera,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Subunit recombinant vaccine for the prevention of coronavirus infection|Placebo,1
NCT05137418,11/27/2021,2/27/2022,Interventional,"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","Active, not recruiting",Phase 3,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,"COVID-19 Vaccine,Inactivated",1
NCT04904744,5/28/2021,10/31/2021,Interventional,"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination",Completed,Not Applicable,"Children's Hospital Medical Center, Cincinnati",NA,NA,NA,NA,NA,NA,United States,0,2,Low tailored message|No message|Low tailored message plus COVID-19 vaccine message,1
NCT04530539,10/5/2020,7/1/2021,Interventional,The Effect of Melatonin and Vitamin C on COVID-19,"Active, not recruiting",Not Applicable,Lancaster General Hospital,NA,NA,NA,NA,NA,NA,United States,0,3,Vitamin C|melatonin|Placebo|Symptom Survey,0
NCT04456153,7/22/2020,1/31/2021,Interventional,Atovaquone for Treatment of COVID-19,Completed,Phase 2,University of Texas Southwestern Medical Center,NA,NA,NA,NA,NA,NA,United States,1,9,Experimental Group|Placebo Group,0
NCT04460014,9/30/2020,8/1/2022,Interventional,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,Not Applicable,Karolinska Institutet,NA,NA,NA,NA,NA,NA,Sweden,0,5,Simple cognitive task intervention|Attention Placebo,0
NCT04351243,4/15/2020,12/1/2020,Interventional,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),Completed,Phase 2,Kinevant Sciences GmbH,NA,NA,NA,NA,NA,NA,United States,1,15,Gimsilumab|Placebo,0
NCT04379518,11/17/2020,11/17/2023,Interventional,Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients,Recruiting,Phase 1/Phase 2,Roswell Park Cancer Institute,NA,NA,NA,NA,NA,NA,United States,0,13,Best Practice|Recombinant Interferon Alfa-2b|Rintatolimod,0
NCT05158855,6/1/2021,4/20/2022,Interventional,Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine,Recruiting,Not Applicable,DreamTec Research Limited,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Bacillus subtilis spore extract,1
NCT05158842,10/8/2021,1/31/2022,Interventional,Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study,Recruiting,Not Applicable,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,NA,NA,NA,NA,NA,Bangladesh,0,0,Adult bubble CPAP oxygen therapy device,0
NCT05115071,11/8/2021,11/25/2021,Interventional,Online Childbirth Preparation Education in Covid-19 Pandemic,Completed,Not Applicable,Pamukkale University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Childbirth preparation education,0
NCT05076253,9/1/2021,12/1/2021,Interventional,Efficacy of Ivermectin in COVID-19,Completed,Phase 1/Phase 2,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,NA,NA,NA,NA,NA,Thailand,0,1,Ivermectin|Placebo,0
NCT05030974,10/21/2021,11/30/2022,Interventional,RECOVAC Third Vaccination Study,Recruiting,Phase 4,University Medical Center Groningen,NA,NA,NA,NA,NA,NA,Netherlands,0,1,mRNA-1273|Ad26.COV2.S vaccine,1
NCT04739020,1/18/2021,12/30/2021,Interventional,Respiratory Aerosols in Patients With COVID-19 and Healthy Controls,Recruiting,Not Applicable,Johann Wolfgang Goethe University Hospital,NA,NA,NA,NA,NA,NA,Germany,0,2,Resp-Aer-Meter|Spirometry|Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations,0
NCT04644172,11/1/2020,11/30/2023,Interventional,Improving Thinking in Everyday Life After Covid-19,Recruiting,Not Applicable,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,1,Speed of Processing Training|Instrumental Activities of Daily Living Shaping|Transfer Package from CI Therapy|Usual Care,0
NCT04682197,12/14/2021,11/30/2022,Interventional,Cereset Research In Healthcare Workers During COVID-19,Recruiting,Not Applicable,Wake Forest University Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,9,Cereset Research,0
NCT04377672,5/28/2020,9/1/2021,Interventional,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Completed,Phase 1,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,5,Anti-SARS-CoV-2 Human Convalescent Plasma,0
NCT04519216,7/31/2020,10/30/2021,Interventional,Breastfeeding Education in the Time of COVID-19,Completed,Not Applicable,"University of California, Davis",NA,NA,NA,NA,NA,NA,United States,0,2,Telesimulation,0
NCT05022472,7/16/2021,12/31/2022,Interventional,Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California,Recruiting,Phase 4,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,1,COVID-19 Individual Awareness and Education.|COVID-19 Community Outreach & Health Promotion.|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|Pop-up community vaccination sites,1
NCT04345861,4/11/2020,2/9/2021,Interventional,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Phase 2/Phase 3,"University Hospital, Montpellier",halted prematurely.,NA,NA,NA,NA,NA,France,0,4,Hydroxychloroquine + placebo|hydroxychloroquine + azithromycin,0
NCT05160766,11/8/2021,4/30/2022,Interventional,Assessing Immune Response of Different COVID-19 Vaccines in Older Adults,Recruiting,Phase 2,University of Cologne,NA,NA,NA,NA,NA,NA,Germany,0,0,Comirnaty(BTN162b2)|Spikevax (mRNA-1273),1
NCT05132855,11/30/2021,4/30/2023,Interventional,The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine,Recruiting,Phase 1/Phase 2,Chang Gung Memorial Hospital,NA,NA,NA,NA,NA,NA,Taiwan,0,1,BNT162b2|mRNA-1273|MCV COVID-19 vaccine,1
NCT05000216,8/13/2021,1/31/2022,Interventional,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,11,Moderna mRNA-1273|BNT162b2|Ad26.COV2.S|IS (MMF or MPA)|IS (MTX)|IS (B cell depletion therapy),1
NCT04967742,8/5/2021,8/22/2021,Interventional,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",Completed,Phase 1,"United Biomedical Inc., Asia",NA,NA,NA,NA,NA,NA,Taiwan,0,2,UB-612,1
NCT04880642,9/16/2021,2/28/2022,Interventional,A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects,Recruiting,Phase 3,Vicore Pharma AB,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Colombia|Czechia|India|Peru|Philippines|Ukraine,0,5,C21|Placebo,0
NCT04805671,7/26/2021,1/31/2022,Interventional,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,Recruiting,Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,Argentina|Brazil|Bulgaria|Germany|Greece|Hungary|Poland|Romania|South Africa|Ukraine,0,15,ADG20|Normal saline,0
NCT04784559,6/4/2021,3/31/2022,Interventional,Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection,Recruiting,Phase 3,PharmaMar,NA,NA,NA,NA,NA,NA,Argentina|Brazil|Bulgaria|Colombia|France|Greece|Mexico|Peru|Portugal|Romania|South Africa|Spain|Turkey,0,13,Plitidepsin|Dexamethasone|Remdesivir|Favipiravir,0
NCT04690387,12/7/2020,1/13/2021,Interventional,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",Completed,Phase 1,"Aivita Biomedical, Inc.",NA,NA,NA,NA,NA,NA,Indonesia,0,4,AV-COVID-19|GM-CSF,1
NCT04661813,3/1/2021,12/31/2022,Interventional,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Recruiting,Not Applicable,Case Western Reserve University,NA,NA,NA,NA,NA,NA,United States,0,2,EXTRA-CVD Virtual Care,0
NCT04545008,10/20/2020,6/2/2021,Interventional,Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,Terminated,Phase 1,Prisma Health-Upstate,Study was stopped due to poor accrual.,NA,NA,NA,NA,NA,United States,0,3,Famotidine|N-Acetyl cysteine,0
NCT04439071,7/9/2020,12/31/2021,Interventional,A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Phase 2/Phase 3,PTC Therapeutics,NA,NA,NA,NA,NA,NA,United States|Australia|Belgium|Brazil|Colombia|France|Mexico|Poland|Portugal|South Africa|Spain,0,9,PTC299|SOC|Placebo,0
NCT04378920,4/14/2020,8/24/2021,Interventional,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Completed,Phase 1/Phase 2,Institut de cancÃ©rologie Strasbourg Europe,NA,NA,NA,NA,NA,NA,France,0,8,LEAF-4L6715,0
NCT04390178,4/10/2020,6/30/2020,Interventional,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Completed,Phase 1/Phase 2,Karolinska University Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,1,SARS-CoV-2 convalescent plasma,0
NCT05135624,12/1/2021,3/31/2023,Interventional,SP16 as a Therapeutic for COVID-19 Induced ARDS,Recruiting,Phase 1/Phase 2,"Serpin Pharma, LLC",NA,NA,NA,NA,NA,NA,United States,0,1,SP16 (6mg)|Placebo|SP16 (12 mg),0
NCT05067933,10/1/2021,3/31/2022,Interventional,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,Recruiting,Phase 2,Vaxart,NA,NA,NA,NA,NA,NA,United States,0,2,VXA-CoV2-1.1-S|Placebo Tablets,1
NCT04765449,9/15/2021,7/29/2022,Interventional,Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection,Recruiting,Phase 1,Thomas Jefferson University,NA,NA,NA,NA,NA,NA,United States,0,10,Cytotoxic T Lymphocytes,0
NCT04911777,8/24/2021,12/31/2021,Interventional,"Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandirâ„¢ UPPTA for Patients With Early COVID-19",Recruiting,Phase 2,SyneuRx International (Taiwan) Corp,NA,NA,NA,NA,NA,NA,United States,0,6,Pentarlandirâ„¢ UPPTA|Placebo,0
NCT04518410,8/19/2020,12/31/2023,Interventional,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Phase 2/Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Canada|Costa Rica|Guatemala|Mexico|Philippines|Puerto Rico|South Africa,0,93,"bamlanivimab|Placebo (IV)|BRII-196/BRII-198|AZD7442 (IV)|AZD7442 (IM)|SNG001|Camostat|Placebo (IM)|Placebo (Inhaled solution)|Placebo (oral tablet)|BMS-986414 + BMS-986413|Placebo (SC injections)|SAB-185 (3,840 Units/kg)|SAB-185 (10,240 Units/kg)|CASIRIVIMAB + IMDEVIMAB",0
NCT04526912,8/28/2020,4/8/2021,Interventional,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Terminated,Phase 1,Viela Bio,Study met predefined futility criteria for efficacy endpoints.,NA,NA,NA,NA,NA,United States,0,6,VIB7734|Placebo,0
NCT04402944,7/5/2020,12/31/2021,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,NA,NA,NA,NA,NA,United States,0,4,Pulmozyme|Placebo,0
NCT04376593,5/1/2020,6/30/2022,Interventional,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Early Phase 1,"University of California, Davis",NA,NA,NA,NA,NA,NA,United States,0,5,18F-Î±vÎ²6-BP,0
NCT05163496,12/15/2021,1/31/2023,Interventional,Frontline Clinician Psilocybin Study,Recruiting,Phase 1/Phase 2,University of Washington,NA,NA,NA,NA,NA,NA,United States,0,0,Psilocybin (Usona Institute)|Active placebo,0
NCT05164120,12/14/2021,4/1/2022,Interventional,"Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19",Recruiting,Phase 2,Medstar Health Research Institute,NA,NA,NA,NA,NA,NA,United States,0,0,Belnacasan|Placebo,0
NCT05163743,5/23/2021,12/31/2021,Interventional,Diet and COVID-19 Vaccination,Recruiting,Not Applicable,University of Roma La Sapienza,NA,NA,NA,NA,NA,NA,Italy,0,0,Low Calorie Ketogenic Diet,1
NCT05163730,11/1/2021,5/31/2022,Interventional,Clinical Evaluation of the Panbioâ„¢ COVID-19/ Flu A&B Rapid Panel,Recruiting,Not Applicable,Abbott Rapid Diagnostics Jena GmbH,NA,NA,NA,NA,NA,NA,United States,0,0,COVID-19/ Flu A&B Rapid Panel,0
NCT05163613,1/1/2021,4/1/2021,Interventional,Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients,"Active, not recruiting",Not Applicable,Medical University of Lodz,NA,NA,NA,NA,NA,NA,Poland,0,0,magnetostimulation,0
NCT04969250,8/25/2021,7/31/2022,Interventional,Vaccination for Recovered Inpatients With COVID-19 (VATICO),Recruiting,Phase 4,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States|Nigeria|Spain|Switzerland|Uganda,0,12,Moderna mRNA-1273 COVID-19 vaccine|Pfizer BNT162b2 COVID-19 vaccine,1
NCT05140005,12/6/2021,12/14/2021,Interventional,GlowTest COVID-19 Antigen Home Test Kit QRI Use Study,Completed,Not Applicable,Arion Bio,NA,NA,NA,NA,NA,NA,United States,0,2,GlowTest COVID-19 Antigen Home Test,0
NCT05074446,11/15/2021,1/1/2022,Interventional,Stereotype Threat Effect On the Performance of the Non-Intensivist Physicians Assigned in Covid-19 Intensive Care Unit,Recruiting,Not Applicable,Hacettepe University,NA,NA,NA,NA,NA,NA,Turkey,0,2,stereotype threat manipulation,0
NCT04959760,6/3/2021,3/30/2022,Interventional,BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test,Recruiting,Not Applicable,Abbott Rapid Diagnostics Jena GmbH,NA,NA,NA,NA,NA,NA,United States,0,1,The BinaxNOWâ„¢ Antibody Tests measure IgG antibodies against SARS-CoV-2.,0
NCT04813497,2/5/2021,12/25/2021,Interventional,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Enrolling by invitation,Not Applicable,Grand HÃ´pital de Charleroi,NA,NA,NA,NA,NA,NA,Belgium,0,2,Serology to determine SARS-CoV-2 infection,0
NCT04858425,4/30/2021,12/31/2021,Interventional,Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection,Recruiting,Phase 2,"AzurRx BioPharma, Inc.",NA,NA,NA,NA,NA,NA,United States|India|Ukraine,0,14,Niclosamide|Placebo,0
NCT04843761,4/20/2021,10/31/2022,Interventional,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,29,Remdesivir|Remdesivir Placebo|Aviptadil|Aviptadil Placebo|Corticosteroid,0
NCT04816669,4/1/2021,12/1/2021,Interventional,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults",Completed,Phase 3,BioNTech SE,NA,NA,NA,NA,NA,NA,United States,0,7,BNT162b2,1
NCT04762186,12/8/2021,2/1/2023,Interventional,Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19,Recruiting,Phase 1,UniversitÃ¤tsklinikum KÃ¶ln,NA,NA,NA,NA,NA,NA,Germany,0,1,human SARS-CoV 2 specific T lymphocytes,0
NCT04760730,7/13/2021,3/1/2022,Interventional,Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 1/Phase 2,R-Pharm,NA,NA,NA,NA,NA,NA,United Arab Emirates,0,1,AZD1222|rAd26-S,0
NCT04681092,4/6/2021,2/28/2022,Interventional,Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study,"Active, not recruiting",Phase 1/Phase 2,University Medical Center Groningen,NA,NA,NA,NA,NA,NA,Netherlands,0,4,AKS-452,1
NCT04662086,4/23/2021,8/31/2022,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,Recruiting,Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,5,Acebilustat|Camostat,0
NCT04662073,4/23/2021,8/31/2022,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,"Active, not recruiting",Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,5,Camostat|Placebo,0
NCT04662060,4/23/2021,8/31/2022,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,Recruiting,Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,4,Acebilustat|Placebo,0
NCT04591015,2/1/2021,12/31/2021,Interventional,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Recruiting,Phase 3,Scripps Whittier Diabetes Institute,NA,NA,NA,NA,NA,NA,United States,0,6,Hospital: DD-CA|Hospital: Usual Care (UC),0
NCT04588428,6/21/2021,6/15/2024,Interventional,"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers",Recruiting,Phase 2,Inovio Pharmaceuticals,NA,NA,NA,NA,NA,NA,Jordan|Kenya|Lebanon,0,15,INO-4700|Placebo|CELLECTRAâ„¢ 2000,0
NCT04568122,11/20/2020,11/30/2022,Interventional,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,Not Applicable,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,11,Saliva test kit,0
NCT04466800,7/30/2020,7/31/2022,Interventional,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,Not Applicable,Rennes University Hospital,NA,NA,NA,NA,NA,NA,France,0,7,Intervention group_rehabilitation program,0
NCT04373707,5/13/2020,4/29/2021,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Completed,Phase 4,"Central Hospital, Nancy, France",NA,NA,NA,NA,NA,NA,France,0,6,Enoxaparin|Enoxaparin,0
NCT04431453,7/21/2020,2/28/2022,Interventional,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2/Phase 3,Gilead Sciences,NA,NA,NA,NA,NA,NA,United States|Italy|Spain|United Kingdom,0,34,Remdesivir,0
NCT04372628,6/1/2020,4/1/2022,Interventional,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,"Active, not recruiting",Phase 2,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,10,Lopinavir/Ritonavir 400 mg/100 mg|Placebo,0
NCT05166005,4/1/2020,8/23/2021,Interventional,Severity of COVID-19 and Vitamin D Supplementation,"Active, not recruiting",Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,NA,NA,NA,NA,NA,Russian Federation,0,0,vitamin D,0
NCT05165966,10/20/2021,2/20/2022,Interventional,"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","Active, not recruiting",Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,0,"High-dosage of COVID-19 vaccine (Vero cell), Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated",1
NCT05096832,11/3/2021,1/27/2023,Interventional,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study,Recruiting,Phase 3,Livzon Pharmaceutical Group Inc.,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),1
NCT04952857,8/1/2021,11/30/2021,Interventional,"Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease",Completed,Phase 4,Postgraduate Institute of Medical Education and Research,NA,NA,NA,NA,NA,NA,India,0,3,cholecalciferol 6 lakh IU,0
NCT04904471,6/15/2021,2/28/2022,Interventional,A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells),Enrolling by invitation,Phase 3,"WestVac Biopharma Co., Ltd.",NA,NA,NA,NA,NA,NA,Indonesia|Kenya|Mexico|Philippines,0,7,Recombinant COVID-19 vaccine (Sf9 cells)|Placebo control,1
NCT04899232,7/6/2021,6/30/2022,Interventional,Antithrombin III in Infectious Disease Caused by COVID-19,Recruiting,Phase 2,University of Miami,NA,NA,NA,NA,NA,NA,United States,0,5,Antithrombin III,0
NCT04821934,3/26/2021,12/20/2021,Interventional,Tele-rehabilitation Program After Hospitalization for COVID-19,Completed,Not Applicable,Istituti Clinici Scientifici Maugeri SpA,NA,NA,NA,NA,NA,NA,Italy,0,2,TR|TSu,0
NCT04860297,4/16/2021,3/31/2023,Interventional,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,Recruiting,Phase 3,"ModernaTX, Inc.",NA,NA,NA,NA,NA,NA,United States,0,4,mRNA-1273,1
NCT04792567,4/19/2021,1/17/2022,Interventional,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),"Active, not recruiting",Phase 4,Novartis,NA,NA,NA,NA,NA,NA,Germany,0,5,BAF312|Baseline disease modifying therapies (DMTs),1
NCT04788459,2/25/2021,12/31/2021,Interventional,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","Active, not recruiting",Phase 1/Phase 2,Takis,NA,NA,NA,NA,NA,NA,Italy,0,3,COVID-eVax|CliniporatorÂ® and EPSGun,1
NCT04482595,11/11/2020,3/31/2022,Interventional,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Phase 2,Humanetics Corporation,NA,NA,NA,NA,NA,NA,United States,0,8,BIO 300 Oral Suspension|Placebo,0
NCT04401410,11/4/2020,10/12/2021,Interventional,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Terminated,Phase 1,Baylor College of Medicine,"Due to trial's eligibility criteria and the low census of hospitalized COVID-19 patients meeting eligibility criteria, the Sponsor will be unable to enroll a meaningful number of patients in this single-center trial in a reasonable time frame.",NA,NA,NA,NA,NA,United States,0,6,Dose Finding Phase (MTD)|Partially HLA-matched SARS-CoVSTs|Routine care (no SARS-CoVSTs),0
NCT05167227,11/30/2021,7/31/2024,Interventional,Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?,Recruiting,Not Applicable,Family Health Centers of San Diego,NA,NA,NA,NA,NA,NA,United States,0,0,Extension for Community Healthcare Outcomes,0
NCT05167357,3/18/2021,11/30/2022,Interventional,Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19,Recruiting,Not Applicable,Institut de Formation et de Recherche en MÃ©decine de Montagne,NA,NA,NA,NA,NA,NA,France,0,0,COVID19,0
NCT05167279,12/17/2021,9/30/2022,Interventional,A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19,Recruiting,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,1,JS026/placebo|JS016/placebo,0
NCT05166915,12/31/2021,6/30/2022,Interventional,"Respiratory COVID-19: A Randomized, Sham-Controlled Study",Recruiting,Not Applicable,"Aytu BioPharma, Inc.",NA,NA,NA,NA,NA,NA,Spain,0,1,UVA Light Emitting Catheter|Sham Control Catheter,0
NCT05148949,12/22/2021,5/10/2022,Interventional,Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients,Recruiting,Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,1,Standard dosage inactivated vaccine|Double dosage inactivated vaccine,1
NCT05148832,5/1/2021,8/20/2021,Interventional,Administration of Systemic Corticosteroids and the Recovery of Gustatory Functions in Patients With COVID-19,Completed,Not Applicable,Fayoum University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Administration of Systemic Corticosteroid,0
NCT05143567,11/1/2021,11/1/2026,Interventional,Hemostasis and Inflammation in COVID19 Patients With Venous and Arterial Thrombotic Complications,Recruiting,Not Applicable,Ryazan State Medical University,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,standard of care anticoagulation in absence of thrombotic complications|standard of care anticoagulation in presence of thrombotic complications|standard of care anticoagulation in combination with elastic compression,0
NCT05135585,12/1/2021,10/12/2022,Interventional,Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population,Recruiting,Not Applicable,Institut Pasteur,NA,NA,NA,NA,NA,NA,New Caledonia,0,1,Blood sample collection|Questionnaires,1
NCT05097053,10/7/2021,3/31/2022,Interventional,A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19,Recruiting,Phase 4,Taoyuan General Hospital,NA,NA,NA,NA,NA,NA,Taiwan,0,1,MVC-COV1901(3 Months)|MVC-COV1901(6 Months),1
NCT05063825,10/6/2021,12/13/2021,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19 - Study 2,Completed,Not Applicable,Uppsala University,NA,NA,NA,NA,NA,NA,Sweden,0,2,Simple cognitive task intervention|Attention placebo,0
NCT05087173,10/11/2021,1/31/2022,Interventional,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Recruiting,Not Applicable,Sun Yat-sen University,NA,NA,NA,NA,NA,NA,China,0,1,Chatbot,1
NCT05067894,12/10/2021,3/31/2022,Interventional,Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine,Recruiting,Phase 1,PT Bio Farma,NA,NA,NA,NA,NA,NA,Indonesia,0,4,SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 Inactivated Vaccine,1
NCT05057923,7/10/2021,10/20/2021,Interventional,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,Completed,Not Applicable,DreamTec Research Limited,NA,NA,NA,NA,NA,NA,Hong Kong,1,1,Bacillus subtilis,1
NCT05036941,11/13/2021,2/28/2022,Interventional,A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW),Recruiting,Not Applicable,Ascend Performance Materials,NA,NA,NA,NA,NA,NA,India,0,2,Acteevâ„¢ Masks|Comparison Masks,0
NCT05007080,9/27/2021,8/31/2023,Interventional,A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive,Recruiting,Phase 2/Phase 3,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,Argentina|Brazil|Colombia|India|Mexico|Philippines|South Africa|Thailand,0,5,Ad26.COV2.S,0
NCT04992273,9/13/2021,11/17/2022,Interventional,COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age,Recruiting,Phase 2,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,2,casirivimab+imdevimab,0
NCT04956887,8/3/2021,1/31/2022,Interventional,Cognitive Training in Survivors of Covid-19: A Randomized Trial,Recruiting,Not Applicable,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,AKL-T01|Control Group,0
NCT04955626,7/1/2021,9/20/2023,Interventional,"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a Booster Dose of BNT162b2 Against COVID-19 in Participants â‰¥12 Years of Age.","Active, not recruiting",Phase 3,BioNTech SE,NA,NA,NA,NA,NA,NA,United States|Brazil|Canada|South Africa,0,9,BNT162b2|Placebo,1
NCT05057169,11/18/2021,3/31/2023,Interventional,Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study),Recruiting,Phase 4,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,3,BNT162b2|CoronaVac,1
NCT04988035,7/21/2021,10/31/2022,Interventional,ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,33,Danicopan|Placebo|Remdesivir,0
NCT04987957,12/8/2021,5/31/2022,Interventional,Effect Of MusÄ±c Therapy On AnxÄ±ety Levels In COVID-19 PandemÄ±c,Recruiting,Not Applicable,Abant Izzet Baysal University,NA,NA,NA,NA,NA,NA,Turkey,0,4,Music Therapy,0
NCT04951310,6/7/2021,8/14/2021,Interventional,COVID-19 Vaccinations With a Sweepstakes,Completed,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,1,Philly Vax Sweepstakes,1
NCT04939428,8/11/2021,4/3/2022,Interventional,Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013),Recruiting,Phase 3,Merck Sharp & Dohme Corp.,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Colombia|Dominican Republic|France|Guatemala|Hungary|Japan|Mexico|Philippines|Romania|Russian Federation|South Africa|Spain|Turkey|Ukraine,0,20,Molnupiravir|Placebo,0
NCT04935476,11/22/2021,3/31/2022,Interventional,Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19,Recruiting,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,United States|Canada,0,3,Dapsone 85 mg PO BID|Placebo 85 mg PO BID,0
NCT04920890,5/16/2021,7/20/2021,Interventional,Radiofrequency Intervention in Post COVID-19 Patients,Completed,Not Applicable,Clinica Gema Leon,NA,NA,NA,NA,NA,NA,Spain,0,2,Radiofrequency therapy|Placebo without radiofrequency.,0
NCT04908722,6/18/2021,4/18/2022,Interventional,A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults,Recruiting,Phase 3,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,United States|Brazil|Germany|Poland|South Africa,0,9,Ad26.COV2.S,0
NCT04894305,5/25/2021,12/8/2021,Interventional,A Study of Ad26.COV2.S in Healthy Adults (COVID-19),Completed,Phase 1,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,Netherlands,0,7,Ad26.COV2.S,0
NCT04871854,4/26/2021,7/26/2022,Interventional,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Recruiting,Phase 2,Beni-Suef University,NA,NA,NA,NA,NA,NA,Egypt,0,4,Tocilizumab|traditional Covid -19 therapy,0
NCT04828161,5/24/2021,5/31/2022,Interventional,"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19",Recruiting,Phase 2/Phase 3,Molecular Partners AG,NA,NA,NA,NA,NA,NA,United States|Hungary|India|Netherlands|Poland|South Africa,0,4,ensovibep|Placebo,0
NCT04826588,5/23/2021,7/31/2022,Interventional,Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Recruiting,Phase 3,University Children's Hospital Basel,NA,NA,NA,NA,NA,NA,Switzerland,0,5,Methylprednisolone sodium succinate 10 mg/kg intravenously|Human normal immunoglobulin (IVIg)|Methylprednisolone sodium succinate 2 mg/kg,0
NCT04780321,10/30/2020,3/30/2022,Interventional,JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects,Recruiting,Phase 1/Phase 2,"Shanghai Junshi Bioscience Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,2,Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|Placebo,0
NCT04885530,6/8/2021,12/31/2022,Interventional,ACTIV-6: COVID-19 Study of Repurposed Medications,Recruiting,Phase 3,Duke University,NA,NA,NA,NA,NA,NA,United States,0,7,Ivermectin|Fluvoxamine|Fluticasone|Placebo,0
NCT04858451,4/30/2021,4/30/2023,Interventional,COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2,Recruiting,Phase 2,Thirty Respiratory Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,RESP301,0
NCT04842747,5/18/2021,1/5/2022,Interventional,VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study,Recruiting,Phase 3,Veru Inc.,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Bulgaria|Colombia|Mexico,0,25,VERU-111,0
NCT04841759,4/1/2021,12/3/2021,Interventional,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,Completed,Not Applicable,Medical University of Vienna,NA,NA,NA,NA,NA,NA,Austria,0,4,Exercise,0
NCT04795557,4/19/2021,11/11/2021,Interventional,Efficacy of Adaptogens in Patients With Long COVID-19,Completed,Phase 2/Phase 3,Swedish Herbal Institute AB,NA,NA,NA,NA,NA,NA,Georgia,0,2,ADAPT-232 oral solution|Placebo oral solution,0
NCT04745351,3/31/2021,8/31/2022,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 3,Gilead Sciences,NA,NA,NA,NA,NA,NA,United States|Portugal|Spain|United Kingdom,0,15,Remdesivir|RDV Placebo|Standard of Care,0
NCT04758962,2/15/2021,6/4/2021,Interventional,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,GlaxoSmithKline,NA,NA,NA,NA,NA,NA,United States,0,3,1 Âµg CoV2 SAM (LNP),1
NCT04762680,2/24/2021,3/30/2023,Interventional,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Recruiting,Phase 2/Phase 3,Sanofi,NA,NA,NA,NA,NA,NA,United States|Australia|France|Honduras|Kenya|Spain|United Kingdom,0,12,"SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, Dosage A|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, Dosage A|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, Dosage B|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, Dosage B|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4",1
NCT04659746,12/9/2020,2/28/2021,Interventional,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Completed,Not Applicable,Universidad AutÃ³noma de EncarnaciÃ³n,NA,NA,NA,NA,NA,NA,Paraguay,0,4,MejoraCare,0
NCT04715243,2/2/2021,8/9/2021,Interventional,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Completed,Not Applicable,Sultan Qaboos University,NA,NA,NA,NA,NA,NA,Oman,0,4,High flow nasal cannula (HFNC)|Helmet NIV|Face-mask NIV,0
NCT04646044,11/13/2020,5/11/2021,Interventional,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Completed,Phase 1,Nektar Therapeutics,NA,NA,NA,NA,NA,NA,United States,0,10,Bempegaldesleukin|Standard of Care|Placebo,0
NCT04708327,12/5/2021,6/30/2022,Interventional,Single-Blind Study of STAT-205 in Mild COVID-19,Recruiting,Phase 1,"Cytocom, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,STAT-205,0
NCT04685655,1/7/2020,12/31/2021,Interventional,RescuE pLAsma eXchange in Severe COVID-19,Recruiting,Not Applicable,Heidelberg University,NA,NA,NA,NA,NA,NA,Germany,0,5,Therapeutic plasma exchange,0
NCT04673292,2/8/2021,5/31/2023,Interventional,Community Collaboration to Combat COVID-19 (C-FORWARD),Enrolling by invitation,Not Applicable,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,4,"Fixed site standard of care testing|Community-based, mobile van testing|Self-collected, home-based testing",0
NCT04652518,12/11/2020,12/31/2021,Interventional,LYT-100 in Post-acute COVID-19 Respiratory Disease,Recruiting,Phase 2,PureTech,NA,NA,NA,NA,NA,NA,"United States|Argentina|Brazil|Moldova, Republic of|Philippines|Romania|Ukraine|United Kingdom",0,9,LYT-100|Placebo,0
NCT04640194,12/16/2020,6/12/2022,Interventional,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,NA,NA,NA,NA,NA,Austria|Belgium|Brazil|Denmark|France|Germany|Italy|Netherlands|Portugal|Russian Federation|Spain,0,28,Alteplase|Standard of care,0
NCT04614948,11/16/2020,5/10/2022,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,United States|Belgium|Brazil|Colombia|France|Germany|Philippines|South Africa|Spain|United Kingdom,0,18,Ad26.COV2.S|Placebo,0
NCT04632706,9/22/2020,3/9/2021,Interventional,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Completed,Phase 1,MedinCell S.A,NA,NA,NA,NA,NA,NA,United Kingdom,1,3,Ivermectin|Placebo,0
NCT04583956,10/14/2020,12/31/2021,Interventional,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,"Active, not recruiting",Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,58,Placebo|Remdesivir|Risankizumab,0
NCT04559035,9/24/2020,1/18/2021,Interventional,Nasal Irrigation to Reduce COVID-19 Morbidity,Completed,Not Applicable,Augusta University,NA,NA,NA,NA,NA,NA,United States,0,2,Nasal lavage,0
NCT04565665,7/29/2020,4/30/2023,Interventional,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Phase 1/Phase 2,M.D. Anderson Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,6,Best Practice|Mesenchymal Stem Cell,0
NCT04535791,7/15/2020,12/30/2020,Interventional,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Completed,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,1,Cholecalciferol,0
NCT04535453,8/28/2020,3/28/2022,Interventional,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents,"Active, not recruiting",Phase 2,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,Germany|Netherlands|Spain|United Kingdom,0,16,Ad26.COV2.S|Placebo,1
NCT04523246,9/1/2020,11/30/2021,Interventional,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Active, not recruiting",Early Phase 1,University of Oklahoma,NA,NA,NA,NA,NA,NA,United States,0,6,"SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Normal Saline",1
NCT04498247,8/27/2020,3/5/2021,Interventional,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",Terminated,Phase 1/Phase 2,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity,NA,NA,NA,NA,NA,United States|Austria|Belgium,1,13,V591|Placebo,1
NCT04513990,4/9/2020,4/30/2023,Interventional,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),"Active, not recruiting",Not Applicable,M.D. Anderson Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,3,Biospecimen Collection|Questionnaire Administration,0
NCT04359797,4/27/2020,12/17/2020,Interventional,COVID-19 Patient Positioning Pragmatic Trial,Completed,Not Applicable,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,1,15,Prone|Usual Care,0
NCT05172050,1/22/2021,6/12/2021,Interventional,"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.",Completed,Phase 2/Phase 3,DompÃ© Farmaceutici S.p.A,NA,NA,NA,NA,NA,NA,France|Italy|Spain,0,0,Raloxifene|Placebo,0
NCT05172037,10/28/2021,3/31/2022,Interventional,Phase III Study of Novaferon in Non-hospitalized Adult Patients With Mild COVID-19,Recruiting,Phase 3,Genova Inc.,NA,NA,NA,NA,NA,NA,Japan,0,0,Novaferon|Placebo,0
NCT05171829,12/27/2021,5/15/2022,Interventional,An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission,Enrolling by invitation,Not Applicable,Hospital Clinic of Barcelona,NA,NA,NA,NA,NA,NA,Spain,0,0,Track U,0
NCT05168813,12/1/2021,6/1/2023,Interventional,Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern,Recruiting,Phase 2/Phase 3,COVID-19 Prevention Network,NA,NA,NA,NA,NA,NA,Botswana|Kenya|Malawi|South Africa|Swaziland|Uganda|Zambia|Zimbabwe,0,1,Moderna mRNA-1273|Vaccine 3 Dose|Vaccine 2 Dose + Placebo|Vaccine 2 Dose|Vaccine 1 Dose + Placebo,1
NCT05077969,12/29/2021,4/30/2022,Interventional,Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2),Recruiting,Phase 2,Leidos Life Sciences,NA,NA,NA,NA,NA,NA,United States,0,2,Famotidine|Celecoxib|Placebo,0
NCT05123755,12/20/2021,5/31/2022,Interventional,AV-001 for Hospitalized Patients With COVID-19 Disease,Recruiting,Phase 2,"Vasomune Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,AV-001 Injection|AV-001 Placebo Injection,0
NCT05077332,12/29/2021,4/30/2022,Interventional,LEAP-CT for Treatment of COVID-19 Patients (Master Protocol),"Active, not recruiting",Phase 2,Leidos Life Sciences,NA,NA,NA,NA,NA,NA,United States,0,2,Famotidine|Celecoxib|Placebo,0
NCT04999111,8/6/2021,10/27/2021,Interventional,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"Active, not recruiting",Phase 2,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,United States,0,5,Ad26.COV2.S,1
NCT04690400,1/15/2021,12/30/2021,Interventional,Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic,"Active, not recruiting",Not Applicable,Federal University of Pelotas,NA,NA,NA,NA,NA,NA,Brazil,0,1,Experimental: Active care group|Active Comparator: Self-care group,0
NCT04941703,11/4/2021,6/25/2023,Interventional,"""CHANGE COVID-19 Severity""",Recruiting,Phase 1/Phase 2,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Magnesium Citrate plus probiotic,0
NCT04682873,5/15/2020,3/26/2021,Interventional,"A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,Phase 3,"Joint Stock Company ""Farmak""",NA,NA,NA,NA,NA,NA,Ukraine,0,1,Enisamium Iodide|Placebo,0
NCT04607928,8/1/2020,1/30/2022,Interventional,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Phase 2,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,NA,NA,NA,NA,NA,NA,Spain,0,4,Pirfenidone|Placebo,0
NCT04569786,10/29/2020,2/18/2021,Interventional,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),Terminated,Phase 1,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity.,NA,NA,NA,NA,NA,United States,1,12,V590|Placebo,1
NCT04569266,8/7/2020,8/6/2022,Interventional,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,Not Applicable,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,NA,NA,France,0,1,specific exercise rehabilitation treatment,0
NCT04475185,7/20/2020,12/19/2020,Interventional,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Terminated,Not Applicable,Nantes University Hospital,Manufacturer's decision following failure of sequence 2. Protocol unadapted to the security and performance evaluation of the new MakAir device capabilities in non-invasive ventilation (NIV).,NA,NA,NA,NA,NA,France,0,5,MakAir,0
NCT04407286,5/19/2020,8/30/2020,Interventional,Vitamin D Testing and Treatment for COVID 19,Completed,Phase 1,Arizona State University,NA,NA,NA,NA,NA,NA,United States,0,3,Vitamin D3,0
NCT04333472,1/6/2021,3/6/2022,Interventional,Piclidenoson for Treatment of COVID-19,"Active, not recruiting",Phase 2,Can-Fite BioPharma,NA,NA,NA,NA,NA,NA,Bulgaria|Israel|Romania,0,12,Piclidenoson|Placebo,0
NCT04978259,7/24/2021,2/28/2023,Interventional,SOLIDARITY Finland Long COVID-19,Recruiting,Phase 4,Clinical Urology and Epidemiology Working Group,NA,NA,NA,NA,NA,NA,Finland,0,1,Remdesivir,0
NCT04964570,8/4/2021,12/25/2021,Interventional,Digital Mental Health Care for COVID-19 High-Risk Populations,"Active, not recruiting",Not Applicable,"Research Foundation for Mental Hygiene, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,Video _ behavioral change module,0
NCT04931888,6/23/2021,8/31/2021,Interventional,Implementing and Evaluating a Social-Emotional Learning Program for Refugee Children During the COVID-19 Pandemic,Enrolling by invitation,Not Applicable,Yale University,NA,NA,NA,NA,NA,NA,United States,0,2,EMPOWER,0
NCT04951323,3/22/2021,12/1/2021,Interventional,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,Phase 3,University of Liege,NA,NA,NA,NA,NA,NA,Belgium,0,1,"anti-COVID19 mRNA-based vaccine (BNT162b2, ComirnatyÂ®, commercialized by Pfizer)",1
NCT04497415,10/21/2020,11/30/2020,Interventional,The COVID-19 and Healthcare Workers: An Active Intervention,Completed,Not Applicable,"Research Foundation for Mental Hygiene, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,Video-Based intervention,0
NCT04638842,12/24/2020,6/1/2021,Interventional,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Completed,Not Applicable,Universidad Internacional de Valencia,NA,NA,NA,NA,NA,NA,Mexico,0,3,Online Intervention Grief COVID-19,0
NCT04471766,7/20/2020,10/31/2021,Interventional,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,"Active, not recruiting",Not Applicable,Bandim Health Project,NA,NA,NA,NA,NA,NA,Guinea-Bissau,0,6,Certified cloth face mask plus preventive information|Preventive information,0
NCT04346693,4/8/2020,11/1/2020,Interventional,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19,Completed,Phase 3,Burnasyan Federal Medical Biophysical Center,NA,NA,NA,NA,NA,NA,Russian Federation,0,3,Standard therapy recommended by the Ministry of Health of the Russian Federation.|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation,0
NCT04379336,5/4/2020,5/31/2022,Interventional,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Active, not recruiting",Phase 3,TASK Applied Science,NA,NA,NA,NA,NA,NA,South Africa,0,1,Bacille Calmette-GuÃ©rin (BCG)|Placebo Comparator,1
NCT05079152,5/6/2021,5/29/2021,Interventional,Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4,"Active, not recruiting",Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,0,COVAX+PPV23;COVAX+IIV4|COVAX only (1st and 2nd dose)|PPV23 for the 1st dose and IIV4 for the 2nd dose,1
NCT05077943,9/1/2021,1/31/2022,Interventional,The Effect of Home-based Exercise on Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity,Recruiting,Not Applicable,National Cardiovascular Center Harapan Kita Hospital Indonesia,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Breathing and chest mobilization exercises|Second phase cardiac rehabilitation,0
NCT05077930,10/31/2021,12/31/2021,Interventional,Convalescent Plasma Therapy for Hospitalized Patients With COVID-19,Recruiting,Phase 2,Science Valley Research Institute,NA,NA,NA,NA,NA,NA,Brazil,0,0,Convalescent plasma|Standard of care,0
NCT05077306,4/15/2021,5/15/2021,Interventional,Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients.,Completed,Not Applicable,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,NA,NA,NA,NA,NA,NA,Italy,0,0,music therapy group,0
NCT05077241,8/11/2021,5/31/2023,Interventional,Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial,Recruiting,Not Applicable,Universidade Federal do Rio Grande do Norte,NA,NA,NA,NA,NA,NA,Brazil,0,0,Inspiratory muscle training,0
NCT04930965,10/5/2021,3/31/2022,Interventional,Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate,Recruiting,Not Applicable,Tulane University,NA,NA,NA,NA,NA,NA,United States,0,3,Community health worker engagement,1
NCT05047445,9/30/2021,4/30/2022,Interventional,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,Recruiting,Phase 1,Scancell Ltd,NA,NA,NA,NA,NA,NA,South Africa,0,1,COVIDITY administered via needle-free injection (PharmaJet TropisÂ®; intradermal injection).|COVIDITY administered via needle-free injection (PharmaJet StratisÂ®; intramuscular injection).,1
NCT04890509,10/20/2020,5/25/2021,Interventional,A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients,Completed,Phase 2,BerGenBio ASA,NA,NA,NA,NA,NA,NA,India|South Africa,0,1,Bemcentinib|SoC,0
NCT04750343,2/3/2021,7/28/2021,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"SK Bioscience Co., Ltd.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,2,GBP510 adjuvanted with AS03 (RBD 10Î¼g/dose) - Stage 1|GBP510 (RBD 10Î¼g/dose) - Stage 1|Normal saline (0.9% sodium chloride solution) - Stage 1|GBP510 adjuvanted with AS03 (RBD 25Î¼g/dose) - Stage 1|GBP510 (RBD 25Î¼g/dose) - Stage 1|Normal saline (0.9% sodium chloride solution) - Stage 1|GBP510 adjuvanted with AS03 (RBD 10Î¼g/dose) - Stage 2|GBP510 adjuvanted with AS03 (RBD 25Î¼g/dose)- Stage 2|GBP510 (RBD 25Î¼g/dose)- Stage 2|Normal saline (0.9% sodium chloride solution)- Stage 2,1
NCT04808284,8/10/2021,10/11/2021,Interventional,Neuromodulation in COVID-19 Patients,Completed,Phase 1/Phase 2,D'Or Institute for Research and Education,NA,NA,NA,NA,NA,NA,Brazil,0,3,Transcranial direct-current stimulation|Transcranial direct-current stimulation|Sham Transcranial direct-current stimulation,0
NCT04425915,6/14/2020,12/15/2020,Interventional,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Completed,Phase 3,"Institute of Liver and Biliary Sciences, India",NA,NA,NA,NA,NA,NA,India,0,4,Convalescent Plasma|Standard of Care,0
NCT04734886,11/27/2020,9/13/2021,Interventional,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Completed,Not Applicable,"Ã–rebro University, Sweden",NA,NA,NA,NA,NA,NA,Sweden,0,2,L. reuteri DSM 17938 + vitamin D|Placebo + vitamin D,0
NCT04641858,12/3/2020,6/30/2022,Interventional,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Phase 4,University of Southern Denmark,NA,NA,NA,NA,NA,NA,Cape Verde|Guinea-Bissau|Mozambique,0,2,BCG-Denmark|Saline,1
NCT04551911,10/26/2020,10/8/2021,Interventional,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Completed,Phase 2,"OPKO Health, Inc.",NA,NA,NA,NA,NA,NA,United States,0,7,Rayaldee 30Mcg Extended-Release (ER) Capsule|Placebo,0
NCT04510454,11/2/2020,12/31/2021,Interventional,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,"Active, not recruiting",Not Applicable,Centre Leon Berard,NA,NA,NA,NA,NA,NA,France,0,2,Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR,0
NCT04408183,6/10/2020,4/30/2022,Interventional,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,NA,NA,NA,NA,NA,United States,0,6,GLS-1200|Placebo,0
NCT04539275,11/16/2020,6/30/2021,Interventional,COVID-19 (VA CURES-1),Completed,Phase 3,VA Office of Research and Development,NA,NA,NA,NA,NA,NA,United States|Puerto Rico,0,11,Convalescent Plasma|Masked Saline Placebo,0
NCT05012943,8/15/2021,2/28/2023,Interventional,The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01),Recruiting,Phase 2/Phase 3,Vinbiocare Biotechnology Joint Stock Company,NA,NA,NA,NA,NA,NA,Vietnam,0,2,ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|Placebo (normal saline),1
NCT04838795,2/18/2021,3/31/2022,Interventional,Sisonke (Together): OPEN LABEL TRIAL COVID-19,Recruiting,Phase 3,Wits Health Consortium (Pty) Ltd,NA,NA,NA,NA,NA,NA,South Africa,0,2,To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine,1
NCT04522089,8/24/2020,11/20/2020,Interventional,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"Active, not recruiting",Phase 1,Adimmune Corporation,NA,NA,NA,NA,NA,NA,Taiwan,0,5,AdimrSC-2f,1
NCT04516564,9/29/2020,3/4/2021,Interventional,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Completed,Phase 1,Akeso,NA,NA,NA,NA,NA,NA,New Zealand,0,3,AK119|Placebo,0
NCT04357457,9/3/2020,10/1/2021,Interventional,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,"Active, not recruiting",Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,6,Almitrine|Placebo,0
NCT04345991,4/15/2020,5/28/2021,Interventional,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Transfusion of COVID-19 convalescent plasma,0
NCT05081362,10/18/2021,10/6/2022,Interventional,Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease,Recruiting,Not Applicable,IRCCS Policlinico S. Donato,NA,NA,NA,NA,NA,NA,Italy,0,1,"Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity",0
NCT04565249,10/22/2020,6/1/2021,Interventional,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Terminated,Phase 2,"Pliant Therapeutics, Inc.",Study halted and will not resume; participants are no longer being examined or receiving intervention,NA,NA,NA,NA,NA,United States,0,7,PLN-74809|Placebo,0
NCT05082727,7/1/2021,9/15/2022,Interventional,Safety and Efficacy of KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),Recruiting,Phase 2,Sunstar Joint Stock Company,NA,NA,NA,NA,NA,NA,Vietnam,0,0,KOVIR (TD0068) oral capsule|Placebo oral capsule,0
NCT05027815,10/11/2021,8/31/2022,Interventional,Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS),Recruiting,Phase 1,"University of California, San Francisco",NA,NA,NA,NA,NA,NA,United States,0,2,Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells,0
NCT04918927,10/12/2021,1/31/2022,Interventional,Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19,Recruiting,Phase 2,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,1,Favipiravir|Nitazoxanide|Nitazoxanide Placebo,0
NCT05042141,7/28/2021,8/11/2021,Interventional,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),Completed,Not Applicable,Sunstar Joint Stock Company,NA,NA,NA,NA,NA,NA,Vietnam,0,3,KOVIR oral capsule|Placebo oral capsule,0
NCT05032950,9/17/2021,12/3/2021,Interventional,Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants,Recruiting,Phase 1,Pfizer,NA,NA,NA,NA,NA,NA,Belgium,0,2,Midazolam|PF-07321332/ritonavir + Midazolam|Ritonavir + Midazolam,0
NCT04951336,6/10/2021,12/31/2021,Interventional,RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination,Recruiting,Not Applicable,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,2,FoTv,1
NCT04942405,6/21/2021,1/21/2022,Interventional,"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine",Recruiting,Phase 3,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,3,TURCOVAC|CoronaVac,1
NCT04806074,8/14/2020,12/6/2020,Interventional,FOODLIT-Trial: Digital Behaviour Change Intervention to Improve Food Literacy Amidst the COVID-19 Pandemic,Completed,Not Applicable,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",NA,NA,NA,NA,NA,NA,Portugal,0,2,Experimental Group|Comparison Group,0
NCT04869228,8/4/2021,2/28/2022,Interventional,"A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients",Recruiting,Phase 3,"Suzhou Kintor Pharmaceutical Inc,",NA,NA,NA,NA,NA,NA,Brazil,0,4,GT0918 tablets or placebo,0
NCT04852861,5/10/2021,7/30/2021,Interventional,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine,Enrolling by invitation,Phase 4,Sciensano,NA,NA,NA,NA,NA,NA,Belgium,0,3,immunogenicity after first and second dose,1
NCT04527614,9/24/2020,5/30/2022,Interventional,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,Not Applicable,Sciensano,NA,NA,NA,NA,NA,NA,Belgium,0,2,qRT-PCR and serology,0
NCT05084898,10/1/2021,2/28/2023,Interventional,Far-UVC Light Devices in Long-term Care Facilities to Reduce Infections,Enrolling by invitation,Not Applicable,Nova Scotia Health Authority,NA,NA,NA,NA,NA,NA,Canada,0,0,Far-UVC light as an additional method of disinfection|Placebo fluorescent light,0
NCT05085145,9/1/2021,9/1/2022,Interventional,Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV,Recruiting,Phase 4,Beijing 302 Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Coronavirus vaccine,1
NCT05074771,3/26/2021,10/31/2021,Interventional,At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE),Enrolling by invitation,Not Applicable,Camlin Ltd,NA,NA,NA,NA,NA,NA,Italy,0,1,ARC intellicare,0
NCT05028257,9/15/2021,5/31/2022,Interventional,Allergy and COVID-19 Vaccines,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,COVID-19 Vaccines,1
NCT04962204,7/6/2021,3/31/2022,Interventional,Virtual Visitation in Intensive Care Unit Study,Recruiting,Not Applicable,Seoul National University Hospital,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,Virtual meeting between patients/physicians and caregiver,0
NCT04980534,1/8/2021,6/30/2021,Interventional,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,Not Applicable,Catalysis SL,NA,NA,NA,NA,NA,NA,Kazakhstan,0,2,Viusid and Asbrip|COVID-19 Standard Therapy,0
NCT04952376,1/31/2022,6/30/2022,Interventional,Equitable Access to COVID-19 Vaccines,Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,2,SMS delivery of information|Personalized text message delivery of information|Interactive or 2-way SMS delivery of information,1
NCT04927182,10/15/2020,9/30/2021,Interventional,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Completed,Not Applicable,Riphah International University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Moderate Exercise Training (Age Group 3; Above 45 years),0
NCT04790851,3/10/2021,9/5/2021,Interventional,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,Completed,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,5,COVAX+IIV4; COVAX+PPV23|COVAX only (1st and 2nd dose)|IIV4 for the 1st dose and PPV23 for the 2nd dose,1
NCT04896866,3/1/2021,12/31/2021,Interventional,Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP),Recruiting,Not Applicable,University of Alberta,NA,NA,NA,NA,NA,NA,Canada,0,2,Antimicrobial stewardship prospective audit and feedback,0
NCT04726098,1/15/2021,8/31/2021,Interventional,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Completed,Phase 4,Hospital Clinico Universitario de Santiago,NA,NA,NA,NA,NA,NA,Spain,0,1,Dexamethasone high dose|Dexamethasone low dose,0
NCT04528771,8/5/2021,3/31/2022,Interventional,S-Nitrosylation Therapy of COVID-19,"Active, not recruiting",Early Phase 1,University Hospitals Cleveland Medical Center,NA,NA,NA,NA,NA,NA,United States,0,1,SNO|Nitrogen gas,0
NCT04701502,11/9/2020,2/15/2021,Interventional,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,Phase 2,Catalysis SL,NA,NA,NA,NA,NA,NA,Bulgaria,0,3,Viusid|Asbrip|Standard Care,0
NCT04595773,1/22/2021,12/31/2023,Interventional,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Recruiting,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),NA,NA,NA,NA,NA,NA,United States,0,72,Aerobic Exercise Training|Education,0
NCT04581200,1/25/2021,12/30/2021,Interventional,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Recruiting,Not Applicable,Duke University,NA,NA,NA,NA,NA,NA,United States,0,6,Lift,0
NCT04470622,7/20/2020,4/9/2021,Interventional,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Terminated,Phase 2,Heron Therapeutics,"Study was terminated early by Heron, and was not terminated for safety reasons.",NA,NA,NA,NA,NA,United States,0,8,Aprepitant injectable emulsion|Saline Placebo,0
NCT04348864,4/16/2020,4/30/2022,Interventional,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,Not Applicable,Neuroganics LLC,NA,NA,NA,NA,NA,NA,United States,0,11,"COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Telemedicine",0
NCT04335084,6/22/2020,12/31/2024,Interventional,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Phase 2,ProgenaBiome,NA,NA,NA,NA,NA,NA,United States,0,8,Hydroxychloroquine|Vitamin C|Vitamin D|Zinc,0
NCT04400305,5/20/2020,8/30/2021,Interventional,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Completed,Not Applicable,University of Victoria,NA,NA,NA,NA,NA,NA,Canada,0,6,Digital Health Online Platform,0
NCT05089045,8/31/2021,9/16/2021,Interventional,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,Completed,Not Applicable,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,0,Recombinant new coronavirus vaccine (CHO cell) group,1
NCT05084911,10/18/2021,6/30/2022,Interventional,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3),Recruiting,Phase 3,Shin Poong Pharmaceutical Co. Ltd.,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,Pyramax|Placebo,0
NCT04932915,9/3/2021,11/30/2021,Interventional,Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19,Recruiting,Phase 2,UNION therapeutics,NA,NA,NA,NA,NA,NA,Germany,0,2,Niclosamide|Placebo,0
NCT05007951,8/30/2021,3/31/2022,Interventional,Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19),Recruiting,Phase 3,"SK Bioscience Co., Ltd.",NA,NA,NA,NA,NA,NA,"Korea, Republic of|New Zealand|Philippines|Thailand|Ukraine|Vietnam",0,2,GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|ChAdOx1-S not less than 2.5 Ã— 10^8 infectious units,1
NCT05077267,8/19/2021,12/1/2021,Interventional,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,Recruiting,Phase 2,Bavarian Nordic,NA,NA,NA,NA,NA,NA,Germany,0,1,ABNCoV2,1
NCT05075083,10/8/2021,6/30/2022,Interventional,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,1,Inactivated COVID-19 vaccine,1
NCT05075070,10/8/2021,6/30/2022,Interventional,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,1,Inactivated COVID-19 vaccine,1
NCT05075057,10/8/2021,6/30/2022,Interventional,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and COPD,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,1,Inactivated COVID-19 vaccine,1
NCT05075044,10/8/2021,12/30/2022,Interventional,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged â‰¥18 Years With HIV Infected,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,1,Inactivated COVID-19 vaccine,1
NCT04952389,12/31/2021,7/31/2023,Interventional,Acupuncture Therapy for COVID-Related Olfactory Loss,Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,4,Acupuncture Therapy|Budesonide|Olfactory Training,0
NCT04484025,10/12/2021,6/30/2022,Interventional,SPI-1005 Treatment in Moderate COVID-19 Patients,Enrolling by invitation,Phase 2,"Sound Pharmaceuticals, Incorporated",NA,NA,NA,NA,NA,NA,United States,0,4,Ebselen|Placebo,0
NCT04483973,8/27/2021,6/30/2022,Interventional,SPI-1005 Treatment in Severe COVID-19 Patients,Enrolling by invitation,Phase 2,"Sound Pharmaceuticals, Incorporated",NA,NA,NA,NA,NA,NA,United States,0,4,Ebselen|Placebo,0
NCT05091411,9/9/2021,11/30/2021,Interventional,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,0,Recombinant new coronavirus vaccine (CHO cell) group,1
NCT05092607,7/15/2021,1/15/2022,Interventional,Evaluation of the Detection Performance of the N Antigenemia of SARS-CoV-2 in the General Population for the Diagnosis and Screening of COVID-19,Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,0,Venous and Capillary blood sampling,0
NCT05092542,10/18/2021,3/1/2022,Interventional,Multilevel Community-Based Mental Health Intervention to Address Structural Inequities and Adverse Disparate Consequences of COVID-19 Pandemic on Latinx Immigrant and African Refugees,Recruiting,Phase 3,University of New Mexico,NA,NA,NA,NA,NA,NA,United States,0,0,Refugee and Immigrant Well-being Project (RIWP),0
NCT05072210,5/1/2021,7/1/2022,Interventional,Mobile Interventions for the Prevention and Detection of Distress,Recruiting,Not Applicable,Unity Health Toronto,NA,NA,NA,NA,NA,NA,Canada,0,1,Mobile Intervention,0
NCT05069129,10/14/2021,12/31/2023,Interventional,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,Phase 1/Phase 2,"National Vaccine and Serum Institute, China",NA,NA,NA,NA,NA,NA,United Arab Emirates,0,2,Recombinant COVID-19 Vaccine (CHO cellï¼ŒNVSI-06-08)|Inactivated COVID-19 vaccine (Vero cells)|3 doses Recombinant COVID-19 Vaccine (CHO cellï¼ŒNVSI-06-08),1
NCT04952350,8/14/2021,11/30/2021,Interventional,Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT,"Active, not recruiting",Phase 3,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Atorvastatin 40 Mg Oral Tablet|Placebo,0
NCT04415151,10/14/2020,2/28/2021,Interventional,Tofacitinib for Treatment of Moderate COVID-19,Terminated,Phase 2,Yale University,Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.,NA,NA,NA,NA,NA,United States,0,7,Tofacitinib 10 mg|Placebo,0
NCT04716985,1/22/2021,5/22/2022,Interventional,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,Recruiting,Not Applicable,AGIR Ã  Dom,NA,NA,NA,NA,NA,NA,France|Morocco|Serbia,0,4,MOLECULAR HYDROGEN|PLACEBO MAGNESIUM,0
NCT04710199,2/23/2021,7/8/2021,Interventional,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,NA,NA,NA,NA,NA,Spain,0,2,Maraviroc experimental group|Standard treatment,0
NCT04399889,6/18/2020,4/1/2022,Interventional,hCT-MSCs for COVID19 ARDS,Recruiting,Phase 1/Phase 2,Duke University,NA,NA,NA,NA,NA,NA,United States,0,5,Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Placebo,0
NCT05093530,10/13/2021,4/15/2022,Interventional,Safety and Tolerability of Single and Multiple Doses of Neumifil,Recruiting,Phase 1,Pneumagen Ltd.,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Neumifil|Placebo,0
NCT05094726,9/8/2021,10/30/2021,Interventional,Effect of PBM on Functional Capacity and Fatigability in Post Covid-19 Elderly,Recruiting,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,0,photobiomodulation|placebo intervention by photobiomodulation device,0
NCT05094674,10/22/2021,6/22/2022,Interventional,Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.,Recruiting,Not Applicable,Tera Group,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Breath Sample analysis,0
NCT05094661,2/18/2021,10/31/2022,Interventional,Predictors of Non-invasive Respiratory Support Failure in COVID-19 Pneumonia,Recruiting,Not Applicable,Germans Trias i Pujol Hospital,NA,NA,NA,NA,NA,NA,Spain,0,0,BiPAP|CPAP,0
NCT05082935,9/15/2021,8/31/2022,Interventional,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II,Recruiting,Not Applicable,University of Oregon,NA,NA,NA,NA,NA,NA,United States,0,1,Phase II Promotores de Salud|Phase I Promotores de Salud Outreach,0
NCT05079308,3/1/2021,6/30/2021,Interventional,"Clinical Trial on the Efficacy of Different Masks With and Without a Peripheral Sealing Device, Against Covid-19",Completed,Not Applicable,University of the Balearic Islands,NA,NA,NA,NA,NA,NA,Spain,0,1,Peripheral sealing device for surgical mask or filtering face piece|IIR Surgical mask with Filtering face piece,0
NCT05037201,10/11/2021,10/25/2021,Interventional,Text Message Nudges for COVID-19 Vaccination,"Active, not recruiting",Not Applicable,Ascension South East Michigan,NA,NA,NA,NA,NA,NA,United States,0,1,Text message,1
NCT05054621,9/15/2021,8/31/2022,Interventional,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,Recruiting,Phase 2,Chang Gung Memorial Hospital,NA,NA,NA,NA,NA,NA,Taiwan,0,1,Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Homologous prime-boost schedule with two doses of AZD1222,1
NCT04657809,10/1/2020,2/18/2021,Interventional,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,Completed,Phase 2,Deraya University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Insulin film|Fast dissolving film,0
NCT04655638,2/10/2021,9/22/2021,Interventional,HFNT vs. COT in COVID-19,Completed,Not Applicable,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,NA,NA,NA,NA,NA,NA,Greece|Italy|Poland|Portugal|Spain|Turkey,0,8,High Flow Nasal Therapy|Conventional Oxygen Therapy,0
NCT04880109,10/20/2021,2/28/2023,Interventional,A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.,Recruiting,Phase 2,"Aptabio Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,APX-115|Placebo,0
NCT04859699,4/5/2021,6/30/2022,Interventional,Reopening Schools Safely and Educating Youth (ROSSEY) COVID-19 Health Disparities Research Study,"Active, not recruiting",Not Applicable,University of Washington,NA,NA,NA,NA,NA,NA,United States,0,1,COVID-19 Health Education Comic Books and Videos,0
NCT04853836,11/15/2020,2/28/2021,Interventional,Olfactory Disfunction and Co-ultraPEALut,Completed,Phase 4,University Of Perugia,NA,NA,NA,NA,NA,NA,Italy,0,5,co-ultraPEALut|Olfactory Rehab,0
NCT04704544,9/15/2021,11/30/2022,Interventional,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE),Recruiting,Not Applicable,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,4,Tele-rheumatology,0
NCT04703205,9/16/2020,10/22/2021,Interventional,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),Recruiting,Phase 2,Kitasato University,NA,NA,NA,NA,NA,NA,Japan,0,4,Ivermectin 3 MG|Placebo,0
NCT04631705,12/14/2020,9/23/2021,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,Completed,Phase 1/Phase 2,University of Cologne,NA,NA,NA,NA,NA,NA,Germany,0,6,DZIF-10c|DZIF-10c|Placebo|Placebo,0
NCT04575610,11/27/2020,10/6/2021,Interventional,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Terminated,Phase 2,Yale University,Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.,NA,NA,NA,NA,NA,United States,0,5,PF-06650833|Placebo,0
NCT04619680,11/18/2020,4/30/2024,Interventional,The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States,0,4,Nintedanib|Placebo,0
NCT04542850,11/15/2020,8/31/2021,Interventional,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Recruiting,Not Applicable,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,NA,NA,NA,NA,NA,Bahrain,0,5,5-ALA-Phosphate + SFC (5-ALA + SFC),0
NCT04504240,8/1/2020,4/15/2021,Interventional,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Completed,Phase 3,Chattogram General Hospital,NA,NA,NA,NA,NA,NA,Bangladesh,0,3,Famotidine 20 MG,0
NCT04444700,7/4/2020,5/10/2021,Interventional,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Completed,Phase 3,University of Sao Paulo General Hospital,NA,NA,NA,NA,NA,NA,Brazil,0,3,Therapeutic anticoagulation,0
NCT04435379,6/18/2020,10/12/2021,Interventional,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,Completed,Phase 3,Vakzine Projekt Management GmbH,NA,NA,NA,NA,NA,NA,Germany,0,12,VPM1002|Placebo,0
NCT04469179,8/20/2020,2/25/2021,Interventional,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","Active, not recruiting",Phase 1,"SAb Biotherapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,SAB-185|Normal Saline,0
NCT04387760,8/11/2020,3/6/2021,Interventional,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Completed,Phase 2,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,NA,NA,NA,NA,NA,Bahrain,0,6,Hydroxychloroquine|Favipiravir|Routine care for COVID-19 patients,0
NCT04839042,6/28/2021,12/31/2021,Interventional,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers",Recruiting,Phase 1,Tetherex Pharmaceuticals Corporation,NA,NA,NA,NA,NA,NA,Australia,0,5,SC-Ad6-1|SC-Ad6-1,1
NCT05074745,2/18/2021,12/30/2021,Interventional,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay and a Rapid ELISA Test Among Symptomatic and Asymptomatic Patients,Recruiting,Not Applicable,Centre Scientifique de Monaco,NA,NA,NA,NA,NA,NA,Monaco,0,1,ELISA POCT vs RT-PCR,0
NCT04960228,7/30/2021,9/13/2021,Interventional,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Completed,Not Applicable,Sir Mortimer B. Davis - Jewish General Hospital,NA,NA,NA,NA,NA,NA,Canada,0,2,Altruism Video|COVID-19 Informational Text,1
NCT04952402,7/16/2021,6/30/2023,Interventional,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,Recruiting,Phase 4,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States|Puerto Rico,0,9,Moderna mRNA-1273 COVID-19 vaccine|Community-provided mRNA-based COVID-19 vaccine|Community-Provided Moderna mRNA-1273 COVID-19 Vaccine,1
NCT05096845,8/25/2021,3/2/2023,Interventional,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III,Recruiting,Phase 3,Livzon Pharmaceutical Group Inc.,NA,NA,NA,NA,NA,NA,Philippines,0,0,Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),1
NCT05096026,3/29/2021,5/20/2021,Interventional,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,Not Applicable,Kaiser Permanente,NA,NA,NA,NA,NA,NA,United States,0,0,Standard PCP Outreach|Culturally Tailored PCP Outreach,1
NCT04478071,8/22/2020,12/31/2023,Interventional,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"The University of Texas Health Science Center, Houston",NA,NA,NA,NA,NA,NA,United States,0,2,vadadustat|placebo,0
NCT04632381,7/1/2021,12/29/2021,Interventional,Intravenous Zotatifin in Adults With Mild or Moderate COVID-19,Recruiting,Phase 1,Effector Therapeutics,NA,NA,NA,NA,NA,NA,United States,0,5,Zotatifin|Placebo,0
NCT04514302,10/27/2021,2/20/2022,Interventional,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19,Recruiting,Phase 1,Hospital San Jose Tec de Monterrey,NA,NA,NA,NA,NA,NA,Mexico,0,2,Placebo|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS),0
NCT04507256,8/18/2020,10/19/2021,Interventional,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,Completed,Phase 1,AstraZeneca,NA,NA,NA,NA,NA,NA,United Kingdom,0,8,AZD7442|Placebo,0
NCT04492891,11/23/2020,11/23/2025,Interventional,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Phase 2,Baylor College of Medicine,NA,NA,NA,NA,NA,NA,United States,0,2,Cyclosporine|Standard of Care Treatment,0
NCT04449276,6/18/2020,1/31/2022,Interventional,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","Active, not recruiting",Phase 1,CureVac AG,NA,NA,NA,NA,NA,NA,Belgium|Germany,0,5,CVnCoV Vaccine|Placebo,1
NCT04415086,6/1/2020,4/20/2022,Interventional,Treatment of Patients With COVID-19 With Convalescent Plasma,"Active, not recruiting",Phase 2,University of Sao Paulo General Hospital,NA,NA,NA,NA,NA,NA,Brazil,0,3,convalescent plasma,0
NCT04410549,6/1/2020,9/30/2021,Interventional,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Completed,Not Applicable,IRCCS San Raffaele,NA,NA,NA,NA,NA,NA,Brazil|Italy,0,3,Optical Coherence Tomography (OCT),0
NCT04400058,6/1/2020,2/28/2022,Interventional,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,"Active, not recruiting",Phase 3,Octapharma,NA,NA,NA,NA,NA,NA,United States|Russian Federation|Ukraine,0,18,Octagam 10%|Placebo,0
NCT05087524,1/9/2021,4/8/2021,Interventional,BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19),Terminated,Not Applicable,"University of Wisconsin, Madison",changes in in-person schooling per COVID-19 pandemic,NA,NA,NA,NA,NA,United States,0,1,BinaxNOW Ag Card,0
NCT05069623,10/27/2021,6/30/2022,Interventional,A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers,Recruiting,Phase 1/Phase 2,Vaccibody AS,NA,NA,NA,NA,NA,NA,Norway,0,3,VB10.2129|VB10.2210,1
NCT05062473,10/4/2021,12/31/2021,Interventional,Utilizing Telemedicine for Hypertension Treatment Lifestyle Modification in Central Harlem,Recruiting,Not Applicable,Weill Medical College of Cornell University,NA,NA,NA,NA,NA,NA,United States,0,1,Lifestyle Modification Webinars Focused on Hypertension Control,0
NCT04901689,10/23/2021,2/28/2022,Interventional,Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation,Recruiting,Phase 3,Hospital Israelita Albert Einstein,NA,NA,NA,NA,NA,NA,Brazil,0,2,Leronlimab|Placebo,0
NCT04956224,8/9/2021,4/30/2022,Interventional,Immunogenicity of VLA2101 Compared to VLA2001.,"Active, not recruiting",Phase 3,Valneva Austria GmbH,NA,NA,NA,NA,NA,NA,New Zealand,0,3,VLA2001|VLA2101,1
NCT04919031,8/1/2021,1/23/2022,Interventional,Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Persistent Symptoms,Recruiting,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Inspiratory muscle trainer,0
NCT04773067,1/30/2021,6/27/2021,Interventional,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers",Recruiting,Phase 2,"United Biomedical Inc., Asia",NA,NA,NA,NA,NA,NA,Taiwan,0,4,UB-612|Placebo,1
NCT04756271,2/11/2021,11/30/2021,Interventional,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Recruiting,Phase 3,Zagazig University,NA,NA,NA,NA,NA,NA,Egypt,0,2,SARS-Cov-2 neutralizing antibody titer,1
NCT04593940,10/15/2020,8/31/2022,Interventional,Immune Modulators for Treating COVID-19,Recruiting,Phase 3,Duke University,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Mexico|Peru,0,26,Infliximab|Abatacept|Remdesivir|cenicriviroc (closed to enrollment as of 3-Sep-2021),0
NCT04414241,6/25/2020,11/23/2020,Interventional,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,Completed,Phase 3,Universidad Peruana Cayetano Heredia,NA,NA,NA,NA,NA,NA,Peru,0,1,Hydroxychloroquine,0
NCT04399356,10/1/2020,4/20/2021,Interventional,Niclosamide for Mild to Moderate COVID-19,Completed,Phase 2,Tufts Medical Center,NA,NA,NA,NA,NA,NA,United States,0,6,Niclosamide|Placebo|Telehealth monitoring,0
NCT04573322,9/10/2020,3/17/2021,Interventional,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Completed,Phase 1/Phase 2,Diffusion Pharmaceuticals Inc,NA,NA,NA,NA,NA,NA,Romania,0,1,Trans Sodium Crocetinate|Normal saline,0
NCT04992208,7/24/2021,2/25/2022,Interventional,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents,Recruiting,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,Experimental Group,1
NCT04864561,4/26/2021,2/28/2022,Interventional,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine",Recruiting,Phase 3,Valneva Austria GmbH,NA,NA,NA,NA,NA,NA,United Kingdom,0,7,VLA2001|AZD1222|VLA2001 - adolescent part|Placebo,1
NCT04671017,12/16/2020,2/26/2021,Interventional,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","Active, not recruiting",Phase 1/Phase 2,Valneva Austria GmbH,NA,NA,NA,NA,NA,NA,United Kingdom,0,5,VLA2001,1
NCT04347538,5/1/2020,3/31/2022,Interventional,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",Not Applicable,Vanderbilt University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,6,Saline Nasal Irrigation|Saline with Baby Shampoo Nasal Irrigation,0
NCT05099497,9/21/2021,1/31/2022,Interventional,Supporting Audit and Feedback to Encourage Vaccine Uptake,"Active, not recruiting",Not Applicable,Women's College Hospital,NA,NA,NA,NA,NA,NA,Canada,0,0,Using Practice Facilitators to Support Physicians,1
NCT05080244,10/28/2021,8/31/2022,Interventional,WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID,Recruiting,Not Applicable,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,NA,NA,NA,NA,NA,Canada,0,2,Probiotics|Placebo,0
NCT04911790,6/5/2021,10/5/2021,Interventional,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults,Recruiting,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,3,Experimental Group,1
NCT04621071,1/12/2021,8/19/2021,Interventional,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Completed,Not Applicable,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,NA,NA,NA,NA,NA,Canada,0,6,Probiotics (2 strains 10x10^9 UFC)|Placebo (potato starch and magnesium stearate),0
NCT05102565,8/20/2021,4/30/2022,Interventional,A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers,Recruiting,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,0,sleep education program,0
NCT04937556,10/25/2021,2/28/2022,Interventional,Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).,Recruiting,Not Applicable,ProbiSearch SL,NA,NA,NA,NA,NA,NA,Spain,0,2,Probiotic: Lactobacillus salivarius + Vit D + Zinc|Placebo,0
NCT04927065,5/28/2021,6/16/2022,Interventional,A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants,Recruiting,Phase 2/Phase 3,"ModernaTX, Inc.",NA,NA,NA,NA,NA,NA,United States,0,4,mRNA-1273.211|mRNA-1273|mRNA-1273.617.2|mRNA-1273.213,1
NCT04894266,11/1/2021,3/22/2022,Interventional,An Open-Label Study of Apabetalone in Covid Infection,Recruiting,Phase 2/Phase 3,Resverlogix Corp,NA,NA,NA,NA,NA,NA,Canada,0,1,Apabetalone|Standard of care,0
NCT04870606,3/5/2021,1/24/2022,Interventional,Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness,Recruiting,Phase 3,"Suzhou Kintor Pharmaceutical Inc,",NA,NA,NA,NA,NA,NA,United States,0,4,Proxalutamide (GT0918)|Placebo,0
NCT04685681,1/7/2021,4/6/2022,Interventional,The Get Outside Study,"Active, not recruiting",Not Applicable,State University of New York at Buffalo,NA,NA,NA,NA,NA,NA,United States,0,3,Hiking challenge|Activity list,0
NCT04896840,8/27/2021,10/27/2021,Interventional,Tele-rehabilitation in Children With Cerebral Palsy in the Covid-19 Pandemic,Recruiting,Not Applicable,Inonu University,NA,NA,NA,NA,NA,NA,Turkey,0,2,"Telerehabilitation Ä°ntervention, Motor learning",0
NCT04500626,4/15/2021,8/31/2022,Interventional,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Recruiting,Phase 2/Phase 3,Ottawa Hospital Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,6,Oxygen,0
NCT04422613,5/28/2020,7/1/2021,Interventional,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Completed,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,3,pulmonary anomalies 4 months after documented COVID-19 pneumonia,0
NCT04425031,8/25/2020,12/1/2022,Interventional,Handling Oxygenation Targets in COVID-19,Recruiting,Phase 4,Aalborg University Hospital,NA,NA,NA,NA,NA,NA,Denmark|Norway|Switzerland,0,3,Oxygen|Oxygen,0
NCT04396106,5/26/2020,6/30/2022,Interventional,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting,Recruiting,Phase 2,"Atea Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,"United States|Argentina|Belgium|Brazil|Egypt|Moldova, Republic of|Romania|South Africa|Spain|Ukraine",0,7,AT-527|Placebo|AT-527|Placebo,0
NCT04333732,9/4/2020,8/10/2021,Interventional,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,"Active, not recruiting",Phase 3,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States|Ghana|South Africa|United Kingdom|Zambia,0,16,MR or M-M-R II Â® vaccine|Placebo,0
NCT05052580,10/1/2021,9/26/2023,Interventional,Test to Stay in School: COVID-19 Testing Following Exposure in School Communities,Enrolling by invitation,Not Applicable,Duke University,NA,NA,NA,NA,NA,NA,United States,0,1,COVID-19 Testing,0
NCT04930861,3/29/2021,5/27/2021,Interventional,Study of Codivir in Patients With COVID-19,Completed,Phase 1,Code Pharma,NA,NA,NA,NA,NA,NA,Brazil,0,3,Covidir injections|One Step Test|IgM and IgG dosage|RT-PCR SARS-CoV-2|Screening blood test|ECG|Medical evaluation|NEWS-2 score|WHO score,0
NCT04504734,11/27/2020,10/31/2021,Interventional,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Phase 3,"Revive Therapeutics, Ltd.",NA,NA,NA,NA,NA,NA,United States|Puerto Rico,0,32,Bucillamine|Placebo|Bucillamine,0
NCT04642638,11/30/2020,1/31/2023,Interventional,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,Phase 2/Phase 3,Inovio Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States|Brazil|Colombia|Mexico|Philippines,0,9,INO-4800|CELLECTRAÂ® 2000|Placebo|CELLECTRAÂ® 2000,1
NCT04482686,12/9/2020,5/31/2022,Interventional,Trial of Combination Therapy to Treat COVID-19 Infection,"Active, not recruiting",Phase 1,ProgenaBiome,NA,NA,NA,NA,NA,NA,United States,0,10,Ivermectin|Doxycycline Hcl|Zinc|Vitamin D3|Vitamin C,0
NCT04667780,12/1/2020,7/9/2021,Interventional,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Completed,Phase 3,Ayub Teaching Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Colchicine|Standard COVID-19 care,0
NCT04341116,4/11/2020,12/31/2021,Interventional,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2/Phase 3,I-Mab Biopharma Co. Ltd.,NA,NA,NA,NA,NA,NA,United States,0,18,TJ003234|Placebo,0
NCT05104827,12/31/2020,12/31/2022,Interventional,Integrative Medicine Impact on Frontline COVID-19 Personnel Wellbeing,Recruiting,Not Applicable,Carmel Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Complementary Integrative Medicine,0
NCT05104749,9/15/2021,2/28/2022,Interventional,Homeopathic Treatment of Post-acute COVID-19 Syndrome,Recruiting,Phase 3,Southwest College of Naturopathic Medicine,NA,NA,NA,NA,NA,NA,United States,0,0,Homeopathic Medication|Placebo,0
NCT05104372,5/1/2021,11/15/2021,Interventional,Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan,Recruiting,Not Applicable,"The Allergy and Asthma Institute, Pakistan",NA,NA,NA,NA,NA,NA,Pakistan,0,0,Hypertonic Saline Nasal Irrigation and Gargles (HSNIG),0
NCT04700462,2/5/2021,10/30/2021,Interventional,COVID-19 Preventive Behavior in African Americans,Completed,Not Applicable,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,3,Sm-EMA,0
NCT04847141,4/28/2021,12/31/2021,Interventional,A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients,Recruiting,Phase 3,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,Spain,0,5,C19-IG 20%|0.9% Sodium chloride,0
NCT04546737,9/8/2020,7/1/2021,Interventional,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Active, not recruiting",Not Applicable,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,3,Magnetic Resonance Spectroscopy (MRS).,0
NCT04642950,12/17/2020,10/25/2021,Interventional,A Phase II/III Study of Sargramostim,Completed,Phase 2/Phase 3,Nobelpharma,NA,NA,NA,NA,NA,NA,Japan,0,4,Sargramostim|Placebo,0
NCT04528667,1/6/2021,8/23/2021,Interventional,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,Completed,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,Brazil,0,3,STI-5656|Placebo,0
NCT05107375,9/3/2021,11/19/2021,Interventional,Clinical Study of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell) Combined With Influenza Vaccine,Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,0,Tetravalent influenza virus lysis vaccine|Recombinant new coronavirus vaccine (CHO cell) group,1
NCT04440007,10/9/2020,7/1/2021,Interventional,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,Completed,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,8,Abivertinib|Standard of Care,0
NCT04951388,7/22/2021,12/31/2021,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,NA,NA,NA,NA,NA,Taiwan,0,3,MVC-COV1901(S protein with adjuvant)|MVC-COV1901(Saline),1
NCT05048849,7/19/2021,12/31/2021,Interventional,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,NA,NA,NA,NA,NA,Taiwan,0,3,MVC-COV1901(S protein with adjuvant),1
NCT05038618,8/2/2021,11/30/2021,Interventional,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,NA,NA,NA,NA,NA,Taiwan,0,2,MVC-COV1901(S protein with adjuvant),1
NCT05083000,8/16/2021,12/31/2021,Interventional,Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care,Recruiting,Phase 1,"National University Hospital, Singapore",NA,NA,NA,NA,NA,NA,India,0,1,Topotecan,0
NCT04977024,9/27/2021,6/1/2023,Interventional,SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,Recruiting,Phase 2,City of Hope Medical Center,NA,NA,NA,NA,NA,NA,United States,0,3,COVID-19 Vaccine|Diagnostic Laboratory Biomarker Analysis|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1,1
NCT04611425,11/30/2020,12/2/2020,Interventional,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,Completed,Phase 2,Nantes University Hospital,NA,NA,NA,NA,NA,NA,France,0,2,Remimazolam,0
NCT04822025,5/20/2021,12/31/2021,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,NA,NA,NA,NA,NA,Taiwan,0,4,MVC-COV1901 (High-Dose)|MVC-COV1901(Mid-Dose),1
NCT04821999,4/10/2021,9/20/2021,Interventional,Diode Laser 940 nm in Management of Loss of Taste Sensation,Completed,Not Applicable,Fayoum University,NA,NA,NA,NA,NA,NA,Egypt,0,4,a 940-nm diode laser,0
NCT04732949,1/12/2021,11/30/2021,Interventional,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,Recruiting,Phase 3,Synairgen Research Ltd.,NA,NA,NA,NA,NA,NA,United States|Argentina|Belgium|Brazil|Colombia|France|Germany|India|Israel|Italy|Mexico|Netherlands|Portugal|Romania|Serbia|Spain|United Kingdom,0,7,Placebo|SNG001,0
NCT04426292,5/12/2020,12/23/2021,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,1,Serological testing,0
NCT04498377,1/26/2021,12/31/2021,Interventional,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Phase 2,Generon (Shanghai) Corporation Ltd.,NA,NA,NA,NA,NA,NA,United States,0,6,F-652|Placebo,0
NCT05102084,7/1/2021,12/31/2021,Interventional,The Effect Of Music On Compliance Of Patients Ä°n COVÄ°D-19 Intensive Care Unit With CPAP Device,Recruiting,Not Applicable,Ataturk University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Listening to music with a bluetooth headset to patients receiving CPAP support,0
NCT04980573,8/5/2021,9/30/2021,Interventional,Essential Oils and Post COVID-19 Fatigue,"Active, not recruiting",Not Applicable,Franklin School of Integrative Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,2,Aromatherapy|Placebo,0
NCT05024474,8/24/2021,12/31/2022,Interventional,Effects of Inspiratory Muscle Training After Covid-19 (ReCOV),Recruiting,Not Applicable,Karolinska Institutet,NA,NA,NA,NA,NA,NA,Sweden,0,1,Inspiratory muscle training (IMT)|Physical exercise,0
NCT04909905,5/30/2021,10/25/2021,Interventional,Glutamine Supplementation and Short-term Mortality in Covid-19,Completed,Phase 3,Assiut University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Standard enteral nutrition|Glutamine,0
NCT04958902,10/22/2021,11/1/2021,Interventional,RESTORE in Patients Who Had COVID-19 and Close Others,Recruiting,Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,2,RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health,0
NCT04953078,9/11/2021,3/31/2022,Interventional,"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19",Recruiting,Phase 1,"Baiya Phytopharm Co., Ltd.",NA,NA,NA,NA,NA,NA,Thailand,0,2,Baiya SARS-CoV-2 Vax 1,1
NCT04849598,4/13/2021,8/27/2021,Interventional,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Completed,Not Applicable,SchÃ¶n Klinik Berchtesgadener Land,NA,NA,NA,NA,NA,NA,Germany,0,1,Oxygen therapy,0
NCT04799392,4/1/2021,10/28/2021,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,Terminated,Not Applicable,"NOWDiagnostics, Inc.",FDA will not authorize COVID-19 Ab tests for use over-the-counter.,NA,NA,NA,NA,NA,United States,0,4,NOWDx COVID-19 Test,0
NCT04625738,11/6/2020,5/14/2021,Interventional,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,Completed,Phase 2,"Central Hospital, Nancy, France",NA,NA,NA,NA,NA,NA,France,0,1,Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Placebo,0
NCT04488575,8/26/2020,5/16/2021,Interventional,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Terminated,Phase 2,"Evelo Biosciences, Inc.",Insufficient study defined patient population,NA,NA,NA,NA,NA,United States,0,5,EDP1815|Placebo,0
NCT04569383,10/5/2020,8/24/2021,Interventional,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,Completed,Phase 1,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,NA,NA,Germany,0,3,Comirnaty|MVA-SARS-2-S vaccinations (days 0 & 28),1
NCT04472494,10/14/2020,9/12/2021,Interventional,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Terminated,Phase 2,Bristol-Myers Squibb,Slow accrual,NA,NA,NA,NA,NA,United States|Puerto Rico,0,6,Abatacept|Placebo,0
NCT04468087,2/15/2021,11/28/2021,Interventional,Antiviral Agents Against COVID-19 Infection,Recruiting,Phase 2/Phase 3,Hospital do Coracao,NA,NA,NA,NA,NA,NA,Brazil,0,6,Atazanavir|Daclatasvir 60 mg|Sofusbuvir + Daclastavir 60 mg|Placebo Atazanavir|Placebo Daclatasvir 60 mg|Placebo Sofusbuvir + Daclatasvir 60 mg,0
NCT04460677,8/12/2020,5/31/2022,Interventional,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Enrolling by invitation,Not Applicable,"Rutgers, The State University of New Jersey",NA,NA,NA,NA,NA,NA,United States,0,6,Emotional Support Plan|Daily Monitoring,0
NCT05110560,6/1/2021,8/1/2021,Interventional,Effects of the Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study,Completed,Not Applicable,Namik Kemal University,NA,NA,NA,NA,NA,NA,Turkey,0,0,"""Stay at Home Take a Step Program (SHTSP)""",0
NCT04790240,2/1/2021,12/31/2022,Interventional,Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID),Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,NA,NA,NA,NA,NA,United States,0,2,Inflammation (I)|Inflammation (II)|Inflammation (III)|Standard of care,0
NCT04910230,3/1/2020,4/2/2020,Interventional,Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19,Completed,Not Applicable,Shenyang Northern Hospital,NA,NA,NA,NA,NA,NA,China,0,1,nicotinamide,0
NCT04709835,2/3/2021,9/17/2021,Interventional,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,Completed,Phase 2,Hoffmann-La Roche,NA,NA,NA,NA,NA,NA,Bulgaria|Canada|Greece|Ireland|Latvia|Lithuania|Poland|Spain|United Kingdom,0,8,AT-527|Placebo,0
NCT04842734,3/27/2021,6/27/2021,Interventional,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,"Active, not recruiting",Not Applicable,Yeditepe University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Physical exercise|Physical exercise and computerized cognitive training,0
NCT04689542,1/1/2021,4/2/2021,Interventional,Surgical Face Mask Effects in Patients With COVID-19,Completed,Not Applicable,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,NA,NA,Belgium,0,3,Sit-To-Stand test,0
NCT04615936,10/13/2020,7/7/2021,Interventional,Nasal Photodisinfection COVID-19 Proof of Concept Study,Completed,Not Applicable,Sunnybrook Health Sciences Centre,NA,NA,NA,NA,NA,NA,Canada,0,1,Methylene-Blue Photodisinfection,0
NCT04531254,8/10/2020,8/31/2020,Interventional,Back to School COVID-19 Simulation Study,Completed,Not Applicable,The Hospital for Sick Children,NA,NA,NA,NA,NA,NA,Canada,0,3,Wearing a face mask at all times,0
NCT04409743,6/7/2020,10/14/2021,Interventional,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,6,Remote Cognitive Behavioral Therapy for Insomnia,0
NCT04353206,6/27/2020,11/1/2020,Interventional,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Terminated,Early Phase 1,Cedars-Sinai Medical Center,The initiation of the expanded access program for convalescent plasma.,NA,NA,NA,NA,NA,United States,0,4,Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,0
NCT05115435,3/1/2021,8/1/2021,Interventional,The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant,Completed,Not Applicable,Inonu University,NA,NA,NA,NA,NA,NA,Turkey,0,0,neuro linguistic programming,0
NCT05109624,10/1/2021,1/1/2022,Interventional,Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?,Recruiting,Not Applicable,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,1,prolonged prone position ventilation,0
NCT05112887,3/31/2021,9/13/2021,Interventional,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Completed,Not Applicable,Ohio University,NA,NA,NA,NA,NA,NA,United States,0,0,Osteopathic Manipulative Therapy,0
NCT05115162,12/1/2020,1/17/2021,Interventional,The Effects of the Hybrid Telerehabilitation Exercise in Inactive Students,Completed,Not Applicable,Marmara University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Exercise,0
NCT05113849,9/16/2021,2/28/2023,Interventional,Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19),Recruiting,Phase 1,HK inno.N Corporation,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,IN-B009 (Low-dose)|IN-B009 (High-dose),1
NCT05113823,11/16/2020,11/19/2020,Interventional,In Situ Simulation Training in Transferring Critically Ill COVID-19 Patients,Completed,Not Applicable,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Simulation Training,0
NCT05087381,10/1/2021,12/31/2021,Interventional,Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community,Recruiting,Phase 4,Chulalongkorn University,NA,NA,NA,NA,NA,NA,Thailand,0,1,"FluvoxaMINE Maleate 50 MG|Fluvoxamine, Bromhexine|Fluvoxamine, Cyproheptadine|Niclosamide Pill|Niclosamide, Bromhexine",0
NCT05065619,10/2/2021,12/31/2021,Interventional,Safety Immunogenicity Study of MT-2766 in Japanese Adultsï¼ˆCOVID-19ï¼‰,Recruiting,Phase 1/Phase 2,Medicago,NA,NA,NA,NA,NA,NA,Japan,0,2,MT-2766 High dose|Placebo|MT-2766 Low dose,0
NCT04841707,5/10/2021,2/22/2022,Interventional,Total-Body Parametric 18F-FDG PET of COVID-19,Recruiting,Not Applicable,"University of California, Davis",NA,NA,NA,NA,NA,NA,United States,0,3,uEXPLORER/mCT,0
NCT04953052,11/30/2021,2/28/2022,Interventional,A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.,Recruiting,Phase 2,Exvastat Ltd.,NA,NA,NA,NA,NA,NA,India,0,3,Imatinib Mesylate|Placebo,0
NCT04864548,5/27/2021,11/30/2022,Interventional,COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study,Recruiting,Phase 1,University of Oxford,NA,NA,NA,NA,NA,NA,United Kingdom,0,6,SARS-CoV-2 virus,0
NCT04818489,3/25/2021,8/25/2021,Interventional,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Completed,Phase 4,ClinAmygate,NA,NA,NA,NA,NA,NA,Egypt,0,3,Colchicine 0.5 MG|the standard protocol only,0
NCT04802408,10/1/2021,5/30/2022,Interventional,SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial,Recruiting,Phase 2/Phase 3,Milton S. Hershey Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Shampoo and saline|Saline and Listerine|Shampoo and Listerine|Saline and Saline,0
NCT04633772,8/5/2020,11/1/2021,Interventional,Use of Angiotensin-(1-7) in COVID-19,Completed,Phase 1/Phase 2,Erasme University Hospital,NA,NA,NA,NA,NA,NA,Brazil,0,3,Angiotensin-(1-7)|Placebo,0
NCT04672564,3/30/2021,7/28/2022,Interventional,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,Recruiting,Phase 3,"Shenyang Tonglian Group CO., Ltd",NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Colombia|India|Mexico|Peru|Philippines|Ukraine,0,9,Carrimycin|Placebo,0
NCT04389671,11/2/2020,12/31/2021,Interventional,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,Windtree Therapeutics,NA,NA,NA,NA,NA,NA,United States|Argentina,0,8,Lucinactant,0
NCT04547140,1/29/2021,11/30/2021,Interventional,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,United States|Brazil|Chile|Colombia|Mexico,0,11,Liquid Alpha1-Proteinase Inhibitor (Human)|Placebo|Standard Medical Treatment,0
NCT04359654,6/16/2020,8/12/2021,Interventional,Nebulised Dornase Alfa for Treatment of COVID-19,Completed,Phase 2,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Dornase Alfa Inhalation Solution [Pulmozyme],0
NCT04822818,4/17/2021,6/30/2022,Interventional,EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEVÂ®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,BEVA+SOC|SOC,0
NCT05046561,11/4/2021,12/31/2022,Interventional,Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial,Recruiting,Phase 2,"Eyecheck, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,STRI Formula|Placebo,0
NCT05089305,9/4/2021,11/25/2022,Interventional,Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection,Enrolling by invitation,Phase 2,"Centro Universitario de Ciencias de la Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,2,Ozone plasma,0
NCT04540939,10/19/2020,4/30/2022,Interventional,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,Not Applicable,University of Michigan,NA,NA,NA,NA,NA,NA,United States,0,3,Muscle Relaxation Therapy|Mindfulness-Based Cognitive Therapy,0
NCT04625725,11/21/2020,5/5/2021,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","Active, not recruiting",Phase 3,AstraZeneca,NA,NA,NA,NA,NA,NA,United States|Belgium|France|Spain|United Kingdom,0,7,AZD7442|Placebo,0
NCT04482699,12/30/2020,9/13/2021,Interventional,RAPA-501-Allo Therapy of COVID-19-ARDS,Terminated,Phase 1/Phase 2,Rapa Therapeutics LLC,Change in eligible patient population,NA,NA,NA,NA,NA,United States,0,11,RAPA-501-Allo off-the-shelf Therapy of COVID-19|Placebo,0
NCT04523571,7/28/2020,9/30/2020,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,Completed,Phase 1,BioNTech SE,NA,NA,NA,NA,NA,NA,China,0,3,BNT162b1|Placebo,1
NCT04375735,11/23/2020,9/1/2021,Interventional,London's Exogenous Surfactant Study for COVID19,Completed,Phase 1/Phase 2,Lawson Health Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,2,Bovine Lipid Extract Surfactant,0
NCT04363814,6/10/2020,1/1/2022,Interventional,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,"Active, not recruiting",Phase 3,Inmunotek S.L.,NA,NA,NA,NA,NA,NA,Dominican Republic,0,4,Bactek-R,0
NCT04480424,9/17/2020,8/19/2021,Interventional,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,United States,0,10,GAMUNEX-C|Standard Medical Treatment,0
NCT05118373,8/18/2021,9/23/2021,Interventional,Generic Behavioural Change Campaign for COVID-19 Prevention,Completed,Not Applicable,Centre for Infectious Disease Research in Zambia,NA,NA,NA,NA,NA,NA,Zambia,0,0,BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA,0
NCT05046548,10/3/2020,10/15/2020,Interventional,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19",Completed,Phase 1/Phase 2,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Vaccine for intramuscular injection|Placebo comparator (without active ingredient) for intramuscular injection,1
NCT05037097,8/30/2021,3/31/2023,Interventional,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,Recruiting,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States|Singapore,0,1,ARCT-165|ARCT-154|ARCT-021,1
NCT04860518,8/23/2021,12/31/2021,Interventional,Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With CoronavirUS,Recruiting,Phase 2,Faron Pharmaceuticals Ltd,NA,NA,NA,NA,NA,NA,United States,0,3,IFN beta-1a|Dexamethasone,0
NCT04530604,10/1/2020,3/26/2021,Interventional,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Completed,Phase 1,University of Michigan,NA,NA,NA,NA,NA,NA,United States,0,3,Defibrotide,0
NCT05119634,10/18/2021,8/21/2022,Interventional,The Effect of Whole Body Vibration Training in Individuals With Post COVID - 19,Recruiting,Not Applicable,Istanbul University-Cerrahpasa,NA,NA,NA,NA,NA,NA,Turkey,0,0,whole body vibration training|home based exercises,0
NCT04650087,2/15/2021,5/31/2022,Interventional,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,Recruiting,Phase 3,Duke University,NA,NA,NA,NA,NA,NA,United States,0,17,Apixaban 2.5 MG|Placebo,0
NCT05056883,11/12/2021,3/31/2022,Interventional,A Phase III Confirmatory Study of K-237,Recruiting,Phase 3,"Kowa Company, Ltd.",NA,NA,NA,NA,NA,NA,Japan,0,1,K-237 0.3-0.4mg/kg (once daily)|Placebo 0.3-0.4mg/kg (once daily),0
NCT04969601,9/29/2021,5/29/2022,Interventional,Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings,Recruiting,Phase 1/Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,vaccine COMIRNATYÂ® (BNT162b2),1
NCT04816019,4/1/2021,3/31/2022,Interventional,A Study of Intranasal ChAdOx1 nCOV-19,Recruiting,Phase 1,University of Oxford,NA,NA,NA,NA,NA,NA,United Kingdom,0,5,ChAdOx1 nCov-19,1
NCT04884295,8/26/2021,4/30/2022,Interventional,"Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19",Recruiting,Phase 1/Phase 2,ExeVir Bio BV,NA,NA,NA,NA,NA,NA,Belgium|Italy,0,3,XVR011|Normal saline,0
NCT04602507,12/10/2020,12/9/2021,Interventional,Ivermectin in Adults With Severe COVID-19.,Recruiting,Phase 2,CES University,NA,NA,NA,NA,NA,NA,Colombia,0,2,Ivermectin|Placebo,0
NCT05122260,11/11/2021,12/15/2021,Interventional,PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray,Recruiting,Phase 1,University of Louisville,NA,NA,NA,NA,NA,NA,United States,0,0,Q-Griffithsin|Placebo,0
NCT04354831,5/11/2020,5/1/2022,Interventional,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Medical College of Wisconsin,NA,NA,NA,NA,NA,NA,United States,0,5,anti-SARS-CoV-2 convalescent plasma,0
NCT05122234,8/10/2020,7/30/2021,Interventional,Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19,Completed,Phase 3,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Injection of secretome - mesenchymal stem cell|Placebo|Standard treatment of Covid-19,0
NCT04910269,8/6/2021,8/31/2023,Interventional,Outpatient Treatment With Anti-Coronavirus Immunoglobulin,Recruiting,Phase 3,University of Minnesota,NA,NA,NA,NA,NA,NA,United States|Denmark,0,8,Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Placebo,0
NCT04905888,11/8/2021,12/31/2022,Interventional,Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela,Recruiting,Phase 2,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,2,Hyperbaric oxygen therapy,0
NCT04954157,6/29/2020,1/29/2022,Interventional,Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients,Recruiting,Not Applicable,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,2,Phase-1: Breath Holding Test|Phase 2: 6-Minute Walk Test (6MWT),0
NCT04723537,2/16/2021,9/30/2022,Interventional,"Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","Active, not recruiting",Phase 2/Phase 3,RedHill Biopharma Limited,NA,NA,NA,NA,NA,NA,United States|South Africa,0,22,Part A: Upamostat 200 mg|Part A: Upamostat 400 mg|Part A and B: Placebo|Part B: Upamostat 200 or 400 mg,0
NCT04723446,5/19/2021,10/25/2021,Interventional,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Completed,Not Applicable,Queen Mary University of London,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,CorsodylÂ® Alcohol free -0.2 % Chlorhexidine digluconate|Colgate PeroxylÂ® -1.5% Hydrogen peroxide|Oral-BÂ® Gum & Enamel Care -Cetylpyridinium chloride|No rinsing,0
NCT05124132,1/31/2022,8/31/2026,Interventional,Resilience and Brain Health of Older Adults During the COVID-19 Pandemic (MEDEX-2),Enrolling by invitation,Not Applicable,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,0,Mindfulness-Based Stress Reduction|Exercise|Mindfulness-Based Stress Reduction + Exercise|Health Education,0
NCT04652596,2/8/2021,6/30/2022,Interventional,Reducing Food Insecurity During COVID-19,Enrolling by invitation,Not Applicable,Boston Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Produce prescription program|Grocery store gift cards,0
NCT05087329,5/5/2021,2/28/2022,Interventional,Mindfulness Practice in Pregnancy as an Intervention to Decrease Prenatal Stress During the COVID-19 Pandemic,Recruiting,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,1,Virtual Mindfulness Meditation,0
NCT05113862,12/31/2021,10/31/2022,Interventional,Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19,Recruiting,Phase 1,Emergex Vaccines Holding Ltd.,NA,NA,NA,NA,NA,NA,Switzerland,0,1,LD Vehicle-GNP|LD PepGNP-SARSCoV2|HD Vehicle-GNP|HD PepGNP-SARSCoV2,1
NCT04921228,11/8/2021,3/1/2022,Interventional,Biofeedback for CHAMPS,Recruiting,Not Applicable,Villanova University,NA,NA,NA,NA,NA,NA,United States,0,1,Heart rate variability biofeedback,0
NCT04870593,4/17/2021,7/10/2023,Interventional,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",Not Applicable,"National Bureau of Economic Research, Inc.",NA,NA,NA,NA,NA,NA,India,0,2,Information|Buddy|Gossip intervention|Information assigned in community|Buddy assigned in community,1
NCT05037110,10/25/2021,6/30/2023,Interventional,Physical Activity and Smell Trainings to Help Individuals With Coronavirus Disease (COVID-19) Recover From Persistent Smell and Taste Impairments - A Pilot Study,Recruiting,Not Applicable,UniversitÃ© de MontrÃ©al,NA,NA,NA,NA,NA,NA,Canada,0,4,Physical activity|Smell training,0
NCT04979858,9/6/2021,10/30/2021,Interventional,Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask,Recruiting,Not Applicable,Georgia Institute of Technology,NA,NA,NA,NA,NA,NA,United States,0,6,Focal Mask,0
NCT04913675,6/10/2021,9/18/2021,Interventional,Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19,"Active, not recruiting",Phase 3,"Vir Biotechnology, Inc.",NA,NA,NA,NA,NA,NA,United States|France|Ukraine,0,8,VIR-7831|VIR-7831|VIR-7831,0
NCT04640168,11/24/2020,5/18/2021,Interventional,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,"United States|Denmark|Germany|Greece|Indonesia|Japan|Korea, Republic of|Mexico|Poland|Singapore|Spain|United Kingdom",0,26,Baricitinib|Dexamethasone|Placebo|Remdesivir,0
NCT04793464,2/4/2021,8/31/2022,Interventional,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos),Recruiting,Not Applicable,University of Oregon,NA,NA,NA,NA,NA,NA,United States,0,4,Promotores de Salud|Services as usual,0
NCT04828538,1/1/2021,11/30/2021,Interventional,"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","Active, not recruiting",Not Applicable,Hospital de la Soledad,NA,NA,NA,NA,NA,NA,Mexico,0,2,"Vitamin D|Omega DHA / EPA|Vitamin C, Vitamin B complex and Zinc Acetate|Placebo",0
NCT04828434,4/1/2021,4/1/2023,Interventional,Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study,Recruiting,Not Applicable,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Virtual Individual Cognitive Simulation Therapy,0
NCT04384965,5/12/2020,5/1/2022,Interventional,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,Centre for Addiction and Mental Health,NA,NA,NA,NA,NA,NA,Canada,0,3,"MagPro X100 Stimulator, B70 Fluid-Cooled Coil",0
NCT05126563,12/20/2021,12/20/2023,Interventional,Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome,Recruiting,Phase 2,Hope Biosciences,NA,NA,NA,NA,NA,NA,United States,0,0,HB-adMSCs (allogeneic)|Placebo,0
NCT05126628,3/6/2021,3/16/2021,Interventional,The South Proxa-Rescue AndroCoV Trial Against COVID-19,Completed,Phase 3,Corpometria Institute,NA,NA,NA,NA,NA,NA,Brazil,0,0,Proxalutamide|Placebo,0
NCT05126602,4/1/2021,9/30/2021,Interventional,Vitamin D Supplementation and Clinical Improvement in COVID-19,Completed,Not Applicable,Hasanuddin University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Vitamin D3 10000 IU|Vitamin D3 1000 IU,0
NCT05125874,9/30/2021,8/30/2023,Interventional,Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization,"Active, not recruiting",Not Applicable,Livzon Pharmaceutical Group Inc.,NA,NA,NA,NA,NA,NA,China,0,0,Recombinant SARS-CoV-2 Fusion Protein Vaccine,1
NCT05125562,5/7/2021,8/7/2022,Interventional,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,Recruiting,Phase 2,"Direct Biologics, LLC",NA,NA,NA,NA,NA,NA,United States,0,0,ExoFlo,0
NCT04847102,7/22/2021,11/30/2021,Interventional,A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above,Recruiting,Phase 3,"Walvax Biotechnology Co., Ltd.",NA,NA,NA,NA,NA,NA,Indonesia|Mexico,0,3,SARS-CoV-2 mRNA Vaccine|Placebo,1
NCT05049226,9/24/2021,9/30/2022,Interventional,Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine,Enrolling by invitation,Phase 2,Mahidol University,NA,NA,NA,NA,NA,NA,Thailand,0,1,AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose,1
NCT05047718,10/5/2021,9/1/2022,Interventional,Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19,Recruiting,Phase 4,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,NA,NA,NA,NA,France,0,1,COVID-19 vaccine Pfizer (2 doses)|COVID-19 vaccine Pfizer (1 dose)|COVID-19 mRNA Vaccine Moderna (2 doses)|COVID-19 mRNA Vaccine Moderna (1 dose),1
NCT04869358,5/27/2021,5/31/2022,Interventional,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Recruiting,Phase 4,Novartis,NA,NA,NA,NA,NA,NA,Germany,0,6,Ofatumumab,1
NCT04822701,4/21/2021,7/2/2021,Interventional,A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19,Terminated,Phase 2/Phase 3,Boehringer Ingelheim,not due to safety reasons,NA,NA,NA,NA,NA,United States|Spain,0,14,BI 767551 intravenous|BI 767551 inhaled|Placebo intravenous|Placebo inhaled,0
NCT04949061,11/17/2021,5/31/2022,Interventional,The Effectiveness of Culturally Adapted Cognitive Behavioral Intervention Among COVID-19 Survivors,Recruiting,Not Applicable,KoÃ§ University,NA,NA,NA,NA,NA,NA,Turkey,0,3,Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|Enhanced Treatment as Usual (ETA-U),0
NCT04663945,12/11/2020,8/12/2021,Interventional,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,"Active, not recruiting",Not Applicable,"University of Colorado, Denver",NA,NA,NA,NA,NA,NA,United States,0,6,Biobehavioral Tele-rehabilitation Sessions,0
NCT04800133,5/8/2021,3/31/2025,Interventional,Covid-19 Vaccination in Adolescents and Children,Recruiting,Phase 2,The University of Hong Kong,NA,NA,NA,NA,NA,NA,China,0,3,"Tozinameran|CoronaVac|CoronaVac, intradermal",1
NCT04798027,3/12/2021,11/2/2022,Interventional,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Phase 1/Phase 2,Sanofi,NA,NA,NA,NA,NA,NA,United States|Australia|Brazil|Honduras,0,12,SARS-CoV-2 mRNA vaccine formulation 1|SARS-CoV-2 mRNA vaccine formulation 2|SARS-CoV-2 mRNA vaccine formulation 3|Placebo (0.9% normal saline),1
NCT04729595,9/1/2021,6/30/2022,Interventional,Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.,Recruiting,Phase 2/Phase 3,Adamis Pharmaceuticals Corporation,NA,NA,NA,NA,NA,NA,United States,0,5,Tempol|Placebo,0
NCT04705597,3/18/2021,9/30/2022,Interventional,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure",Recruiting,Phase 2,"BioAge Labs, Inc.",NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil,0,11,BGE-175|Placebo,0
NCT04510194,1/1/2021,12/31/2021,Interventional,COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 3,University of Minnesota,NA,NA,NA,NA,NA,NA,United States,0,14,Metformin|Placebo|Fluvoxamine|Ivermectin,0
NCT04584567,11/20/2020,2/1/2021,Interventional,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Completed,Phase 3,"General Administration of Military Health, Tunisia",NA,NA,NA,NA,NA,NA,Tunisia,0,5,Doxycyclin,0
NCT04539795,1/25/2021,10/29/2021,Interventional,COVID-19 Study of Safety and Tolerability of Alvelestat,Completed,Phase 1/Phase 2,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,4,Alvelestat|Placebo,0
NCT05126511,11/19/2021,3/31/2022,Interventional,Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19,Recruiting,Not Applicable,SchÃ¶n Klinik Berchtesgadener Land,NA,NA,NA,NA,NA,NA,Germany,0,1,Application of CES via ear clips|Sham: No application of CES via ear clips,0
NCT04373733,5/1/2020,6/25/2021,Interventional,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Completed,Phase 3,Chelsea and Westminster NHS Foundation Trust,NA,NA,NA,NA,NA,NA,Brazil|Mexico|United Kingdom,0,6,Favipiravir|Standard of care management,0
NCT04346615,4/25/2020,4/30/2022,Interventional,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Phase 2/Phase 3,"Biohaven Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United States,0,16,Zavegepant (BHV-3500)|Placebo,0
NCT04405934,10/15/2020,4/26/2021,Interventional,COG-UK Project Hospital-Onset COVID-19 Infections Study,Completed,Not Applicable,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures,0
NCT04399967,6/13/2020,6/30/2021,Interventional,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020","Active, not recruiting",Not Applicable,The University of Hong Kong,NA,NA,NA,NA,NA,NA,China,0,6,Chat-based support|AWARD plus COVID-specific advice|AWARD advice|COVID-19 related health warning leaflet|Health warning leaflet|SMS-based support|Referral card|COSH Self-help smoking cessation booklet,0
NCT05128721,11/14/2021,2/23/2023,Interventional,Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19),Recruiting,Phase 1,"National Research Centre, Egypt",NA,NA,NA,NA,NA,NA,Egypt,0,0,Covi Vax,1
NCT05128643,9/17/2021,4/12/2022,Interventional,Clinical Study on the Immune Program of Recombinant Novel Coronavirusï¼ˆCOVID-19) Vaccine (CHO Cell),Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,0,Recombinant new coronavirus vaccine (CHO cell),1
NCT04839146,3/11/2021,12/20/2021,Interventional,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),"Active, not recruiting",Phase 1,Radboud University,NA,NA,NA,NA,NA,NA,Netherlands,0,2,ABNCoV2 Vaccine,1
NCT05109598,11/4/2021,2/28/2022,Interventional,Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell),Recruiting,Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,1,Recombinant new coronavirus vaccine (CHO cell),1
NCT04442087,6/19/2020,4/30/2021,Interventional,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,4,Serology SARS-CoV2|Data collection,0
NCT04742595,12/18/2020,3/31/2022,Interventional,Viral Specific T Cell Therapy for COVID-19 Related Pneumonia,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,2,SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes,0
NCT04558450,9/21/2020,3/31/2023,Interventional,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,carotid-femoral pulse-wave velocity,0
NCT04765371,3/3/2021,10/31/2023,Interventional,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19",Recruiting,Phase 3,Centre Hospitalier RenÃ© Dubos,NA,NA,NA,NA,NA,NA,France,0,3,DEXAMETHASONE|PREDNISOLONE,0
NCT04458363,7/4/2020,9/1/2020,Interventional,Convalescent Plasma in Pediatric COVID-19,Completed,Early Phase 1,Emory University,NA,NA,NA,NA,NA,NA,United States,0,2,Convalescent Plasma (CP)|Standard COVID-19 therapies,0
NCT04373460,6/3/2020,12/21/2022,Interventional,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,"Active, not recruiting",Phase 2,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,26,SARS-CoV-2 convalescent plasma|Plasma from a volunteer donor,0
NCT05130736,8/1/2021,7/31/2022,Interventional,Rehabilitation Robot in Patients With Post-Coronavirus Disease (COVID-19) Fatigue Syndrome,Recruiting,Not Applicable,Poznan University of Medical Sciences,NA,NA,NA,NA,NA,NA,Poland,0,0,Robot rehabilitation,0
NCT05130671,10/25/2021,12/31/2021,Interventional,"Nutritional Supplementation of Vitamin D, Quercetin and Curcumin With Standard of Care for Managing Mild Early Symptoms of COVID-19",Recruiting,Not Applicable,King Edward Medical University,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Standard of care|Investigational treatment,0
NCT05130541,6/1/2020,3/1/2021,Interventional,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Completed,Not Applicable,New York Hospital Queens,NA,NA,NA,NA,NA,NA,United States,0,0,Proning|Supportive Care,0
NCT05107557,11/5/2021,12/5/2021,Interventional,"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)",Recruiting,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,Experimental Group,1
NCT05043376,9/10/2021,11/21/2021,Interventional,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19,Completed,Not Applicable,King Edward Medical University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Standard of care|BLIS K12,0
NCT04954287,8/6/2021,3/31/2022,Interventional,Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults,Recruiting,Phase 1,CyanVac LLC,NA,NA,NA,NA,NA,NA,United States,0,5,CVXGA1 low dose|CVXGA1 high dose,1
NCT05028361,10/4/2021,4/5/2022,Interventional,Simultaneous mRNA COVID-19 and IIV4 Vaccination Study,Recruiting,Phase 4,Duke University,NA,NA,NA,NA,NA,NA,United States,0,3,mRNA COVID-19|IIV4|Placebo,1
NCT04873401,6/10/2021,10/31/2022,Interventional,Leveraging Social Networks to Increase COVID-19 Testing Uptake,Recruiting,Not Applicable,New York State Psychiatric Institute,NA,NA,NA,NA,NA,NA,United States,0,2,Chain-referral|Credible Messenger,0
NCT05022329,9/30/2021,9/30/2022,Interventional,COVID-19 Vaccine Boosters in Patients With CKD,Recruiting,Phase 2/Phase 3,Sunnybrook Health Sciences Centre,NA,NA,NA,NA,NA,NA,Canada,0,3,Pfizer-BioNTech COVID-19 Vaccine|MODERNA SARS-CoV-2 Vaccine,1
NCT04847362,4/11/2021,11/22/2021,Interventional,The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic,Recruiting,Not Applicable,Saglik Bilimleri Universitesi,NA,NA,NA,NA,NA,NA,Turkey,0,2,Experimental,0
NCT04830774,4/15/2021,12/31/2021,Interventional,Natural History of COVID-19-Related Atrial Fibrillation,Recruiting,Not Applicable,Texas Cardiac Arrhythmia Research Foundation,NA,NA,NA,NA,NA,NA,United States|Belgium|Italy,0,3,"ILR, PMK, ICD",0
NCT04590586,11/24/2020,8/3/2021,Interventional,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Completed,Phase 3,Amgen,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Chile|Mexico|Russian Federation|South Africa|Ukraine,0,18,Standard of care|Apremilast|Apremilast placebo|Lanadelumab|Lanadelumab placebo|Zilucoplan|Zilucoplan placebo,0
NCT04590547,5/7/2021,5/31/2022,Interventional,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,NA,NA,NA,NA,NA,United States|Bulgaria|North Macedonia|Puerto Rico,0,9,GLS-1027|Placebo,0
NCT04377100,5/8/2020,4/9/2021,Interventional,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),NA,NA,NA,NA,NA,NA,United States,0,373,Computer task questionnaires,0
NCT04353128,4/20/2020,10/1/2020,Interventional,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Completed,Phase 2/Phase 3,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,NA,NA,NA,NA,NA,Spain,0,3,Melatonin 2mg|Placebo oral tablet,0
NCT05019456,3/9/2021,12/25/2022,Interventional,Exercise and COVID-19 Viral T-cell Immunity,Recruiting,Not Applicable,University of Arizona,NA,NA,NA,NA,NA,NA,United States,0,1,COVID-19 Vaccine,0
NCT05133609,1/15/2021,8/1/2022,Interventional,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,Recruiting,Phase 1/Phase 2,Federal University of Espirito Santo,NA,NA,NA,NA,NA,NA,Brazil,0,0,ChAdOx1 nCoV-19 vaccine (AZD1222),1
NCT05133622,12/1/2021,2/25/2022,Interventional,Physical Fitness in Young Healthy Adults After COVID-19 Infection,Enrolling by invitation,Not Applicable,Baskent University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Physical Activity Level|Evaluation of knee extension and elbow flexion muscle strength|Evaluation of functional strength of trunk muscles|Muscle Endurance|Flexibility|Balance|Fatigue,0
NCT05132933,10/1/2021,6/30/2022,Interventional,Gas Exchange Derangement Physiopathology in Critically Ill Patients With COVID-19,Recruiting,Not Applicable,Policlinico Hospital,NA,NA,NA,NA,NA,NA,Italy,0,0,PEEP trial - Electrical Impedance Tomography,0
NCT05119348,9/14/2020,8/4/2021,Interventional,Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments,"Active, not recruiting",Not Applicable,Desmond Tutu HIV Foundation,NA,NA,NA,NA,NA,NA,South Africa,0,1,STOPCOV,0
NCT05074433,10/25/2021,4/3/2023,Interventional,A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults,Recruiting,Phase 3,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States|Mexico,0,3,casirivimab+imdevimab|Placebo,0
NCT05037266,9/20/2021,4/30/2022,Interventional,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Recruiting,Phase 4,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,NA,NA,NA,NA,France,0,3,COVID-19 Vaccine Janssen (Ad26.COV2-S),1
NCT04818320,2/16/2021,7/1/2021,Interventional,Favipiravir in High-risk COVID-19 Patients,Completed,Phase 3,"Penang Hospital, Malaysia",NA,NA,NA,NA,NA,NA,Malaysia,0,4,Favipiravir,0
NCT04765384,8/27/2021,1/16/2023,Interventional,A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19),Recruiting,Phase 2,Janssen Vaccines & Prevention B.V.,NA,NA,NA,NA,NA,NA,United States|Brazil|South Africa,0,8,Ad26.COV2.S,0
NCT04754594,2/16/2021,8/24/2022,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,NA,NA,NA,NA,NA,United States|Brazil|South Africa|Spain|United Kingdom,0,12,BNT162b2|Placebo,1
NCT04589117,5/27/2020,8/2/2020,Interventional,Expressive Writing for COVID-19 Resilience for Parents,Completed,Not Applicable,Duke University,NA,NA,NA,NA,NA,NA,United States,0,1,Expressive writing,0
NCT05135598,3/1/2020,2/28/2023,Interventional,Partners For Life: Off-line Health Promotion Program for Ultra-orthodox Jewish Women During the COVID-19 Pandemic,Recruiting,Not Applicable,Hadassah Medical Organization,NA,NA,NA,NA,NA,NA,Israel,0,0,Partners for Life health behavior change program,0
NCT04509947,8/11/2020,2/22/2021,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),Completed,Phase 1,Janssen Pharmaceutical K.K.,NA,NA,NA,NA,NA,NA,Japan,0,8,Ad26.COV2.S|Placebo,0
NCT04445428,7/15/2020,11/30/2021,Interventional,OPV as Potential Protection Against COVID-19,"Active, not recruiting",Phase 4,Bandim Health Project,NA,NA,NA,NA,NA,NA,Guinea-Bissau,0,6,oral polio vaccine + information|Information,1
NCT04374084,5/10/2020,12/31/2021,Interventional,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,Not Applicable,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,NA,NA,NA,NA,NA,NA,China,0,4,Moxibustion plus Cupping,0
NCT05054075,10/1/2021,6/30/2022,Interventional,Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19,Enrolling by invitation,Phase 2,Universidade do Porto,NA,NA,NA,NA,NA,NA,Portugal,0,2,Marine liquid and fluids|Impregnation|Incubation|Manipulation|Refrigeration,0
NCT05081388,11/8/2021,11/10/2022,Interventional,"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease",Recruiting,Phase 1/Phase 2,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,2,REGN14256|imdevimab|casirivimab + imdevimab|Placebo,0
NCT05074888,10/15/2021,12/31/2024,Interventional,Ð¡linical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.,Recruiting,Phase 3,Materia Medica Holding,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Prospekta|Placebo,0
NCT05069649,10/6/2021,12/31/2022,Interventional,Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2,Recruiting,Phase 3,Materia Medica Holding,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Ergoferon|Placebo,1
NCT05009732,9/30/2021,6/30/2022,Interventional,A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects,Recruiting,Phase 3,"Suzhou Kintor Pharmaceutical Inc,",NA,NA,NA,NA,NA,NA,United States,0,6,GT0918|Standard of care|Matching placebo,0
NCT04867174,5/24/2021,8/15/2021,Interventional,COVID-19 Vaccination Take-Up,"Active, not recruiting",Not Applicable,University of Southern California,NA,NA,NA,NA,NA,NA,United States,0,5,Financial incentives|Convenient scheduling link|Race concordant|Gender concordant,1
NCT04928430,4/28/2021,4/1/2022,Interventional,Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19,Recruiting,Phase 2/Phase 3,Xenothera SAS,NA,NA,NA,NA,NA,NA,Bulgaria|Greece|Romania|Spain|Turkey,0,1,XAV-19|Placebo,0
NCT04904549,5/26/2021,3/8/2023,Interventional,Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older,Recruiting,Phase 3,Sanofi,NA,NA,NA,NA,NA,NA,United States|Colombia|Ghana|Honduras|India|Japan|Kenya|Mexico|Nepal|Sri Lanka,0,8,SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent)|Placebo,1
NCT04903327,11/16/2021,12/31/2021,Interventional,Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,Brazil,0,3,COVI-MSC|Placebo,0
NCT04720612,10/15/2021,3/31/2022,Interventional,COVID-19 Immunologic Antiviral Therapy With Omalizumab,Recruiting,Phase 2,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,Canada,0,2,Omalizumab|Placebo,0
NCT04776044,4/12/2021,4/30/2022,Interventional,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,Recruiting,Phase 2,Atriva Therapeutics GmbH,NA,NA,NA,NA,NA,NA,Germany|India|Netherlands|Poland|Romania|South Africa|Spain,0,6,ATR-002|Placebo,0
NCT04622332,12/18/2020,12/15/2021,Interventional,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,"Active, not recruiting",Phase 1,"Sironax USA, Inc.",NA,NA,NA,NA,NA,NA,United States|Mexico|Pakistan,0,2,SIR1-365|Matching Placebo,0
NCT04644705,11/2/2020,5/3/2021,Interventional,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Completed,Phase 1,CharitÃ© Research Organisation GmbH,NA,NA,NA,NA,NA,NA,Germany,0,1,Niclosamide|Placebo,0
NCT04639466,12/11/2020,11/10/2022,Interventional,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Phase 1,City of Hope Medical Center,NA,NA,NA,NA,NA,NA,United States,0,5,Placebo Administration|Vaccine Therapy,1
NCT04636034,1/12/2021,3/31/2022,Interventional,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Recruiting,Phase 3,University Hospital Bispebjerg and Frederiksberg,NA,NA,NA,NA,NA,NA,Denmark,0,4,"Sphenopalatine Ganglion Block with Local Anesthetic|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|""Sham""-block with Placebo (Isotone NaCl)",0
NCT04387955,4/30/2020,7/30/2021,Interventional,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Completed,Not Applicable,Poitiers University Hospital,NA,NA,NA,NA,NA,NA,France,0,3,Biological Sample Collection,0
NCT04387253,5/23/2020,7/25/2022,Interventional,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,Not Applicable,Poitiers University Hospital,NA,NA,NA,NA,NA,NA,France,0,4,Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus,0
NCT04359329,4/20/2020,7/30/2020,Interventional,Estrogen Patch for COVID-19 Symptoms,Terminated,Phase 2,Stony Brook University,Poor accrual,NA,NA,NA,NA,NA,United States,0,1,Estradiol patch,0
NCT05082714,10/18/2021,4/30/2022,Interventional,Tocilizumab Versus Baricitinib in Patients With Severe COVID-19,Recruiting,Not Applicable,University Hospital of Patras,NA,NA,NA,NA,NA,NA,Greece,0,1,Tocilizumab|Baricitinib,0
NCT05047783,11/23/2021,6/30/2022,Interventional,Masitinib in Patients With Symptomatic Mild to Moderate COVID-19,Recruiting,Phase 2,AB Science,NA,NA,NA,NA,NA,NA,France|Russian Federation|South Africa,0,1,Masitinib Mesylate|Placebo,0
NCT04979949,7/12/2021,3/11/2022,Interventional,Booster Vaccination Against COVID-19,"Active, not recruiting",Phase 2,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,5,CoronaVac|Turkovac,1
NCT04905836,11/16/2021,12/31/2021,Interventional,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,COVI-MSC|Placebo,0
NCT04878211,6/10/2021,11/26/2021,Interventional,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Recruiting,Phase 4,Novartis,NA,NA,NA,NA,NA,NA,United States,0,4,Ofatumumab|mRNA COVID-19 vaccine|interferon or glatiramer acetate,1
NCT04895449,7/16/2021,3/1/2022,Interventional,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19",Recruiting,Phase 1,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,NA,NA,Germany,0,2,MVA-SARS-2-ST,1
NCT04803812,1/26/2021,9/2/2021,Interventional,Supporting the Wellness of Ontario Physicians During COVID-19,Completed,Not Applicable,Ontario Medical Association,NA,NA,NA,NA,NA,NA,Canada,0,1,"Remote SMS (short message service, also known as ""text message"") delivery",0
NCT04844138,4/30/2021,4/30/2022,Interventional,Evaluating Overcoming Anxiety in Pregnancy and Postpartum as an Online Self-Directed Program,Recruiting,Not Applicable,University of Manitoba,NA,NA,NA,NA,NA,NA,Canada,0,2,Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program,0
NCT04602000,9/25/2020,5/21/2021,Interventional,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Completed,Phase 2/Phase 3,Celltrion,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,CT-P59/Placebo,0
NCT04568564,10/1/2020,12/1/2021,Interventional,Telerehabilitation in Lung Surgery Patients,Recruiting,Not Applicable,Istanbul Medipol University Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,5,"Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|Exercise booklet",0
NCT04409834,8/5/2020,3/31/2022,Interventional,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Phase 4,The TIMI Study Group,NA,NA,NA,NA,NA,NA,United States,0,4,Unfractionated Heparin IV|Enoxaparin 1 mg/kg|Clopidogrel|Unfractionated heparin SC|Enoxaparin 40 Mg/0.4 mL Injectable Solution,0
NCT04377659,5/1/2020,5/1/2022,Interventional,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,6,Tocilizumab,0
NCT04347226,4/16/2020,3/1/2021,Interventional,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Terminated,Phase 2,Columbia University,Interim analysis indicated that futility boundary was reached.,NA,NA,NA,NA,NA,United States,0,4,BMS-986253,0
NCT04334980,11/2/2020,2/8/2022,Interventional,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Active, not recruiting",Phase 1,Symvivo Corporation,NA,NA,NA,NA,NA,NA,Australia,0,9,bacTRL-Spike,1
NCT04629703,2/22/2021,4/30/2022,Interventional,"Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,Phase 3,Rigel Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Mexico|Peru,0,7,Fostamatinib|Placebo,0
NCT05069454,5/10/2021,5/20/2022,Interventional,Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Recruiting,Not Applicable,Public health and reforms Center of Ministry of Health,NA,NA,NA,NA,NA,NA,Azerbaijan,0,0,COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine,1
NCT05069103,7/5/2021,6/30/2022,Interventional,ImplementatioN of Remote Surgical wOund Assessment During the coviD-19 pandEmic,Recruiting,Not Applicable,University of Edinburgh,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Intervention,0
NCT05060939,7/30/2021,7/30/2022,Interventional,SARS-CoV-2 Infection in COVID-19 Vaccinated Patients,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,0,COVID-19 vaccinated people,1
NCT05062681,9/15/2021,12/15/2021,Interventional,RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow,Recruiting,Phase 4,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Dexamethasone|Methylprednisolone,0
NCT05060991,9/24/2021,12/24/2021,Interventional,Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients,Recruiting,Phase 4,"University of California, Davis",NA,NA,NA,NA,NA,NA,United States,0,0,Reduction in antimetabolite immunosuppression,1
NCT05058742,7/15/2021,12/31/2021,Interventional,Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS,Recruiting,Not Applicable,Vienna Hospital Association,NA,NA,NA,NA,NA,NA,Austria,0,1,AuriStim,0
NCT05060510,9/14/2021,9/14/2021,Interventional,The School SPIT Study - COVID-19 Testing in Secondary Schools,"Active, not recruiting",Not Applicable,The Hospital for Sick Children,NA,NA,NA,NA,NA,NA,Canada,0,1,Take home saliva kit,0
NCT05059106,6/1/2021,6/1/2022,Interventional,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",Recruiting,Phase 2/Phase 3,Federal University of Espirito Santo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Half dose of ChAdOx1 nCoV-19 (AZD1222)|Standard dose of ChAdOx1 nCoV-19 (AZD1222),1
NCT05057182,9/27/2021,12/31/2022,Interventional,Third Dose of mRNA Vaccination to Boost COVID-19 Immunity,Recruiting,Phase 4,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,BNT162b2,1
NCT05055427,8/20/2021,12/20/2021,Interventional,Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients,Recruiting,Phase 2/Phase 3,University of Medicine and Pharmacy at Ho Chi Minh City,NA,NA,NA,NA,NA,NA,Vietnam,0,0,Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng),0
NCT05054114,12/21/2020,5/25/2021,Interventional,"Study of the Use of Nasal IFN-Î³ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19",Completed,Not Applicable,SPP Pharmaclon Ltd.,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,Interferon gamma human recombinant (IFN-G),0
NCT05055492,9/14/2021,9/14/2021,Interventional,The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions,"Active, not recruiting",Not Applicable,The Hospital for Sick Children,NA,NA,NA,NA,NA,NA,Canada,0,1,Take home saliva kits,0
NCT05055505,9/14/2021,9/14/2021,Interventional,The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions,"Active, not recruiting",Not Applicable,The Hospital for Sick Children,NA,NA,NA,NA,NA,NA,Canada,0,1,Take home saliva kits,0
NCT05054322,9/22/2021,1/31/2022,Interventional,FLuticasone in cOvid Treatment (FLOT),Recruiting,Phase 2/Phase 3,University of Medicine and Pharmacy at Ho Chi Minh City,NA,NA,NA,NA,NA,NA,Vietnam,0,0,Fluticasone Propionate,0
NCT05050201,4/20/2021,4/20/2022,Interventional,Implementation of Digital CBT for Insomnia in First Episode Psychosis,Recruiting,Not Applicable,NHS Greater Glasgow and Clyde,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Sleepio,0
NCT05050474,8/7/2021,8/23/2021,Interventional,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),"Active, not recruiting",Phase 1,Livzon Pharmaceutical Group Inc.,NA,NA,NA,NA,NA,NA,China,0,0,Recombinant SARS-CoV-2 Fusion Protein Vaccine,1
NCT05047952,9/16/2021,6/30/2022,Interventional,Vortioxetine for Post-Covid-19 Syndrome,Recruiting,Phase 2,Brain and Cognition Discovery Foundation,NA,NA,NA,NA,NA,NA,Canada,0,1,Vortioxetine|Placebo,0
NCT05047692,9/9/2021,9/30/2022,Interventional,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,Recruiting,Phase 1,"Cellid Co., Ltd.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,AdCLD-CoV19-1,1
NCT05045989,4/1/2021,7/31/2021,Interventional,Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot,Completed,Not Applicable,University of Nottingham,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions),0
NCT05043259,9/13/2021,10/13/2021,Interventional,Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine,Recruiting,Phase 1/Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,1,inactive SARS-CoV-2 vaccine (Vero cell)|Low dose aerosolized Ad5-nCoV|High dose aerosolized Ad5-nCoV,1
NCT05043220,9/29/2021,6/30/2022,Interventional,Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Chemotherapy,Recruiting,Not Applicable,Technische UniversitÃ¤t MÃ¼nchen,NA,NA,NA,NA,NA,NA,Germany,0,1,PPG and PROM,0
NCT05041907,9/30/2021,8/31/2023,Interventional,Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),Recruiting,Phase 2,University of Oxford,NA,NA,NA,NA,NA,NA,Thailand,0,1,Favipiravir|Monoclonal antibodies|Ivermectin|No treatment|Remdesivir,0
NCT05035576,9/1/2021,10/31/2021,Interventional,A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19,Recruiting,Phase 1,Optinose US Inc.,NA,NA,NA,NA,NA,NA,Mexico,0,0,OPN-019,0
NCT05040724,5/28/2021,5/31/2022,Interventional,Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19,"Active, not recruiting",Phase 3,Raincy Montfermeil Hospital Group,NA,NA,NA,NA,NA,NA,France,0,0,Ivermectin,0
NCT05038488,10/26/2021,4/28/2022,Interventional,Phase 2a MIB-626 vs. Placebo COVID-19,Recruiting,Phase 2,"Metro International Biotech, LLC",NA,NA,NA,NA,NA,NA,United States,0,2,MIB-626|Placebo|Home Treatment,0
NCT05038514,9/1/2021,9/1/2021,Interventional,The Effect of Music Therapy in COVID-19 Patients Given Prone Position,Recruiting,Not Applicable,Kutahya Health Sciences University,NA,NA,NA,NA,NA,NA,Turkey,0,0,musÄ±c therapy,0
NCT05037188,8/10/2021,8/31/2022,Interventional,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),Recruiting,Phase 1/Phase 2,Biocad,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Low dose BCD-250 injection|High dose BCD-250 injection|Low dose or high dose BCD-250 injection|Placebo injection,1
NCT05040737,4/17/2020,2/8/2021,Interventional,PMMA vs Polysulfone in SARS-CoV-2 Infection Hemodialysis Patients,"Active, not recruiting",Not Applicable,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,NA,NA,NA,NA,NA,Spain,0,0,"PS membrane versus PMMA membrane,",0
NCT05037253,10/30/2020,5/30/2021,Interventional,COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation,Completed,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Vitamin D,0
NCT05037240,1/12/2021,4/6/2021,Interventional,Quercetin in the Prevention of Covid-19 Infection,Completed,Not Applicable,Azienda di Servizi alla Persona di Pavia,NA,NA,NA,NA,NA,NA,Italy,0,0,Quercetin|Placebo,0
NCT05037448,8/17/2020,2/28/2021,Interventional,Exploring Telehealth to Deliver Me & My Wishes During Coronavirus-19,Completed,Not Applicable,University of Utah,NA,NA,NA,NA,NA,NA,United States,0,0,Me & My Wishes,0
NCT05035628,8/15/2021,8/15/2022,Interventional,Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue,Recruiting,Not Applicable,Montreal Heart Institute,NA,NA,NA,NA,NA,NA,Canada,0,0,Cardiopulmonary exercise training,0
NCT05035563,6/1/2021,3/1/2022,Interventional,Impact of a Communication Strategy in the Prevention of Depressive Symptoms in Patients With Covid-19,Recruiting,Not Applicable,Pontificia Universidad Catolica de Chile,NA,NA,NA,NA,NA,NA,Chile,0,0,Intervention. Early and integral communication strategy (EICS),0
NCT05035550,2/4/2021,5/5/2021,Interventional,Effects of Open-label Placebos on COVID-related Psychological Health,Completed,Not Applicable,Michigan State University,NA,NA,NA,NA,NA,NA,United States,0,0,Non-Deceptive Placebo,0
NCT05035524,9/1/2021,3/1/2022,Interventional,A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19,"Active, not recruiting",Not Applicable,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Sodium Bicarbonate Solution|Placebo,0
NCT05035186,3/21/2021,9/20/2021,Interventional,Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era,Recruiting,Not Applicable,Alexandria University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Amoxicillin,0
NCT04922905,4/2/2020,5/7/2020,Interventional,Nervous System Symptoms Associated With COVID 19,Completed,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,0,NEURO +|NEURO -,0
NCT05033860,8/18/2021,9/20/2021,Interventional,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents,Recruiting,Not Applicable,Ningbo No. 1 Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Read leaflets containing knowledge of COVID-19 and vaccination.,1
NCT05032885,4/4/2021,9/1/2021,Interventional,Early Physiotherapy in Covid Patients,Recruiting,Not Applicable,Hospital Universitario Getafe,NA,NA,NA,NA,NA,NA,Spain,0,0,physiotherapy,0
NCT05033158,4/1/2021,12/31/2021,Interventional,The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.,Recruiting,Not Applicable,"University Hospital, Antwerp",NA,NA,NA,NA,NA,NA,Belgium,0,0,Blood sampling,1
NCT05028374,8/17/2021,1/31/2022,Interventional,COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies,Recruiting,Phase 2,Barbara Ann Karmanos Cancer Institute,NA,NA,NA,NA,NA,NA,United States,0,0,"A single ""booster"" dose of the Moderna mRNA COVID-19 vaccine",1
NCT05028244,6/15/2021,12/31/2021,Interventional,Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients,Recruiting,Not Applicable,Hospital Universitari Vall d'Hebron Research Institute,NA,NA,NA,NA,NA,NA,Spain,0,0,venous ultrasound of lower extremity,0
NCT05024461,8/10/2020,11/12/2020,Interventional,Comparison of Detection of SARS-CoV2 (COVID-19) Between Nasopharyngeal Swab Specimens and Those Obtained by Salivary Sputum,"Active, not recruiting",Not Applicable,Centre Hospitalier de Cayenne,NA,NA,NA,NA,NA,NA,French Guiana,0,0,Salivary test for COVID19,0
NCT05024500,1/4/2021,10/11/2021,Interventional,Clinical and Functional Outcomes of Critically Ill Patients With COVID-19,Recruiting,Not Applicable,University of Pernambuco,NA,NA,NA,NA,NA,NA,Brazil,0,1,ARDSNet table|Driving Pressure|Electrical Impedance Tomography,0
NCT05027672,7/30/2021,8/30/2021,Interventional,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Active, not recruiting",Phase 2,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,NA,NA,NA,NA,NA,Argentina,0,0,Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5),1
NCT05024006,4/23/2020,1/27/2021,Interventional,Public Health Emergency: SOLIDARITY TRIAL Philippines,"Active, not recruiting",Not Applicable,University of the Philippines,NA,NA,NA,NA,NA,NA,Philippines,0,0,Acalabrutinib|Remdesivir|Hydroxychloroquine|Lopinavir / Ritonavir|Interferon beta-1a,0
NCT05022303,10/31/2021,9/30/2022,Interventional,AT1001 for the Treatment of COVID-19 Related MIS-C,Recruiting,Phase 2,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Larazotide Acetate|Placebo,0
NCT05021588,4/12/2020,8/2/2020,Interventional,Steroid and Anticoagulant Therapy in covid19,Completed,Not Applicable,Assiut University,NA,NA,NA,NA,NA,NA,Egypt,0,0,steroid and anticoagulants according to different protocols.,0
NCT05021016,11/19/2020,1/30/2021,Interventional,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,Completed,Phase 3,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,NA,NA,NA,NA,NA,Russian Federation,0,1,EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19),1
NCT05019287,4/17/2021,5/21/2021,Interventional,Menstrual Blood Stem Cells in Severe Covid-19,Completed,Phase 1/Phase 2,Avicenna Research Institute,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,Allogeneic human menstrual blood stem cells secretome|Intravenous saline injection,0
NCT05019326,8/30/2021,5/30/2022,Interventional,Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19,Recruiting,Phase 3,Mahidol University,NA,NA,NA,NA,NA,NA,Thailand,0,1,Andrographis Paniculata|Boesenbergia|Standard supportive treatment,0
NCT05018065,5/1/2020,12/1/2020,Interventional,Sexual Functions and Covid-19,Completed,Not Applicable,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,1,Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI),0
NCT05018078,8/30/2021,12/30/2022,Interventional,Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer,Recruiting,Not Applicable,Beijing 302 Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Coronavirus vaccine,1
NCT05017792,8/30/2021,9/30/2022,Interventional,"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt",Recruiting,Phase 3,Theodor Bilharz Research Institute,NA,NA,NA,NA,NA,NA,Egypt,0,1,Astrazenica vaccine,1
NCT05014373,10/12/2020,8/31/2021,Interventional,Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19,Recruiting,Phase 3,University of the Philippines,NA,NA,NA,NA,NA,NA,Philippines,0,0,Favipiravir + Standard of Care|Standard of Care,0
NCT05012826,9/20/2021,6/6/2023,Interventional,Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID,Recruiting,Not Applicable,Centro UniversitÃ¡rio Augusto Motta,NA,NA,NA,NA,NA,NA,Brazil,0,3,Physiotherapy|Osteopathic Manipulative Treatment in addition to Physiotherapy,0
NCT05011513,8/25/2021,12/12/2021,Interventional,Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).,Recruiting,Phase 3,Pfizer,NA,NA,NA,NA,NA,NA,"United States|Argentina|Brazil|Bulgaria|Colombia|Czechia|Hungary|Japan|Korea, Republic of|Malaysia|Mexico|Poland|Puerto Rico|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine",0,3,PF-07321332|Ritonavir|Placebo|Placebo,0
NCT05012319,8/5/2021,3/30/2022,Interventional,Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19,Recruiting,Phase 3,Salmaniya Medical Complex,NA,NA,NA,NA,NA,NA,Bahrain,0,0,to be given as a treatment,0
NCT05012800,7/28/2021,8/31/2022,Interventional,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults,Recruiting,Phase 4,Beijing 302 Hospital,NA,NA,NA,NA,NA,NA,China,0,0,COVID-19 Vaccine,1
NCT05011344,7/15/2020,7/15/2022,Interventional,Evolution of Protective Immunization Against COVID-19 Among Hospital Workers in Health Care Facilities,Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,1,Blood sample,0
NCT05009186,4/1/2020,10/1/2021,Interventional,Changing of Prostate Specific Antigen Value in Patients With Covid-19,Recruiting,Not Applicable,Saglik Bilimleri Universitesi,NA,NA,NA,NA,NA,NA,Turkey,0,0,PSA value,0
NCT05010876,2/4/2021,6/13/2021,Interventional,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Completed,Phase 2,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,NA,NA,NA,NA,NA,France,0,0,C1 Inhibitor Human|Icatibant Injection|Placebo,0
NCT05009563,1/4/2021,1/4/2022,Interventional,COvid iMaging With POSitron Emission Tomography,Recruiting,Not Applicable,Semmelweis University Heart and Vascular Center,NA,NA,NA,NA,NA,NA,Hungary,0,0,FDG-PET/CT,0
NCT05007457,6/12/2021,6/12/2022,Interventional,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,Recruiting,Not Applicable,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,NA,NA,NA,NA,NA,Italy,0,0,Telerehabilitation,0
NCT05008003,9/5/2021,11/30/2021,Interventional,"Dietary Supplements Vit D, Quercetin and Curcumin Combination for Early Symptoms of COVID-19",Recruiting,Not Applicable,Ayub Teaching Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,2,"Standard of care|combination of curcumin, quercetin and Vitamin D",0
NCT05008393,9/25/2021,11/30/2021,Interventional,Efficacy of PJS-539 for Adult Patients With COVID-19.,Recruiting,Phase 2,Hospital do Coracao,NA,NA,NA,NA,NA,NA,Brazil,0,3,PJS-539 Dose 1|PJS-539 Dose 2|Placebo,0
NCT05008380,8/16/2021,5/1/2022,Interventional,Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia,Recruiting,Not Applicable,University of Milano Bicocca,NA,NA,NA,NA,NA,NA,Italy,0,1,prone positioning,0
NCT05007678,9/16/2020,7/1/2022,Interventional,Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease,"Active, not recruiting",Phase 3,Ashford and St. Peter's Hospitals NHS Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,leflunomide,0
NCT05007496,4/14/2021,5/31/2021,Interventional,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19",Completed,Phase 2,"Aivita Biomedical, Inc.",NA,NA,NA,NA,NA,NA,Indonesia,0,1,AV-COVID-19,1
NCT05007600,2/1/2021,7/1/2021,Interventional,Online Interactive Courses on Loneliness and Quality of Life of Older Adults,Completed,Not Applicable,National Cheng Kung University,NA,NA,NA,NA,NA,NA,Taiwan,0,0,Online Interactive Courses,0
NCT05005559,8/7/2021,3/1/2022,Interventional,Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"Active, not recruiting",Phase 3,Cinnagen,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,1,SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|Saline placebo,1
NCT05007509,8/16/2021,11/30/2021,Interventional,Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Laboratorios Hipra, S.A.",NA,NA,NA,NA,NA,NA,Spain,0,3,COVID-19 vaccine HIPRA 10|COVID-19 vaccine HIPRA 20|COVID-19 vaccine HIPRA 40|Commercial COVID-19 vaccine,1
NCT05007236,9/20/2021,12/31/2021,Interventional,"Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.",Recruiting,Phase 2,Rhizen Pharmaceuticals SA,NA,NA,NA,NA,NA,NA,India,0,3,RP7214 + Standard of care (SOC)|Placebo + Standard of care (SOC),0
NCT04997551,9/8/2020,9/1/2021,Interventional,Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19,"Active, not recruiting",Phase 3,Asociacion Instituto Biodonostia,NA,NA,NA,NA,NA,NA,Spain,0,0,Colchcine,0
NCT05002517,9/3/2020,7/31/2021,Interventional,"Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab","Active, not recruiting",Phase 3,Asociacion Instituto Biodonostia,NA,NA,NA,NA,NA,NA,Spain,0,0,Tociliziumab group|Methylprednisolone group,0
NCT05000307,7/28/2020,12/1/2021,Interventional,Co-SÃ©r: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection,Recruiting,Not Applicable,"University Hospital, Ghent",NA,NA,NA,NA,NA,NA,Belgium,0,1,Blood sample,0
NCT05000255,1/18/2021,6/30/2022,Interventional,"Coping With Covid-19: Loneliness, Self-Efficacy, Social Support, Depression & Anxiety in Patients in Medical Rehab.",Recruiting,Not Applicable,Helios Research Center,NA,NA,NA,NA,NA,NA,Germany,0,0,"Intervention 1: According to DGP|Intervention 2: According to Cacioppo ""E.A.S.E.""",0
NCT04998708,12/1/2020,4/30/2021,Interventional,Relaxation Exercise in Patients With COVID-19,Completed,Not Applicable,Beni-Suef University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Relaxation technique,0
NCT05005156,6/24/2021,9/30/2022,Interventional,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,Recruiting,Phase 2,FundaciÃ³n HuÃ©sped,NA,NA,NA,NA,NA,NA,Argentina,0,1,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV),1
NCT05004753,9/30/2020,2/28/2021,Interventional,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,Completed,Phase 4,Mateon Therapeutics,NA,NA,NA,NA,NA,NA,India,0,1,Artemisinin|Dexamethasone,0
NCT05002348,12/1/2020,11/30/2023,Interventional,Laser Acupuncture Improves Constipation in Patients Hospitalized for Stroke During the COVID-19 Pandemic,Recruiting,Not Applicable,Far Eastern Memorial Hospital,NA,NA,NA,NA,NA,NA,Taiwan,0,1,Laser acupoint stimulation(Laser pen),0
NCT05000008,1/1/2021,10/1/2021,Interventional,Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19,Recruiting,Not Applicable,Istanbul Gelisim University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Exercises,0
NCT04996238,2/11/2021,1/31/2022,Interventional,Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers,"Active, not recruiting",Not Applicable,"University Hospital, Ghent",NA,NA,NA,NA,NA,NA,Belgium,0,0,Blood and nasal fluid sampling before and after COVID-19 vaccination,1
NCT04993586,7/29/2021,3/26/2022,Interventional,Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,NA,NA,NA,NA,NA,Japan,0,2,AG0302-COVID19 for Intramuscular Injection|AG0302-COVID19 for Intramuscular Injection|AG0302-COVID19 for Intramuscular Injection|AG0302-COVID19 for Intradermal Injection|AG0302-COVID19 for Intradermal Injection,1
NCT04993547,3/31/2021,6/9/2021,Interventional,Cluster-RCT Collective Nasopharyngeal COVID-19 Testing Amongst Pupils,Completed,Not Applicable,"University Hospital, Ghent",NA,NA,NA,NA,NA,NA,Belgium,0,0,Parent and peer presence,0
NCT04992182,7/8/2021,8/31/2021,Interventional,"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","Active, not recruiting",Phase 2,Universidad del Desarrollo,NA,NA,NA,NA,NA,NA,Chile,0,0,Placebo|Inactivated vaccine booster|mRNA vaccine booster|Viral vector vaccine booster,1
NCT04993209,7/9/2021,4/30/2023,Interventional,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil",Recruiting,Phase 1/Phase 2,Butantan Institute,NA,NA,NA,NA,NA,NA,Brazil,0,0,NDV-HXP-S 1Î¼g (Stage A)|NDV-HXP-S 3Î¼g (Stage A)|NDV-HXP-S 10Î¼g (Stage A)|NDV-HXP-S parental vaccine in 3 consecutive lots (Group B1a)|Active vaccine control (Group B1a)|NDV-HXP-S parental vaccine (Group B1b)|Active vaccine control (Group B1b)|NDV-HXP-S parental vaccine (Group B1c)|Active vaccine control (Group B1c)|Placebo (Stage A)|NDV-HXP-S parental vaccine simple dose (Group B1d)|Active vaccine control (Group B1d)|NDV-HXP-S parental vaccine simple dose (Group B1d) - 60 years old or more|Active vaccine control simple dose (Group B1d)|NDV-HXP-S P.1 vaccine (Group B1e)|NDV-HXP-S B.1351 vaccine (Group B1e)|NDV-HXP-S vaccine based in variant / 3 consecutive lots (Group C1a)|NDV-HXP-S vaccine based in variant (Group C1b)|NDV-HXP-S vaccine based in variant (Group C1c)|NDV-HXP-S vaccine based in variant (Group C1c) - 60 years old or more|NDV-HXP-S P.1 vaccine (Group B2a)|NDV-HXP-S P.1.351 vaccine (Group B2a)|NDV-HXP-S vaccine based in variant / 3 consecutive lots (Group C2a)|Active vaccine control (Group C2a)|NDV-HXP-S vaccine based in variant (Group C2b)|Active vaccine control (Group C2b)|NDV-HXP-S vaccine based in variant (Group C2c)|Active vaccine control (Group C2c)|NDV-HXP-S parental vaccine simple dose (Group C2d)|Active vaccine control simple dose (Group C2d)|NDV-HXP-S parental vaccine simple dose (Group C2d) - 60 years old or more|Active vaccine control simple dose (Group C2d) - 60 years old or more,1
NCT04992000,6/1/2020,9/1/2020,Interventional,Self-Care of Hypertension Among Older Adults During COVID-19,Completed,Not Applicable,"Near East University, Turkey",NA,NA,NA,NA,NA,NA,Cyprus,0,1,4-free app + PHN intervention,0
NCT04992390,8/24/2021,1/31/2022,Interventional,A Brief GAmeplay Intervention for NHS ICU Staff Affected by COVID-19 Trauma (GAINS Study),Recruiting,Not Applicable,P1vital Products Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Brief digital imagery-competing task intervention,0
NCT04990830,2/3/2021,4/21/2021,Interventional,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,Completed,Phase 2/Phase 3,Istanbul University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Inhaled Low molecular weight heparin|Standard Treatment,0
NCT04990531,8/9/2021,11/1/2021,Interventional,Low-field Magnetic Resonance Imaging of Pediatric COVID-19,Recruiting,Not Applicable,University of Erlangen-NÃ¼rnberg Medical School,NA,NA,NA,NA,NA,NA,Germany,0,1,Low-field magnetic resonance imaging,0
NCT04988217,9/15/2021,6/30/2022,Interventional,Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19),Recruiting,Phase 1/Phase 2,Pontificia Universidad Catolica de Chile,NA,NA,NA,NA,NA,NA,Chile,0,1,Interferon-Alpha2B|Placebo,0
NCT04988048,8/3/2021,9/30/2021,Interventional,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Recruiting,Phase 2,"Ministry of Public Health, Argentina",NA,NA,NA,NA,NA,NA,Argentina,0,2,COVID-19 vaccines,1
NCT04988282,5/24/2021,11/30/2021,Interventional,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,Recruiting,Phase 4,Turkish Thoracic Society,NA,NA,NA,NA,NA,NA,Turkey,0,0,Methylprednisolone Tablet,0
NCT04987554,4/1/2021,12/31/2021,Interventional,Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2,Recruiting,Not Applicable,University of Valladolid,NA,NA,NA,NA,NA,NA,Spain,0,0,glycophosphopeptical AM3|Placebo,0
NCT04982757,8/18/2021,5/31/2026,Interventional,Accelerated TMS for Depression and OCD,Recruiting,Not Applicable,Weill Medical College of Cornell University,NA,NA,NA,NA,NA,NA,United States,0,1,MagVenture MagPro System with Brainsight neuronavigation device,0
NCT04983537,7/26/2021,9/26/2021,Interventional,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,Recruiting,Phase 2,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,NA,NA,NA,NA,NA,Argentina,0,0,Gam-COVID-Vac / Gam-COVID-Vac,1
NCT04983394,8/1/2021,10/30/2021,Interventional,The Effect of Virtual Reality Exercises on Patients With Post-SARS-CoV-2 Syndrome,Recruiting,Not Applicable,Sivas Cumhuriyet University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Virtual Realty Exercises|Aerobic exercises|conventional exercises,0
NCT04982887,5/8/2021,5/8/2021,Interventional,Tele-Rehabilitation in Parkinson's Disease,Enrolling by invitation,Not Applicable,Hacettepe University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Exercise,0
NCT04982068,7/12/2021,12/31/2021,Interventional,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),Recruiting,Phase 1,"Shanghai Zerun Biotechnology Co.,Ltd",NA,NA,NA,NA,NA,NA,China,0,1,202-CoV low adjuvant dose|202-CoV low antigen dose|202-CoV standard dose|Placebo,1
NCT04981743,7/21/2021,9/30/2021,Interventional,The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19),Recruiting,Not Applicable,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Nigella Sativa capsule twice daily,0
NCT04981379,11/16/2020,1/31/2021,Interventional,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,Completed,Phase 3,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,0,Hydroxychloroquine|Favipiravir|Favipiravir + Hydroxychloroquine|Placebo,0
NCT04981314,6/18/2021,10/1/2021,Interventional,Echinacea Drug for Covid-19,Recruiting,Phase 4,University of Santiago de Compostela,NA,NA,NA,NA,NA,NA,Spain,0,1,Equinacea Arkopharma|Placebo,0
NCT04982042,3/1/2021,12/30/2021,Interventional,Post COVID-19 Pulmonary Rehabilitation Program,Recruiting,Not Applicable,Centro UniversitÃ¡rio de Anapolis,NA,NA,NA,NA,NA,NA,Brazil,0,1,Pulmonary Rehabilitation,0
NCT04980508,2/20/2021,4/30/2021,Interventional,Effects of COVID-19 on Cavernous Smooth Muscle,Completed,Not Applicable,Ankara Yildirim BeyazÄ±t University,NA,NA,NA,NA,NA,NA,Turkey,0,0,corpus cavernosum electromyography,0
NCT04979923,7/1/2021,7/31/2021,Interventional,"Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial",Recruiting,Phase 1,Sheikh Zayed Medical College,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Lidocaine,0
NCT04979221,7/26/2021,1/26/2022,Interventional,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Recruiting,Phase 3,Hospital de Clinicas de Porto Alegre,NA,NA,NA,NA,NA,NA,Brazil,0,1,Cyproheptadine,0
NCT04978207,6/6/2021,12/31/2022,Interventional,A Faithful Response to COVID-19 Project,Recruiting,Phase 2/Phase 3,"University of Missouri, Kansas City",NA,NA,NA,NA,NA,NA,United States,0,0,A Faithful Response to COVID-19,0
NCT04977479,9/8/2021,12/30/2022,Interventional,The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),NA,NA,NA,NA,NA,NA,United States,0,33,Pfizer-BioNTech COVID-19 Vaccine (comirnaty)|Placebo,1
NCT04978025,11/1/2020,11/1/2021,Interventional,"Colloidal Silver, Treatment of COVID-19",Recruiting,Not Applicable,HÃ´pital Universitaire Sahloul,NA,NA,NA,NA,NA,NA,Tunisia,0,0,Colloidal Silver|Placebo,0
NCT04977921,1/17/2021,5/15/2021,Interventional,Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,Completed,Not Applicable,Beni-Suef University,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,0,lab session,0
NCT04978051,4/12/2021,11/30/2021,Interventional,Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Hospital Universitari de Bellvitge,NA,NA,NA,NA,NA,NA,Spain,0,0,Firazyr|SoC,0
NCT04973462,8/1/2021,9/30/2021,Interventional,Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19,Recruiting,Phase 4,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,standard treatment COVID-19 + Triazavirin,0
NCT04974203,7/31/2021,8/31/2021,Interventional,Saliva-based COVID-19 DNA Aptamer Test,Recruiting,Not Applicable,Achiko AG,NA,NA,NA,NA,NA,NA,Indonesia,0,0,AptameX,0
NCT04972864,3/1/2021,7/18/2021,Interventional,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Completed,Not Applicable,Gazi University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Exercise training group|Control training group,0
NCT04970563,6/21/2021,2/1/2022,Interventional,"Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: ""Proof of Concept"" Study (CoviDetectionDog)-Covid-19",Recruiting,Not Applicable,HÃ´pital EuropÃ©en Marseille,NA,NA,NA,NA,NA,NA,France,0,0,Body odor samples|Body odor samples,0
NCT04967794,6/1/2021,7/9/2021,Interventional,Effectiveness of Teleorientation in Oral Hygiene During the COVID-19 Pandemic,Recruiting,Early Phase 1,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Teleorientation and Tooth Brushing Orientation,0
NCT04969991,6/30/2021,12/31/2021,Interventional,Study of Varespladib in Patients Hospitalized With Severe COVID-19,Recruiting,Phase 2,"Ophirex, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,Varespladib|Placebo,0
NCT04969263,8/10/2021,11/30/2021,Interventional,COVID-19 Protection After Transplant Pilot Study,"Active, not recruiting",Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,4,mRNA-1273 vaccine (Pfizer/BioNTech)|mRNA-1273 vaccine (Moderna),1
NCT04969172,7/11/2021,7/11/2022,Interventional,"A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection","Active, not recruiting",Phase 2,Tel-Aviv Sourasky Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Exosomes overexpressing CD24,0
NCT04967430,8/27/2021,10/14/2021,Interventional,TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19,Recruiting,Phase 3,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,2,Peginterferon Lambda-1A|Placebo,0
NCT04969276,7/16/2021,2/2/2022,Interventional,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,"Active, not recruiting",Phase 2,Sanofi,NA,NA,NA,NA,NA,NA,United States,0,4,Quadrivalent Inactivated Influenza High Dose|COVID-19 mRNA Vaccine (nucleoside modified),1
NCT04967729,6/10/2021,8/31/2021,Interventional,COVID-19 and Lung Ultrasound Utility,Recruiting,Not Applicable,Rocket Doctor Inc.,NA,NA,NA,NA,NA,NA,Canada,0,1,Device: Butterfly iQ,0
NCT04967755,6/1/2021,8/31/2021,Interventional,Jing-Si-Herbal-Tea Accelerates SARS-Cov-2 Load Reduction Among COVID-19 Patients,Recruiting,Not Applicable,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",NA,NA,NA,NA,NA,NA,Taiwan,0,0,Jing-Si-Herbal-Tea,0
NCT04967807,8/5/2021,6/14/2022,Interventional,Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Recruiting,Not Applicable,"University Health Network, Toronto",NA,NA,NA,NA,NA,NA,Canada,0,1,Cardiac PET/MRI|Blood Biomarkers,1
NCT04966910,4/6/2021,12/31/2021,Interventional,Stay Connected: Testing an Intervention to Combat COVID-19 Related Social Isolation Among Seattle-area Older Adults,Recruiting,Not Applicable,University of Washington,NA,NA,NA,NA,NA,NA,United States,0,0,Stay Connected|Treatment as usual,0
NCT04962308,6/19/2021,8/19/2021,Interventional,Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,Recruiting,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,3,SARS-CoV-2 Inactivated Vaccine|The SARS-CoV-2 Inactivated Vaccine,1
NCT04964154,2/17/2021,3/30/2022,Interventional,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Recruiting,Not Applicable,North Carolina Central University,NA,NA,NA,NA,NA,NA,United States,0,0,Protect Your Elders Campaign,1
NCT04964414,9/30/2021,12/31/2023,Interventional,Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19,Recruiting,Phase 1/Phase 2,University of Pittsburgh,NA,NA,NA,NA,NA,NA,United States,0,3,Smell Retraining|Budesonide,0
NCT04962906,7/5/2021,8/5/2021,Interventional,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,Completed,Phase 2,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,NA,NA,NA,NA,NA,Argentina,0,1,Gam-COVID-Vac / Gam-COVID-Vac,1
NCT04962893,6/26/2021,12/31/2021,Interventional,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,Recruiting,Phase 2,The Scientific and Technological Research Council of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,1,SARS-CoV-2 VLP Vaccine-Wuhan|SARS-CoV-2 VLP Vaccine-Alpha (British) variant|SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant,1
NCT04964583,1/20/2021,8/31/2021,Interventional,Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19,Recruiting,Phase 2/Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,1,Hydroxychloroquine with Azithromycin,0
NCT04961333,4/23/2021,12/31/2021,Interventional,Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome,Recruiting,Not Applicable,Danderyd Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,0,Multidisciplinary Rehabilitation,0
NCT04961359,7/3/2021,11/30/2021,Interventional,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),Recruiting,Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,1,Recombinant new coronavirus vaccine (CHO cell) group|Recombinant new coronavirus vaccine (CHO cells) placebo group,1
NCT04961502,3/11/2021,8/31/2021,Interventional,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Recruiting,Not Applicable,GÃ©rond'if,NA,NA,NA,NA,NA,NA,France,0,0,Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly,1
NCT04958863,1/1/2021,3/31/2021,Interventional,Impact of Facemasks on Running During COVID-19 Pandemic,Completed,Not Applicable,Fundacion Clinica Valle del Lili,NA,NA,NA,NA,NA,NA,Colombia,0,0,Surgical mask|Polyester reusable mask,0
NCT04959786,4/1/2021,11/30/2022,Interventional,MANS-NRIZ Trial for COVID-19 Treatment : Extension Study,Recruiting,Phase 2/Phase 3,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,0,"Ivermectin,ribavirin ,nitazoxanide and zinc",0
NCT04957017,8/15/2020,1/25/2021,Interventional,Effect of Hand-Washing Training in Covid-19,Completed,Not Applicable,Mehmet Akif Ersoy University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Training,0
NCT04957940,7/5/2021,9/20/2021,Interventional,Lipid Emulsion Infusion and COVID-19 Patients,Completed,Phase 3,Assiut University,NA,NA,NA,NA,NA,NA,Egypt,0,2,SMOFlipid|0.9% saline,0
NCT04954118,3/20/2020,3/20/2020,Interventional,A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation,Completed,Not Applicable,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,Internal jugular vein cannulation,0
NCT04954469,6/30/2021,2/1/2022,Interventional,B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,Recruiting,Phase 1/Phase 2,University Hospital Tuebingen,NA,NA,NA,NA,NA,NA,Germany,0,0,CoVAC-1,1
NCT04954092,7/5/2021,11/6/2022,Interventional,Study of Gam-COVID-Vac in Adolescents,Recruiting,Phase 2/Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Gam-COVID-vac M|Placebo,1
NCT04954014,9/1/2020,8/31/2021,Interventional,Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients,Terminated,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,"Lack of financing, lack of COVID19 patients in the ICU.",NA,NA,NA,NA,NA,Spain,0,1,Bevacizumab|BAT,0
NCT04954040,2/10/2021,10/31/2021,Interventional,Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19,Recruiting,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,NA,NA,NA,NA,NA,Spain,0,0,Hydroxychloroquine Pill + Azithromycin Pill|SOC,0
NCT04953325,7/9/2021,12/31/2021,Interventional,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine,Recruiting,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,Inactivated COVID-19 Vaccine|23-valent pneumococcal polysaccharide vaccine|Inactivated Hepatitis A Vaccine,1
NCT04952766,3/29/2021,3/31/2022,Interventional,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Recruiting,Phase 4,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,NA,NA,NA,NA,NA,France,0,1,Biological samples,1
NCT04952805,6/6/2021,3/31/2022,Interventional,Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.,Recruiting,Phase 2/Phase 3,Toscana Life Sciences Sviluppo s.r.l.,NA,NA,NA,NA,NA,NA,Italy,0,1,MAD0004J08|Placebo,0
NCT04952727,8/26/2021,11/26/2021,Interventional,Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults,Recruiting,Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,4,Recombinant SARS-CoV-2 Ad5 vectored vaccine|Inactive SARS-CoV-2 vaccine (Vero cell),1
NCT04894617,6/1/2021,1/31/2022,Interventional,Amantadine for COVID-19,Recruiting,Phase 3,"Copenhagen University Hospital, Hvidovre",NA,NA,NA,NA,NA,NA,Denmark,0,2,Lactose monohydrate|Amantadine,0
NCT04952519,3/30/2021,2/28/2022,Interventional,Efficacy of Amantadine Treatment in COVID-19 Patients,Recruiting,Phase 3,Noblewell,NA,NA,NA,NA,NA,NA,Poland,0,0,Amantadine,0
NCT04953234,2/23/2021,4/26/2021,Interventional,"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge",Completed,Not Applicable,NovoCure Ltd.,NA,NA,NA,NA,NA,NA,Israel,0,0,NovoTTF-100L,0
NCT04951362,4/20/2021,9/12/2021,Interventional,Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia,Recruiting,Phase 2/Phase 3,South Valley University,NA,NA,NA,NA,NA,NA,Egypt,0,1,ivermectin nasal spray,0
NCT04951349,1/21/2021,5/30/2021,Interventional,Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.,Completed,Phase 2,Turn Therapeutics,NA,NA,NA,NA,NA,NA,Panama,0,0,GX-03|Petrolatum ointment,0
NCT04950803,6/25/2021,5/31/2025,Interventional,A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients,Recruiting,Not Applicable,Chinese University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Microbiome immunity formula|Active placebo,0
NCT04950725,7/27/2021,5/12/2022,Interventional,Covid-19 Virtual Recovery Study,Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,1,Strength RMT|Strength RMT and nasal breathing|Endurance RMT|Endurance RMT and nasal breathing|Low dose RMT,0
NCT04948203,7/9/2021,6/30/2022,Interventional,Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis,Recruiting,Phase 2/Phase 3,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,3,Sirolimus,0
NCT04947488,6/18/2021,9/18/2021,Interventional,Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital,Recruiting,Not Applicable,University of Milan,NA,NA,NA,NA,NA,NA,Italy,0,1,Bioarginina C,0
NCT04945356,10/28/2020,10/31/2021,Interventional,Telerehabilitation During Pandemic Containment Measures of COVID19,Recruiting,Not Applicable,UniversitÃ© de Sherbrooke,NA,NA,NA,NA,NA,NA,Canada,0,0,upper limb training,0
NCT04945811,4/1/2020,5/15/2021,Interventional,Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Completed,Not Applicable,"Combined Military Hospital, Pakistan",NA,NA,NA,NA,NA,NA,Pakistan,0,0,Interlukein 6 and procalcitonin serum levels,0
NCT04945564,6/30/2021,8/30/2021,Interventional,Covid-19 Patients Management During Home Isolation,"Active, not recruiting",Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,2,Oxygen therapy and physical therapy|Oxygen therapy,0
NCT04944368,5/30/2021,7/19/2021,Interventional,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"Active, not recruiting",Phase 2,Cinnagen,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",0,3,SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|Saline placebo,1
NCT04944121,6/25/2021,3/31/2022,Interventional,Phase 2 Study of RSLV-132 in Subjects With Long COVID,Recruiting,Phase 2,Resolve Therapeutics,NA,NA,NA,NA,NA,NA,United States,0,1,RSLV-132|Sodium Chloride 0.9%,0
NCT04942990,4/1/2021,6/21/2021,Interventional,The Effectiveness of Calistenic Exercise Training in Adolescents,Completed,Not Applicable,Baskent University,NA,NA,NA,NA,NA,NA,Turkey,0,1,calisthenic exercises,0
NCT04942392,9/4/2020,12/3/2020,Interventional,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic,Completed,Not Applicable,UmeÃ¥ University,NA,NA,NA,NA,NA,NA,Sweden,0,0,Digital dance for PD,0
NCT04941183,4/14/2021,11/30/2021,Interventional,"Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients",Recruiting,Phase 1,Neutrolis,NA,NA,NA,NA,NA,NA,Austria,0,0,NTR-441|Placebo,0
NCT04941105,6/1/2021,7/31/2021,Interventional,Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19,Recruiting,Phase 3,Collegium Medicum w Bydgoszczy,NA,NA,NA,NA,NA,NA,Poland,0,0,Evolocumab|Saline solution,0
NCT04939519,3/29/2021,9/22/2022,Interventional,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers,"Active, not recruiting",Not Applicable,University of Utah,NA,NA,NA,NA,NA,NA,United States,0,1,Text-Messaging (TM)|Patient Navigation (PN),1
NCT04939714,6/7/2021,12/31/2021,Interventional,Caregiving During Crisis,Recruiting,Not Applicable,Emory University,NA,NA,NA,NA,NA,NA,United States,0,0,Psychoeducational Intervention,0
NCT04939532,3/29/2021,9/30/2022,Interventional,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers,"Active, not recruiting",Not Applicable,University of Utah,NA,NA,NA,NA,NA,NA,United States,0,1,Text-Messaging (TM)|Patient Navigation (PN),0
NCT04940182,6/26/2021,12/31/2021,Interventional,A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19,Recruiting,Phase 3,RSV Therapeutics LLC,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,XC221|Placebo,0
NCT04939402,5/5/2021,5/31/2022,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,0,Serological testing,1
NCT04939415,7/1/2021,7/1/2022,Interventional,Chinese Herbal Formula for COVID-19,Recruiting,Phase 1,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,2,mQFPD|organic brown rice,0
NCT04936503,6/18/2020,3/2/2021,Interventional,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Completed,Not Applicable,"University Hospital, Bordeaux",NA,NA,NA,NA,NA,NA,France,0,0,Resting electrocardiogram|Stress test|Cardiac echocardiography|Cardiac rhythm monitoring|Questionnaire|Injected Cardiac MRI|Blood sampling for biobank,0
NCT04936893,5/19/2020,3/31/2021,Interventional,Effects of Mindfulness Practice on Healthcare Workers,"Active, not recruiting",Not Applicable,Yale-NUS College,NA,NA,NA,NA,NA,NA,Singapore,0,0,Mindfulness Practice|Cognitive training,0
NCT04935515,4/15/2021,5/9/2021,Interventional,C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.,Completed,Not Applicable,UR Anoop Research Group,NA,NA,NA,NA,NA,NA,India,0,0,"Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral low dose steroid|Intravenous Antibiotics with Low dose steroid.|Oral anti-coagulant",0
NCT04935528,6/2/2021,6/2/2022,Interventional,Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Recruiting,Not Applicable,Centre Georges Francois Leclerc,NA,NA,NA,NA,NA,NA,France,0,0,serology and ELISPOT test|serology,1
NCT04935437,1/21/2021,9/1/2021,Interventional,Implementing a Rehabilitation Program in Patients Recovering From Covid-19 Infection,Recruiting,Not Applicable,Evangelismos Hospital,NA,NA,NA,NA,NA,NA,Greece,0,0,Supervised rehabilitation program.,0
NCT04935502,3/15/2021,8/30/2021,Interventional,Home Based Exercises With and Without Posture and Ergonomics Training Among Students During COVID-19,Completed,Not Applicable,Riphah International University,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Home based exercises with postural and ergonomic training|Home based exercises,0
NCT04933864,4/24/2020,5/20/2020,Interventional,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,Completed,Phase 1,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Methylene Blue and Photodynamic Therapy,0
NCT04933799,1/6/2021,3/6/2022,Interventional,IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.,Recruiting,Phase 2,Bronx-Lebanon Hospital Center Health Care System,NA,NA,NA,NA,NA,NA,United States,0,0,PF-06650833|Matching Placebo,0
NCT04933929,3/5/2021,12/31/2021,Interventional,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization,Recruiting,Not Applicable,GÃ©rond'if,NA,NA,NA,NA,NA,NA,France,0,0,Post-hospitalization nutritional monitoring,0
NCT04932850,3/1/2021,10/31/2021,Interventional,Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.,"Active, not recruiting",Phase 1,Toscana Life Sciences Sviluppo s.r.l.,NA,NA,NA,NA,NA,NA,Italy,0,0,MAD0004J08|Placebo,0
NCT04932824,1/19/2021,5/31/2023,Interventional,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,Recruiting,Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,NA,NA,NA,NA,NA,Australia,0,0,SCB-2019,1
NCT04932369,3/1/2020,2/1/2021,Interventional,"The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt",Completed,Not Applicable,British University In Egypt,NA,NA,NA,NA,NA,NA,Egypt,0,2,Emotion Regulation training based on DBT,0
NCT04930874,6/22/2021,12/16/2021,Interventional,Cerebral Autoregulation and COVID-19,Recruiting,Not Applicable,University of Athens,NA,NA,NA,NA,NA,NA,Greece,0,1,NIRS (Near-Infrared Spectroscopy),0
NCT04930003,6/15/2021,12/31/2021,Interventional,"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","Active, not recruiting",Phase 1/Phase 2,Research Institute for Biological Safety Problems,NA,NA,NA,NA,NA,NA,Kazakhstan,0,1,QazCoVac-P -COVID-19 Subunit Vaccine|Placebo,1
NCT04928456,6/11/2021,9/1/2022,Interventional,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps,Recruiting,Not Applicable,Western University of Health Sciences,NA,NA,NA,NA,NA,NA,United States,0,0,Osteopathic Manipulative Treatment (OMT),1
NCT04926779,5/24/2021,9/20/2021,Interventional,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test",Recruiting,Not Applicable,Mach-E B.V.,NA,NA,NA,NA,NA,NA,United States,0,0,Biozek Covid-19 Antigen Rapid Test (Saliva),0
NCT04927845,5/19/2021,5/31/2022,Interventional,StriveWeekly Trial Post-pandemic,Enrolling by invitation,Not Applicable,Harvard University,NA,NA,NA,NA,NA,NA,United States,0,1,StriveWeekly,0
NCT04926428,12/25/2020,3/30/2021,Interventional,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,Completed,Not Applicable,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,NA,NA,NA,NA,NA,Mexico,0,1,tPA,0
NCT04922827,6/18/2021,9/30/2022,Interventional,Infliximab in the Treatment of Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Jena University Hospital,NA,NA,NA,NA,NA,NA,Germany,0,2,Infliximab|Standard of Care,0
NCT04923061,4/6/2021,6/30/2021,Interventional,The Effect of Acupressure on the Sleep Quality and Fatigue,Recruiting,Not Applicable,Mersin University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Acupressure|Sham acupressure group,0
NCT04922957,9/30/2021,6/30/2022,Interventional,"A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,Phase 2,Enlivex Therapeutics Ltd.,NA,NA,NA,NA,NA,NA,Israel,0,2,ALLOCETRA-OTS|Placebo,0
NCT04922918,10/1/2020,6/24/2021,Interventional,Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home,Recruiting,Not Applicable,Universidad Complutense de Madrid,NA,NA,NA,NA,NA,NA,Spain,0,0,Ligilactobacillus salivarius MP101,0
NCT04922788,6/7/2021,7/7/2022,Interventional,"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19",Recruiting,Phase 3,Nanogen Pharmaceutical Biotechnology Joint Stock Company,NA,NA,NA,NA,NA,NA,Vietnam,0,0,Nanocovax|Placebo,1
NCT04920838,4/12/2021,12/31/2021,Interventional,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,"ANRS, Emerging Infectious Diseases",NA,NA,NA,NA,NA,NA,Burkina Faso|Guinea,0,0,Nitazoxanide and CiclÃ©sonide|Telmisartan 20Mg Oral Tablet|Paracetamol,0
NCT04920773,5/3/2021,5/21/2021,Interventional,Community-based Post-exposure Prophylaxis for COVID-19,Completed,Not Applicable,NMP Medical Research Institute,NA,NA,NA,NA,NA,NA,India,0,0,Guduchi Ghanvati|Standard guidelines,0
NCT04920916,5/25/2021,8/14/2022,Interventional,Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients,Recruiting,Phase 2,University of Virginia,NA,NA,NA,NA,NA,NA,United States,0,1,Dupilumab|Placebo,0
NCT04918940,5/21/2021,8/21/2021,Interventional,Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma,Recruiting,Not Applicable,Centre Henri Becquerel,NA,NA,NA,NA,NA,NA,France,0,0,Determination of COVID-19 vacciantion efficacy,1
NCT04918914,10/18/2020,12/31/2021,Interventional,Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment,Recruiting,Early Phase 1,Hunt Regional Medical Center,NA,NA,NA,NA,NA,NA,United States,0,0,Dapsone 100 MG,0
NCT04918797,5/26/2021,8/15/2021,Interventional,COVAXIN in a Pediatric Cohort,Recruiting,Phase 2/Phase 3,Bharat Biotech International Limited,NA,NA,NA,NA,NA,NA,India,0,1,COVAXIN,1
NCT04916886,6/3/2021,5/31/2022,Interventional,A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.,Recruiting,Not Applicable,CanSino Biologics Inc.,NA,NA,NA,NA,NA,NA,China,0,0,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml,1
NCT04916821,5/15/2021,7/15/2021,Interventional,Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19),"Active, not recruiting",Not Applicable,Trabzon Kanuni Education and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,propolis,0
NCT04915820,5/29/2021,9/9/2021,Interventional,Iron and COVID-19 Vaccine Response,Completed,Not Applicable,Jomo Kenyatta University of Agriculture and Technology,NA,NA,NA,NA,NA,NA,Kenya,0,3,Ferinject,1
NCT04916574,3/20/2021,3/28/2021,Interventional,Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Completed,Not Applicable,Icosagen Cell Factory,NA,NA,NA,NA,NA,NA,Estonia,0,1,Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum,0
NCT04915989,2/16/2021,7/31/2021,Interventional,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","Active, not recruiting",Phase 1,"Genexine, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,GX-19N,1
NCT04914767,3/1/2021,10/30/2021,Interventional,Nigella 5 in the Treatment of SARS COV2 (COVID-19),Recruiting,Phase 1,HÃ´pital Universitaire Sahloul,NA,NA,NA,NA,NA,NA,Tunisia,0,0,Nigella|Placebo,0
NCT04914377,6/8/2021,9/30/2021,Interventional,To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants,Recruiting,Phase 2,Novatek Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,3,TQ Formula/Tab,0
NCT04913740,6/1/2021,9/1/2021,Interventional,Nursing Study of Skin Lesions Related to Health Care Protection in Novel Nursing Study of Skin Lesions Related to Health Care Protection in Novel Coronavirus Epidemic,"Active, not recruiting",Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,NA,NA,NA,NA,NA,China,0,0,Ointment and dressing for external use,0
NCT04913779,6/1/2021,11/30/2021,Interventional,Safety and Effectiveness of an Immunobiological Drug in CoViD-19,Recruiting,Phase 2/Phase 3,Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran,NA,NA,NA,NA,NA,NA,Argentina,0,2,Anti-SARS-CoV-2|Placebo,0
NCT04912895,4/14/2021,12/31/2022,Interventional,Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19,Recruiting,Not Applicable,Emory University,NA,NA,NA,NA,NA,NA,United States,0,0,PneumoniaCheck,0
NCT04912011,1/1/2021,8/31/2021,Interventional,Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.,Recruiting,Phase 4,Pomeranian Medical University Szczecin,NA,NA,NA,NA,NA,NA,Poland,0,1,Canrenoate Potassium|Normal Saline,0
NCT04910932,6/10/2021,9/14/2021,Interventional,"Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic",Completed,Not Applicable,Izmir Bakircay University,NA,NA,NA,NA,NA,NA,Turkey,0,3,Breathing Exercises|Information on COVID-19,0
NCT04910516,4/10/2021,5/25/2021,Interventional,Emotional Freedom Technique (EFT) Effect on Nurses,"Active, not recruiting",Not Applicable,Marmara University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Emotional Freedom Techniques (EFT),0
NCT04910542,3/9/2021,11/12/2021,Interventional,Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing,Recruiting,Not Applicable,"Ponce Medical School Foundation, Inc.",NA,NA,NA,NA,NA,NA,Puerto Rico,0,0,Epi-Net Intervention,0
NCT04910191,5/27/2020,12/31/2021,Interventional,Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients,Recruiting,Not Applicable,Sanolla,NA,NA,NA,NA,NA,NA,Israel,0,0,Electronic stethoscope,0
NCT04909996,5/20/2021,7/31/2021,Interventional,Study on the Performance and Safety of Sentinox in COVID-19 Patients,Recruiting,Not Applicable,APR Applied Pharma Research s.a.,NA,NA,NA,NA,NA,NA,Italy,0,0,Sentinox--Group A|Sentinox--Group B,0
NCT04909918,5/28/2021,8/15/2021,Interventional,Impact of Steroids on Inflammatory Response in Covid-19,Completed,Phase 3,Assiut University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Dexamethasone|Methylprednisolone,0
NCT04907331,5/10/2021,11/30/2021,Interventional,Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2,Recruiting,Phase 2,Medical University Innsbruck,NA,NA,NA,NA,NA,NA,Austria,0,1,Vaxzevria|Comirnaty,1
NCT04904510,11/20/2020,3/9/2021,Interventional,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test,Completed,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,0,Rapid antigen testing and offsite PCR testing|Rapid antigen testing and onsite PCR testing,0
NCT04904783,6/1/2021,12/31/2021,Interventional,Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study,Recruiting,Not Applicable,Mahatma Gandhi Institute of Medical Sciences,NA,NA,NA,NA,NA,NA,India,0,4,Low dose radiotherapy,0
NCT04904497,4/1/2021,12/1/2021,Interventional,Early Occupational Therapy in Mechanical Ventilated Patients With Covid-19,Recruiting,Not Applicable,University of Chile,NA,NA,NA,NA,NA,NA,Chile,0,0,Early Occupational Therapy,0
NCT04902911,4/13/2021,3/17/2022,Interventional,Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Recruiting,Not Applicable,Medical College of Wisconsin,NA,NA,NA,NA,NA,NA,United States,0,1,COVID-19 SARS-CoV IgG/IgM antibody rapid test,0
NCT04903184,12/9/2020,9/30/2021,Interventional,Exploratory Study to Evaluate the Efficacy of RUTIÂ® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,Phase 2,RUTI Immunotherapeutics S.L.,NA,NA,NA,NA,NA,NA,Argentina,0,1,RUTIÂ® vaccine|Placebo,0
NCT04901676,9/9/2021,1/31/2022,Interventional,Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia,Recruiting,Phase 3,Hospital Israelita Albert Einstein,NA,NA,NA,NA,NA,NA,Brazil,0,2,Leronlimab|Placebo,0
NCT04902976,4/4/2021,5/31/2021,Interventional,Evaluation of SARS-COV-2 Viral Load of Covid-19 Patients After Rinsing With Oral Antimicrobial Mouthwashes,Recruiting,Not Applicable,Hospital Israelita Albert Einstein,NA,NA,NA,NA,NA,NA,Brazil,0,1,CPC+ZN|CPC|Negative Control,0
NCT04902183,6/9/2021,9/1/2021,Interventional,Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19,Recruiting,Phase 2,Athens Medical Society,NA,NA,NA,NA,NA,NA,Greece,0,1,CovenD24,0
NCT04901624,6/29/2021,4/30/2022,Interventional,Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities,Enrolling by invitation,Not Applicable,University of Southern California,NA,NA,NA,NA,NA,NA,United States,0,1,Family Risk Messaging|Personal Risk Messaging|Loss Protection|Lottery Incentive,0
NCT04900961,6/1/2021,4/30/2023,Interventional,CISCO-21 Prevent and Treat Long COVID-19.,Recruiting,Not Applicable,NHS Greater Glasgow and Clyde,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Resistance Exercise,0
NCT04900428,7/18/2021,1/31/2022,Interventional,Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPSâ„¢) in Outpatient Adults With COVID-19 (UK),Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United Kingdom,0,3,COVI-DROPS|Placebo,0
NCT04900467,5/28/2021,7/2/2021,Interventional,Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine,"Active, not recruiting",Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Pfizer|Moderna,1
NCT04900415,7/22/2020,3/12/2021,Interventional,Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction,Recruiting,Phase 2,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Vitamin A|Electronic portable aromatic rehabilitation (EPAR) diffuser,0
NCT04900337,2/9/2021,12/31/2021,Interventional,"Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.",Recruiting,Phase 1/Phase 2,Amorphical Ltd.,NA,NA,NA,NA,NA,NA,Israel,0,0,AMOR 18 Powder & Inhalation|Placebo,0
NCT04900454,8/2/2021,10/31/2022,Interventional,Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19,Recruiting,Phase 1,"Deverra Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,2,DVX201,0
NCT04900155,11/20/2020,1/31/2022,Interventional,Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19,Recruiting,Not Applicable,Penza State University,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Atorvastatin 80mg|Atorvastatin-Ezetimibe,0
NCT04900129,12/1/2020,12/30/2020,Interventional,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Completed,Phase 1,Sher-E-Bangla Medical College,NA,NA,NA,NA,NA,NA,Bangladesh,0,0,"Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%",0
NCT04899245,5/4/2021,8/31/2022,Interventional,ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff,Enrolling by invitation,Not Applicable,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,2,BinaxNOW Rapid Antigen System,0
NCT04898205,1/21/2021,1/20/2022,Interventional,Cardiopulmonary Rehabilitation in COVID-19 Longhaulers,Recruiting,Not Applicable,Pulmonary Wellness Foundation,NA,NA,NA,NA,NA,NA,United States,0,1,Treadmill Exercise|Concentrated Oxygen|Concentrated Air,0
NCT04898088,1/1/2020,8/30/2020,Interventional,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,Completed,Not Applicable,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,NA,NA,NA,NA,NA,Turkey,0,0,Mesenchymal Stem Cells Transplantation,0
NCT04898062,5/5/2021,6/30/2022,Interventional,"CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19",Recruiting,Not Applicable,"University Hospital, Essen",NA,NA,NA,NA,NA,NA,Germany,0,1,CRP-apheresis,0
NCT04896710,5/26/2021,8/31/2021,Interventional,COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample,Enrolling by invitation,Not Applicable,University of British Columbia,NA,NA,NA,NA,NA,NA,Canada,0,3,SD Biosensor,0
NCT04896853,5/18/2021,9/30/2024,Interventional,Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTransÂ®,Recruiting,Phase 1,NextCell Pharma Ab,NA,NA,NA,NA,NA,NA,Sweden,0,0,ProTransÂ®,0
NCT04896788,5/19/2021,11/1/2023,Interventional,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Recruiting,Not Applicable,"University Hospital, Clermont-Ferrand",NA,NA,NA,NA,NA,NA,France,0,1,Monitoring of the immune response,1
NCT04895085,4/27/2021,7/31/2022,Interventional,"ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance","Active, not recruiting",Not Applicable,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,2,BinaxNOW Rapid Antigen System,0
NCT04894435,5/20/2021,3/31/2023,Interventional,Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity,Recruiting,Phase 2,Canadian Immunization Research Network,NA,NA,NA,NA,NA,NA,Canada,0,2,"mRNA-1273 SARS-CoV-2 vaccine|BNT162b2|ChAdOx1-S [recombinant]|0, 28 day schedule|0, 112 day schedule",1
NCT04894409,4/24/2020,6/30/2020,Interventional,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,Completed,Not Applicable,"Cluster de Bioeconomia de Baja California, A.C",NA,NA,NA,NA,NA,NA,Mexico,0,0,Mouthwash and nose rinse with the AgNPs solution|Mouthwashes and nose rinse in a conventional way,0
NCT04894227,5/11/2021,5/11/2021,Interventional,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,2,Inactivated SARS-CoV-2 Vaccine (Vero cellï¼‰,1
NCT04893512,6/30/2021,10/5/2021,Interventional,First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects,Recruiting,Phase 1,Syneos Health,NA,NA,NA,NA,NA,NA,New Zealand,0,3,Orally Suspension of CoV2-OGEN1,0
NCT04892979,10/1/2020,3/31/2022,Interventional,3R Rehabilitation Management of COVID-19 Survivors,Recruiting,Not Applicable,The Hong Kong Polytechnic University,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Cardiopulmonary exercise (centre-based)|Cardiopulmonary exercise (online-based),0
NCT04892459,5/25/2021,7/25/2021,Interventional,Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector),"Active, not recruiting",Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,3,Recombinant SARS-CoV-2 Ad5 vectored vaccine|Inactive SARS-CoV-2 vaccine (Vero cell),1
NCT04890626,4/4/2020,11/30/2021,Interventional,Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19,Recruiting,Phase 3,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,NA,NA,NA,NA,NA,Spain,0,1,Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Baricitinib + dexamethasone|Dexamethasone,0
NCT04891172,8/1/2021,3/1/2022,Interventional,Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients,Recruiting,Phase 2/Phase 3,Dow University of Health Sciences,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Anti COVID 19 Intravenous Immunoglobulin (C-IVIG),0
NCT04891302,3/19/2021,7/31/2021,Interventional,The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19,Recruiting,Phase 2,Bukwang Pharmaceutical,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,Clevudine|Placebo,0
NCT04890483,5/17/2021,5/17/2021,Interventional,tDCS in Post-Acute COVID-19 Patients With SARDs,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Transcranial direct current stimulation,0
NCT04888949,6/15/2021,9/30/2022,Interventional,A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,"Rohto Pharmaceutical Co., Ltd.",NA,NA,NA,NA,NA,NA,Japan,0,3,Mesenchymal stem cell|Placebo,0
NCT04889040,4/28/2021,11/17/2021,Interventional,Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19,Recruiting,Phase 3,"Atea Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,Argentina|Belgium|Brazil|Bulgaria|Chile|Colombia|Costa Rica|Croatia|Denmark|France|Germany|Greece|Hungary|India|Italy|Japan|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|South Africa|Spain|Switzerland|Turkey|Ukraine|United Kingdom,0,3,RO7496998|Placebo,0
NCT04887350,8/9/2021,8/8/2022,Interventional,SSIPP vs. PST vs. WLC,Recruiting,Phase 1,Lawson Health Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,1,Student-Senior Isolation Prevention Partnership (SSIPP)|Problem Solving Therapy (PST).,0
NCT04887129,5/3/2021,12/31/2022,Interventional,Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD),Recruiting,Not Applicable,University of Rochester,NA,NA,NA,NA,NA,NA,United States,0,0,COVID-19 RT-PCR test|COVID-19 Vaccine Education Campaign,0
NCT04885491,5/7/2021,7/15/2021,Interventional,"A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH",Recruiting,Phase 1/Phase 2,Attgeno AB,NA,NA,NA,NA,NA,NA,Sweden,0,1,Placebo|PDNO,0
NCT04885764,2/23/2021,10/1/2021,Interventional,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Recruiting,Phase 2/Phase 3,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Astrazeneca/Oxford Vaccine|Sinopharm vaccine,1
NCT04885361,5/26/2021,9/30/2021,Interventional,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults",Recruiting,Phase 1,OSE Immunotherapeutics,NA,NA,NA,NA,NA,NA,Belgium,0,1,CoVepiT (OSE13E),1
NCT04884776,6/1/2021,5/31/2024,Interventional,Modulation of Gut Microbiota to Enhance Health and Immunity,Recruiting,Not Applicable,Chinese University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,2,Microbiome immunity formula|Active placebo,0
NCT04884685,5/3/2021,8/1/2021,Interventional,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"Active, not recruiting",Phase 2,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,3,SARS-CoV-2 Inactivated Vaccine|Placebo,1
NCT04884529,9/1/2021,12/31/2021,Interventional,Virtual Chair Yoga for Older Adults and Caregivers: Randomized Controlled Trial,Recruiting,Not Applicable,Lady Davis Institute,NA,NA,NA,NA,NA,NA,Canada,0,2,Chair-yoga program,0
NCT04883528,8/6/2021,8/30/2022,Interventional,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,Recruiting,Phase 1/Phase 2,Duke University,NA,NA,NA,NA,NA,NA,United States,0,1,Sacubitril / Valsartan Oral Tablet [Entresto]|Placebo,0
NCT04883203,4/22/2020,9/30/2020,Interventional,The Effect of Vitamin D Supplementation on COVID-19 Recovery,Completed,Phase 3,University of Monastir,NA,NA,NA,NA,NA,NA,Tunisia,0,0,Vit-D 0.2 MG/ML Oral Solution [Calcidol]|Physiological Irrigating Solution,0
NCT04883138,5/24/2021,8/15/2021,Interventional,Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients,Recruiting,Phase 1,"GigaGen, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,GIGA-2050,0
NCT04880694,5/20/2021,11/30/2021,Interventional,A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia,Recruiting,Phase 2,Grand Medical Pty Ltd.,NA,NA,NA,NA,NA,NA,Belgium,0,1,STC3141|STC3141,0
NCT04880174,3/22/2021,3/31/2022,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,NA,NA,Belgium,0,0,serological testing,1
NCT04881227,5/25/2021,5/31/2023,Interventional,The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT),Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,Chatbot on COVID-19 vaccine hesitancy|Control intervention,1
NCT04881214,7/1/2020,7/1/2022,Interventional,"COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program",Recruiting,Not Applicable,"University Hospital, Geneva",NA,NA,NA,NA,NA,NA,Switzerland,0,0,Pulmonary rehabilitation,0
NCT04878809,4/22/2021,6/17/2021,Interventional,"Rapid Screening Circuit of COVID 19 in Schools, Pilot Study",Completed,Not Applicable,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,NA,NA,NA,NA,NA,Spain,0,1,Escola L'HoritzÃ³|Escola John Talabot,0
NCT04880161,5/31/2021,10/31/2021,Interventional,A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID),Recruiting,Phase 1,Ampio Pharmaceuticals. Inc.,NA,NA,NA,NA,NA,NA,United States,0,0,Ampion|Placebo,0
NCT04880135,3/1/2021,8/30/2021,Interventional,Supervised Versus Home Based Exercises Neck and Low Back Pain Among Students Due to Quarantine During COVID-19,Completed,Not Applicable,Riphah International University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,Supervised stretching and strengthening exercise|Home-based stretching and strengthening exercise,0
NCT04880122,8/1/2020,9/30/2020,Interventional,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,Completed,Not Applicable,University Ghent,NA,NA,NA,NA,NA,NA,Belgium,0,0,Dried blood spot and venous blood collection,0
NCT04878042,4/9/2021,6/30/2021,Interventional,COVID-19 Infection Control Using H2O2 Mouth Wash and Nasal Spray,Recruiting,Not Applicable,EPISTATA,NA,NA,NA,NA,NA,NA,Italy,0,0,Hydrogen peroxide|Placebo,0
NCT04878328,7/1/2021,7/1/2026,Interventional,Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO,Recruiting,Not Applicable,Montefiore Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Onsite Point-of-care,0
NCT04877769,4/25/2021,8/31/2021,Interventional,Bronchopulmonary PK of AT-527 (R07496998),Recruiting,Phase 1,"Atea Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United Kingdom,0,0,AT-527,0
NCT04878055,2/14/2021,9/30/2021,Interventional,Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.,Recruiting,Phase 3,DompÃ© Farmaceutici S.p.A,NA,NA,NA,NA,NA,NA,United States|Italy,0,3,Reparixin|Placebo,0
NCT04876417,2/1/2021,2/1/2023,Interventional,tDCS for Post COVID-19 Fatigue,Recruiting,Not Applicable,University of Iowa,NA,NA,NA,NA,NA,NA,United States,0,0,Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation,0
NCT04876560,3/11/2020,10/10/2020,Interventional,Implementation of a CDSS in Oncology Patients During COVID-19,Completed,Not Applicable,"Iaso Maternity Hospital, Athens, Greece",NA,NA,NA,NA,NA,NA,Greece,0,0,Application of CDSS to provide nutritional care in breast cancer patients from home|General lifestyle advice to breast cancer patients by phone,0
NCT04873128,6/10/2021,7/1/2022,Interventional,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Recruiting,Not Applicable,University Hospital Tuebingen,NA,NA,NA,NA,NA,NA,Germany,0,1,Multi-OMICS,1
NCT04872686,4/10/2021,5/31/2021,Interventional,Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx,Recruiting,Phase 3,Bangladesh Reference Institute of Chemical Measurements (BRICM),NA,NA,NA,NA,NA,NA,Bangladesh,0,1,0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|0.6% PVP-I Oral and nasal spray to healthy volunteer|Oral and nasal spray by distilled water to control group,0
NCT04873414,12/1/2020,10/30/2021,Interventional,Convalescent Plasma as Adjunct Therapy for COVID-19,Recruiting,Phase 2/Phase 3,"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",NA,NA,NA,NA,NA,NA,Indonesia,0,3,Convalescent plasma treatment,0
NCT04872712,5/4/2021,4/7/2022,Interventional,Comparing Press and Filiform Needle Acupuncture Effectiveness for Improving Insomnia in COVID-19 Healthcare Workers,Recruiting,Not Applicable,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,1,Press needles|Filiform Needles,0
NCT04871958,3/19/2021,8/31/2021,Interventional,"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward",Enrolling by invitation,Not Applicable,Federico II University,NA,NA,NA,NA,NA,NA,Italy,0,0,"Continuous glucose monitoring (CGM, Dexcom G6)",0
NCT04871633,8/1/2020,11/15/2020,Interventional,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Completed,Not Applicable,King Edward Medical University,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Remdesivir|Conventional,0
NCT04870385,4/11/2021,6/25/2021,Interventional,An Islamic Psychospiritual-Acceptance and Commitment-based Prevention Program for At-risk Young Adults in the COVID-19 Pandemic,"Active, not recruiting",Not Applicable,International Islamic University Malaysia,NA,NA,NA,NA,NA,NA,Malaysia,0,2,5-week prevention program|Control,0
NCT04871828,2/28/2021,9/30/2021,Interventional,The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19),Recruiting,Phase 3,King Abdullah International Medical Research Center,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,1,Leukotriene Receptor Antagonist|Placebo,0
NCT04871815,4/27/2021,6/30/2022,Interventional,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,"Active, not recruiting",Phase 2/Phase 3,"Cellular Sciences, inc.",NA,NA,NA,NA,NA,NA,United States,1,2,sodium pyruvate nasal spray,0
NCT04871737,5/20/2021,8/31/2021,Interventional,Study of a Live rNDV Based Vaccine Against COVID-19,Recruiting,Phase 1,"Laboratorio Avi-Mex, S.A. de C.V.",NA,NA,NA,NA,NA,NA,Mexico,0,1,Recombinant NDV Vectored Vaccine for SARS-CoV-2,1
NCT04871646,6/30/2021,3/31/2022,Interventional,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314,Recruiting,Phase 3,Chong Kun Dang Pharmaceutical,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,2,CKD-314+SOC|CKD-314 Placebo+SOC,0
NCT04870333,2/19/2021,12/31/2021,Interventional,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Niclosamide|Placebo,0
NCT04870164,11/18/2020,1/31/2022,Interventional,"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)",Recruiting,Phase 1,Molecular Partners AG,NA,NA,NA,NA,NA,NA,United Kingdom,0,4,Ensovibep|Placebo,0
NCT04869592,4/25/2021,10/25/2022,Interventional,A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19,Recruiting,Phase 1/Phase 2,"National Vaccine and Serum Institute, China",NA,NA,NA,NA,NA,NA,China,0,1,low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|placebo,1
NCT04868890,4/30/2021,10/31/2021,Interventional,A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,NA,NA,NA,NA,NA,United States,0,0,Ampion|Placebo,0
NCT04869072,4/29/2020,11/30/2020,Interventional,Convalescent Plasma Therapy - Zurich Protocol,Completed,Phase 1,University of Zurich,NA,NA,NA,NA,NA,NA,Switzerland,0,0,Convalescent plasma,0
NCT04868903,11/30/2020,6/30/2022,Interventional,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Recruiting,Not Applicable,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,0,Vitamin D3,0
NCT04869397,6/14/2021,6/30/2022,Interventional,Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells,Recruiting,Phase 2,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,Canada,0,2,Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Placebo,0
NCT04867226,5/8/2021,6/18/2021,Interventional,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,Phase 2,Hawler Medical University,NA,NA,NA,NA,NA,NA,Iraq,0,3,Colchicine 0.5 MG|usual care treatment,0
NCT04867265,5/3/2021,6/2/2021,Interventional,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Completed,Not Applicable,Brno University Hospital,NA,NA,NA,NA,NA,NA,Czechia,0,2,Mout-to-mouth ventilation|Mout-to-mouth ventilation with quantitative analysis,0
NCT04866303,4/26/2021,8/31/2021,Interventional,Protecting Our Community: COVID-19 Testing,Recruiting,Not Applicable,Montana State University,NA,NA,NA,NA,NA,NA,United States,0,2,Home-based SARS-CoV-2 test kit,0
NCT04866069,4/25/2021,10/31/2021,Interventional,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,1,SARS-CoV-2 vaccine|Placebo,1
NCT04865237,3/6/2021,6/3/2022,Interventional,SARS-CoV-2 Human Challenge Characterisation Study,"Active, not recruiting",Not Applicable,Imperial College London,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,SARS-CoV-2 Virus|Remdesivir,0
NCT04865107,4/27/2021,4/30/2022,Interventional,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Recruiting,Phase 2,Ottawa Hospital Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,1,UC-MSCs|Placebo,0
NCT04864899,9/1/2021,3/30/2023,Interventional,Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Recruiting,Not Applicable,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,Cardiac Magnetic Resonance Imaging (CMR)|Blood test|6-minute walk test,0
NCT04864015,3/17/2021,5/15/2021,Interventional,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,Completed,Not Applicable,Universitaire Ziekenhuizen Leuven,NA,NA,NA,NA,NA,NA,Belgium,0,2,"Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable",0
NCT04863638,4/29/2021,3/31/2022,Interventional,"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated",Recruiting,Phase 4,China National Biotec Group Company Limited,NA,NA,NA,NA,NA,NA,China,0,1,"3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine",1
NCT04863131,4/28/2021,1/31/2023,Interventional,Safety and Immunogenicity of EXG-5003,Recruiting,Phase 1/Phase 2,Fujita Health University,NA,NA,NA,NA,NA,NA,Japan,0,1,EXG-5003|Placebo,1
NCT04861298,1/11/2021,8/29/2021,Interventional,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Completed,Not Applicable,King Edward Medical University,NA,NA,NA,NA,NA,NA,Pakistan,0,2,standard of care for COVID-19 as per the hospital guidelines|Quercetin Phytosome (QP),0
NCT04860895,2/11/2021,5/1/2021,Interventional,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,Recruiting,Not Applicable,Fable Biyoteknoloji San ve Tic A.S,NA,NA,NA,NA,NA,NA,Turkey,0,1,AP-23,0
NCT04860271,3/9/2021,4/30/2021,Interventional,Manual Acupuncture Using Acupuncture Needle vs Press Needle for COVID-19 Healthcare Anxiety,Recruiting,Not Applicable,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Manual Acupuncture,0
NCT04860258,4/22/2021,9/21/2021,Interventional,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19",Completed,Phase 3,CureVac AG,NA,NA,NA,NA,NA,NA,Belgium,0,3,CVnCoV Vaccine,1
NCT04860219,7/8/2020,9/18/2020,Interventional,Lactoferrin Use in (SARS-CoV-2) Management,Recruiting,Not Applicable,Zagazig University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Lactoferrin,0
NCT04859023,2/22/2021,2/28/2021,Interventional,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Completed,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,NA,NA,NA,NA,France,0,1,saliva sample combined to an anterior nare self-swabbing (Self-samples)|saliva sample (Self-sample)|Survey of SARS-COV-19 knowledge|Survey of acceptability of the different self-samples.,0
NCT04859244,1/1/2021,5/1/2021,Interventional,First-in-Human Study of Orally Administered GS-441524 for COVID-19,Completed,Phase 1,Copycat Sciences LLC,NA,NA,NA,NA,NA,NA,United States,0,3,GS-441524,0
NCT04858633,3/22/2021,6/30/2021,Interventional,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Recruiting,Phase 3,Postgraduate Institute of Medical Education and Research,NA,NA,NA,NA,NA,NA,India,0,1,Hydroxychloroquine (HCQ)|Standard care|Placebo,0
NCT04858789,6/24/2021,12/31/2021,Interventional,The Effectiveness of a CA-CBI on Psychological Distress of University Students During the COVID-19 Pandemic,Recruiting,Not Applicable,KoÃ§ University,NA,NA,NA,NA,NA,NA,Turkey,0,5,Culturally Adapted Cognitive Behavioral Intervention (CA-CBI),0
NCT04858412,4/1/2021,3/31/2022,Interventional,Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19,Recruiting,Not Applicable,The Cleveland Clinic,NA,NA,NA,NA,NA,NA,United States,0,0,Î²-hydroxy Î²-methyl butyrate (HMB) enriched amino acid|Balanced amino acid,0
NCT04857060,7/1/2021,1/31/2023,Interventional,Palliative Care Educator,Recruiting,Not Applicable,Boston Medical Center,NA,NA,NA,NA,NA,NA,United States,0,3,"ACP Educator led, video assisted discussion",0
NCT04856111,3/17/2021,12/31/2021,Interventional,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,Phase 4,Postgraduate Institute of Medical Education and Research,NA,NA,NA,NA,NA,NA,India,0,1,Pirfenidone|Nintedanib,0
NCT04858542,2/26/2021,5/31/2021,Interventional,Evaluating the Impact of Vocal Health Education on Mask-wearing Workers During COVID-19,Recruiting,Not Applicable,University of Cincinnati,NA,NA,NA,NA,NA,NA,United States,0,0,Educational Vocal Health Modules,0
NCT04854941,12/10/2020,3/10/2021,Interventional,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,Completed,Not Applicable,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Probiotics,0
NCT04854928,5/3/2021,2/28/2022,Interventional,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.,Recruiting,Phase 2,Pharma Holdings AS,NA,NA,NA,NA,NA,NA,Sweden,0,3,"LTX-109 gel, 3%|Placebo gel",0
NCT04854772,5/15/2021,5/31/2022,Interventional,Mind Body Intervention for COVID-19 Long Haul Syndrome,Recruiting,Not Applicable,Beth Israel Deaconess Medical Center,NA,NA,NA,NA,NA,NA,United States,0,1,Mind Body Syndrome Therapy for Long Covid,0
NCT04854382,4/14/2021,11/30/2021,Interventional,Tailored Information About the Coronavirus in Chronic Kidney Disease Patients,Recruiting,Not Applicable,"University Hospital, Akershus",NA,NA,NA,NA,NA,NA,Norway,0,1,Tailored information,0
NCT04854798,4/29/2021,8/31/2021,Interventional,UNITE Study (UMN-SW) for COVID-19,Enrolling by invitation,Not Applicable,University of Minnesota,NA,NA,NA,NA,NA,NA,United States,0,3,Splenic Ultrasound,0
NCT04854759,3/15/2021,3/31/2022,Interventional,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms,Recruiting,Phase 3,Independent Public Clinical Hospital No. 4 in Lublin,NA,NA,NA,NA,NA,NA,Poland,0,2,Amantadine Hydrochloride|Placebo,0
NCT04853979,5/16/2021,8/30/2021,Interventional,Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure,Recruiting,Not Applicable,Hamad Medical Corporation,NA,NA,NA,NA,NA,NA,Qatar,0,1,PRONE POSITION,0
NCT04853927,2/8/2021,10/30/2021,Interventional,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Recruiting,Phase 3,"Applied Biology, Inc.",NA,NA,NA,NA,NA,NA,Brazil,0,1,Proxalutamide|Placebo,0
NCT04853966,4/17/2021,4/17/2022,Interventional,The Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,Recruiting,Not Applicable,Gazi University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Physical activity counseling,0
NCT04853199,6/1/2021,7/30/2021,Interventional,Quercetin In The Treatment Of SARS-COV 2,Recruiting,Early Phase 1,HÃ´pital Universitaire Sahloul,NA,NA,NA,NA,NA,NA,Tunisia,0,3,Quercetin|Placebo,0
NCT04853134,11/1/2020,12/1/2021,Interventional,Proxalutamide Treatment for COVID-19 Female Outpatients,"Active, not recruiting",Phase 3,"Applied Biology, Inc.",NA,NA,NA,NA,NA,NA,Brazil,0,1,Proxalutamide|Standard of Care,0
NCT04853901,7/27/2020,1/1/2021,Interventional,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,Phase 3,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Remdesivir|Standard of care_1|Standard of care_2,0
NCT04851821,1/4/2021,5/30/2021,Interventional,The Effectiveness of Phytotherapy in SARS-COV2(COVID-19),Completed,Phase 1,HÃ´pital Universitaire Sahloul,NA,NA,NA,NA,NA,NA,Tunisia,0,3,Quercetin,0
NCT04849793,4/13/2021,5/13/2021,Interventional,The Effect of Acupressure on the Anxiety Level,Enrolling by invitation,Not Applicable,Mersin University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Acupressure,0
NCT04849637,10/22/2020,6/30/2021,Interventional,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Recruiting,Phase 2,University of the Philippines,NA,NA,NA,NA,NA,NA,Philippines,0,0,Virgin Coconut Oil,0
NCT04847583,7/29/2021,12/31/2021,Interventional,"A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients",Recruiting,Phase 2,"Qurient Co., Ltd.",NA,NA,NA,NA,NA,NA,South Africa,0,2,Telacebec|COVID-19 Standard of care,0
NCT04847661,3/28/2021,7/30/2021,Interventional,"Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial",Recruiting,Phase 2/Phase 3,Helwan University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases,0
NCT04847791,1/14/2021,1/31/2022,Interventional,Lactoferrin in Covid-19 Hospitalized Patients,Recruiting,Not Applicable,Paolo Manzoni,NA,NA,NA,NA,NA,NA,Italy,0,0,Bovine lactoferrin|Placebo administration,0
NCT04847349,4/13/2021,10/13/2021,Interventional,Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial,Recruiting,Not Applicable,"Rutgers, The State University of New Jersey",NA,NA,NA,NA,NA,NA,United States,0,1,"OL-1, standard dose|OL-1, high dose|Placebo",0
NCT04847544,3/31/2021,12/31/2021,Interventional,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.",Recruiting,Phase 2,"Aldeyra Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,0,ADX-629|Placebo,0
NCT04847518,5/26/2021,1/31/2022,Interventional,Assessment of Efficacy of KAN-JANGÂ® in Mild COVID-19,Recruiting,Phase 2/Phase 3,Swedish Herbal Institute AB,NA,NA,NA,NA,NA,NA,Georgia,0,1,Kan Jang capsules|Placebo capsules,0
NCT04847479,5/6/2021,5/10/2022,Interventional,COVID-19 Close Contact Self-Testing Study,Recruiting,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,3,COVID-19 self-test|COVID-19 test referral,0
NCT04845880,10/1/2020,3/1/2021,Interventional,SARS Cov_2 Incidence of Healthy Health Workers,Completed,Not Applicable,Baskent University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2,0
NCT04846790,7/16/2021,12/1/2022,Interventional,The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers,Enrolling by invitation,Not Applicable,National Institutes of Health Clinical Center (CC),NA,NA,NA,NA,NA,NA,United States,0,2,Nature Only|Nature+Mindfulness,0
NCT04846010,3/1/2021,5/1/2022,Interventional,"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2",Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,NA,NA,NA,NA,NA,United States,0,2,PurWet|FurFat|PurApo|PurPhl|PurClo|PurInf|Smoliv,0
NCT04845971,11/5/2020,4/30/2021,Interventional,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Completed,Phase 2,Ospedale del Mare,NA,NA,NA,NA,NA,NA,Italy,0,2,Saisei Maf capsules,0
NCT04844580,3/10/2021,9/30/2022,Interventional,A Clinical Study Evaluating Inhaled Aviptadil on COVID-19,Recruiting,Phase 2,Centurion Pharma,NA,NA,NA,NA,NA,NA,Turkey,0,2,Inhaled Aviptadil|Placebo,0
NCT04844554,6/20/2021,4/12/2022,Interventional,Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS,Recruiting,Not Applicable,Federal University of ParaÃ­ba,NA,NA,NA,NA,NA,NA,Brazil,0,1,HD-tDCS 4mA|HD-tDCS 2mA,0
NCT04844710,9/1/2020,11/15/2020,Interventional,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,Completed,Not Applicable,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,acupuncture and standard care|standard care,0
NCT04844567,11/26/2020,12/31/2021,Interventional,Virtual Reality Intervention to Alleviate Breathlessness (COVID-19),Recruiting,Not Applicable,Ecole Polytechnique FÃ©dÃ©rale de Lausanne,NA,NA,NA,NA,NA,NA,Switzerland,0,0,COVVR,0
NCT04844489,4/16/2021,4/16/2023,Interventional,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19,1
NCT04843930,6/17/2021,7/31/2022,Interventional,Improving Cognitive Health in COVID-19 Survivors,Recruiting,Phase 2,Weill Medical College of Cornell University,NA,NA,NA,NA,NA,NA,United States,0,1,AKL-T01,0
NCT04844346,4/19/2021,8/31/2021,Interventional,Plant Stanol Esters and COVID-19 Vaccination Response,Recruiting,Not Applicable,Maastricht University Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,NA,Plant stanol mini drinks|Placebo mini drinks|COVID-19 vaccine,1
NCT04842708,12/24/2020,10/24/2021,Interventional,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,Not Applicable,Scentech Medical Technologies Ltd,NA,NA,NA,NA,NA,NA,Israel,0,0,vaccination against COVID19,1
NCT04842292,5/20/2021,2/28/2022,Interventional,Nebulized Heparin for COVID19-associated Acute Respiratory Failure,Recruiting,Phase 2,University of Kentucky,NA,NA,NA,NA,NA,NA,United States,0,1,Heparin|Placebo,0
NCT04842448,9/15/2021,12/31/2022,Interventional,Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome,Recruiting,Phase 2,Karolinska University Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,3,Hyperbaric oxygen|Sham treatment,0
NCT04842435,4/12/2021,9/30/2021,Interventional,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19,Recruiting,Phase 2/Phase 3,Microgen,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,COVID-globulin|Placebo,0
NCT04840992,4/20/2021,4/15/2022,Interventional,Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation,Recruiting,Phase 1/Phase 2,CanSino Biologics Inc.,NA,NA,NA,NA,NA,NA,China,0,1,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Placebo for Inhalation|Placebo,1
NCT04842331,4/30/2021,1/31/2022,Interventional,PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT),Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,"RESP301, a Nitric Oxide generating solution",0
NCT04841746,6/2/2021,9/2/2022,Interventional,Efficacy of FES Cycling After a Severe Form of COVID-19,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,2,Physical therapy that include a standardized cycling training with functional electrical stimulation|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation,0
NCT04840459,11/20/2020,12/31/2021,Interventional,Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Recruiting,Phase 2,DHR Health Institute for Research and Development,NA,NA,NA,NA,NA,NA,United States,0,0,BAMLANIVIMAB|CASIRIVIMAB|IMDEVIMAB,0
NCT04839965,5/31/2021,10/31/2021,Interventional,Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,NA,NA,NA,NA,NA,United States,0,3,Ampion|Saline,0
NCT04839315,2/15/2021,12/31/2021,Interventional,COVID-19 Vaccination in Rheumatic Disease Patients,Recruiting,Early Phase 1,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,0,mRNA COVD19 vaccine,1
NCT04838821,3/29/2021,7/29/2021,Interventional,Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Caja Costarricense de Seguro Social,NA,NA,NA,NA,NA,NA,Costa Rica,0,1,Anti SARS-CoV-2 equine hyperimmune serum|placebo,0
NCT04838080,3/19/2021,6/1/2021,Interventional,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,Recruiting,Phase 1,Kocak Farma,NA,NA,NA,NA,NA,NA,Turkey,0,1,KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine 4 Âµg/0.5 ml Vaccine|KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine 6 Âµg/0.5 ml Vaccine|Placebo,1
NCT04836260,4/8/2021,12/31/2021,Interventional,Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19,Recruiting,Phase 3,"University Hospital, Geneva",NA,NA,NA,NA,NA,NA,Switzerland,0,0,SARS-CoV-2 convalescent plasma,0
NCT04834908,6/30/2021,3/31/2022,Interventional,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,Recruiting,Phase 1/Phase 2,Bharat Serums and Vaccines Limited,NA,NA,NA,NA,NA,NA,India,0,2,Equine COVID-19 Antiserum|Standard of care,0
NCT04836052,12/24/2020,8/24/2021,Interventional,Omega-3 Oil Use in COVID-19 Patients in Qatar,Recruiting,Phase 3,Hamad Medical Corporation,NA,NA,NA,NA,NA,NA,Qatar,0,0,Omega 3 fatty acid,0
NCT04836351,3/1/2021,12/30/2023,Interventional,Rehabilitation for Patients With Persistent Symptoms Post COVID-19,Recruiting,Not Applicable,Western Norway University of Applied Sciences,NA,NA,NA,NA,NA,NA,Norway,0,0,Concentrated rehabilitation for patients with persistent symptoms post COVID-19,0
NCT04834856,4/1/2021,8/20/2021,Interventional,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients",Completed,Phase 2,Molecular Partners AG,NA,NA,NA,NA,NA,NA,Netherlands,0,2,ensovibep,0
NCT04834739,1/4/2021,3/28/2021,Interventional,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Completed,Not Applicable,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,1,6 minute walk test|1 minute Sit to Stand Test|Fatigue Severity Scale|Medical Research Council (MRC) dyspnea scale|SF-12|Beck Depression Inventory|Beck Anxiety Inventory|5 times sit to stand test|6 point Likert Scale,0
NCT04834726,4/29/2021,6/4/2021,Interventional,COVID-19 Vaccine Text Outreach,Completed,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,4,Opt-In (Call-Back)|Opt-in (In-Bound)|Standard Message|Clinician Endorsement|Scarcity|Opt-Out Framing|Phone Call,1
NCT04834115,11/17/2020,4/30/2021,Interventional,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Recruiting,Phase 3,Universidad Nacional de AsunciÃ³n,NA,NA,NA,NA,NA,NA,Paraguay,0,0,Ivermectin Tablets|Placebo,0
NCT04833101,4/7/2021,6/15/2021,Interventional,Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,"Active, not recruiting",Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,5,recombinant Ad5 vectored COVID-19 vaccine|RBD-based protein subunit vaccine (ZF2001) against COVID-19|trivalent split influenza vaccine,1
NCT04832919,7/23/2021,5/31/2022,Interventional,A Nurse-Community Health Worker-Family Partnership Model: Addressing Uptake of COVID-19 Testing and Control Measures,Recruiting,Not Applicable,New York University,NA,NA,NA,NA,NA,NA,United States,0,3,Nurse-Community-Family Partnership Intervention,0
NCT04830800,3/10/2021,5/30/2022,Interventional,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,Recruiting,Phase 1/Phase 2,"Institute of Vaccines and Medical Biologicals, Vietnam",NA,NA,NA,NA,NA,NA,Vietnam,0,0,COVIVAC|Phosphate-buffered saline,1
NCT04830020,2/26/2021,8/31/2021,Interventional,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Recruiting,Phase 2,Campus Bio-Medico University,NA,NA,NA,NA,NA,NA,Italy,0,0,HMW-HA,0
NCT04828135,5/26/2021,12/30/2022,Interventional,Dual MRI for Cardiopulmonary COVID-19 Long Haulers,Recruiting,Phase 2,Duke University,NA,NA,NA,NA,NA,NA,United States,0,3,Hyperpolarized 129Xenon gas,0
NCT04826822,2/24/2021,7/8/2021,Interventional,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Recruiting,Phase 3,Chita State Regional Clinical Hospital Number 1,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Spironolactone + Dexamethasone|Standard-of-care SARS-CoV-2 treatment,0
NCT04826367,1/20/2021,12/31/2021,Interventional,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,Recruiting,Not Applicable,Hacettepe University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Telerehabilitation-based relaxation exercise group (EG),0
NCT04824638,3/8/2021,6/29/2021,Interventional,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,"Active, not recruiting",Phase 2,"ANRS, Emerging Infectious Diseases",NA,NA,NA,NA,NA,NA,France,0,1,two doses of BNT162b2 vaccine|one dose of BNT162b2 vaccine,1
NCT04824443,3/29/2021,3/29/2023,Interventional,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,2,Aerobic Exercise Therapy,0
NCT04824365,4/12/2021,5/31/2022,Interventional,Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections,Recruiting,Phase 2/Phase 3,"Cellular Sciences, inc.",NA,NA,NA,NA,NA,NA,United States,0,3,Sodium Pyruvate|Saline,0
NCT04824391,2/10/2021,4/30/2021,Interventional,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19",Recruiting,Phase 2,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,0,ERUCOV-VAC 3 Âµg/0.5 ml Vaccine|ERUCOV-VAC 6 Âµg/0.5 ml Vaccine|Placebo,1
NCT04822285,1/22/2020,4/22/2020,Interventional,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Completed,Not Applicable,Alexandria University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Psychological Triaging Intervention|Routine psychological support,0
NCT04821037,6/1/2021,7/1/2021,Interventional,Nurse Health Pilot: Feasibility and Acceptability of a Virtual ACT-intervention in Nurses During COVID-19,Recruiting,Not Applicable,University of Basel,NA,NA,NA,NA,NA,NA,Switzerland,0,1,ACT,0
NCT04821973,9/22/2020,5/15/2021,Interventional,Respiratory Tele Monitoring COVID 19 (TMR COVID-19),Recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,0,Radius PPG Tetherless Pulse Oximetry (Masimo)|usual monitoring,0
NCT04820803,2/3/2021,4/29/2021,Interventional,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,Completed,Not Applicable,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,NA,NA,NA,NA,NA,Spain,0,1,ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|PLACEBO,0
NCT04818970,5/21/2021,12/31/2021,Interventional,Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients,Recruiting,Not Applicable,"Cytokind, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,Narrow Band ultraviolet B-Band Light|non Narrow Band ultraviolet B-Band Light,0
NCT04818216,6/11/2021,6/30/2022,Interventional,Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection,Recruiting,Phase 2,The University of Texas Health Science Center at San Antonio,NA,NA,NA,NA,NA,NA,United States,0,4,Placebo|Nicotinamide riboside,0
NCT04818281,3/27/2021,1/31/2022,Interventional,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,3,SARS-CoV-2 VLP Vaccine|Placebo,1
NCT04817371,3/1/2021,3/31/2022,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.,Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,1,Canine odor detection of Volatile Organic Compounds|Volatile Organic Compounds analysis (mass spectrometry)|Volatile Organic Compounds analysis in sweat (mass spectrometry)|Volatile Organic Compounds analysis (e-noses),0
NCT04817332,6/5/2020,2/28/2021,Interventional,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,Completed,Phase 3,University of Dundee,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Brensocatib|Placebo,0
NCT04816942,4/23/2020,7/21/2020,Interventional,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,Phase 3,"Ministry of Health and Population, Egypt",NA,NA,NA,NA,NA,NA,Egypt,0,0,Convalescent Plasma,0
NCT04816656,8/3/2020,2/1/2021,Interventional,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,Not Applicable,Jessa Hospital,NA,NA,NA,NA,NA,NA,Belgium,0,1,ePROMs assessment,0
NCT04816084,11/5/2020,12/1/2020,Interventional,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,Completed,Not Applicable,UniversitÃ© de Reims Champagne-Ardenne,NA,NA,NA,NA,NA,NA,France,0,0,Anti-SARS-CoV2 Serology,0
NCT04815096,4/15/2021,3/1/2023,Interventional,Imaging Immune Activation in COVID-19,Recruiting,Early Phase 1,"CellSight Technologies, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,[18F]F-AraG (2'-deoxy-2'-fluoro-9-Î²-D-arabinofuranosylguanine),0
NCT04815057,11/2/2020,11/23/2020,Interventional,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,Completed,Not Applicable,Saglik Bilimleri Universitesi,NA,NA,NA,NA,NA,NA,Turkey,0,3,Wellness Education,0
NCT04813796,3/11/2021,4/13/2022,Interventional,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","Active, not recruiting",Phase 1,"ModernaTX, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,mRNA-1283|mRNA-1273|Placebo,1
NCT04813471,1/20/2021,3/20/2021,Interventional,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH,Recruiting,Phase 3,Lebanese American University Medical Center,NA,NA,NA,NA,NA,NA,Lebanon,0,0,Endothelial Protocol,0
NCT04813718,6/2/2021,5/1/2022,Interventional,Post COVID-19 Syndrome and the Gut-lung Axis,Recruiting,Not Applicable,Medical University of Graz,NA,NA,NA,NA,NA,NA,Austria,0,1,Omni-Biotic Pro Vi 5|Placebo,0
NCT04813562,3/23/2021,7/30/2021,Interventional,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,1,"a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56",1
NCT04811664,3/24/2021,12/22/2021,Interventional,A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,5,Moderna COVID-19 Vaccine,1
NCT04811859,1/10/2021,1/10/2022,Interventional,The Effect of Inspiratory Muscle Training in Post COVID-19 Patients,Recruiting,Not Applicable,Istinye University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Inspiratory Muscle Training,0
NCT04811339,9/2/2020,8/31/2023,Interventional,Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol),Recruiting,Phase 4,University of Louisville,NA,NA,NA,NA,NA,NA,United States,0,1,open label BSS (pepto Bismol),0
NCT04810949,8/5/2020,3/1/2021,Interventional,Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml,Terminated,Not Applicable,Hospital Clinica Nova,patients enrolled got vaccinated vs COVID-19 and Influenza,NA,NA,NA,NA,NA,Mexico,0,0,Vitamine D3 supplementation|Diet and sun exposure,0
NCT04810689,3/1/2021,3/1/2022,Interventional,"Pilot Trial of XFBD, a TCM, in Persons With COVID-19",Recruiting,Phase 2,University of Southern California,NA,NA,NA,NA,NA,NA,United States,0,0,Xuanfei Baidu Granules|Placebo,0
NCT04810637,11/1/2020,6/30/2021,Interventional,A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19,Recruiting,Phase 2,PT Kalbe Genexine Biologics,NA,NA,NA,NA,NA,NA,Indonesia,0,1,GX-I7,0
NCT04809974,7/22/2021,12/31/2022,Interventional,Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID),Recruiting,Phase 4,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Niagen,0
NCT04810728,6/20/2020,12/4/2020,Interventional,Efficacy of Psidii Guava's Extract For COVID-19,Completed,Phase 3,Faculty of Medicine Baiturrahmah University,NA,NA,NA,NA,NA,NA,Indonesia,0,1,Extract Psidii guava|Standard therapy for Covid-19 patient,0
NCT04810065,3/29/2021,7/29/2021,Interventional,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,Completed,Not Applicable,University of Limerick,NA,NA,NA,NA,NA,NA,Ireland,0,2,SingStrong: Strong lungs through Song,0
NCT04809389,3/29/2021,9/30/2022,Interventional,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,"Active, not recruiting",Phase 1,The University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,3,DelNS1-nCoV-RBD LAIV|Matching placebo,0
NCT04809272,3/8/2021,11/1/2021,Interventional,ePLH Pilot Study: Online Support Parent Groups - ParentChat,Recruiting,Not Applicable,University of Oxford,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,ParentChat for parents of children ages 2-17,0
NCT04808882,4/14/2021,12/1/2021,Interventional,ANTIcoagulation in Severe COVID-19 Patients,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,"Tinzaparin, Low dose prophylactic anticoagulation|Tinzaparin, High dose prophylactic anticoagulation|Tinzaparin,Therapeutic anticoagulation",0
NCT04808921,1/9/2021,1/18/2021,Interventional,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Completed,Not Applicable,"Sky Medical Supplies & Equipments, LLC",NA,NA,NA,NA,NA,NA,United States,0,2,"Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test",0
NCT04805931,3/15/2021,5/1/2021,Interventional,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,Not Applicable,VA Puget Sound Health Care System,NA,NA,NA,NA,NA,NA,United States,0,2,Behavioral economics,1
NCT04806113,3/11/2021,6/13/2021,Interventional,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,Canada,0,2,Moderna COVID-19 vaccine,1
NCT04805892,3/17/2021,7/27/2021,Interventional,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.",Recruiting,Not Applicable,Mach-E B.V.,NA,NA,NA,NA,NA,NA,United States,0,1,BIOZEK COVID-19 Antigen Rapid Test,0
NCT04805203,12/16/2020,12/31/2022,Interventional,Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma,Recruiting,Not Applicable,Intergroupe Francophone du Myelome,NA,NA,NA,NA,NA,NA,France,0,0,blood sample analyses,0
NCT04805684,1/1/2021,3/5/2021,Interventional,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Completed,Not Applicable,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,LUS Twelve area|LUS Fourteen area,0
NCT04803227,3/11/2021,4/30/2021,Interventional,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Recruiting,Phase 1,Histogen,NA,NA,NA,NA,NA,NA,United States,0,0,Emricasan|Placebo,0
NCT04805086,3/8/2021,6/1/2022,Interventional,The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Recruiting,Phase 1/Phase 2,Guy's and St Thomas' NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,MON002,0
NCT04803370,7/8/2020,9/1/2021,Interventional,Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma,Recruiting,Not Applicable,Hospital Son Llatzer,NA,NA,NA,NA,NA,NA,Spain,0,0,Convalescent Plasma with antibody against SARS-CoV-2.|Standard treatment for COVID-19,0
NCT04802187,12/1/2020,8/31/2022,Interventional,Implementation of COVID-19 Testing Strategies in Community Health Centers,Recruiting,Not Applicable,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,1,RADx CHCs testing intervention strategy|Usual care control,0
NCT04802382,6/11/2021,12/31/2021,Interventional,Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19,Recruiting,Phase 3,MGC Pharmaceuticals d.o.o,NA,NA,NA,NA,NA,NA,Israel,0,2,Placebo administration|Confirm SARS-CoV-2 infection|Physical Examination|Vital Signs|Hematology blood test|Biochemistry blood test|NEWS score|PK test|blood test for inflammatory markers|D-dimer test|VAS scale|Urine pregnancy test for women of childbearing potential|ECG|COVID-19-Impact on Quality of Life Questionnaire|CimetrA-1|CimetrA-2,0
NCT04801836,11/19/2020,3/4/2022,Interventional,Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection,"Active, not recruiting",Phase 2,NEURALIS s.a.,NA,NA,NA,NA,NA,NA,Belgium|Hungary|Poland|Russian Federation,0,2,Estetrol monohydrate 15 mg|Placebo,0
NCT04801888,3/23/2021,5/28/2021,Interventional,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,Completed,Phase 4,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,"Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.",1
NCT04801940,5/19/2021,1/31/2024,Interventional,HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID),Recruiting,Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Apixaban|Atorvastatin,0
NCT04802018,3/9/2021,11/30/2021,Interventional,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients,"Active, not recruiting",Not Applicable,Increase-Tech,NA,NA,NA,NA,NA,NA,Spain,0,2,Clinical decision support system based on non-invasive multimodal monitoring,0
NCT04801524,2/7/2021,12/31/2021,Interventional,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,1,Self-benefit|Prosocial-benefit|Early access|Fresh start,1
NCT04800939,3/25/2021,5/15/2021,Interventional,The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness,Enrolling by invitation,Not Applicable,Mersin University,NA,NA,NA,NA,NA,NA,Turkey,0,3,Acupressure|Plasebo acupressure,0
NCT04800965,1/31/2021,12/31/2021,Interventional,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,Not Applicable,"University of California, Los Angeles",NA,NA,NA,NA,NA,NA,United States,0,1,Patient MyChart Scheduling Link|Patient Educational Video|Enhanced Follow through Message,1
NCT04800120,2/15/2021,12/31/2021,Interventional,Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress,Recruiting,Not Applicable,"Steward St. Elizabeth's Medical Center of Boston, Inc.",NA,NA,NA,NA,NA,NA,United States,0,0,Hyperbaric Oxygen Therapy,0
NCT04800224,4/12/2021,6/30/2021,Interventional,Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2),Recruiting,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,NA,NA,NA,NA,NA,Brazil,0,2,Standardized Brazilian Green Propolis Extract|Placebo,0
NCT04799743,4/1/2021,5/31/2022,Interventional,The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients,Recruiting,Not Applicable,Hong Kong Baptist University,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,Resveratrol|Placebo capsules,0
NCT04799561,3/12/2021,9/15/2022,Interventional,Teleprehabilitation for Surgical Cancer Patients,Recruiting,Not Applicable,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,NA,NA,Canada,0,1,Multimodal Teleprehabilitation,0
NCT04798001,4/12/2021,10/31/2022,Interventional,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,Recruiting,Phase 1,"Meissa Vaccines, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,"Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray",1
NCT04798599,12/1/2020,6/30/2021,Interventional,Information and Communication Technologies (ICTS) in Dentistry for SUS,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Telemonitoring and teleorientation|Control Group - Waiting list,0
NCT04798053,4/8/2021,10/31/2022,Interventional,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Recruiting,Not Applicable,"University Hospital, Bordeaux",NA,NA,NA,NA,NA,NA,France,0,2,Questionnaire|blood sample and salivary sample,0
NCT04797871,3/8/2021,3/15/2022,Interventional,Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19,Enrolling by invitation,Not Applicable,Universidad PÃºblica de Navarra,NA,NA,NA,NA,NA,NA,Spain,0,0,Resistance training|Standard care,0
NCT04797858,5/5/2021,3/30/2022,Interventional,COVID-19 Self-Testing Through Rapid Network Distribution,Recruiting,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,2,COVID-19 self-test|COVID-19 test referral,0
NCT04797936,5/1/2020,12/19/2020,Interventional,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,Completed,Phase 4,Ivano-Frankivsk National Medical University,NA,NA,NA,NA,NA,NA,Ukraine,0,0,BNO 1030|Standard care,0
NCT04796402,3/17/2021,6/7/2021,Interventional,A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19,"Active, not recruiting",Phase 4,Fraser Health,NA,NA,NA,NA,NA,NA,Canada,0,3,Bamlanivimab|Standard of Care,0
NCT04794946,3/19/2021,3/19/2022,Interventional,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis",Recruiting,Not Applicable,"Institute of Liver and Biliary Sciences, India",NA,NA,NA,NA,NA,NA,India,0,2,Covishield,1
NCT04796064,3/30/2020,11/5/2020,Interventional,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Completed,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,0,low-intensity aerobic training,0
NCT04794036,4/5/2021,12/31/2021,Interventional,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Recruiting,Not Applicable,Universidad San Jorge,NA,NA,NA,NA,NA,NA,Spain,0,3,Asynchronous telerehabilitation programme|Rehabilitation programme,0
NCT04794803,5/5/2020,11/30/2020,Interventional,Reparixin in COVID-19 Pneumonia - Efficacy and Safety,Terminated,Phase 2/Phase 3,DompÃ© Farmaceutici S.p.A,The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.,NA,NA,NA,NA,NA,Brazil|Italy,0,1,Reparixin|Standard of care,0
NCT04794374,11/16/2020,1/16/2022,Interventional,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,Recruiting,Not Applicable,Hacettepe University,NA,NA,NA,NA,NA,NA,Turkey,0,1,Telerehabilitation,0
NCT04794400,2/4/2021,3/31/2021,Interventional,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,Not Applicable,Region Skane,NA,NA,NA,NA,NA,NA,Sweden,0,6,oxygen mask,0
NCT04793984,3/8/2021,6/30/2021,Interventional,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Recruiting,Not Applicable,Marinomed Biotech AG,NA,NA,NA,NA,NA,NA,Austria,0,0,Carragelose|NaCl,0
NCT04794088,3/14/2021,12/31/2021,Interventional,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,Recruiting,Phase 2,VU University Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,1,Imatinib Mesylate intravenous solution|Placebo,0
NCT04793243,8/17/2020,10/10/2020,Interventional,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Completed,Not Applicable,University of Guadalajara,NA,NA,NA,NA,NA,NA,Mexico,0,0,Vitamin D3,0
NCT04792021,3/9/2021,6/30/2021,Interventional,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Recruiting,Phase 3,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,N-acetylcysteine,0
NCT04791423,3/15/2021,10/30/2021,Interventional,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"Active, not recruiting",Phase 2/Phase 3,ReiThera Srl,NA,NA,NA,NA,NA,NA,Italy,0,4,GRAd-COV2|Placebo,1
NCT04791241,3/3/2021,1/3/2022,Interventional,A Check-list Including Lung Ultrasound for ED Patients With ARF,Recruiting,Not Applicable,Centre Hospitalier Metropole Savoie,NA,NA,NA,NA,NA,NA,France,0,1,check-list including lung ultrasound,0
NCT04789525,3/10/2020,10/1/2020,Interventional,Physical Training and Diet for Childhood Obesity,Completed,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,1,High-intensity aerobic training with high protein diet,0
NCT04789499,3/15/2021,8/31/2021,Interventional,Smell in Covid-19 and Efficacy of Nasal Theophylline,Recruiting,Phase 2,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,2,Theophylline Powder,0
NCT04789603,5/10/2021,6/1/2021,Interventional,Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19,Recruiting,Not Applicable,Universitat Internacional de Catalunya,NA,NA,NA,NA,NA,NA,Spain,0,2,6-min-walk surgical mask|6-min-walk Fpp2|6-min-walk without mask,0
NCT04787211,6/20/2021,12/31/2021,Interventional,"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198",Recruiting,Phase 2,Brii Biosciences Limited,NA,NA,NA,NA,NA,NA,China,0,4,BRII-196 and BRII-198|Placebo,0
NCT04789356,3/18/2021,7/5/2021,Interventional,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,"Active, not recruiting",Phase 4,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,NA,NA,NA,NA,NA,Brazil,0,3,Adsorbed SARS-CoV-2 (inactivated) vaccine,1
NCT04788355,7/1/2020,11/15/2020,Interventional,Prevention of Complications (SARS-CoV-2): Clinical Study,Completed,Phase 3,Universidade do Vale do Sapucai,NA,NA,NA,NA,NA,NA,Brazil,0,0,Control group (standard hospital treatment)|Group Hydroxychloroquine|Group Hydroxychloroquine and apixaban|Group Apixaban,0
NCT04788407,12/1/2020,4/30/2022,Interventional,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts,Recruiting,Phase 4,FundaciÃ³n HuÃ©sped,NA,NA,NA,NA,NA,NA,Argentina,0,2,Nitazoxanide|Placebo,0
NCT04785898,11/9/2020,12/22/2020,Interventional,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay,"Active, not recruiting",Not Applicable,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,NA,NA,France,0,1,ID Nowâ„¢ COVID-19 Screening Test,0
NCT04784754,4/1/2021,9/30/2021,Interventional,Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Phase 2,State University of New York at Buffalo,NA,NA,NA,NA,NA,NA,United States,0,1,Melatonin|Placebo,0
NCT04784897,2/22/2021,7/1/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,Completed,Phase 2,"Innovation Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United States|Russian Federation,0,6,Brilacidin|Placebo|Standard of Care (SoC),0
NCT04784767,4/5/2021,10/30/2022,Interventional,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,U.S. Army Medical Research and Development Command,NA,NA,NA,NA,NA,NA,United States,0,3,"25 Âµg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|Sodium chloride, USP, for injection (0.9% NaCl)|50 Âµg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",1
NCT04783025,6/1/2021,3/31/2022,Interventional,A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes,Recruiting,Not Applicable,The Hong Kong Polytechnic University,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,"Blended Gaming COVID-19 Training System (BGCTS)|Usual care, infection control briefing",0
NCT04782700,4/1/2021,6/8/2021,Interventional,P-Co-Li (Pulmonary Covid-19 Study),Completed,Not Applicable,Northwell Health,NA,NA,NA,NA,NA,NA,United States,0,2,Steroid Taper (Prednisone),0
NCT04782336,12/12/2020,3/31/2022,Interventional,"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test",Recruiting,Not Applicable,LumiraDx UK Limited,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Group A (Sample Collection)|Group B (Sample Collection)|On-Site Testing (LumiraDx),0
NCT04780659,2/23/2021,12/31/2022,Interventional,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),"Active, not recruiting",Phase 4,Karolinska University Hospital,NA,NA,NA,NA,NA,NA,Sweden,0,1,"Comirnaty (COVID-19, mRNA vaccine)",1
NCT04780698,2/12/2021,10/31/2021,Interventional,DCI COVID-19 Surveillance Project,Recruiting,Not Applicable,Temple University,NA,NA,NA,NA,NA,NA,United States,0,1,SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection,0
NCT04780672,3/9/2021,5/31/2022,Interventional,Clinical Study in the Treatment of Patients With COVID-19,Recruiting,Phase 3,Pharma VAM,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Molixan|Placebo,0
NCT04780581,2/1/2021,12/1/2021,Interventional,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,Recruiting,Phase 4,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,NA,NA,NA,NA,NA,NA,Spain,0,1,Dexamethasone|Methylprednisolone,0
NCT04780685,3/20/2021,8/31/2021,Interventional,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,Recruiting,Phase 2,"Stemedica Cell Technologies, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,hMSC,0
NCT04780425,1/26/2021,5/22/2021,Interventional,"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana","Active, not recruiting",Not Applicable,"Korle-Bu Teaching Hospital, Accra, Ghana",NA,NA,NA,NA,NA,NA,Ghana,0,1,DESMOND|usual care,0
NCT04780035,11/18/2020,8/31/2021,Interventional,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 3,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,NA,NA,NA,NA,NA,Russian Federation,0,0,"EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)",1
NCT04779827,5/4/2021,10/30/2022,Interventional,Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks,Recruiting,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,2,Online Social Network and Collective Intelligence Intervention|Independent Control,1
NCT04780061,7/12/2021,1/31/2022,Interventional,Dietary Supplements for COVID-19,Recruiting,Phase 3,The Canadian College of Naturopathic Medicine,NA,NA,NA,NA,NA,NA,Canada,0,3,"Vitamin D3 50,000 IU|Vitamin C/Zinc|Vitamin K2/D|Microcrystalline Cellulose Capsule|Medium Chain Triglyceride Oil",0
NCT04779879,2/18/2021,10/29/2021,Interventional,"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19","Active, not recruiting",Phase 2,"Vir Biotechnology, Inc.",NA,NA,NA,NA,NA,NA,"United States|Canada|Italy|Korea, Republic of|Spain",0,4,Sotrovimab (Gen1)|Sotrovimab (Gen2),0
NCT04779450,8/1/2021,8/31/2021,Interventional,"Effect of Telemonitoring on Functionality, Quality of Life and Risk of Lymphedema in Breast Cancer Survivors",Recruiting,Not Applicable,University of the State of Santa Catarina,NA,NA,NA,NA,NA,NA,Brazil,0,1,Kinesiotherapy protocol|Usual orientations,0
NCT04778059,7/27/2021,3/31/2022,Interventional,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,Recruiting,Phase 2,"US Biotest, Inc.",NA,NA,NA,NA,NA,NA,United States,0,2,USB002|Placebo,0
NCT04776941,8/7/2020,12/31/2021,Interventional,Expressive Writing for the Management of Stress in Cancer Survivors,Recruiting,Not Applicable,M.D. Anderson Cancer Center,NA,NA,NA,NA,NA,NA,United States,0,0,Behavioral Intervention|Behavioral Intervention|Behavioral Intervention|Behavioral Intervention|Quality-of-Life Assessment|Questionnaire Administration,0
NCT04775069,5/21/2021,12/31/2021,Interventional,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,Recruiting,Phase 4,Humanity & Health Medical Group Limited,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,BNT162b2|CoronaVac|AZD1222,1
NCT04773665,3/15/2021,11/30/2022,Interventional,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a",Recruiting,Phase 1,VBI Vaccines Inc.,NA,NA,NA,NA,NA,NA,Canada|Mexico,0,2,VBI-2902a|Placebo|VBI-2905a,1
NCT04772859,2/1/2021,7/16/2021,Interventional,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,Completed,Not Applicable,Universidad de Sonora,NA,NA,NA,NA,NA,NA,Mexico,0,3,Online Lifestyle Intervention|Control Group,0
NCT04771585,3/29/2021,8/20/2021,Interventional,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Completed,Not Applicable,Fraunhofer-Institute of Toxicology and Experimental Medicine,NA,NA,NA,NA,NA,NA,Germany,0,2,Community Mask|Surgical Mask|FFP2 respirator|FFP3 respirator,0
NCT04771559,3/1/2021,6/1/2021,Interventional,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,Not Applicable,Bezmialem Vakif University,NA,NA,NA,NA,NA,NA,Turkey,0,2,COVID-19 antibody test,1
NCT04771611,7/14/2021,12/31/2022,Interventional,COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications,Enrolling by invitation,Phase 2,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,4,Fisetin,0
NCT04771351,4/30/2021,8/31/2021,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,COVI-AMG|Placebo,0
NCT04771000,2/8/2021,7/31/2022,Interventional,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,Recruiting,Phase 2,Noorik Biopharmaceuticals AG,NA,NA,NA,NA,NA,NA,Spain,0,7,Ambrisentan|Placebo,0
NCT04771013,2/10/2021,5/14/2021,Interventional,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,Completed,Phase 2,Universidad CatÃ³lica de Honduras,NA,NA,NA,NA,NA,NA,Honduras,0,2,Thymic peptides,0
NCT04770740,2/22/2021,6/1/2021,Interventional,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,Recruiting,Phase 2,Canisius-Wilhelmina Hospital,NA,NA,NA,NA,NA,NA,Netherlands,0,1,Vitamin K2 in the form of Menaquinone-7 (MK-7)|Placebo,0
NCT04769297,4/15/2020,4/30/2021,Interventional,"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","Active, not recruiting",Phase 4,Limbic Medical,NA,NA,NA,NA,NA,NA,United States,0,0,Sublingual Micro-Dose Ketamine,0
NCT04769999,6/4/2020,10/16/2020,Interventional,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,Completed,Not Applicable,University of Oxford,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Simple cognitive task,0
NCT04767477,3/28/2021,8/31/2021,Interventional,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Completed,Not Applicable,Universidade Federal de Pernambuco,NA,NA,NA,NA,NA,NA,Brazil,0,2,Face-to-face rehabilitation|Telerehabilitation,0
NCT04767958,3/19/2021,2/28/2022,Interventional,The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing,Recruiting,Not Applicable,Ottawa Heart Institute Research Corporation,NA,NA,NA,NA,NA,NA,Canada,0,1,Spartan COVID-19 Platform,0
NCT04766931,3/26/2021,2/28/2022,Interventional,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,Recruiting,Phase 1,Frontier Biotechnologies Inc.,NA,NA,NA,NA,NA,NA,United States,0,2,FB2001|FB2001 Placebo,0
NCT04765475,3/8/2021,2/28/2022,Interventional,Protecting Native Families From COVID-19,Recruiting,Not Applicable,Johns Hopkins Bloomberg School of Public Health,NA,NA,NA,NA,NA,NA,United States,0,1,Motivational Interviewing|COVID-19 Symptom Monitoring System|Motivational Interviewing and COVID-19 Symptom Monitoring System|Supportive Services,0
NCT04764981,5/31/2021,5/31/2022,Interventional,Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19),Enrolling by invitation,Not Applicable,Universidade do Estado do ParÃ¡,NA,NA,NA,NA,NA,NA,Brazil,0,0,Essence oils,0
NCT04765839,2/12/2021,4/3/2021,Interventional,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Completed,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,2,"Educational, culturally appropriate COVID-19 messages",1
NCT04765436,1/14/2021,2/12/2022,Interventional,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","Active, not recruiting",Phase 1,Providence Therapeutics Holdings Inc.,NA,NA,NA,NA,NA,NA,Canada,0,1,PTX-COVID19-B|Placebo,1
NCT04762628,10/27/2020,7/5/2021,Interventional,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients",Completed,Not Applicable,Saisei Pharma,NA,NA,NA,NA,NA,NA,Ukraine,0,2,MAF capsules 148 mg|M capsules 148 mg|Standard of care,0
NCT04762173,11/6/2020,5/31/2021,Interventional,Self-Help for Stress Related to COVID-19,Completed,Not Applicable,Penn State University,NA,NA,NA,NA,NA,NA,United States,0,3,Online self-help intervention,0
NCT04763681,1/1/2021,8/31/2021,Interventional,Couple HOPES (Helping Overcome PTSD and Enhance Satisfaction),Recruiting,Not Applicable,York University,NA,NA,NA,NA,NA,NA,Canada,0,2,"Couple HOPES Guided, Internet-Delivered, Self-Help Intervention",0
NCT04761822,4/7/2021,10/31/2021,Interventional,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,United States,0,20,Moderna COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine|Placebo,1
NCT04760743,12/17/2020,4/30/2021,Interventional,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"Active, not recruiting",Phase 1,"SK Chemicals Co., Ltd.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,NBP2001 adjuvanted with alum (RBD 30Î¼g/dose)|NBP2001 adjuvanted with alum (RBD 50Î¼g/dose)|Normal Saline,1
NCT04761874,12/1/2019,6/29/2020,Interventional,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,Not Applicable,University of Minnesota,NA,NA,NA,NA,NA,NA,United States,0,1,Telestroke,0
NCT04760821,12/10/2020,4/30/2021,Interventional,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19,Recruiting,Phase 2,"Ministry of Health, Brazil",NA,NA,NA,NA,NA,NA,Brazil,0,1,Trimetazidine,0
NCT04760418,5/26/2021,8/1/2022,Interventional,Trauma and Trauma-Focused Therapy in the University of Kentucky SMART Clinic,Recruiting,Not Applicable,University of Kentucky,NA,NA,NA,NA,NA,NA,United States,0,1,Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE),0
NCT04756141,3/3/2021,1/28/2022,Interventional,CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)),Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,2,Continuous Glucose Monitor (CGM),0
NCT04760132,2/8/2021,12/31/2024,Interventional,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),Recruiting,Phase 4,"Rigshospitalet, Denmark",NA,NA,NA,NA,NA,NA,Denmark,0,1,COMIRNATY - BioNTech Manufacturing GmbH|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|COVID-19 Vaccine AstraZeneca suspension for injection,1
NCT04758286,7/1/2020,2/1/2021,Interventional,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Completed,Not Applicable,Benha University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Emergency surgical procedures,0
NCT04756466,1/1/2021,4/30/2021,Interventional,Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly,"Active, not recruiting",Not Applicable,Biosearch S.A.,NA,NA,NA,NA,NA,NA,Spain,0,2,Placebo|Lactobacillus,0
NCT04756128,1/25/2021,12/31/2021,Interventional,Impact of Colchicine and Low-dose Naltrexone on COVID-19,Enrolling by invitation,Phase 2,HealthPartners Institute,NA,NA,NA,NA,NA,NA,United States,0,2,Colchicine 0.6 mg|Naltrexone,0
NCT04758273,10/7/2020,6/30/2021,Interventional,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 1,"Beijing Minhai Biotechnology Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,0,medium dosage inactivated SARS-CoV-2 vaccine|high dosage inactivated SARS-CoV-2 vaccine|Placebo,1
NCT04758299,3/13/2021,4/15/2021,Interventional,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,Completed,Not Applicable,Carnegie Mellon University,NA,NA,NA,NA,NA,NA,United States,0,3,decision science-based design,0
NCT04757818,2/17/2021,5/25/2021,Interventional,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.",Completed,Not Applicable,Dentaid SL,NA,NA,NA,NA,NA,NA,Spain,0,1,0.07% cetylpyridinium chloride (CPC) in mouthwash|Distilled water with the same colorant as the experimental product,0
NCT04757857,9/29/2020,9/28/2021,Interventional,COVID-19 Antithrombotic Rivaroxaban Evaluation,Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,NA,NA,NA,NA,NA,Brazil,0,2,Rivaroxaban 10 mg,0
NCT04757298,2/12/2021,1/30/2022,Interventional,COVID-19 Treatment Cascade Optimization Study,Recruiting,Not Applicable,University of Illinois at Urbana-Champaign,NA,NA,NA,NA,NA,NA,United States,0,1,Navigation Services|Critical Dialogue|Brief Counseling|Referral and Digital Brochure,0
NCT04756856,4/21/2021,12/1/2021,Interventional,Muscle-targeted Nutritional Therapy for the Recovery From COVID-19,Recruiting,Not Applicable,IRCCS Policlinico S. Matteo,NA,NA,NA,NA,NA,NA,Italy,0,1,Muscle-target oral nutritional supplementation,0
NCT04756830,2/19/2021,9/30/2021,Interventional,A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19,"Active, not recruiting",Phase 4,D'Or Institute for Research and Education,NA,NA,NA,NA,NA,NA,Brazil,0,2,Adsorbed COVID-19 (inactivated) Vaccine,1
NCT04756323,10/27/2020,6/30/2021,Interventional,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 2,"Beijing Minhai Biotechnology Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,medium dosage inactivated SARS-CoV-2 vaccine|high dosage inactivated SARS-CoV-2 vaccine|Placebo,1
NCT04530409,2/10/2021,8/1/2021,Interventional,Timing of Corticosteroids in COVID-19,Recruiting,Phase 4,ClinAmygate,NA,NA,NA,NA,NA,NA,Egypt,0,4,Early-Dexamethasone|Late-Dexamethasone,0
NCT04755972,1/29/2021,7/29/2021,Interventional,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,Not Applicable,"Clinical Hospital Center, Split",NA,NA,NA,NA,NA,NA,Croatia,0,0,"Inhalation of N-acetylcysteine|Inhalation of 5% sodium chloride|Inhalation of 8,4% sodium bicarbonate",0
NCT04754113,2/8/2021,9/20/2021,Interventional,Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19,Recruiting,Not Applicable,"Southeast University, China",NA,NA,NA,NA,NA,NA,China,0,3,prone position,0
NCT04753645,9/19/2020,5/31/2021,Interventional,BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition,"Active, not recruiting",Not Applicable,BRAC University,NA,NA,NA,NA,NA,NA,Bangladesh,0,1,Handwashing stations at the public places and no soap|No activities of the HBCC project and also no soap (Pure Control)|Soap distributed but no activities of the HBCC project|HBCC project and Soap,0
NCT04753619,1/3/2021,12/3/2021,Interventional,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,Recruiting,Phase 2,University of Baghdad,NA,NA,NA,NA,NA,NA,Iraq,0,3,Niclosamide Oral Tablet,0
NCT04751617,1/1/2021,1/31/2021,Interventional,Pulmonary Rehabilitation of Patients With a History of COVID-19,Enrolling by invitation,Not Applicable,University of Rzeszow,NA,NA,NA,NA,NA,NA,Poland,0,0,Pulmonary rehabilitation,0
NCT04751630,6/1/2021,10/1/2021,Interventional,Effects of COVID-19 Hospitalization on Physical Performance,Recruiting,Not Applicable,Universitat Internacional de Catalunya,NA,NA,NA,NA,NA,NA,Spain,0,2,Therapeutic Exercise,0
NCT04751604,2/1/2021,12/31/2021,Interventional,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Recruiting,Not Applicable,University Hospital Schleswig-Holstein,NA,NA,NA,NA,NA,NA,Germany,0,1,Nicotinamide|Placebo,0
NCT04751682,3/1/2021,6/25/2021,Interventional,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"Active, not recruiting",Phase 1,Bharat Biotech International Limited,NA,NA,NA,NA,NA,NA,India,0,3,BBV154 Vaccine|Placebo,1
NCT04751643,4/19/2021,12/31/2022,Interventional,Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,1,Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|Usual treatments in intensive care unit according to the current state of knowledge,0
NCT04750720,8/27/2020,12/31/2023,Interventional,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection,Recruiting,Not Applicable,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,NA,NA,NA,NA,NA,France,0,3,Sampling by venipuncture (and eventually by nasopharyngeal swab),0
NCT04750265,1/21/2021,11/30/2021,Interventional,Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19,Recruiting,Not Applicable,"Charite University, Berlin, Germany",NA,NA,NA,NA,NA,NA,Germany,0,2,Robotic assisted early mobilization,0
NCT04750278,4/6/2021,2/28/2022,Interventional,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,Phase 2/Phase 3,"Foresee Pharmaceuticals Co., Ltd.",NA,NA,NA,NA,NA,NA,United States,0,2,FP-025 100 mg|FP-025 300 mg|Placebo,0
NCT04750317,5/11/2020,8/1/2020,Interventional,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,Phase 2,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,Tofacitinib,0
NCT04749121,4/1/2020,2/5/2021,Interventional,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,Completed,Not Applicable,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,NA,NA,NA,NA,NA,Thailand,0,0,UVC Irradiation|UVC Irradiation|Fit test|Tensile strength,0
NCT04748757,4/20/2021,3/31/2022,Interventional,Annexin A5 in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Lawson Health Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,1,recombinant human annexin A5|Placebo,0
NCT04748783,3/26/2021,4/7/2021,Interventional,Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19,Terminated,Phase 2,"University of North Carolina, Chapel Hill",Funding withdrawn,NA,NA,NA,NA,NA,United States,0,2,Water|Peroxyl|Periogard|Colgate Total Zero,0
NCT04748536,1/29/2021,4/5/2021,Interventional,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,Completed,Phase 1,Revolo Biotherapeutics,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,IRL201104|Placebo,0
NCT04748120,12/28/2020,4/6/2021,Interventional,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients,Terminated,Not Applicable,The Cleveland Clinic,Insufficient eligible patients,NA,NA,NA,NA,NA,United States,0,1,Operative management|Non-operative management,0
NCT04747756,3/1/2021,12/31/2022,Interventional,Creating a Virtual Village for People Aging With HIV During COVID-19,Enrolling by invitation,Not Applicable,"University of California, Riverside",NA,NA,NA,NA,NA,NA,United States,0,1,Virtual Village,0
NCT04747574,9/25/2020,2/25/2021,Interventional,Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection,Recruiting,Phase 1,Tel-Aviv Sourasky Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,1,EXO-CD24,0
NCT04747821,2/7/2021,5/31/2021,Interventional,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,"Active, not recruiting",Phase 4,Butantan Institute,NA,NA,NA,NA,NA,NA,Brazil,0,1,Adsorbed COVID-19 (Inactivated) Vaccine,1
NCT04747158,8/10/2020,12/10/2020,Interventional,COVID-19 Convalescent Plasma Therapy,Completed,Phase 2/Phase 3,Universidad Nacional de AsunciÃ³n,NA,NA,NA,NA,NA,NA,Paraguay,0,1,Convalescent plasma,0
NCT04747249,6/18/2021,12/31/2021,Interventional,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19,Recruiting,Not Applicable,Centre Francois Baclesse,NA,NA,NA,NA,NA,NA,France,0,1,Psychological support,0
NCT04747132,7/20/2020,10/20/2020,Interventional,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,Not Applicable,"Universidad Iberoamericana A.C., Mexico",NA,NA,NA,NA,NA,NA,Mexico,0,0,Telegeriatric intervention,0
NCT04746430,2/16/2021,4/23/2021,Interventional,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study,Terminated,Phase 4,General Practitioners Research Institute,Too few patients,NA,NA,NA,NA,NA,Netherlands,0,2,Dexamethasone,0
NCT04746365,12/6/2020,1/31/2021,Interventional,Ivermectin Role in Covid-19 Clinical Trial,Completed,Phase 4,Elaraby Hospital,NA,NA,NA,NA,NA,NA,Egypt,0,0,ivermectin|hydroxychloroquine|Placebo,0
NCT04746339,3/4/2021,8/31/2021,Interventional,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19,Recruiting,Phase 4,Brazilian Clinical Research Institute,NA,NA,NA,NA,NA,NA,Brazil,0,1,Apixaban 2.5 MG|Placebo,0
NCT04745442,4/27/2020,12/20/2020,Interventional,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,NA,NA,NA,NA,NA,Spain,0,0,Antithrombin + best available treatment|Best available treatment,0
NCT04743349,1/26/2021,10/31/2021,Interventional,Steam Inhalations in COVID-19 Patients,Recruiting,Not Applicable,Meyer Children's Hospital,NA,NA,NA,NA,NA,NA,Italy,0,0,Steam inhalations,0
NCT04743232,3/1/2021,12/31/2021,Interventional,COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Recruiting,Not Applicable,Erasmus Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,2,Decision tool for clinicians,0
NCT04743401,7/5/2021,9/30/2022,Interventional,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients,Recruiting,Phase 1/Phase 2,VA Office of Research and Development,NA,NA,NA,NA,NA,NA,United States,0,3,Tele-exergaming Tablet,0
NCT04743011,6/1/2021,11/30/2021,Interventional,Enriched Heparin Anti COVID-19 Trial,Recruiting,Phase 1/Phase 2,UPECLIN HC FM Botucatu Unesp,NA,NA,NA,NA,NA,NA,Brazil,0,3,Heparin sodium|Placebo,0
NCT04742725,5/25/2021,7/30/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",Phase 2,"Prothione, LLC",NA,NA,NA,NA,NA,NA,Rwanda,0,6,Placebo|Prothioneâ„¢ (6g),0
NCT04739462,9/28/2021,2/28/2022,Interventional,SMS Maama Project COVID-19,"Active, not recruiting",Not Applicable,University of Minnesota,NA,NA,NA,NA,NA,NA,United States|Uganda,0,2,mHealth Platform,0
NCT04739410,5/1/2020,6/30/2020,Interventional,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Ivermectin,0
NCT04738045,11/1/2020,3/28/2021,Interventional,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Recruiting,Phase 4,October 6 University,NA,NA,NA,NA,NA,NA,Egypt,0,2,Remdesivir|Lopinavir/ Ritonavir and Remdesivir combination,0
NCT04734717,1/12/2021,4/12/2021,Interventional,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,Not Applicable,Somogy Megyei Kaposi MÃ³r Teaching Hospital,NA,NA,NA,NA,NA,NA,Hungary,0,0,Neurology test,0
NCT04734873,2/25/2021,8/16/2021,Interventional,CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients,Terminated,Phase 3,"Corvus Pharmaceuticals, Inc.",Sponsor decision. Not related to safety issues.,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Canada|Chile|Colombia|Germany|Italy|Mexico|Peru|Spain|Ukraine,0,18,CPI-006 2 mg/kg + SOC|CPI-006 1 mg/kg + SOC|Placebo + SOC,0
NCT04734912,1/13/2021,6/15/2021,Interventional,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Recruiting,Not Applicable,Johannes Gutenberg University Mainz,NA,NA,NA,NA,NA,NA,Germany,0,0,gastroscopy in transnasal techique,0
NCT04734860,4/30/2021,9/30/2021,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,COVI-AMG|Placebo,0
NCT04734561,2/8/2021,7/31/2021,Interventional,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,Completed,Not Applicable,Universidad Complutense de Madrid,NA,NA,NA,NA,NA,NA,Spain,0,2,Inspiratory muscle training group|Inspiratory muscle training placebo group|Inspiratory + expiratory muscle training group|Inspiratory + expiratory muscle training placebo group,0
NCT04734171,4/2/2020,4/16/2020,Interventional,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak",Completed,Not Applicable,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,0,Digital social activity video intervention|Informational sheet|Stigma awareness video intervention,0
NCT04733833,1/26/2021,6/30/2022,Interventional,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,Recruiting,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,NA,NA,NA,NA,NA,NA,Israel,0,0,VB-201 + Standard of care|Standard of care,0
NCT04733625,9/15/2020,12/17/2020,Interventional,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,Not Applicable,Kasr El Aini Hospital,NA,NA,NA,NA,NA,NA,Egypt,0,0,Cholecalciferol|Placebo,0
NCT04732819,12/21/2020,3/31/2021,Interventional,Improving COVID-19 Vaccine Uptake in Nursing Homes,Completed,Not Applicable,Brown University,NA,NA,NA,NA,NA,NA,United States,1,3,High touch multi-pronged behavioral intervention,1
NCT04732468,2/24/2021,4/30/2022,Interventional,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Active, not recruiting",Phase 1,"ImmunityBio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,hAd5-S-Fusion+N-ETSD (Suspension for injection)|hAd5-SFusion+ N-ETSD (Oral capsule),1
NCT04731116,1/10/2021,12/31/2021,Interventional,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Recruiting,Phase 1/Phase 2,Rabin Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Cannabidiol,0
NCT04730401,1/27/2021,8/31/2021,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Phase 2,Helsinki University Central Hospital,NA,NA,NA,NA,NA,NA,Finland,0,1,Convalescent plasma from COVID-19 donors|Placebo,0
NCT04730284,8/25/2020,9/30/2021,Interventional,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,Not Applicable,Chinese University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,0,Health supplements,0
NCT04730661,12/21/2020,12/21/2021,Interventional,Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19,Recruiting,Not Applicable,"University Hospital, Rouen",NA,NA,NA,NA,NA,NA,France,0,1,Sit to stand test,0
NCT04730427,1/31/2021,5/31/2021,Interventional,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,Recruiting,Phase 1,"Genexine, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,0,GX-I7|GX-I7 vehicle,0
NCT04730206,6/15/2021,5/31/2022,Interventional,The DAWN Camostat Trial for Ambulatory COVID-19 Patients,Recruiting,Phase 3,KU Leuven,NA,NA,NA,NA,NA,NA,Belgium,0,3,Camostat|Placebo,0
NCT04729491,6/30/2020,9/15/2020,Interventional,EAT-DUTA AndroCoV Trial,Completed,Phase 2/Phase 3,Corpometria Institute,NA,NA,NA,NA,NA,NA,Brazil,0,0,Dutasteride 0.5 mg|Azithromycin|Nitazoxanide|Placebo,0
NCT04728802,2/1/2021,4/15/2021,Interventional,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,Phase 3,"Applied Biology, Inc.",NA,NA,NA,NA,NA,NA,Brazil,1,4,Proxalutamide|Placebo,0
NCT04728594,1/15/2021,1/17/2021,Interventional,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,Not Applicable,Geisinger Clinic,NA,NA,NA,NA,NA,NA,United States,1,3,Social Proof|Reframing|Scarcity Message,1
NCT04729140,12/28/2020,12/28/2021,Interventional,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,Recruiting,Phase 4,"Max Health, Subsero Health",NA,NA,NA,NA,NA,NA,United States,0,2,Ivermectin Tablets|Doxycycline Tablets|Placebo,0
NCT04726111,12/30/2020,7/30/2021,Interventional,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,0,Specimens specific for the study,0
NCT04726371,1/8/2021,10/31/2022,Interventional,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,Not Applicable,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,0,Generic Best Practices|Tailored Best Practices,0
NCT04726163,1/29/2021,6/14/2021,Interventional,Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection,Recruiting,Not Applicable,"University Hospital, Strasbourg, France",NA,NA,NA,NA,NA,NA,France,0,1,Continuous blind glucose measurement device (Free style Pro),0
NCT04724720,1/19/2021,5/3/2021,Interventional,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,Northwell Health,NA,NA,NA,NA,NA,NA,United States,0,3,Famotidine|Placebo,0
NCT04724629,1/5/2021,3/31/2021,Interventional,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),Recruiting,Phase 3,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Ixekizumab|Aldesleukin|Colchicine|Standard of care (SOC),0
NCT04724616,1/6/2021,6/30/2021,Interventional,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,Recruiting,Not Applicable,Medical University of Vienna,NA,NA,NA,NA,NA,NA,Austria,0,0,Educational Program (CARTOON),0
NCT04724681,2/1/2021,12/31/2021,Interventional,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Recruiting,Not Applicable,University Hospital Bispebjerg and Frederiksberg,NA,NA,NA,NA,NA,NA,Denmark,0,0,WARD CSS,0
NCT04724538,10/15/2020,2/10/2021,Interventional,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Completed,Phase 1/Phase 2,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,NA,NA,NA,NA,NA,Russian Federation,1,1,99mTc-pertechnetate aerosol|99mTc-pertechnetate aerosol,0
NCT04723394,1/28/2021,8/21/2021,Interventional,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,"Active, not recruiting",Phase 3,AstraZeneca,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Bulgaria|Czechia|Germany|Hungary|Italy|Japan|Mexico|Peru|Poland|Russian Federation|Spain|Ukraine|United Kingdom,0,5,AZD7442|Placebo,0
NCT04723576,12/3/2020,2/28/2022,Interventional,Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Recruiting,Not Applicable,RAND,NA,NA,NA,NA,NA,NA,United States,0,0,Stress First Aid,0
NCT04723550,1/5/2021,11/5/2021,Interventional,COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes,Recruiting,Not Applicable,Xuzhou No.1 Peoples Hospital,NA,NA,NA,NA,NA,NA,China,0,1,Hospital telemedicine management system|Usual care,0
NCT04723563,2/22/2021,8/23/2021,Interventional,Nebulized Heparin for the Treatment of COVID-19,Completed,Phase 4,Frederick Health,NA,NA,NA,NA,NA,NA,United States,0,2,Heparin|0.9%sodium chloride,0
NCT04723524,9/22/2020,8/23/2021,Interventional,Jinhua Qinggan Granules in the Treatment of COVID-19,Completed,Phase 2,University of Karachi,NA,NA,NA,NA,NA,NA,Pakistan,0,3,"Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Placebo Comparator",0
NCT04723459,1/23/2021,2/19/2021,Interventional,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,Not Applicable,South Valley University,NA,NA,NA,NA,NA,NA,Egypt,0,3,ivermectin impregnated mask,0
NCT04723290,6/20/2020,10/31/2020,Interventional,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,Completed,Not Applicable,Grand HÃ´pital de Charleroi,NA,NA,NA,NA,NA,NA,Belgium,0,3,Serological tests for SARS Cov-2,0
NCT04719208,10/6/2020,5/31/2021,Interventional,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,Not Applicable,Augusta University,NA,NA,NA,NA,NA,NA,United States,0,0,Water (E) Mouth rinse with the solution provided|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Hydrogen peroxide (B) Mouth rinse with the solution provided|Betadine (C) Mouth rinse with the solution provided|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided,0
NCT04720794,9/25/2020,10/20/2020,Interventional,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,Completed,Not Applicable,Lucira Health Inc,NA,NA,NA,NA,NA,NA,United States,0,2,Lucira COVID-19 All-In-One test kit,0
NCT04720235,12/9/2020,3/9/2021,Interventional,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,Completed,Not Applicable,Lucira Health Inc,NA,NA,NA,NA,NA,NA,United States,0,1,Lucira COVID-19 All-In-One test kit,0
NCT04721236,11/19/2020,11/19/2021,Interventional,Early Use of Hyperimmune Plasma in COVID-19,Recruiting,Not Applicable,IRCCS Policlinico S. Matteo,NA,NA,NA,NA,NA,NA,Italy,0,0,hyperimmune plasma,0
NCT04720404,6/23/2020,2/28/2022,Interventional,Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Recruiting,Not Applicable,Radboud University,NA,NA,NA,NA,NA,NA,Netherlands,0,0,Mindfulness-Based Stress Reduction|Self-help mindfulness/compassion exercises|Support as usual,0
NCT04720378,5/30/2021,3/31/2022,Interventional,Safety and Tolerability Study of IV ST266 in COVID-19 Subjects,Recruiting,Phase 1,"Noveome Biotherapeutics, formerly Stemnion",NA,NA,NA,NA,NA,NA,United States,0,4,ST266,0
NCT04718220,3/1/2021,11/30/2022,Interventional,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19",Recruiting,Not Applicable,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,1,Antibody testing for SARS-CoV-2 IgG|Testing for SARS-CoV-2 RNA|Testing for SARS-CoV-2 IgM/IgG,0
NCT04718480,11/27/2020,8/31/2022,Interventional,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,Recruiting,Phase 2,SigmaDrugs Research Ltd.,NA,NA,NA,NA,NA,NA,Hungary,0,1,Placebo|Fluvoxamine,0
NCT04718506,1/12/2021,6/12/2021,Interventional,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,Recruiting,Not Applicable,Universidad de Murcia,NA,NA,NA,NA,NA,NA,Spain,0,0,Exercise|Controls,0
NCT04716998,1/14/2021,1/31/2022,Interventional,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,Recruiting,Phase 1/Phase 2,BonusBio Group Ltd,NA,NA,NA,NA,NA,NA,Israel,0,2,MesenCure,0
NCT04716647,10/9/2020,12/12/2020,Interventional,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Ayurveda,0
NCT04716179,1/18/2021,5/18/2021,Interventional,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,Not Applicable,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,NA,NA,Russian Federation,0,1,"Sperm test|hormone levels (testosterone, FSH, LH, prolactin)|SARS-CoV-2 Ig G levels|Testis pathology samples",0
NCT04716426,1/28/2021,3/25/2021,Interventional,APTâ„¢ T3X on the COVID-19 Contamination Rate,Completed,Not Applicable,University of Nove de Julho,NA,NA,NA,NA,NA,NA,Brazil,1,4,Tetracycline hydrochloride 3%|Placebo,0
NCT04715932,2/18/2021,5/25/2021,Interventional,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),Completed,Phase 2,Montreal Heart Institute,NA,NA,NA,NA,NA,NA,Canada,0,5,Hesperidin|Placebo,0
NCT04715763,9/1/2021,1/31/2022,Interventional,INvestigating TELmisartin Study,Recruiting,Phase 2,University of Hawaii,NA,NA,NA,NA,NA,NA,United States,0,2,Telmisartan Oral Product|Placebo,0
NCT04715360,12/29/2020,11/29/2021,Interventional,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,Phase 1/Phase 2,Hayandra Peduli Foundation,NA,NA,NA,NA,NA,NA,Indonesia,0,0,autologous activated platelet-rich plasma|Avigan,0
NCT04715295,10/5/2020,5/30/2021,Interventional,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,Recruiting,Phase 4,Yaounde Central Hospital,NA,NA,NA,NA,NA,NA,Cameroon,0,0,Doxycycline Tablets|Rivaroxaban 15Mg Tab|Hydroxychloroquine and Azithromycin,0
NCT04713878,5/8/2020,6/30/2020,Interventional,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,1,Mesenchymal stem cells,0
NCT04713488,1/15/2021,7/20/2021,Interventional,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","Active, not recruiting",Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,NA,NA,NA,NA,NA,Russian Federation,0,2,Sputnik Light,1
NCT04713553,2/15/2021,7/22/2021,Interventional,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants",Completed,Phase 3,BioNTech SE,NA,NA,NA,NA,NA,NA,United States,0,6,BNT162b2|BNT162b2.B.1.351,1
NCT04712357,11/9/2020,1/31/2022,Interventional,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,Recruiting,Not Applicable,Universidade Federal do Ceara,NA,NA,NA,NA,NA,NA,Brazil,0,0,Vitamin C 500 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet,0
NCT04713176,2/2/2021,6/30/2021,Interventional,Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients,Recruiting,Phase 3,Daewoong Pharmaceutical Co. LTD.,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,2,DWJ1248 with Remdesivir|Placebo with Remdesivir,0
NCT04712110,2/24/2021,4/4/2022,Interventional,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,NA,NA,NA,NA,NA,Japan,0,4,TAK-019|Placebo,0
NCT04709172,1/5/2021,8/15/2021,Interventional,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,Completed,Phase 4,Meiji Pharma Spain S.A.,NA,NA,NA,NA,NA,NA,Spain,0,2,Cefditoren pivoxil 400mg,0
NCT04712344,1/18/2021,9/30/2021,Interventional,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Recruiting,Phase 2,University of Erlangen-NÃ¼rnberg Medical School,NA,NA,NA,NA,NA,NA,Germany,0,2,COVID-19 convalescent plasma,0
NCT04712045,8/1/2020,12/12/2020,Interventional,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Completed,Not Applicable,University of Oxford,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,New PPE|Old PPE,0
NCT04710394,1/11/2021,3/11/2022,Interventional,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,"Active, not recruiting",Not Applicable,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States,0,4,Smell Training,0
NCT04710381,2/1/2021,6/2/2021,Interventional,IMUNORÂ® Preparation in the Prevention of COVID-19,Completed,Phase 4,University Hospital Ostrava,NA,NA,NA,NA,NA,NA,Czechia,0,2,IMUNOR,0
NCT04710303,3/2/2021,4/30/2022,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,NA,NA,NA,NA,NA,South Africa,0,4,hAd5-S-Fusion+N-ETSD vaccine,1
NCT04710316,2/15/2021,4/30/2022,Interventional,"Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali",Recruiting,Not Applicable,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,NA,NA,NA,NA,Mali,0,1,SARS-CoV-2 screening by molecular biology|Serological screening,0
NCT04708340,3/25/2021,10/31/2022,Interventional,Tolerability and Efficacy of RJX in Patients With COVID-19,Recruiting,Phase 1/Phase 2,"Reven Pharmaceuticals, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,Rejuveinix (RJX) Active Comparator|Placebo Comparator,0
NCT04707833,11/26/2020,12/1/2023,Interventional,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,Not Applicable,"University Hospital, Rouen",NA,NA,NA,NA,NA,NA,France,0,0,Serological testing for COVID-19 infection,0
NCT04707703,3/16/2021,1/31/2022,Interventional,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Recruiting,Phase 3,"University of California, San Diego",NA,NA,NA,NA,NA,NA,United States,0,2,Isavuconazonium Injection [Cresemba]|Placebo,0
NCT04707820,4/16/2020,6/10/2021,Interventional,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,Not Applicable,"University Hospital, Rouen",NA,NA,NA,NA,NA,NA,France,0,0,ELISPOT,0
NCT04707534,1/21/2021,8/21/2021,Interventional,Dexamethasone for COVID-19,Recruiting,Phase 4,University of Oklahoma,NA,NA,NA,NA,NA,NA,United States,0,2,Dexamethasone,0
NCT04706403,1/12/2021,2/1/2021,Interventional,Views on COVID-19 and Vaccination,Completed,Not Applicable,"University of Massachusetts, Worcester",NA,NA,NA,NA,NA,NA,United States,0,3,Healthcare Providers' Communication about the COVID-19 Vaccine,1
NCT04705831,12/30/2020,1/31/2022,Interventional,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,Recruiting,Phase 4,IMMUNOe Research Centers,NA,NA,NA,NA,NA,NA,United States,0,0,Ruconest,0
NCT04706039,3/1/2021,9/30/2021,Interventional,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air,Recruiting,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,1,Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process,0
NCT04703907,12/3/2020,8/31/2021,Interventional,Auricular Stimulation for Relief of Stress and Anxiety,Recruiting,Not Applicable,University Medicine Greifswald,NA,NA,NA,NA,NA,NA,Germany,0,0,Auricular stimulation,0
NCT04704063,1/1/2021,1/30/2023,Interventional,Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL),Recruiting,Phase 2,Universiti Sains Malaysia,NA,NA,NA,NA,NA,NA,Malaysia,0,1,Tocotrienols / Vitamin E|Placebo control,0
NCT04703608,1/22/2021,3/31/2022,Interventional,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Recruiting,Phase 3,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,Gambia,0,4,Ivermectin|ASP|Placebo,0
NCT04703036,1/11/2021,12/31/2021,Interventional,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Recruiting,Early Phase 1,Baylor College of Medicine,NA,NA,NA,NA,NA,NA,United States,0,2,Glycine|N-acetylcysteine|Alanine,0
NCT04703140,2/11/2021,8/11/2022,Interventional,COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19,Recruiting,Not Applicable,CMC Ambroise ParÃ©,NA,NA,NA,NA,NA,NA,France,0,2,Rapid Diagnostic Test vs PCR,0
NCT04703114,2/5/2021,9/15/2021,Interventional,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Completed,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,3,Blood count|Blood collection|Nasopharyngeal swab|Saliva samples|Faeces samples|Genetic blood collection|Data collection,0
NCT04701710,10/15/2020,12/18/2020,Interventional,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,NA,NA,NA,NA,NA,Argentina,0,2,Ivermectin / Iota-Carrageenan,0
NCT04701528,11/15/2020,3/25/2022,Interventional,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,Recruiting,Phase 2,Leiden University Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,0,Voclosporin|Tacrolimus,0
NCT04701606,3/29/2021,4/15/2022,Interventional,The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Shin Poong Pharmaceutical Co. Ltd.,NA,NA,NA,NA,NA,NA,Philippines,0,3,ArtecomÂ® (pyronaridine-artesunate)|Placebo,0
NCT04701489,1/14/2021,3/15/2021,Interventional,UNITE Study (UMN-GE) for COVID-19,Completed,Not Applicable,University of Minnesota,NA,NA,NA,NA,NA,NA,United States,0,5,Splenic ultrasound,0
NCT04700137,1/18/2021,1/17/2022,Interventional,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",Enrolling by invitation,Not Applicable,"St. Luke's Health System, Boise, Idaho",NA,NA,NA,NA,NA,NA,United States,0,3,Caring Contacts Plus Introductory Phone Call (CC+)|Caring Contacts without an introductory phone call (CC),0
NCT04699851,11/18/2020,4/18/2021,Interventional,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,Not Applicable,Laval University,NA,NA,NA,NA,NA,NA,Canada,0,1,Tailored recommendations|General recommendation,0
NCT04699916,1/4/2021,5/23/2021,Interventional,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,Completed,Not Applicable,University of Chile,NA,NA,NA,NA,NA,NA,Chile,0,5,EEG based protocol for deep sedation,0
NCT04698993,2/12/2021,3/22/2021,Interventional,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,Terminated,Not Applicable,DrÃ¤gerwerk AG & Co. KGaA,poor recruitment,NA,NA,NA,NA,NA,Germany,1,6,DrÃ¤ger Antigen Test SARS-CoV-2,0
NCT04698798,1/2/2021,4/3/2021,Interventional,Skeletal Muscle Wasting in SARS-CoV-2,Completed,Not Applicable,Hasselt University,NA,NA,NA,NA,NA,NA,Belgium,0,3,Muscle Biopsy,0
NCT04695743,9/1/2020,6/1/2022,Interventional,Group CST Using Zoom: A Proof of Concept Study,Recruiting,Not Applicable,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Online Cognitive Stimulation Therapy,0
NCT04695197,1/8/2021,11/1/2022,Interventional,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Recruiting,Phase 3,Liverpool School of Tropical Medicine,NA,NA,NA,NA,NA,NA,Burkina Faso|Kenya,0,1,Artemether-lumefantrine (AL)|Pyronaridine-artesunate (PA),0
NCT04695301,7/1/2020,7/1/2021,Interventional,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,Not Applicable,Hospital Israelita Albert Einstein,NA,NA,NA,NA,NA,NA,Brazil,0,2,Rehabilitation protocol through a digital platform,0
NCT04694612,1/1/2021,3/31/2021,Interventional,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,Recruiting,Phase 3,Nepal Health Research Council,NA,NA,NA,NA,NA,NA,Nepal,0,0,Favipiravir|Placebo|Remdesivir,0
NCT04694638,5/21/2020,7/31/2022,Interventional,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,1,Body position change,0
NCT04693026,9/10/2020,2/15/2021,Interventional,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Recruiting,Phase 3,M Abdur Rahim Medical College and Hospital,NA,NA,NA,NA,NA,NA,Bangladesh,0,0,Remdesivir|Baricitinib|Tocilizumab,0
NCT04691947,11/5/2020,3/1/2021,Interventional,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,Recruiting,Phase 1,Health Institutes of Turkey,NA,NA,NA,NA,NA,NA,Turkey,0,1,ERUCOV-VAC|Placebo Vaccine,1
NCT04690920,7/23/2020,12/10/2020,Interventional,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Completed,Not Applicable,University of Lahore,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Tocilizumab,0
NCT04690413,9/1/2020,12/31/2020,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,Not Applicable,"NOWDiagnostics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,NOWDx COVID-19 Test,0
NCT04691908,12/25/2020,4/26/2021,Interventional,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine",Completed,Phase 3,Research Institute for Biological Safety Problems,NA,NA,NA,NA,NA,NA,Kazakhstan,0,3,QazCovid-inÂ®-vaccine against COVID-19|Placebo,1
NCT04689399,12/26/2020,3/25/2021,Interventional,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,Not Applicable,"Rigshospitalet, Denmark",NA,NA,NA,NA,NA,NA,Denmark,0,3,"Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.",0
NCT04687488,7/23/2020,11/9/2020,Interventional,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,Completed,Not Applicable,Universitaire Ziekenhuizen Leuven,NA,NA,NA,NA,NA,NA,Belgium,0,0,Fluorescein|Particle measurement,0
NCT04686760,11/15/2020,11/15/2021,Interventional,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Recruiting,Not Applicable,University of Lahore,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Nitroglycerin,0
NCT04686539,1/20/2021,11/30/2021,Interventional,Synthetic CBD as a Therapy for COVID-19,Recruiting,Phase 1,Sheba Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,1,CBD|Placebo,0
NCT04684446,9/15/2021,4/8/2022,Interventional,Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19,Recruiting,Phase 1/Phase 2,R-Pharm,NA,NA,NA,NA,NA,NA,Belarus|Russian Federation,0,5,rAd26-S|AZD1222,0
NCT04685447,3/16/2020,4/20/2020,Interventional,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Recruiting,Not Applicable,Universita degli Studi di Genova,NA,NA,NA,NA,NA,NA,Italy,0,2,Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients,0
NCT04685603,12/7/2020,1/31/2021,Interventional,Dendritic Cell Vaccine to Prevent COVID-19,Recruiting,Phase 1,Indonesia-MoH,NA,NA,NA,NA,NA,NA,Indonesia,0,1,AV-COVID-19,1
NCT04685213,8/18/2020,8/18/2021,Interventional,Electrical Stimulation for Critically Ill Covid-19 Patients,Recruiting,Phase 1,Baylor College of Medicine,NA,NA,NA,NA,NA,NA,United States,0,4,Electrical Stimulation|Electrical Stimulation - Sham,0
NCT04681859,4/17/2021,7/9/2021,Interventional,Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients,"Active, not recruiting",Not Applicable,Bangladesh University of Engineering and Technology,NA,NA,NA,NA,NA,NA,Bangladesh,0,4,High Flow Nasal Oxygen (HFNO) treatment|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet,0
NCT04682574,11/2/2020,12/30/2020,Interventional,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Recruiting,Not Applicable,University of Lahore,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Vitamin C,0
NCT04682041,12/22/2020,6/30/2021,Interventional,Evaluating the Impact of EnteraGam In People With COVID-19,Recruiting,Not Applicable,"Entera Health, Inc",NA,NA,NA,NA,NA,NA,Spain,0,1,Bovine Plasma-Derived Immunoglobulin Concentrate|Standard of care,0
NCT04680858,7/1/2020,1/31/2021,Interventional,Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19,Enrolling by invitation,Not Applicable,University of Ulm,NA,NA,NA,NA,NA,NA,Germany,0,1,DECT,0
NCT04679909,2/25/2021,2/28/2022,Interventional,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),"Active, not recruiting",Phase 1,"Altimmune, Inc.",NA,NA,NA,NA,NA,NA,United States,0,4,AdCOVID|Placebo,1
NCT04679493,12/17/2020,4/9/2021,Interventional,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers",Completed,Phase 1,NP Therapeutics,NA,NA,NA,NA,NA,NA,Russian Federation,0,2,XC7 100 mg single|XC7 200 mg single|Placebo single|XC7 200 mg multiple|Placebo multiple,0
NCT04681053,2/25/2021,4/30/2021,Interventional,Inhaled Ivermectin and COVID-19,Recruiting,Phase 3,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,2,Ivermectin Powder,0
NCT04681001,12/20/2020,5/30/2021,Interventional,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Recruiting,Not Applicable,Marinomed Biotech AG,NA,NA,NA,NA,NA,NA,Austria,0,1,nasal spray,0
NCT04680949,12/23/2020,3/31/2021,Interventional,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,"Active, not recruiting",Phase 3,Hellenic Institute for the Study of Sepsis,NA,NA,NA,NA,NA,NA,Greece|Italy,0,4,Anakinra|Placebo,0
NCT04679350,3/18/2021,11/30/2021,Interventional,Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,hzVSF-v13|Placebo (Normal saline solution),0
NCT04679415,12/17/2020,8/19/2021,Interventional,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,Completed,Phase 2,"ImmuneMed, Inc.",NA,NA,NA,NA,NA,NA,Indonesia,0,2,hzVSF-v13|Placebo (Normal saline solution),0
NCT04676867,1/11/2021,5/17/2021,Interventional,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,Completed,Phase 2,DalCor Pharmaceuticals,NA,NA,NA,NA,NA,NA,Canada,0,NA,Dalcetrapib|Placebo,0
NCT04678700,3/1/2021,6/1/2021,Interventional,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,Not Applicable,European University of Madrid,NA,NA,NA,NA,NA,NA,Spain,0,1,Chest physiotherapy post-covid19,0
NCT04678739,8/15/2020,1/30/2021,Interventional,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,Phase 3,M Abdur Rahim Medical College and Hospital,NA,NA,NA,NA,NA,NA,Bangladesh,0,3,Remdesivir|Tocilizumab,0
NCT04678830,3/1/2021,6/5/2021,Interventional,COVID-19 Long-Haulers Study,Completed,Phase 2,"CytoDyn, Inc.",NA,NA,NA,NA,NA,NA,United States,0,7,Placebos|Leronlimab (700mg),0
NCT04678778,3/19/2019,2/19/2021,Interventional,Virtual Reality Study - COVID-19 Protocol,Completed,Not Applicable,University of Southern California,NA,NA,NA,NA,NA,NA,United States,0,2,Physical and Cognitive Activity,0
NCT04678687,1/1/2021,6/1/2021,Interventional,COVID-19 and Tissue Damage in Vital Organs,"Active, not recruiting",Not Applicable,Dokuz Eylul University,NA,NA,NA,NA,NA,NA,Turkey,0,1,"Liver, lung, heart and kidney biopsy",0
NCT04677660,1/21/2021,3/3/2022,Interventional,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,NA,NA,NA,NA,NA,Japan,0,5,TAK-919|Placebo,0
NCT04676971,12/11/2020,8/29/2021,Interventional,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,Completed,Phase 2,"ImmuneMed, Inc.",NA,NA,NA,NA,NA,NA,Italy|Russian Federation,0,4,hzVSF-v13|Placebo (Normal saline solution),0
NCT04674189,12/23/2020,6/30/2022,Interventional,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,"Active, not recruiting",Phase 3,CureVac AG,NA,NA,NA,NA,NA,NA,Germany,0,4,CVnCoV Vaccine|Placebo,1
NCT04674644,10/16/2020,10/23/2020,Interventional,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Completed,Not Applicable,Suleyman Demirel University,NA,NA,NA,NA,NA,NA,Turkey,1,2,The psychosocial effects of COVID-19 pandemic on dental professionals,0
NCT04674566,4/21/2021,10/30/2021,Interventional,Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19,Recruiting,Phase 1/Phase 2,Corat Therapeutics Gmbh,NA,NA,NA,NA,NA,NA,Germany,0,5,COR-101|Placebo,0
NCT04673149,12/23/2020,7/31/2022,Interventional,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),Recruiting,Phase 1/Phase 2,"GeneOne Life Science, Inc.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,2,GLS-5310|Placebo,1
NCT04673318,2/26/2021,12/31/2024,Interventional,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Recruiting,Not Applicable,"University of Massachusetts, Amherst",NA,NA,NA,NA,NA,NA,United States,0,1,heat therapy|exercise training,0
NCT04673214,12/16/2020,2/25/2021,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Completed,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,NA,NA,NA,NA,Mexico,1,4,Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Azithromycin / Ribaroxaban / Paracetamol,0
NCT04669015,6/10/2021,8/31/2021,Interventional,Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,Genova Inc.,NA,NA,NA,NA,NA,NA,Brazil|Chile|Colombia,0,5,Novaferon|Placebo,0
NCT04668339,1/7/2021,4/30/2022,Interventional,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"Active, not recruiting",Phase 2,"Arcturus Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States|Singapore,0,3,"ARCT-021 single dose priming|ARCT-021 two lower dose priming|ARCT-021 two higher dose priming|Placebo (two doses), priming|Randomized booster|Placebo booster",1
NCT04668469,6/8/2020,9/15/2020,Interventional,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,Not Applicable,Benha University,NA,NA,NA,NA,NA,NA,Egypt,0,0,Hydroxychloroquine|Ivermectin|personal protective Measures,0
NCT04668950,12/22/2020,6/4/2021,Interventional,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),Completed,Phase 3,Washington University School of Medicine,NA,NA,NA,NA,NA,NA,United States|Canada,0,10,Fluvoxamine|Placebo,0
NCT04668235,4/23/2021,11/30/2021,Interventional,Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected),Recruiting,Phase 3,HRH Pharmaceuticals Limited,NA,NA,NA,NA,NA,NA,Brazil,0,3,AZVUDINE|AZVUDINE placebo,0
NCT04665193,11/23/2020,2/28/2021,Interventional,An Approach to Screening for COVID-19 at Vancouver Airport,Completed,Not Applicable,University of British Columbia,NA,NA,NA,NA,NA,NA,Canada,0,1,Rapid Antigen Test,0
NCT04666012,12/29/2020,7/9/2021,Interventional,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,"Cellid Co., Ltd.",NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,3,AdCLD-CoV19,1
NCT04666116,4/1/2020,12/31/2020,Interventional,Changes in Viral Load in COVID-19 After Probiotics,Recruiting,Not Applicable,Hospital de Sagunto,NA,NA,NA,NA,NA,NA,Spain,0,1,Dietary supplementation in patients with covid disease admitted to hospital,0
NCT04667286,1/16/2021,6/1/2021,Interventional,Awake Pronation for Covid-19 Treatment,Recruiting,Not Applicable,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,NA,NA,NA,NA,NA,Italy,0,1,Prone Position (PP),0
NCT04666441,12/15/2020,3/4/2021,Interventional,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,Completed,Phase 2,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,3,REGN10933+REGN10987 combination therapy|Placebo,0
NCT04666558,11/30/2020,12/17/2021,Interventional,Heal-Me Personalized Online Nutrition and Exercise Routines,Recruiting,Not Applicable,University of Alberta,NA,NA,NA,NA,NA,NA,Canada,0,0,Exercise & Nutrition|Exercise & Nutrition,0
NCT04666493,12/4/2020,11/30/2021,Interventional,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19,Recruiting,Not Applicable,"Anagnostou, Evdokia, M.D.",NA,NA,NA,NA,NA,NA,Canada,0,0,"Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum",0
NCT04664010,2/6/2020,1/14/2021,Interventional,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting",Not Applicable,Xi'an International Medical Center Hospital,NA,NA,NA,NA,NA,NA,China,0,0,"Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment",0
NCT04662021,12/10/2020,2/10/2021,Interventional,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Aerobic Exercises,0
NCT04661839,12/24/2020,7/27/2021,Interventional,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,Completed,Phase 1,Emergent BioSolutions,NA,NA,NA,NA,NA,NA,United States,0,3,COVID-HIGIV|Placebo (saline),0
NCT04663737,12/3/2020,8/16/2021,Interventional,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19","Active, not recruiting",Phase 2,"Senhwa Biosciences, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,Silmitasertib|SOC,0
NCT04662671,11/18/2020,12/9/2020,Interventional,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,Phase 1/Phase 2,KNOWBio Inc.,NA,NA,NA,NA,NA,NA,United States,0,1,RD-X19,0
NCT04661930,12/13/2020,4/1/2021,Interventional,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 3,Hebrew University of Jerusalem,NA,NA,NA,NA,NA,NA,Israel,0,0,TriCorÂ® 145mg tablets|Usual Care|Placebo,0
NCT04661540,3/2/2021,9/30/2021,Interventional,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,CM4620-IE (Injectable Emulsion)|Placebo,0
NCT04661527,4/22/2020,12/30/2020,Interventional,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,NA,NA,NA,NA,NA,Spain,0,1,Sarilumab,0
NCT04659941,10/1/2020,10/1/2021,Interventional,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Phase 2,Universidade Federal do Rio de Janeiro,NA,NA,NA,NA,NA,NA,Brazil,0,0,BCG vaccine,1
NCT04659486,9/24/2020,4/30/2021,Interventional,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Home-based exercise training,0
NCT04659707,2/22/2021,12/31/2021,Interventional,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Recruiting,Phase 1,University of Kansas Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Hyperpolarized Xe129,0
NCT04659239,1/28/2021,9/30/2021,Interventional,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Enrolling by invitation,Phase 3,Chinese Academy of Medical Sciences,NA,NA,NA,NA,NA,NA,Brazil|Malaysia,0,2,Inactivated SARS-CoV-2 Vaccine (Vero cell)|Placebo,1
NCT04659122,8/17/2021,1/31/2022,Interventional,A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection,Recruiting,Phase 1,"Airway Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,1,AT-100,0
NCT04659109,12/16/2020,8/6/2021,Interventional,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,Completed,Phase 2,Acticor Biotech,NA,NA,NA,NA,NA,NA,France,0,2,Placebo|glenzocimab,0
NCT04658979,12/31/2020,3/31/2021,Interventional,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,Not Applicable,"Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University Laval",NA,NA,NA,NA,NA,NA,Canada,0,1,Pulmonary tele-rehabilitation,0
NCT04658433,12/5/2020,2/15/2021,Interventional,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,Not Applicable,Applied Science Private University,NA,NA,NA,NA,NA,NA,Jordan,0,0,300 mg of omega3-FA,0
NCT04657471,12/8/2020,3/8/2021,Interventional,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Completed,Not Applicable,"University Hospital, Angers",NA,NA,NA,NA,NA,NA,France,0,3,revised HOME-CoV score,0
NCT04657497,11/9/2020,3/26/2021,Interventional,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Completed,Phase 3,Ono Pharmaceutical Co. Ltd,NA,NA,NA,NA,NA,NA,Japan,0,2,FOY-305|Placebo,0
NCT04657484,12/8/2020,12/7/2021,Interventional,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Recruiting,Not Applicable,Postgraduate Institute of Medical Education and Research,NA,NA,NA,NA,NA,NA,India,0,3,Medium dose prednisolone|Low dose prednisolone,0
NCT04656626,7/7/2020,7/21/2020,Interventional,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,Not Applicable,Imam Abdulrahman Bin Faisal University,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,2,brief mindfulness based intervention|Progressive muscle relaxation,0
NCT04656691,1/4/2021,4/18/2021,Interventional,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,Phase 4,UnitedHealth Group,NA,NA,NA,NA,NA,NA,United States,0,3,bamlanivimab,0
NCT04655716,7/19/2021,6/30/2022,Interventional,Urine Alkalinisation to Prevent AKI in COVID-19,Recruiting,Phase 3,Guy's and St Thomas' NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Sodium Bicarbonate 150Meq/L/D5W Inj,0
NCT04655625,11/23/2020,4/2/2021,Interventional,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 2/Phase 3,"AnGes, Inc.",NA,NA,NA,NA,NA,NA,Japan,0,2,Group A (AG0302-COVID19)|Group A (Placebo)|Group B (AG0302-COVID19)|Group B (Placebo),1
NCT04654481,12/31/2020,2/28/2021,Interventional,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,Not Applicable,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States,0,0,HCFWO|Standard Care Plus Monitoring,0
NCT04653831,11/8/2020,11/30/2021,Interventional,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,Not Applicable,Soroka University Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Pirfenidone|Standard of care,0
NCT04652674,9/28/2020,6/30/2021,Interventional,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic,Recruiting,Not Applicable,Cedars-Sinai Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Telemedicine visit|In-person postoperative visit,0
NCT04652765,2/3/2021,9/15/2021,Interventional,Camostat With Bicalutamide for COVID-19,Terminated,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,PI Decision to close/stop the study due to no new accrual.,NA,NA,NA,NA,NA,United States,0,4,Camostat Mesilate|Bicalutamide 150 mg,0
NCT04652115,1/1/2021,11/1/2022,Interventional,Defibrotide for the Treatment of Severe COVID-19,Recruiting,Phase 2,Brigham and Women's Hospital,NA,NA,NA,NA,NA,NA,United States,0,1,Defibrotide,0
NCT04649775,4/9/2021,7/31/2022,Interventional,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,Not Applicable,Duke University,NA,NA,NA,NA,NA,NA,United States,0,3,AirFLO2,0
NCT04649424,12/22/2020,4/13/2021,Interventional,COVID-19 Nasal Swab Trial,Completed,Not Applicable,Orthopaedic Innovation Centre,NA,NA,NA,NA,NA,NA,Canada,0,2,CanSwab,0
NCT04649021,12/4/2020,12/31/2021,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Active, not recruiting",Phase 2,BioNTech SE,NA,NA,NA,NA,NA,NA,China,0,2,BNT162b2|Placebo,1
NCT04649086,6/5/2020,10/31/2022,Interventional,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,Not Applicable,"University Hospital, Clermont-Ferrand",NA,NA,NA,NA,NA,NA,France,0,3,Rehabilitation by Eccentric exercises|Rehabilitation by Concentric exercises,0
NCT04646655,7/27/2020,5/31/2021,Interventional,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Phase 3,ASST Fatebenefratelli Sacco,NA,NA,NA,NA,NA,NA,Italy,0,0,Enoxaparin,0
NCT04647747,11/30/2020,3/30/2021,Interventional,Silent Hypoxia and Awake Proning in COVID-19 Patients,Recruiting,Not Applicable,Ostfold Hospital Trust,NA,NA,NA,NA,NA,NA,Norway,0,2,Self measurement with pulse oximeter,0
NCT04646603,1/28/2021,12/31/2021,Interventional,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,"Active, not recruiting",Phase 1/Phase 2,MedRegen LLC,NA,NA,NA,NA,NA,NA,United States,0,7,MRG-001|Placebo,0
NCT04648800,7/7/2020,12/31/2020,Interventional,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Phase 3,University of Rzeszow,NA,NA,NA,NA,NA,NA,Poland,0,0,BCG-10 vaccine|0.9% saline,1
NCT04647305,1/16/2021,3/4/2021,Interventional,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Completed,Not Applicable,"University of Los Andes, Columbia",NA,NA,NA,NA,NA,NA,Colombia,0,2,Closed face shield with Surgical face mask use|Surgical face mask use only,0
NCT04646590,12/16/2020,4/30/2022,Interventional,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China|Ecuador|Indonesia|Pakistan|Uzbekistan,0,4,Recombinant new coronavirus vaccine (CHO cell) group|Recombinant new coronavirus vaccine (CHO cells) placebo group,1
NCT04646616,1/15/2021,10/31/2021,Interventional,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,Recruiting,Not Applicable,Drexel University,NA,NA,NA,NA,NA,NA,United States,0,2,Community popular opinion leader (POL) based intervention,0
NCT04646109,5/11/2020,9/2/2020,Interventional,Ivermectin for Severe COVID-19 Management,Completed,Phase 3,Afyonkarahisar Health Sciences University,NA,NA,NA,NA,NA,NA,Turkey,1,1,Ivermectin,0
NCT04645407,2/1/2020,4/15/2020,Interventional,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Phase 4,ShuGuang Hospital,NA,NA,NA,NA,NA,NA,China,0,0,Fuzheng Huayu tablet,0
NCT04643964,11/17/2020,6/5/2021,Interventional,Brief Video Interventions for Depression,Completed,Not Applicable,Ohio State University,NA,NA,NA,NA,NA,NA,United States,0,1,EntrÃ©e: Behavioral skills|EntrÃ©e: Cognitive skills|EntrÃ©e: Interpersonal skills|Sampler skills,0
NCT04644185,3/27/2021,6/27/2021,Interventional,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Sinocelltech Ltd.,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru,0,4,SCTA01|Placebo,0
NCT04644198,6/1/2021,12/1/2021,Interventional,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Recruiting,Phase 2,The University of The West Indies,NA,NA,NA,NA,NA,NA,Jamaica,0,4,Convalescent Plasma Infusion,0
NCT04644120,12/10/2020,8/24/2021,Interventional,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),Completed,Phase 1,AbbVie,NA,NA,NA,NA,NA,NA,United States|Hungary|Israel|Netherlands|Puerto Rico,0,6,ABBV-47D11|Placebo for ABBV-47D11|ABBV-2B04|Placebo for ABBV-2B04,0
NCT04643691,9/11/2020,9/30/2022,Interventional,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Phase 2,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,0,Losartan 50 mg and Spironolactone 25 mg pillules oral use,0
NCT04643561,11/1/2020,12/31/2020,Interventional,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Hadassah Medical Organization,NA,NA,NA,NA,NA,NA,Israel,0,1,Travelan OTC,0
NCT04643678,10/30/2020,4/30/2021,Interventional,Anakinra in the Management of COVID-19 Infection,Recruiting,Phase 2/Phase 3,Hamad Medical Corporation,NA,NA,NA,NA,NA,NA,Qatar,0,2,Anakinra|Standard of Care,0
NCT04642040,6/30/2020,1/31/2021,Interventional,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,Not Applicable,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,Pulmonary Rehabilitation,0
NCT04641195,4/22/2021,11/30/2021,Interventional,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Recruiting,Phase 3,Harvard School of Public Health (HSPH),NA,NA,NA,NA,NA,NA,India,0,2,Vitamin D3 (cholecalciferol)|Zinc (zinc gluconate)|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|Placebo,0
NCT04640038,12/18/2020,12/31/2022,Interventional,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Phase 3,Children's Hospital of Philadelphia,NA,NA,NA,NA,NA,NA,United States,0,2,Sulfur hexafluoride lipid-type A microspheres,0
NCT04639349,11/19/2020,3/1/2021,Interventional,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,0,exercise group|control group,0
NCT04640402,11/17/2020,2/18/2021,Interventional,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,1,Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Low-dose placebo (18-59 years) & Two dose regimen|Low-dose placebo (18-59 years) & Three dose regimen|High-dose placebo (18-59 years) & Two dose regimen|High-dose placebo (18-59 years) & Three dose regimen|Low-dose placebo (60-85 years) & Two dose regimen|Low-dose placebo (60-85 years) & Three dose regimen|High-dose placebo (60-85 years) & Two dose regimen|High-dose placebo (60-85 years) & Three dose regimen,1
NCT04638673,11/19/2020,6/30/2021,Interventional,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,"Active, not recruiting",Phase 2,Medical University of South Carolina,NA,NA,NA,NA,NA,NA,United States,0,2,Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group,0
NCT04640233,11/30/2020,8/31/2021,Interventional,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,"Active, not recruiting",Phase 2/Phase 3,Dr. Reddy's Laboratories Limited,NA,NA,NA,NA,NA,NA,India,0,2,Gam-COVID-Vac|Placebo,1
NCT04640181,12/1/2020,6/28/2021,Interventional,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),Completed,Phase 2,St. David's HealthCare,NA,NA,NA,NA,NA,NA,United States,0,3,Enoxaparin|Rivaroxaban,0
NCT04639375,11/15/2020,6/12/2021,Interventional,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 4,E-MO Biology Inc,NA,NA,NA,NA,NA,NA,United States,0,5,Vaccinated with polio vaccine (IPV),1
NCT04637477,8/1/2020,12/31/2020,Interventional,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,Completed,Not Applicable,Rush University Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Virtual ELM,0
NCT04636671,4/14/2021,8/1/2021,Interventional,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Recruiting,Phase 3,University of Trieste,NA,NA,NA,NA,NA,NA,Italy,0,1,Methylprednisolone|Dexamethasone,0
NCT04637867,11/23/2020,5/12/2021,Interventional,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Completed,Not Applicable,Hospices Civils de Lyon,NA,NA,NA,NA,NA,NA,France,0,2,"Collection of blood, salivary and nasopharyngeal samples.",0
NCT04637828,11/18/2020,7/30/2021,Interventional,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Genoscience Pharma,NA,NA,NA,NA,NA,NA,France,0,1,GNS561,0
NCT04636697,11/19/2020,12/31/2021,Interventional,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,"Active, not recruiting",Phase 2/Phase 3,Medicago,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Canada|Mexico|United Kingdom,0,19,Intramuscular injection|Intramuscular vaccine,1
NCT04635605,11/5/2020,12/31/2021,Interventional,Methylene Blue Treatment of COVID-19,Recruiting,Phase 2,Fondazione Epatocentro Ticino,NA,NA,NA,NA,NA,NA,Switzerland,0,1,Methylene Blue|Control Test,0
NCT04636320,6/13/2020,1/13/2021,Interventional,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,Not Applicable,"University Hospital, Bordeaux",NA,NA,NA,NA,NA,NA,France,0,0,Contrast-enhanced CMR|Exercise test ECG|Blood sample|Resting 12 lead ECG|24 hour Holter ECG,0
NCT04636333,10/30/2020,12/7/2021,Interventional,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,3,"Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#",1
NCT04636086,11/12/2020,1/31/2022,Interventional,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Phase 4,University of Liege,NA,NA,NA,NA,NA,NA,Belgium,0,1,Cholecalciferol|Placebo,0
NCT04635618,11/5/2020,7/13/2021,Interventional,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,Not Applicable,Hospital de Clinicas de Porto Alegre,NA,NA,NA,NA,NA,NA,Brazil,0,0,Cognitive Behavioral Brief-Telepsychotherapy|Brief Interpersonal Telepsychotherapy|Telepsychoeducation,0
NCT04634799,1/8/2021,11/30/2021,Interventional,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Phase 1/Phase 2,Northwestern University,NA,NA,NA,NA,NA,NA,United States,0,2,TM5614|Placebo,0
NCT04634422,11/16/2020,6/30/2021,Interventional,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Recruiting,Not Applicable,"Rigshospitalet, Denmark",NA,NA,NA,NA,NA,NA,Denmark,0,1,Plasma exchange and convalescent plasma,0
NCT04634318,12/10/2020,1/31/2022,Interventional,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,Not Applicable,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,NA,NA,NA,NA,NA,France,0,5,Respiratory rehabilitation program (RR).|Respiratory tele-rehabilitation program (TRR).,0
NCT04632602,4/14/2020,11/29/2020,Interventional,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Completed,Not Applicable,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,NA,NA,France,0,1,physiological effects of awake prone position in COVID 19 patients,0
NCT04632719,11/8/2020,12/29/2020,Interventional,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,The use of the MentalPlusÂ® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19,0
NCT04632082,11/5/2020,7/13/2021,Interventional,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,Not Applicable,Hospital de Clinicas de Porto Alegre,NA,NA,NA,NA,NA,NA,Brazil,0,1,Telepsychoeducation with personalized videos|Telepsychoeducation without personalized videos,0
NCT04632368,11/20/2020,8/10/2021,Interventional,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Completed,Not Applicable,Duke University,NA,NA,NA,NA,NA,NA,United States,0,3,Transcendental Meditation,0
NCT04631380,8/1/2020,1/31/2021,Interventional,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,Not Applicable,Hospital do Coracao,NA,NA,NA,NA,NA,NA,Brazil,0,0,PRAYER,0
NCT04629989,11/13/2020,3/5/2021,Interventional,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Completed,Not Applicable,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,NA,NA,Belgium,0,3,Standard Oxygen Delivery System|Double-Trunk Mask|Surgical Mask,0
NCT04631536,1/10/2021,5/31/2021,Interventional,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Recruiting,Phase 3,Lebanese American University Medical Center,NA,NA,NA,NA,NA,NA,Lebanon,0,2,Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|Placebo,0
NCT04631666,12/8/2020,8/11/2021,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,Completed,Phase 1/Phase 2,University of Cologne,NA,NA,NA,NA,NA,NA,Germany,0,3,DZIF-10c|Placebo,0
NCT04630054,11/15/2020,6/29/2021,Interventional,Face Masks to Reduce COVID-19 in Bangladesh,Completed,Not Applicable,Yale University,NA,NA,NA,NA,NA,NA,Bangladesh,0,2,Face mask|Face mask awareness,0
NCT04629105,7/24/2020,8/31/2023,Interventional,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER),Recruiting,Phase 1,Longeveron Inc.,NA,NA,NA,NA,NA,NA,United States,0,2,Longeveron Mesenchymal Stem Cells (LMSCs)|Placebo,0
NCT04629157,11/5/2020,2/1/2021,Interventional,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Completed,Not Applicable,Alder Hey Children's NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Innova Lateral Flow Device,0
NCT04628143,12/21/2020,4/5/2021,Interventional,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Completed,Phase 2,Chong Kun Dang Pharmaceutical,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,Nafamostat Mesilate,0
NCT04627675,12/30/2020,7/31/2021,Interventional,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"Active, not recruiting",Phase 1,Providence Health & Services,NA,NA,NA,NA,NA,NA,United States,0,3,CORVax|IL-12 plasmid|Cliniporator,1
NCT04625985,7/14/2020,3/8/2021,Interventional,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Completed,Phase 2,Laboratorios Silanes S.A. de C.V.,NA,NA,NA,NA,NA,NA,Mexico,0,1,Metformin Glycinate|Placebo oral tablet,0
NCT04625114,11/4/2020,10/1/2022,Interventional,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Phase 2,"University Hospital, Ghent",NA,NA,NA,NA,NA,NA,Belgium,0,1,Camostat|Placebo|Camostat|Placebo,0
NCT04623671,11/15/2020,9/30/2021,Interventional,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Phase 2,Capricor Inc.,NA,NA,NA,NA,NA,NA,United States,0,6,CAP-1002|Placebo,0
NCT04622865,6/1/2020,6/30/2022,Interventional,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Phase 2,AB Science,NA,NA,NA,NA,NA,NA,France,0,1,Masitinib|Isoquercetin|Best Supportive Care,0
NCT04623255,10/16/2020,10/15/2021,Interventional,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Phase 2,"University College, London",NA,NA,NA,NA,NA,NA,United Kingdom,0,0,OCTAPLAS,0
NCT04622826,5/15/2020,12/31/2020,Interventional,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Phase 2,Azienda USL Toscana Nord Ovest,NA,NA,NA,NA,NA,NA,Italy,0,0,immune plasma,0
NCT04621461,12/20/2020,2/8/2021,Interventional,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,NA,NA,NA,NA,NA,United States,0,2,Zinc Sulfate 220 MG|Placebo,0
NCT04621903,10/8/2020,10/27/2020,Interventional,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Shanshamani Vati Plus,0
NCT04621058,11/9/2020,11/30/2021,Interventional,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Phase 3,Bioaraba Health Research Institute,NA,NA,NA,NA,NA,NA,Spain,0,2,Vitamin D|PLACEBO,0
NCT04621149,11/15/2020,3/31/2021,Interventional,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,Recruiting,Phase 2,"Profact, Inc.",NA,NA,NA,NA,NA,NA,United States,0,3,"chlorine dioxide|zinc acetate|Famotidine|placebo|lactoferrin, green tea extract",0
NCT04621123,11/10/2020,5/31/2021,Interventional,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Completed,Phase 2,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,NA,NA,NA,NA,NA,Spain,0,2,Convalescent anti-SARS-CoV-2 MBT plasma|Control Group,0
NCT04619628,12/11/2020,6/26/2021,Interventional,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","Active, not recruiting",Phase 1,"Codagenix, Inc",NA,NA,NA,NA,NA,NA,United Kingdom,0,3,COVI-VAC|Placebo,1
NCT04619719,3/15/2021,12/15/2022,Interventional,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia,Recruiting,Not Applicable,Legacy Health System,NA,NA,NA,NA,NA,NA,United States,0,7,Hyperbaric Oxygen Therapy (HBOT),0
NCT04619706,12/14/2020,8/14/2021,Interventional,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"FSD Pharma, Inc.",NA,NA,NA,NA,NA,NA,United States,0,5,FSD201|Placebo,0
NCT04619290,10/12/2020,11/30/2020,Interventional,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,NA,NA,NA,NA,NA,Mexico,0,1,Sublingual Methylene blue|Control patients,0
NCT04618042,11/13/2020,5/14/2021,Interventional,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,FX06|Placebo of FX06,0
NCT04617483,10/31/2020,11/28/2020,Interventional,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Completed,Phase 3,"Sinovac Biotech Co., Ltd",NA,NA,NA,NA,NA,NA,China,0,1,"Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly",1
NCT04617262,1/27/2021,9/30/2021,Interventional,Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19,Recruiting,Not Applicable,The New School,NA,NA,NA,NA,NA,NA,United States,0,3,Remote Problem Management Plus,0
NCT04615975,11/1/2020,7/30/2021,Interventional,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,Not Applicable,University of Padova,NA,NA,NA,NA,NA,NA,Italy,0,0,Ketogenic diet with phytoextracts,0
NCT04615741,11/9/2020,1/22/2021,Interventional,Finding Wellness in the Pandemic,Completed,Not Applicable,University of Lethbridge,NA,NA,NA,NA,NA,NA,Canada,0,4,Trauma Informed Yoga|Trauma Informed Psychotherapy,0
NCT04615416,5/1/2020,3/31/2022,Interventional,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,Not Applicable,"Teachers College, Columbia University",NA,NA,NA,NA,NA,NA,United States,0,1,Emotion Regulation Training via Telehealth,0
NCT04614844,1/6/2021,9/15/2022,Interventional,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),Recruiting,Not Applicable,Yale University,NA,NA,NA,NA,NA,NA,United States,0,3,Simulation Intervention|Control,0
NCT04614883,10/21/2020,2/26/2021,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Completed,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,1,Volatile Organic Compounds analysis|Canine odor detection of Volatile Organic Compounds,0
NCT04615052,9/26/2020,10/31/2021,Interventional,Home-based Exercise in COVID-19 Survivors,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,1,Exercise training,0
NCT04614025,10/19/2020,8/4/2021,Interventional,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,"Active, not recruiting",Phase 2,Pluristem Ltd.,NA,NA,NA,NA,NA,NA,Germany|Israel,0,1,PLX-PAD,0
NCT04614012,7/2/2020,7/2/2022,Interventional,Hyperimmune Plasma for Patients With COVID-19,Recruiting,Not Applicable,A.O. Ospedale Papa Giovanni XXIII,NA,NA,NA,NA,NA,NA,Italy,0,0,treated with hyperimmune plasma,0
NCT04613297,10/19/2020,10/31/2021,Interventional,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,0,Baseline and during hospitalization blood samples|Baseline blood sample,0
NCT04613739,12/8/2020,9/1/2021,Interventional,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Recruiting,Not Applicable,Harvard Pilgrim Health Care,NA,NA,NA,NA,NA,NA,United States,0,2,insurance navigation,0
NCT04613271,10/15/2020,12/30/2021,Interventional,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,Recruiting,Phase 3,Ina-Respond,NA,NA,NA,NA,NA,NA,Indonesia,0,3,Favipiravir|Azithromycin,0
NCT04613050,7/2/2020,12/24/2021,Interventional,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,Not Applicable,Cairo University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Respiratory Training|Aerobic training,0
NCT04613310,9/25/2020,12/31/2020,Interventional,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,Not Applicable,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",NA,NA,NA,NA,NA,NA,Switzerland,0,1,Rapid Diagnostic Test vs PCR,0
NCT04611399,3/5/2021,3/5/2022,Interventional,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Recruiting,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,NA,NA,NA,NA,NA,Italy,0,2,VR for psychoeducation and relaxation|Text material for psychoeducation and audio for relaxation techniques,0
NCT04612972,9/9/2020,2/19/2021,Interventional,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Active, not recruiting",Phase 3,Universidad Peruana Cayetano Heredia,NA,NA,NA,NA,NA,NA,Peru,0,1,Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo,1
NCT04605887,1/18/2021,11/30/2023,Interventional,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Recruiting,Phase 2,Rambam Health Care Campus,NA,NA,NA,NA,NA,NA,Israel,0,2,Angiotensin 1-7,0
NCT04611256,8/1/2020,11/30/2020,Interventional,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,NA,NA,NA,NA,NA,Mexico,0,1,MSC|Control,0
NCT04609969,10/13/2020,10/17/2020,Interventional,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,Not Applicable,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,NA,NA,NA,NA,NA,France,0,3,RT-qPCR test|COVID-VIROÂ® test,0
NCT04609722,7/1/2020,2/1/2021,Interventional,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,Not Applicable,Adiyaman University Research Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,2,Solution-Focused Support Program,0
NCT04610502,9/6/2020,10/6/2020,Interventional,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,Completed,Phase 2,Caja Costarricense de Seguro Social,NA,NA,NA,NA,NA,NA,Costa Rica,0,2,Administration of Equine immunoglobulin anti SARS-CoV-2,0
NCT04610489,11/13/2020,3/10/2021,Interventional,Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19),Terminated,Not Applicable,Carilion Clinic,Difficulty with recruiting for the study and with staffing the study.,NA,NA,NA,NA,NA,United States,1,3,Quidel Sofia SARS Antigen FIA,0
NCT04609371,10/21/2020,3/1/2021,Interventional,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Completed,Not Applicable,"St. Mary's Research Center, Canada",NA,NA,NA,NA,NA,NA,Canada,0,2,self-care tools|lay telephone coaching,0
NCT04608201,12/9/2020,12/31/2021,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|Placebo of NICOTINE Transdermal patch,0
NCT04608097,10/28/2020,3/12/2021,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19,Completed,Not Applicable,Uppsala University,NA,NA,NA,NA,NA,NA,Sweden,0,3,Simple cognitive task intervention|Attention Placebo,0
NCT04608305,10/28/2020,5/1/2021,Interventional,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,Phase 1/Phase 2,Israel Institute for Biological Research (IIBR),NA,NA,NA,NA,NA,NA,Israel,0,3,"IIBR-100, low dose (prime)|IIBR-100 medium dose (prime)|IIBR-100 high-dose (prime)|IIBR-100 low-dose (prime-boost)|Saline Placebo (single)|Saline Placebo (double)|IIBR-100 medium-dose (prime-boost)|IIBR-100 high-dose (prime-boost)|IIBR-100 top-dose (prime-boost)",1
NCT04607915,5/4/2021,3/31/2022,Interventional,Technology-enabled Collaborative Care for Diabetes Management During COVID-19,Recruiting,Not Applicable,Centre for Addiction and Mental Health,NA,NA,NA,NA,NA,NA,Canada,0,2,Intervention for TECC Model,0
NCT04608266,12/3/2020,1/31/2022,Interventional,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,3,Camostat Mesylate|Placebo,0
NCT04606563,10/9/2020,6/30/2021,Interventional,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Phase 3,University of British Columbia,NA,NA,NA,NA,NA,NA,United States|Belgium|Canada|France|Japan|Spain,0,0,Losartan,0
NCT04606069,5/6/2021,11/30/2021,Interventional,Treat COVID-19 Patients With Regadenoson,Recruiting,Phase 1/Phase 2,"University of Maryland, Baltimore",NA,NA,NA,NA,NA,NA,United States,0,1,Regadenoson|Placebo Control,0
NCT04605588,12/2/2020,1/17/2021,Interventional,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Terminated,Phase 2,"Rutgers, The State University of New Jersey",Lack of participants willing to enroll,NA,NA,NA,NA,NA,United States,0,5,Placebo Nitazoxanide|Ribavirin|Placebo Ribavirin|Nitazoxanide|Hydroxychloroquine|Placebo Hydroxychloroquine,0
NCT04604977,9/15/2020,10/31/2021,Interventional,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,NA,NA,NA,NA,NA,Italy,0,0,Mindfulness,0
NCT04604743,4/20/2021,6/30/2023,Interventional,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Recruiting,Not Applicable,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,2,"Intervention, TBN",1
NCT04604704,1/28/2021,3/31/2022,Interventional,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Recruiting,Phase 2,AgelessRx,NA,NA,NA,NA,NA,NA,United States,0,6,Naltrexone|NAD+,0
NCT04604184,11/3/2020,3/24/2021,Interventional,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Terminated,Phase 2,Boehringer Ingelheim,Company decision,NA,NA,NA,NA,NA,United States|Brazil|Chile|Mexico|Puerto Rico|Spain,0,12,BI 764198|Placebo,0
NCT04604145,2/3/2021,8/18/2021,Interventional,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Completed,Not Applicable,David Grant U.S. Air Force Medical Center,NA,NA,NA,NA,NA,NA,United States,0,3,SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen,0
NCT04604223,1/18/2021,6/29/2021,Interventional,Effect of Pioglitazone on T2DM Patients With COVID-19,Recruiting,Phase 4,Dasman Diabetes Institute,NA,NA,NA,NA,NA,NA,Kuwait|Qatar,0,1,Pioglitazone 45 mg,0
NCT04603963,6/1/2020,10/10/2020,Interventional,Inspiratory Muscle Training in Patients With COVID-19,Terminated,Not Applicable,Hospital Israelita Albert Einstein,There was a change in the institutional flow reducing the cases of covid 19,NA,NA,NA,NA,NA,Brazil,0,1,power breathe,0
NCT04603781,12/4/2020,12/31/2021,Interventional,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Phase 2/Phase 3,University of Texas at Austin,NA,NA,NA,NA,NA,NA,United States,0,4,CBD Isolate|Full Spectrum CBD Oil|Broad-Spectrum CBD Oil|Placebo Oil,0
NCT04603924,10/7/2020,12/31/2021,Interventional,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Phase 2/Phase 3,NeuroBo Pharmaceuticals Inc.,NA,NA,NA,NA,NA,NA,United States,0,7,Niclosamide|Placebo,0
NCT04603729,5/30/2020,6/30/2020,Interventional,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Phase 3,Fatima Memorial Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,0,Dexamethasone 2 MG/ML|Methylprednisolone Injection,0
NCT04602949,11/12/2020,7/28/2021,Interventional,Detection of COVID-19 Using Breath Analysis - Validation Study,Recruiting,Not Applicable,Scentech Medical Technologies Ltd,NA,NA,NA,NA,NA,NA,Israel,0,1,Breath Biopsy Analysis,0
NCT04602871,7/3/2020,1/30/2021,Interventional,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Completed,Not Applicable,Scentech Medical Technologies Ltd,NA,NA,NA,NA,NA,NA,Israel,0,1,Breath Biopsy,0
NCT04602832,10/14/2020,12/31/2020,Interventional,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,Not Applicable,University of British Columbia,NA,NA,NA,NA,NA,NA,Canada,0,1,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,0
NCT04602442,10/1/2020,8/1/2021,Interventional,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,NA,NA,NA,NA,NA,Russian Federation,0,0,EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation,0
NCT04602312,10/28/2020,6/30/2021,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,Not Applicable,The University of Queensland,NA,NA,NA,NA,NA,NA,Australia,0,3,Meditation (1 x 20-minute guided audio training),0
NCT04602286,10/28/2020,6/30/2021,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,Not Applicable,The University of Queensland,NA,NA,NA,NA,NA,NA,Australia,0,3,Meditation (1 x 20-minute guided audio training),0
NCT04600999,10/7/2020,6/30/2021,Interventional,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Phase 3,University of Pecs,NA,NA,NA,NA,NA,NA,Hungary,0,0,Favipiravir,0
NCT04601077,11/1/2020,11/1/2021,Interventional,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin,Recruiting,Phase 1/Phase 2,Nitric Oxide Innovations LLC,NA,NA,NA,NA,NA,NA,United States,0,2,"Nitric Oxide lozenges, 30 mg|Placebo",0
NCT04599959,10/26/2020,1/20/2021,Interventional,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,Completed,Not Applicable,Boehringer Ingelheim,NA,NA,NA,NA,NA,NA,Mexico,1,3,Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol,0
NCT04600141,11/10/2020,10/20/2021,Interventional,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Recruiting,Phase 3,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,1,Tocilizumab|Heparin - Therapeutic dosage|Heparin - Prophylactic dosage,0
NCT04598594,11/6/2020,4/29/2021,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Completed,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,8,"Patch, Nicotine|Patch, Placebo",0
NCT04597047,8/20/2020,10/31/2022,Interventional,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,Not Applicable,LumiraDx UK Limited,NA,NA,NA,NA,NA,NA,United States,0,0,Capillary Collection & Testing|Venous Draw & Testing,0
NCT04597034,10/2/2020,12/30/2021,Interventional,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,NA,NA,NA,NA,Mexico,0,0,AN69-Oxiris|AN69-Standard,0
NCT04596085,9/16/2020,12/12/2020,Interventional,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Completed,Not Applicable,"The Herb, Inc",NA,NA,NA,NA,NA,NA,India,1,6,Investigational Product - ViraCide|Placebo - Starch Powder Soft gels,0
NCT04595136,11/2/2020,7/30/2021,Interventional,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,Recruiting,Phase 1/Phase 2,United Medical Specialties,NA,NA,NA,NA,NA,NA,Colombia,0,1,Drug COVID19-0001-USR|normal saline,0
NCT04595084,3/15/2021,11/1/2021,Interventional,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Recruiting,Not Applicable,Cambridge Health Alliance,NA,NA,NA,NA,NA,NA,United States,0,2,Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|Internet Cognitive Behavioral Therapy plus CHAMindWell|CHAMindWell,0
NCT04594668,4/24/2020,4/24/2021,Interventional,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Phase 2,University of Aarhus,NA,NA,NA,NA,NA,NA,Denmark,0,0,Senicapoc,0
NCT04594343,11/20/2020,9/10/2021,Interventional,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Completed,Phase 2,ETICA,NA,NA,NA,NA,NA,NA,Brazil,0,5,Disulfiram|Placebo,0
NCT04593433,3/4/2021,7/4/2021,Interventional,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,Completed,Not Applicable,Jewish General Hospital,NA,NA,NA,NA,NA,NA,Canada,0,3,Museum virtual guided tours,0
NCT04594330,6/1/2020,12/31/2020,Interventional,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Phase 2,Gadjah Mada University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,virgin coconut oil (VCO)|placebo,0
NCT04592549,12/4/2020,3/30/2023,Interventional,Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19,Recruiting,Phase 1,Ology Bioservices,NA,NA,NA,NA,NA,NA,United States,0,4,ADM03820|Placebo,0
NCT04593069,10/7/2020,2/28/2021,Interventional,The COGCOV Study in ICU Patients,Recruiting,Not Applicable,Ziekenhuis Oost-Limburg,NA,NA,NA,NA,NA,NA,Belgium,0,1,Neurocognitive assessment,0
NCT04592354,10/15/2020,4/15/2021,Interventional,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,Not Applicable,Terra Biological LLC,NA,NA,NA,NA,NA,NA,United States,0,0,Oxaloacetate Medical Food/Dietary Supplement,0
NCT04591717,10/19/2020,11/19/2021,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,"Active, not recruiting",Phase 1,"ImmunityBio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,9,hAd5-S-Fusion+N-ETSD vaccine,1
NCT04591600,7/1/2020,9/30/2020,Interventional,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Phase 1/Phase 2,Alkarkh Health Directorate-Baghdad,NA,NA,NA,NA,NA,NA,Iraq,0,0,Ivermectin and Doxycyline|Standard of care,0
NCT04591158,9/15/2020,6/9/2021,Interventional,COVID-19 and Lung Ultrasound Utility,Completed,Not Applicable,Bridge to Health Medical and Dental USA,NA,NA,NA,NA,NA,NA,Canada,0,1,Butterfly iQ,0
NCT04590053,10/20/2020,2/28/2021,Interventional,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Phase 2,Hadassah Medical Organization,NA,NA,NA,NA,NA,NA,Israel,0,2,Allocetra-OTS,0
NCT04591613,12/31/2020,8/31/2022,Interventional,Late Clinical Events Associated With COVID-19 Infection,Recruiting,Not Applicable,Tourcoing Hospital,NA,NA,NA,NA,NA,NA,France|French Guiana,0,1,Questionnaire|Biocollection|Follow-up visit,0
NCT04591210,1/27/2021,8/31/2022,Interventional,The COVID-RASi Trial (COVID-19),Recruiting,Phase 3,Ottawa Heart Institute Research Corporation,NA,NA,NA,NA,NA,NA,Brazil|Canada|Mexico,0,2,Angiotensin converting enzyme inhibitor|Angiotensin II Receptor Blockers,0
NCT04591184,4/7/2021,8/31/2022,Interventional,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,"Active, not recruiting",Phase 1/Phase 2,Entos Pharmaceuticals Inc.,NA,NA,NA,NA,NA,NA,Canada,0,6,Covigenix VAX-001 placebo|Covigenix VAX-001,1
NCT04590469,3/1/2021,12/1/2021,Interventional,Improving Wellbeing and Health for Care Home Residents During COVID-19,Recruiting,Not Applicable,University of Exeter,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,COVID WHELD,0
NCT04590430,10/20/2020,4/30/2021,Interventional,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","Active, not recruiting",Phase 1,HiFiBiO Therapeutics,NA,NA,NA,NA,NA,NA,United States,0,3,HFB30132A|Placebo,0
NCT04589936,9/3/2020,6/30/2021,Interventional,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,Not Applicable,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Prone positioning,0
NCT04589949,10/12/2020,11/1/2022,Interventional,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Phase 3,Erasmus Medical Center,NA,NA,NA,NA,NA,NA,Netherlands,0,0,ConvP|FFP,0
NCT04588415,1/3/2021,12/1/2021,Interventional,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Enrolling by invitation,Not Applicable,Ottawa Hospital Research Institute,NA,NA,NA,NA,NA,NA,Canada,0,1,Bereavement Virtual Support Group,0
NCT04588792,4/16/2021,1/1/2022,Interventional,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Recruiting,Phase 2/Phase 3,Queen's University,NA,NA,NA,NA,NA,NA,Canada,0,5,Nebulized Furosemide|Nebulized Saline,0
NCT04587921,6/22/2020,1/22/2021,Interventional,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,Not Applicable,University of Sao Paulo General Hospital,NA,NA,NA,NA,NA,NA,Brazil,0,0,Digital oximeter monitoring,0
NCT04587414,3/6/2019,10/31/2020,Interventional,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",Not Applicable,UKK Institute,NA,NA,NA,NA,NA,NA,Finland,0,0,eHealth +counselling contacts|eHealth|Usual care,0
NCT04587219,10/22/2020,3/30/2021,Interventional,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,NA,NA,NA,NA,NA,Russian Federation,0,5,Gam-COVID-Vac,1
NCT04586153,2/15/2021,5/31/2022,Interventional,Study to Assess the Effect of Meplazumab on COVID-19,Recruiting,Phase 2/Phase 3,Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd,NA,NA,NA,NA,NA,NA,Brazil,0,2,Meplazumab for Injection|Sterile normal saline (0.9%),0
NCT04584593,10/2/2020,2/28/2022,Interventional,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,Not Applicable,"University Hospital, Toulouse",NA,NA,NA,NA,NA,NA,France,0,2,Sample,0
NCT04584710,10/13/2020,2/28/2021,Interventional,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"Active, not recruiting",Phase 2,Restorbio Inc.,NA,NA,NA,NA,NA,NA,United States,0,4,RTB101|Placebo,0
NCT04584541,6/11/2020,7/31/2023,Interventional,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,Not Applicable,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,1,blood tests|Nasopharyngeal swabs|Stools,0
NCT04583592,11/9/2020,3/31/2021,Interventional,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Completed,Phase 2,Sagent Pharmaceuticals Inc.,NA,NA,NA,NA,NA,NA,United States,0,18,Camostat Mesilate|Placebo,0
NCT04584580,8/1/2020,10/31/2020,Interventional,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 4,Ain Shams University,NA,NA,NA,NA,NA,NA,Egypt,0,0,low-molecular-weight heparin,0
NCT04583410,10/22/2020,12/31/2021,Interventional,Efficacy of Nicotine in Preventing COVID-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,4,Nicotine patch|Placebo patch,0
NCT04583449,8/19/2020,12/1/2020,Interventional,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,Not Applicable,University of East London,NA,NA,NA,NA,NA,NA,United Kingdom,0,0,Mental imagery,0
NCT04582214,9/28/2020,1/1/2021,Interventional,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,Not Applicable,Hill-Rom,NA,NA,NA,NA,NA,NA,United States,0,0,MetaNebÂ® System,0
NCT04583189,10/1/2020,11/25/2020,Interventional,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,Not Applicable,Centre Hospitalier Intercommunal Creteil,NA,NA,NA,NA,NA,NA,France,0,2,Performance of the test antigenic and test RT-PCR,0
NCT04582318,11/8/2020,6/30/2021,Interventional,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Phase 1/Phase 2,"NGM Biopharmaceuticals, Inc",NA,NA,NA,NA,NA,NA,Australia,0,1,NGM621|Placebo,0
NCT04581915,9/8/2020,12/31/2021,Interventional,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Phase 2/Phase 3,Wits Health Consortium (Pty) Ltd,NA,NA,NA,NA,NA,NA,South Africa,0,2,Triazavirin (Riamilovir)|Placebo,0
NCT04581811,11/10/2020,3/20/2021,Interventional,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Completed,Not Applicable,University of Alabama at Birmingham,NA,NA,NA,NA,NA,NA,United States,0,2,Prolonged Proned Positioning|Traditional Proning Arm,0
NCT04581746,11/25/2020,12/31/2021,Interventional,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,Not Applicable,Tourcoing Hospital,NA,NA,NA,NA,NA,NA,France,0,1,questionnaire,0
NCT04581031,7/11/2020,12/1/2021,Interventional,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,Not Applicable,The Christie NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Continuous vital sign monitoring - Isansys Patient Status Engine|Machine Learning/AI Algorithm,0
NCT04581291,1/1/2020,6/1/2020,Interventional,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,Not Applicable,Istanbul Gelisim University,NA,NA,NA,NA,NA,NA,Turkey,0,0,Moderate Intensity Aerobic Exercises,0
NCT04581018,8/13/2020,10/30/2021,Interventional,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,Not Applicable,Chinese University of Hong Kong,NA,NA,NA,NA,NA,NA,Hong Kong,0,1,Health supplements,0
NCT04579549,9/29/2020,3/31/2021,Interventional,Repeat Testing for SARS-CoV-2,Completed,Not Applicable,"University of Wisconsin, Madison",NA,NA,NA,NA,NA,NA,United States,0,4,Saliva Assay,0
NCT04581161,8/28/2020,10/31/2020,Interventional,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,Not Applicable,Hill-Rom,NA,NA,NA,NA,NA,NA,United States,0,0,Life2000Â® Ventilator,0
NCT04579640,10/27/2020,6/30/2021,Interventional,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Phase 3,Queen Mary University of London,NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Vitamin D,0
NCT04575038,11/19/2020,4/28/2021,Interventional,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,Completed,Phase 2,"Clear Creek Bio, Inc.",NA,NA,NA,NA,NA,NA,United States,0,10,Brequinar|Placebo,0
NCT04577534,8/14/2020,6/16/2021,Interventional,COVID-19: Salvage TOcilizumab as a Rescue Measure,Completed,Phase 3,Turku University Hospital,NA,NA,NA,NA,NA,NA,Finland,0,2,iv Tocillizumab (TCZ),0
NCT04577235,6/5/2020,8/5/2020,Interventional,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,Not Applicable,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,0,severity of lung involvement with COVID-19.,0
NCT04575584,10/19/2020,8/11/2021,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Terminated,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,Business reasons,NA,NA,NA,NA,NA,"United States|Brazil|Canada|Chile|Colombia|France|Israel|Italy|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|South Africa|Spain|Ukraine|United Kingdom",0,30,Molnupiravir|Placebo,0
NCT04576728,10/6/2020,7/31/2021,Interventional,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,"Active, not recruiting",Phase 2,Biotest,NA,NA,NA,NA,NA,NA,Brazil|France|Russian Federation|Spain,0,6,Trimodulin|Placebo (human albumin 1%),0
NCT04576312,6/29/2020,12/4/2020,Interventional,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,Completed,Phase 1,UNION therapeutics,NA,NA,NA,NA,NA,NA,Denmark,0,3,Placebo|UNI911 inhalation 1% and intranasal spray 1%,0
NCT04575064,6/29/2020,3/31/2022,Interventional,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Phase 2/Phase 3,"Klinikum Bremen-Mitte, gGmbH",NA,NA,NA,NA,NA,NA,Germany,0,0,Standard of Care (SoC)|Remdesivir,0
NCT04573764,2/1/2021,10/1/2021,Interventional,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Recruiting,Not Applicable,Steno Diabetes Center Copenhagen,NA,NA,NA,NA,NA,NA,Denmark,0,3,"D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|Placebo",0
NCT04574219,11/3/2020,10/31/2022,Interventional,Virtual Parental Presence on Induction,Recruiting,Not Applicable,"Children's Hospital Medical Center, Cincinnati",NA,NA,NA,NA,NA,NA,United States|Canada,0,1,Use of Facetime with child and parents during induction,0
NCT04573361,5/2/2020,5/27/2020,Interventional,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,Not Applicable,Real Centro Universitario Maria Cristina,NA,NA,NA,NA,NA,NA,Spain,0,0,Chiropractic care (one visit)|Chiropractic care (more than one visit),0
NCT04573153,9/21/2020,1/31/2021,Interventional,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Phase 2/Phase 3,ScandiBio Therapeutics AB,NA,NA,NA,NA,NA,NA,Turkey,0,1,Hydroxychloroquine + Metabolic cofactor supplementation|Hydroxychloroquine + Sorbitol,0
NCT04573270,4/24/2020,8/20/2020,Interventional,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Phase 1,Thomas Advanced Medical LLC,NA,NA,NA,NA,NA,NA,United States,0,0,PrimePro|Placebo,0
NCT04572412,11/25/2020,6/30/2022,Interventional,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Recruiting,Not Applicable,Lancashire Teaching Hospitals NHS Foundation Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Low dose Radiotherapy,0
NCT04570488,5/15/2020,12/30/2021,Interventional,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,Not Applicable,NYU Langone Health,NA,NA,NA,NA,NA,NA,United States,0,2,EPIC risk score display,0
NCT04570384,10/15/2020,8/30/2021,Interventional,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Phase 2,"Asklepion Pharmaceuticals, LLC",NA,NA,NA,NA,NA,NA,United States,0,5,L-Citrulline|Placebo,0
NCT04570397,12/18/2020,5/31/2021,Interventional,Ravulizumab and COVID-19,Recruiting,Phase 3,Brigham and Women's Hospital,NA,NA,NA,NA,NA,NA,United States,0,1,Ravulizumab,0
NCT04570254,8/19/2020,12/1/2020,Interventional,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Completed,Not Applicable,Unidad Temporal COVID-19 en Centro Citibanamex,NA,NA,NA,NA,NA,NA,Mexico,0,2,Vitamin C|Vitamin E|Melatonin|N-acetyl cysteine|Pentoxifylline,0
NCT04568811,9/26/2020,10/25/2020,Interventional,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,1,Adenovirus Type-5 Vectored COVID-19 Vaccine,1
NCT04569877,9/24/2020,12/25/2022,Interventional,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Phase 2,University of Giessen,NA,NA,NA,NA,NA,NA,Germany,0,2,Molgramostim nebuliser solution|Placebo nebuliser solution,0
NCT04570202,11/20/2020,2/19/2022,Interventional,Health cAre woRkers exposeD to COVID-19,Recruiting,Not Applicable,"University Hospital, Tours",NA,NA,NA,NA,NA,NA,France,0,4,EMDR,0
NCT04569227,4/30/2021,9/30/2021,Interventional,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,NA,NA,NA,NA,NA,United States,0,3,EC-18|Placebo,0
NCT04568889,9/28/2020,8/31/2022,Interventional,Minnesota COVID-19 Testing Project,"Active, not recruiting",Not Applicable,Harvard University,NA,NA,NA,NA,NA,NA,United States,0,2,A $10 Survey Incentive|A $20 Survey Incentive|Emphasis of Government Involvement|Emphasis of Academic Researchers Involvement|Cost-Benefit Frame|Duty Frame|Racial/Ethnic Frame|No Messaging,0
NCT04568863,6/20/2020,11/30/2020,Interventional,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Completed,Phase 2,Pharmamel S.L.,NA,NA,NA,NA,NA,NA,Spain,0,1,Melatonin intravenous|Placebo intravenous,0
NCT04568876,10/23/2020,2/28/2021,Interventional,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Completed,Phase 4,Epitech Group SpA,NA,NA,NA,NA,NA,NA,Italy,0,3,"Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Standard Therapy",0
NCT04567810,9/18/2020,12/14/2020,Interventional,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Completed,Phase 1,Stanford University,NA,NA,NA,NA,NA,NA,Australia,0,3,anti-SARS-CoV-2 IgY|Placebo,0
NCT04567953,7/28/2020,1/30/2021,Interventional,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",Not Applicable,Paradigm Laboratories LLC,NA,NA,NA,NA,NA,NA,United States,0,0,Saliva collection,0
NCT04566770,9/24/2020,8/21/2021,Interventional,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Phase 2,CanSino Biologics Inc.,NA,NA,NA,NA,NA,NA,China,0,1,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo,1
NCT04567173,9/21/2020,6/30/2021,Interventional,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Phase 2/Phase 3,University of the Philippines,NA,NA,NA,NA,NA,NA,Philippines,0,1,Anti-SARS-CoV-2 convalescent plasma,0
NCT04565379,9/25/2020,4/30/2021,Interventional,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,Recruiting,Phase 2,Shaperon,NA,NA,NA,NA,NA,NA,Romania,0,3,NuSepinÂ® 0.1 mg|NuSepinÂ® 0.2 mg|Placebo,0
NCT04563702,9/21/2020,5/10/2021,Interventional,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,Vaxart,NA,NA,NA,NA,NA,NA,United States,0,3,VXA-CoV2-1,1
NCT04564716,9/28/2020,3/28/2021,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,NA,NA,NA,NA,NA,Belarus,0,3,Gam-COVID-Vac|Placebo,1
NCT04565197,5/1/2020,12/30/2020,Interventional,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Early Phase 1,Lahore General Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,1,convalescent plasma,0
NCT04563689,6/18/2020,10/22/2020,Interventional,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,Not Applicable,Dentaid SL,NA,NA,NA,NA,NA,NA,Colombia,0,1,CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|placebo rinse,0
NCT04563208,12/9/2020,2/28/2022,Interventional,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,NA,NA,NA,NA,NA,South Africa,0,4,Placebo|DuACT,0
NCT04563676,9/22/2020,12/31/2021,Interventional,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,1,blood test,0
NCT04563650,9/18/2020,5/1/2021,Interventional,COVID-19 Serology and Immunosenescence,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,1,blood sample,0
NCT04563065,8/1/2020,11/30/2020,Interventional,Active Pregnancy Against COVID-19,Recruiting,Not Applicable,Universidad Politecnica de Madrid,NA,NA,NA,NA,NA,NA,Spain,0,3,Exercise program|Healthy lifestyle advise,0
NCT04561154,6/11/2020,6/11/2021,Interventional,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,Not Applicable,Centre Hospitalier le Mans,NA,NA,NA,NA,NA,NA,France,0,0,questionnaire,0
NCT04561219,4/19/2020,10/2/2020,Interventional,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,NA,NA,NA,NA,NA,Brazil,0,3,Nitazoxanide|Placebo,0
NCT04560881,9/16/2020,12/1/2021,Interventional,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Phase 3,Laboratorio Elea Phoenix S.A.,NA,NA,NA,NA,NA,NA,Argentina,0,2,Inactivated SARS-CoV-2 vaccine (Vero cell)|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine,1
NCT04561063,12/8/2020,2/28/2022,Interventional,COVID-19 Prophylaxis South Africa (COVER HCW),Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,NA,NA,NA,NA,NA,South Africa,0,3,Nitazoxanide|Sofosbuvir/Daclatasvir,0
NCT04560257,5/1/2020,12/30/2020,Interventional,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,Not Applicable,Lahore General Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,3,High flow nasal cannula HFNC,0
NCT04560231,6/1/2020,11/30/2020,Interventional,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Early Phase 1,Lahore General Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Remdesivir,0
NCT04560205,5/1/2020,12/30/2020,Interventional,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Phase 1,Lahore General Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Tocilizumab,0
NCT04559113,5/1/2020,12/30/2020,Interventional,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,Not Applicable,Lahore General Hospital,NA,NA,NA,NA,NA,NA,Pakistan,0,1,Methylprednisolone Injectable Product,0
NCT04559074,10/23/2020,4/30/2021,Interventional,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Phase 4,Queen Mary University of London,NA,NA,NA,NA,NA,NA,United Kingdom,0,2,Amlodipine,0
NCT04558463,4/16/2020,9/30/2020,Interventional,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Phase 3,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,0,Favipiravir|Oseltamivir 75mg,0
NCT04558411,9/12/2020,12/15/2020,Interventional,"Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Completed,Not Applicable,"Rutgers, The State University of New Jersey",NA,NA,NA,NA,NA,NA,United States,0,2,Dialectical Behavioral Therapy (DBT) Skills,0
NCT04558372,4/1/2020,12/12/2020,Interventional,Genosvid Diagnostic Test for Early Detection of COVID-19,Completed,Not Applicable,Gadjah Mada University,NA,NA,NA,NA,NA,NA,Indonesia,0,3,exhaled breath sampling|exhaled breath sampling|exhaled breath sampling,0
NCT04558021,10/8/2020,1/30/2021,Interventional,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Phase 3,Imuneks Farma ilac San. Tic. A.S.,NA,NA,NA,NA,NA,NA,Turkey,0,1,Niclosamide suspension|Placebo,0
NCT04555213,9/30/2020,8/10/2021,Interventional,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Completed,Phase 1,Noxopharm Limited,NA,NA,NA,NA,NA,NA,"Moldova, Republic of",0,5,NOX66,0
NCT04555148,9/19/2020,1/22/2021,Interventional,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Completed,Phase 2,Green Cross Corporation,NA,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,GC5131|Placebo,0
NCT04554992,3/20/2020,6/30/2022,Interventional,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Phase 1,The Methodist Hospital Research Institute,NA,NA,NA,NA,NA,NA,United States,0,1,COVID 19 Convalescent Plasma,0
NCT04554264,9/1/2020,9/30/2021,Interventional,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,NA,NA,France,0,0,questionnaire,0
NCT04553705,9/20/2020,11/4/2020,Interventional,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Phase 2/Phase 3,Beni-Suef University,NA,NA,NA,NA,NA,NA,Saudi Arabia,0,1,Omega 3/Nigella Sativa Oil|Omega 3/Nigella Sativa Oil/Indian Costus|Omega 3/Nigella Sativa Oil/Quinine pills|Omega 3/Nigella Sativa Oil/Anise seed capsule|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Active Comparator,0
NCT04552951,4/4/2020,9/14/2020,Interventional,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,NA,NA,NA,NA,NA,NA,Spain,0,0,Cholecalciferol,0
NCT04552483,6/8/2020,8/20/2020,Interventional,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,NA,NA,NA,NA,NA,Brazil,0,2,Nitazoxanide|Placebo,0
NCT04551768,2/10/2021,8/17/2021,Interventional,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,Completed,Phase 1,"Bausch Health Americas, Inc.",NA,NA,NA,NA,NA,NA,Greece|Mexico,0,5,50 mg/mL Virazole|100 mg/mL Virazole,0
NCT04551781,4/1/2020,7/30/2020,Interventional,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,Not Applicable,South Valley University,NA,NA,NA,NA,NA,NA,Egypt,0,0,20 Mg Prednisone for 14 days|control,0
NCT04551339,9/28/2020,5/28/2021,Interventional,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Completed,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,4,PreserVision AREDS formulation soft gels or tablets|Multivitamin with 11mg of zinc,0
NCT04536376,1/15/2021,9/2/2021,Interventional,First Responder Resiliency Program During COVID-19,"Active, not recruiting",Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,6,Resilience Program,0
NCT04550325,8/5/2020,11/26/2020,Interventional,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Completed,Phase 1/Phase 2,"Kamada, Ltd.",NA,NA,NA,NA,NA,NA,Israel,0,1,Kamada Anti-SARS-CoV-2,0
NCT04550351,8/19/2020,12/18/2020,Interventional,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,NA,NA,NA,NA,NA,China,0,3,Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group,1
NCT04549922,10/22/2020,2/28/2022,Interventional,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,"Active, not recruiting",Phase 2,Hospital do Coracao,NA,NA,NA,NA,NA,NA,Brazil,0,3,ISIS 721744|Normal Saline,0
NCT04548934,9/13/2020,10/31/2020,Interventional,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,Not Applicable,Institute of Mountain Emergency Medicine,NA,NA,NA,NA,NA,NA,Italy,0,1,Personal protective equipment (PPE)|No Personal protective equipment (PPE),0
NCT04548531,9/10/2020,4/30/2021,Interventional,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Completed,Not Applicable,Massachusetts General Hospital,NA,NA,NA,NA,NA,NA,United States,0,2,Shared Decision Making,0
NCT04548544,10/18/2019,5/20/2020,Interventional,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,Not Applicable,"University of California, San Francisco",NA,NA,NA,NA,NA,NA,United States,0,0,"Training for Awareness, Resilience, and Action (TARA)",0
NCT04547660,7/16/2020,1/7/2021,Interventional,Convalescent Plasma for Severe COVID-19 Patients,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,NA,NA,NA,NA,NA,NA,Brazil,0,1,Convalescent Plasma|Best Supportive Care,0
NCT04547283,6/14/2020,9/20/2020,Interventional,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Completed,Not Applicable,Atrium Health,NA,NA,NA,NA,NA,NA,United States,0,1,Usual Care|APPS,0
NCT04547634,7/1/2020,11/30/2020,Interventional,Telerehabilitation in Oncology Patients,Enrolling by invitation,Not Applicable,University of Malaga,NA,NA,NA,NA,NA,NA,Spain,0,0,Therapeutic Exercise and Education,0
NCT04547257,5/4/2021,8/15/2021,Interventional,Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19,Recruiting,Not Applicable,ExThera Medical Europe BV,NA,NA,NA,NA,NA,NA,Germany|Spain,0,3,Seraph 100,0
NCT04547127,4/29/2020,2/4/2021,Interventional,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,NA,NA,NA,NA,NA,Spain,0,3,Convalescent anti-SARS-CoV-2 MBT Plasma|Standard Medical Treatment,0
NCT04546841,11/27/2020,9/30/2021,Interventional,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,"Active, not recruiting",Phase 1,University Hospital Tuebingen,NA,NA,NA,NA,NA,NA,Germany,0,2,multipeptide cocktail,1
NCT04545541,11/1/2020,4/30/2022,Interventional,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Australian National University,NA,NA,NA,NA,NA,NA,United States,0,2,Nebulised unfractionated heparin (UFH),0
NCT04545749,9/25/2020,1/18/2021,Interventional,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",Completed,Phase 1,"United Biomedical Inc., Asia",NA,NA,NA,NA,NA,NA,Taiwan,0,4,UB-612,1
NCT04543760,10/1/2020,1/15/2021,Interventional,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Completed,Not Applicable,"Hospital St. Joseph, Marseille, France",NA,NA,NA,NA,NA,NA,France,0,3,Prone position|Supine position,0
NCT04542694,5/21/2020,8/10/2020,Interventional,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Phase 3,"Promomed, LLC",NA,NA,NA,NA,NA,NA,Russian Federation,1,3,Favipiravir|Standard of care,0
NCT04542967,6/23/2020,9/2/2020,Interventional,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Completed,Phase 2,Hospital Central Militar,NA,NA,NA,NA,NA,NA,Mexico,0,2,Biological,0
NCT04542993,9/8/2020,2/5/2021,Interventional,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Active, not recruiting",Phase 2,Swedish Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,Zinc Picolinate|Resveratrol|Zinc Picolinate Placebo|Resveratrol Placebo,0
NCT04542876,5/1/2020,7/31/2020,Interventional,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,Not Applicable,Aarogyam UK,NA,NA,NA,NA,NA,NA,India,0,0,Guduchi Ghan Vati,0
NCT04542343,11/1/2020,9/30/2021,Interventional,COVID-19 Risk Reduction Among African American Parishioners,Recruiting,Not Applicable,Charles Drew University of Medicine and Science,NA,NA,NA,NA,NA,NA,United States,0,1,"Change in knowledge, motivation, skills, resources",0
NCT04542330,9/15/2020,1/31/2022,Interventional,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Phase 3,Bandim Health Project,NA,NA,NA,NA,NA,NA,Denmark,0,2,BCG-Denmark|Saline,1
NCT04542213,8/1/2020,2/28/2021,Interventional,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Completed,Phase 3,Hospital Regional de Alta Especialidad del Bajio,NA,NA,NA,NA,NA,NA,Mexico,0,1,Linagliptin tablet|Insulin,0
NCT04542447,9/1/2020,9/30/2020,Interventional,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Phase 1,Natureceuticals Sdn Bhd,NA,NA,NA,NA,NA,NA,India,0,1,Nuvastatic,0
NCT04542421,7/1/2020,7/1/2021,Interventional,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,Not Applicable,"University of Colorado, Denver",NA,NA,NA,NA,NA,NA,United States,0,2,Lung ultrasound use in patients hospitalized with COVID,0
NCT04542395,6/1/2021,11/30/2022,Interventional,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Recruiting,Not Applicable,Charles Drew University of Medicine and Science,NA,NA,NA,NA,NA,NA,United States,0,2,Increasing Willingness and Uptake of COVID-19 Testing and Vaccination,1
NCT04542031,12/14/2020,10/31/2021,Interventional,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,Recruiting,Not Applicable,The Royal Wolverhampton Hospitals NHS Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Questionnaire,0
NCT04541979,6/4/2020,5/1/2021,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,NA,NA,NA,NA,NA,Sweden,0,1,aerosolized DNase|NaCl,0
NCT04540120,9/25/2020,10/31/2021,Interventional,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Phase 2,Olatec Therapeutics LLC,NA,NA,NA,NA,NA,NA,United States|Netherlands|Switzerland,0,18,dapansutrile capsules|placebo capsules,0
NCT04540419,9/11/2020,6/19/2021,Interventional,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Phase 3,NPO Petrovax,NA,NA,NA,NA,NA,NA,Russian Federation,0,4,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Placebo,1
NCT04541680,10/29/2020,3/31/2021,Interventional,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,NA,NA,France,0,2,Nintedanib 150 MG [Ofev]|Placebo,0
NCT04541485,12/4/2020,3/3/2021,Interventional,"To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)",Terminated,Phase 1,Daewoong Pharmaceutical Co. LTD.,Enrolment was suspended since 09Dec2020 due to a lack of COVID-19 patients.,NA,NA,NA,NA,NA,"Korea, Republic of",0,1,DWRX2003|Placebo,0
NCT04540406,10/1/2021,12/1/2021,Interventional,NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Recruiting,Phase 2,Notitia Biotechnologies Company,NA,NA,NA,NA,NA,NA,United States,0,8,NBT-NM108|Usual Care Only,0
NCT04540185,11/1/2020,11/1/2022,Interventional,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Phase 3,"NeuroActiva, Inc.",NA,NA,NA,NA,NA,NA,United States|New Zealand,0,1,Biological: oral polio vaccine|Comparable Placebo|NA-831|Comparable Placebo of drug|Combination of oral polio vaccine and NA-831|Comparable Placebo of Oral Polio Vaccine and Placebo of drug,1
NCT04539262,9/14/2020,2/26/2021,Interventional,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,Phase 1/Phase 2,Gilead Sciences,NA,NA,NA,NA,NA,NA,United States,0,9,Remdesivir (RDV)|Placebo,0
NCT04539626,10/1/2020,7/31/2021,Interventional,Estrogen Therapy in Non-severe COVID-19 Patients,Recruiting,Not Applicable,"CMN ""20 de Noviembre""",NA,NA,NA,NA,NA,NA,Mexico,0,2,Estrogen Therapy,0
NCT04539821,10/1/2020,5/31/2021,Interventional,Virtual Pain Care Management (COVID-19),Completed,Not Applicable,VA Office of Research and Development,NA,NA,NA,NA,NA,NA,United States,0,5,VCPM,0
NCT04537949,9/9/2020,3/12/2021,Interventional,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,NA,NA,NA,NA,NA,Germany,0,5,BNT162b3,1
NCT04537351,8/24/2020,12/31/2021,Interventional,The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause,Recruiting,Phase 1/Phase 2,Cynata Therapeutics Limited,NA,NA,NA,NA,NA,NA,Australia,0,3,CYP-001,0
NCT04537962,6/11/2020,12/30/2020,Interventional,Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices,Enrolling by invitation,Not Applicable,Hospital Israelita Albert Einstein,NA,NA,NA,NA,NA,NA,Brazil,0,1,Colgate PeriogardÂ® mouthwash|Colgate PeroxylÂ® mouthwash|Colgate TotalÂ® Mouthwash|Toothpaste with sodium monofluorophosphate|Toothpaste with sodium fluoride and zinc|Toothpaste with tin fluoride,0
NCT04537663,8/25/2020,6/25/2021,Interventional,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Phase 4,UMC Utrecht,NA,NA,NA,NA,NA,NA,Netherlands,0,1,Bacille Calmette-GuÃ©rin (BCG)|Placebo,1
NCT04537806,12/18/2020,7/1/2021,Interventional,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Terminated,Phase 3,Sage Therapeutics,Internal company decision,NA,NA,NA,NA,NA,United States,0,5,Brexanolone|Placebo,0
NCT04537299,10/31/2021,12/31/2023,Interventional,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,Enrolling by invitation,Phase 2,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,7,Fisetin|Placebo,0
NCT04536935,11/30/2020,6/20/2021,Interventional,Mobile Mental Health Apps for Suicide Prevention,Completed,Not Applicable,University of Washington,NA,NA,NA,NA,NA,NA,United States,0,4,Mobile Mental Health App - 1|Mobile Mental Health App - 2|Mobile Mental Health App - 3|Mobile Mental Health App - 4,0
NCT04536350,5/18/2021,12/31/2021,Interventional,Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS,Recruiting,Phase 2,"Cantonal Hosptal, Baselland",NA,NA,NA,NA,NA,NA,Switzerland,0,4,Aviptadil 67Î¼g|Placebo 0.9% NaCl solution,0
NCT04536441,4/1/2020,5/30/2020,Interventional,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,Not Applicable,Universiti Tunku Abdul Rahman,NA,NA,NA,NA,NA,NA,Malaysia,0,0,Ultra Brief Online Mindfulness-based Intervention|Control,0
NCT04535869,12/28/2020,4/1/2021,Interventional,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,Phase 3,Mansoura University,NA,NA,NA,NA,NA,NA,Egypt,0,3,Sofosbuvir 400 MG plus Daclatasvir 200mg,0
NCT04535856,11/14/2020,1/14/2021,Interventional,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Completed,Phase 1,Ina-Respond,NA,NA,NA,NA,NA,NA,Indonesia,0,6,allogeneic mesenchymal stem cell|Placebo,0
NCT04535674,10/9/2020,11/30/2021,Interventional,Asunercept in Patients With Severe COVID-19,Recruiting,Phase 2,Apogenix AG,NA,NA,NA,NA,NA,NA,Russian Federation|Spain,0,7,Asunercept,0
NCT04536298,12/28/2020,12/31/2021,Interventional,Vitamin D and COVID-19 Trial,Recruiting,Phase 3,Brigham and Women's Hospital,NA,NA,NA,NA,NA,NA,United States,0,4,vitamin D|Placebo,0
NCT04536051,6/2/2020,9/30/2021,Interventional,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Phase 3,University of Oxford,NA,NA,NA,NA,NA,NA,Brazil,0,2,ChAdOx1 nCoV-19 single dose + paracetamol|MenACWY single dose + paracetamol|ChAdOx1 nCoV-19 two dose + paracetamol|MenACWY prime & saline placebo boost + paracetamol,1
NCT04535700,9/18/2020,3/10/2021,Interventional,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Phase 4,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,NA,NA,NA,NA,NA,Spain,0,1,Pioglitazone 30 mg|standard of care,0
NCT04535063,4/18/2020,12/30/2020,Interventional,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,NA,NA,NA,NA,NA,Argentina,0,1,COVID19 convalescent plasma infusion,0
NCT04534790,7/24/2020,12/12/2020,Interventional,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Completed,Not Applicable,Instituto Mexicano del Seguro Social,NA,NA,NA,NA,NA,NA,Mexico,0,1,Low Dose Radiotherapy,0
NCT04534673,8/5/2020,12/31/2021,Interventional,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Phase 2,Soroka University Medical Center,NA,NA,NA,NA,NA,NA,Israel,0,0,Lambda 180 mcg S.C,0
NCT04534725,12/17/2020,12/31/2021,Interventional,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,Recruiting,Phase 3,"Peter MacCallum Cancer Centre, Australia",NA,NA,NA,NA,NA,NA,Australia,0,5,Interferon alfa|Selinexor|Lenzilumab,0
NCT04532931,9/3/2020,8/5/2021,Interventional,COVID-19 Treatment in South Africa,Completed,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,NA,NA,NA,NA,NA,South Africa,0,5,Standard of care (Paracetamol)|Artesunate-amodiaquine|Pyronaridine-artesunate|Favipiravir plus Nitazoxanide|Sofosbuvir/daclatasvir,0
NCT04532372,10/23/2020,9/18/2022,Interventional,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,Phase 1/Phase 2,City of Hope Medical Center,NA,NA,NA,NA,NA,NA,United States,0,3,Best Practice|Leflunomide|Placebo Administration,0
NCT04532294,9/8/2020,1/15/2021,Interventional,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Completed,Phase 1,BeiGene,NA,NA,NA,NA,NA,NA,Australia,0,5,BGB DXP593|Placebo,0
NCT04531774,8/28/2020,6/1/2021,Interventional,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,Not Applicable,University of Zurich,NA,NA,NA,NA,NA,NA,Switzerland,0,2,RECHARGE|Self Study,0
NCT04531618,8/13/2020,12/31/2021,Interventional,Mother-infant Bonding During COVID-19,Recruiting,Not Applicable,Columbia University,NA,NA,NA,NA,NA,NA,United States,0,1,Family Nurture Intervention (FNI),0
NCT04530422,4/15/2020,7/8/2020,Interventional,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Phase 3,Almaza Military Fever Hospital,NA,NA,NA,NA,NA,NA,Egypt,0,0,Sofosbuvir plus Ledipasvir,0
NCT04530370,5/29/2020,9/30/2020,Interventional,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Early Phase 1,South Valley University,NA,NA,NA,NA,NA,NA,Egypt,0,0,recovered covid 19 patients plasma,0
NCT04530656,8/28/2020,10/28/2020,Interventional,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,China,0,2,"Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Two doses of placebo at the schedule of day 0, 28ï¼ˆmiddle-dose groupï¼‰|Two doses of placebo at the schedule of day 0, 28ï¼ˆhigh-dose groupï¼‰|Three doses of placebo at the schedule of day 0, 14, 28ï¼ˆhigh-dose groupï¼‰",1
NCT04530136,11/30/2020,8/15/2021,Interventional,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,Pharming Technologies B.V.,NA,NA,NA,NA,NA,NA,United States,0,2,Ruconest,0
NCT04530448,10/5/2020,7/15/2021,Interventional,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,"Active, not recruiting",Phase 4,West Virginia University,NA,NA,NA,NA,NA,NA,United States,0,4,Sodium bicarbonate|Standard of Care,0
NCT04530578,6/1/2020,10/30/2020,Interventional,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 4,"Clinica San Camilo, Argentina",NA,NA,NA,NA,NA,NA,Argentina,0,1,Heparin sodium|Enoxaparin,0
NCT04529499,8/20/2020,3/31/2021,Interventional,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"Active, not recruiting",Phase 3,Dr. Reddy's Laboratories Limited,NA,NA,NA,NA,NA,NA,Kuwait,0,2,AVIGAN|Placebo Comparator,0
NCT04528368,12/11/2020,12/30/2021,Interventional,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Phase 2,D'Or Institute for Research and Education,NA,NA,NA,NA,NA,NA,Brazil,0,2,Convalescent plasma,0
NCT04528888,11/25/2020,6/30/2021,Interventional,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,Recruiting,Phase 3,University of Modena and Reggio Emilia,NA,NA,NA,NA,NA,NA,Italy,0,1,Enoxaparin|Methylprednisolone|unfractionated heparin,0
NCT04528329,3/30/2021,9/1/2021,Interventional,Anosmia and / or Ageusia and Early Corticosteroid Use,Recruiting,Phase 4,ClinAmygate,NA,NA,NA,NA,NA,NA,Egypt,0,4,Early-Dexamethasone|Late dexamethazone,0
NCT04527575,7/27/2020,5/31/2021,Interventional,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 1/Phase 2,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,NA,NA,NA,NA,NA,Russian Federation,0,3,"EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)",1
NCT04527354,9/1/2020,2/10/2021,Interventional,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,Completed,Phase 2,PHARMENTERPRISES LLC,NA,NA,NA,NA,NA,NA,Russian Federation,0,3,Treamid|Placebo,0
NCT04527432,12/16/2020,3/31/2022,Interventional,COVID-19 Health Professional Impact Study,"Active, not recruiting",Not Applicable,The Royal Wolverhampton Hospitals NHS Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,4,Survey|SARS-CoV-2 antibody test,0
NCT04527562,7/14/2020,11/15/2020,Interventional,Colchicine in Moderate Symptomatic COVID-19 Patients,Completed,Not Applicable,Dhaka Medical College,NA,NA,NA,NA,NA,NA,Bangladesh,0,2,Colchicine|Placebo,0
NCT04527471,9/4/2020,2/15/2021,Interventional,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2,Verona Pharma plc,NA,NA,NA,NA,NA,NA,United States,0,4,Ensifentrine Dose 1|Placebo pMDI,0
NCT05139433,10/15/2021,3/31/2023,Interventional,Brief Internet-delivered Intervention for Children and Adolescents With Anxiety and Depression Symptoms,Recruiting,Not Applicable,University of Sao Paulo,NA,NA,NA,NA,NA,NA,Brazil,0,0,Telepsychotherapy|Psychoeducational Videos,0
NCT05139979,9/15/2021,12/31/2023,Interventional,Yogic Breathing and Guided Meditation for Long Covid Symptoms,Enrolling by invitation,Not Applicable,Beth Israel Deaconess Medical Center,NA,NA,NA,NA,NA,NA,United States,0,0,Breathing and Wellness Webinar|Routine Daily Activity,0
NCT05121701,11/30/2021,2/15/2022,Interventional,Covid-19 Pandemic and Use of Video Laryngoscopy,Recruiting,Not Applicable,Van BÃ¶lge EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,NA,NA,NA,NA,NA,Turkey,0,1,Videolaryngoscope|Macintosh Laryngoscope,0
NCT05108584,11/19/2021,1/4/2022,Interventional,Intubation in Coronavirus Disease 19 With Level 3 PPE,Recruiting,Not Applicable,Indonesia University,NA,NA,NA,NA,NA,NA,Indonesia,0,1,PPE Level 3 and Video Laryngoscope|PPE Level 3 and Direct Laryngoscope|PPE Level 2 and Direct Laryngoscope,0
NCT05107479,11/9/2021,1/31/2022,Interventional,Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo,"Active, not recruiting",Not Applicable,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,2,COVID-19 Vaccine IVR Training|Control Condition,1
NCT05080179,12/11/2020,1/28/2021,Interventional,Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,Completed,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,1,Self-Benefit/Social Norm|Self-Benefit/No Social Norm|Other Benefit/Social Norm|Other Benefit/No Social Norm,0
NCT05047601,9/9/2021,3/2/2022,Interventional,A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19,Recruiting,Phase 3,Pfizer,NA,NA,NA,NA,NA,NA,"United States|Argentina|Brazil|Czechia|Hungary|Japan|Korea, Republic of|Malaysia|Mexico|Poland|Puerto Rico|Russian Federation|South Africa|Taiwan|Thailand|Turkey|Ukraine",0,5,PF-07321332|Placebo for PF-07321332|Placebo for Ritonavir|Ritonavir,0
NCT04844658,2/17/2021,10/29/2021,Interventional,"Covid-19, Hospitalized, PatIents, Nasafytol",Completed,Not Applicable,Tilman S.A.,NA,NA,NA,NA,NA,NA,Belgium,0,2,NASAFYTOLÂ®|FULTIUMÂ® -D3 800,0
NCT04583969,10/19/2020,12/31/2021,Interventional,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,"United States|Korea, Republic of",0,63,Lenzilumab|Placebo|Remdesivir,0
NCT04432272,7/16/2020,11/13/2020,Interventional,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Terminated,Phase 2,William Beaumont Hospitals,"The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible",NA,NA,NA,NA,NA,United States,1,6,COVID-19 convalescent plasma,0
NCT04426695,6/11/2020,5/7/2021,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Completed,Phase 1/Phase 2,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,"United States|Brazil|Chile|Mexico|Moldova, Republic of|Romania",0,22,REGN10933+REGN10987 combination therapy|Placebo,0
NCT04360096,2/15/2021,12/15/2021,Interventional,Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Severe COVID-19,Recruiting,Phase 2/Phase 3,"NeuroRx, Inc.",NA,NA,NA,NA,NA,NA,United States,0,16,ZYESAMIâ„¢ (aviptadil acetate)|Placebo|Nebulized administration of ZYESAMIâ„¢ or Placebo,0
NCT04412486,6/1/2020,5/31/2022,Interventional,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Early Phase 1,University of Mississippi Medical Center,NA,NA,NA,NA,NA,NA,United States,0,2,COVID Convalescent Plasma,0
NCT04389294,5/5/2020,6/16/2020,Interventional,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Completed,Not Applicable,"Hospital for Special Surgery, New York",NA,NA,NA,NA,NA,NA,United States,0,1,SARS-CoV2 serum antibody testing,0
NCT04361344,5/19/2020,10/25/2020,Interventional,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Terminated,Not Applicable,Centre Hospitalier de PAU,objective of the study demonstrated by other research teams,NA,NA,NA,NA,NA,France,0,2,blood samples,0
NCT05142514,11/11/2021,12/27/2021,Interventional,"Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)",Recruiting,Phase 2,"Hipra Scientific, S.L.U",NA,NA,NA,NA,NA,NA,Vietnam,0,0,COVID-19 Vaccine HIPRA|Cominarty (Pfizer-BioNtech),1
NCT05142488,11/9/2021,3/30/2022,Interventional,Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine,Recruiting,Phase 4,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),NA,NA,NA,NA,NA,NA,Brazil,0,0,Covid -19 (recombinante) vaccine,1
NCT05142319,10/12/2021,4/30/2023,Interventional,Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC],Recruiting,Phase 3,Tan Tock Seng Hospital,NA,NA,NA,NA,NA,NA,Singapore,0,0,Homologous mRNA booster vaccine|Heterologous mRNA booster vaccine|Non-mRNA booster vaccine A|Non-mRNA booster vaccine B|Non-mRNA booster vaccine C,1
NCT05141058,10/19/2021,11/1/2025,Interventional,T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS,Recruiting,Phase 1,Children's National Research Institute,NA,NA,NA,NA,NA,NA,United States,0,0,Coronavirus-specific T cell (CST),0
NCT05142553,11/16/2021,1/7/2022,Interventional,"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Healthy Adults Volunteers Fully Vaccinated",Recruiting,Phase 2,"Hipra Scientific, S.L.U",NA,NA,NA,NA,NA,NA,Spain,0,0,COVID-19 Vaccine HIPRA|Cominarty (Pfizer-BioNtech),1
NCT05060978,11/10/2021,1/31/2022,Interventional,Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic,"Active, not recruiting",Not Applicable,Universidad de Sonora,NA,NA,NA,NA,NA,NA,Mexico,0,1,Watch your Weight During the Holidays Program|Relative 5:2 Fasting|Control Group,0
NCT05040763,11/10/2021,3/31/2022,Interventional,Abbott ID NOW COVID-19,Recruiting,Not Applicable,University of Calgary,NA,NA,NA,NA,NA,NA,Canada,0,1,Buccal Swab- Copan flocked swab|Standard of Care COVID-19 swab,0
NCT05017493,7/1/2020,12/7/2020,Interventional,"Treatment of Covid-19 With a Herbal Compound, Xagrotin",Completed,Phase 1/Phase 2,Biomad AS,NA,NA,NA,NA,NA,NA,Iraq,1,1,Xagrotin,0
NCT04960202,7/16/2021,12/9/2021,Interventional,EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19,Recruiting,Phase 3,Pfizer,NA,NA,NA,NA,NA,NA,"United States|Brazil|Bulgaria|Colombia|Czechia|Hungary|India|Japan|Korea, Republic of|Malaysia|Mexico|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|Argentina|Poland|Puerto Rico",0,11,PF-07321332|Ritonavir|Placebo,0
NCT04317040,4/24/2020,10/20/2020,Interventional,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),Completed,Phase 3,"OncoImmune, Inc.",NA,NA,NA,NA,NA,NA,United States,1,15,CD24Fc|Placebo,0
NCT04590365,12/17/2020,3/1/2022,Interventional,Carrageenan Nasal Spray for COVID-19 Prophylaxis,Recruiting,Not Applicable,Swansea University,NA,NA,NA,NA,NA,NA,United Kingdom,0,3,Carrageenan nasal and throat spray|Saline nasal and throat spray,0
NCT04479358,9/10/2020,3/1/2022,Interventional,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Phase 2,University of Chicago,NA,NA,NA,NA,NA,NA,United States,0,2,Tocilizumab|Tocilizumab|Standard of Care|Standard of Care,0
NCT04364763,8/5/2020,12/31/2021,Interventional,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Phase 2,"Renibus Therapeutics, Inc.",NA,NA,NA,NA,NA,NA,United States,0,14,RBT-9 (90 mg)|0.9% sodium chloride (normal saline),0
NCT04363463,8/28/2020,8/28/2022,Interventional,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,Not Applicable,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,NA,NA,NA,NA,NA,France|Monaco,0,4,prone position,0
NCT04912921,10/20/2020,5/31/2022,Interventional,Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19,Recruiting,Not Applicable,Arizona State University,NA,NA,NA,NA,NA,NA,United States,0,1,palmitoylethanolamide|Placebo,0
NCT04348500,4/28/2020,9/30/2020,Interventional,Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,Cedars-Sinai Medical Center,NA,NA,NA,NA,NA,NA,United States,1,6,Clazakizumab,0
NCT04347954,8/15/2020,12/13/2020,Interventional,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Completed,Phase 1/Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,1,8,Povidone-Iodine 2%|Povidone-Iodine 0.5%|Isotonic saline 0.9%,0
NCT04349098,4/17/2020,10/5/2020,Interventional,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Completed,Phase 2,Karyopharm Therapeutics Inc,NA,NA,NA,NA,NA,NA,United States|Austria|France|Israel|Spain|United Kingdom,1,7,Selinexor|Placebo,0
NCT04353037,4/7/2020,7/11/2020,Interventional,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Terminated,Phase 2,UnitedHealth Group,As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.,NA,NA,NA,NA,NA,United States,1,5,Group 1 HCQ|Group 2 Placebo,0
NCT04358068,5/13/2020,7/8/2020,Interventional,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Terminated,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),Slow enrollment and lack of community enthusiasm,NA,NA,NA,NA,NA,United States,1,19,Hydroxychloroquine (HCQ)|Azithromycin (Azithro)|Placebo for Hydroxychloroquine|Placebo for Azithromycin,0
NCT04382053,5/27/2020,12/10/2020,Interventional,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Completed,Phase 2,Novartis,NA,NA,NA,NA,NA,NA,Argentina|Brazil|Denmark|Germany|Hungary|India|Mexico|Netherlands|Peru|Russian Federation|South Africa|Spain,1,31,DFV890|Standard of Care (SoC),0
NCT04388826,6/18/2020,12/18/2020,Interventional,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,Completed,Phase 2,Veru Inc.,NA,NA,NA,NA,NA,NA,United States,1,27,Veru-111,0
NCT04475588,5/1/2020,7/7/2020,Interventional,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,Phase 2,Biocon Limited,NA,NA,NA,NA,NA,NA,India,1,3,Itolizumab IV infusion|Best supportive care (BSC),0
NCT04411628,5/28/2020,8/26/2020,Interventional,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Phase 1,Eli Lilly and Company,NA,NA,NA,NA,NA,NA,United States,1,12,LY3819253|Placebo,0
NCT04418947,6/15/2020,7/17/2020,Interventional,Project Resurgence Communication Trial,Completed,Not Applicable,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,1,3,Communication type,0
NCT04497948,9/21/2020,11/18/2020,Interventional,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Phase 1,Acerta Pharma BV,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints.

Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.",NA,NA,NA,NA,NA,Brazil,1,4,Acalabrutinib,0
NCT04504032,9/2/2020,3/10/2021,Interventional,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Terminated,Phase 2,Bill & Melinda Gates Medical Research Institute,"Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.",NA,NA,NA,NA,NA,United States|United Kingdom,1,12,Rivaroxaban|Placebo,0
NCT04701658,2/1/2021,6/22/2021,Interventional,A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,Eli Lilly and Company,NA,NA,NA,NA,NA,NA,United States,1,12,Bamlanivimab,0
NCT04491994,4/10/2020,5/31/2020,Interventional,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Phase 3,UNICEF,NA,NA,NA,NA,NA,NA,Pakistan,1,1,HCQ,0
NCT04491240,7/20/2020,10/1/2020,Interventional,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Phase 1/Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,NA,NA,NA,NA,NA,Russian Federation,1,4,EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation,0
NCT04420273,7/2/2020,3/1/2021,Interventional,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Completed,Not Applicable,Northwestern University,NA,NA,NA,NA,NA,NA,United States,1,5,SSE educational intervention|Active control:Healthy Living,0
NCT04463004,9/2/2020,11/30/2020,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,Phase 2,Virginia Commonwealth University,NA,NA,NA,NA,NA,NA,United States,1,5,Mavrilimumab|Placebos,0
NCT04452435,7/21/2020,10/13/2020,Interventional,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Phase 2,Vicore Pharma AB,NA,NA,NA,NA,NA,NA,India|United Kingdom,1,8,C21|Placebo,0
NCT04411667,4/28/2020,6/23/2020,Interventional,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Completed,Phase 4,Sharp HealthCare,NA,NA,NA,NA,NA,NA,United States,1,3,Octagam,0
NCT04435808,4/14/2020,7/15/2020,Interventional,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Phase 1/Phase 2,University of New Mexico,Stopped for futility by DSMB,NA,NA,NA,NA,NA,United States,1,2,Hydroxychloroquine,0
NCT04409886,6/1/2020,1/31/2021,Interventional,Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,Terminated,Phase 4,Maimonides Medical Center,"This study is part of a larger national study. Only 1 patient was enrolled at Maimonides; Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no time, or personnel to do the study",NA,NA,NA,NA,NA,United States,1,6,Hyperbaric Oxygen Therapy,0
NCT04399980,5/20/2020,4/23/2021,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,Phase 2,The Cleveland Clinic,NA,NA,NA,NA,NA,NA,United States,1,5,Mavrilimumab|Placebos,0
NCT04410159,6/22/2020,6/29/2020,Interventional,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Phase 2,Universiti Sains Islam Malaysia,NA,NA,NA,NA,NA,NA,Malaysia,1,5,Povidone-Iodine|Essential oils|Tap water,0
NCT04422561,5/31/2020,7/14/2020,Interventional,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Phase 2/Phase 3,Zagazig University,NA,NA,NA,NA,NA,NA,Egypt,1,5,Ivermectin Tablets,0
NCT04421404,6/9/2020,4/30/2021,Interventional,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,Completed,Phase 2,"University of California, San Francisco",NA,NA,NA,NA,NA,NA,United States,1,8,COVID-19 Convalescent Plasma (CCP)|Placebo,0
NCT04392219,4/10/2020,8/11/2020,Interventional,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Phase 1,"Ridgeback Biotherapeutics, LP",NA,NA,NA,NA,NA,NA,United Kingdom,1,5,EIDD-2801|Placebo,0
NCT04392141,4/1/2020,11/1/2020,Interventional,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Completed,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,NA,NA,NA,NA,NA,"Iran, Islamic Republic of",1,3,Standard Treatment|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,0
NCT04370834,5/28/2020,1/14/2021,Interventional,Tocilizumab for Patients With Cancer and COVID-19 Disease,Terminated,Phase 2,National Cancer Institute (NCI),Other - Randomized data no longer support continuation,NA,NA,NA,NA,NA,United States,1,16,Tocilizumab,0
NCT04365699,4/8/2020,1/31/2021,Interventional,Cardiovascular Effects of COVID-19,Completed,Phase 2,NYU Langone Health,NA,NA,NA,NA,NA,NA,United States,1,4,AT-001,0
NCT04365153,4/24/2020,2/2/2021,Interventional,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Completed,Phase 2,The Cleveland Clinic,NA,NA,NA,NA,NA,NA,United States,1,9,Canakinumab Injection 600mg|Canakinumab Injection 300mg|Placebos,0
NCT04382066,5/12/2020,11/26/2020,Interventional,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,Completed,Phase 1,PharmaMar,NA,NA,NA,NA,NA,NA,Spain,1,12,Plitidepsin 1.5 mg/day|Plitidepsin 2.0 mg/day|Plitidepsin 2.5 mg/day,0
NCT04363736,5/5/2020,8/12/2020,Interventional,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Phase 2,Hoffmann-La Roche,NA,NA,NA,NA,NA,NA,United States,1,5,Tociliuzumab,0
NCT04380688,6/13/2020,11/16/2020,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,NA,NA,NA,NA,NA,United States,1,5,Acalabrutinib,0
NCT04346199,6/12/2020,11/17/2020,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,NA,NA,NA,NA,NA,Argentina|Brazil|Chile|France|Germany|India|Italy|Japan|Mexico|Peru|Poland|Russian Federation|South Africa|Turkey,1,7,Acalabrutinib,0
NCT04362137,5/2/2020,10/17/2020,Interventional,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,Completed,Phase 3,Novartis,NA,NA,NA,NA,NA,NA,United States|Argentina|Brazil|Colombia|France|Germany|Mexico|Peru|Russian Federation|Spain|Turkey|United Kingdom,1,21,Ruxolitinib|Placebo,0
NCT04354870,4/3/2020,9/15/2020,Interventional,COVID-19 PrEP HCW HCQ Study,Completed,Phase 2,NYU Langone Health,NA,NA,NA,NA,NA,NA,United States,1,6,Hydroxychloroquine (HCQ),0
NCT04345653,4/14/2020,6/5/2020,Interventional,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,Completed,Phase 2,Hackensack Meridian Health,NA,NA,NA,NA,NA,NA,United States,1,7,Hydroxychloroquine Sulfate (HCQ),0
NCT04358081,5/1/2020,7/27/2020,Interventional,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Phase 3,Novartis,NA,NA,NA,NA,NA,NA,United States,1,9,HCQ|HCQ+AZT|Placebo,0
NCT04343092,4/18/2020,5/31/2020,Interventional,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Phase 1,University of Baghdad,NA,NA,NA,NA,NA,NA,Iraq,1,4,Ivermectin (IVM),0
NCT04342897,4/20/2020,10/12/2020,Interventional,A Study of LY3127804 in Participants With COVID-19,Terminated,Phase 2,Eli Lilly and Company,Trial terminated for futility.,NA,NA,NA,NA,NA,United States,1,20,LY3127804|Placebo,0
NCT04333225,4/3/2020,6/30/2020,Interventional,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,Completed,Phase 2,Baylor Research Institute,NA,NA,NA,NA,NA,NA,United States,1,6,Hydroxychloroquine,0
NCT04338074,6/1/2020,4/21/2021,Interventional,TXA and Corona Virus 2019 (COVID19) in Outpatients,Terminated,Phase 2,University of Alabama at Birmingham,Lack of recruitment,NA,NA,NA,NA,NA,United States,1,8,Tranexamic acid tablets|Placebo oral tablet,0
NCT04332081,4/6/2020,5/29/2020,Interventional,Hyperbaric Oxygen for COVID-19 Patients,Terminated,Not Applicable,NYU Langone Health,The IRB has determined that the design of this trial should be changed to a randomized controlled trial. A new record will be created for the redesigned study.,NA,NA,NA,NA,NA,United States,1,7,hyperbaric oxygen therapy (HBOT),0
NCT04335136,4/30/2020,12/26/2020,Interventional,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,Phase 2,Apeiron Biologics,NA,NA,NA,NA,NA,NA,Austria|Denmark|Germany|Russian Federation|United Kingdom,1,9,RhACE2 APN01|Physiological saline solution,0
NCT04335552,4/17/2020,6/17/2020,Interventional,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Phase 2,Duke University,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",NA,NA,NA,NA,NA,United States,1,5,Standard of care|Hydroxychloroquine|Azithromycin,0
NCT04334876,4/1/2020,11/1/2020,Interventional,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Completed,Not Applicable,Indiana University,NA,NA,NA,NA,NA,NA,United States,1,3,SARS-CoV-2 IgG Antibody Testing Kit,0
NCT04525820,12/15/2020,8/30/2021,Interventional,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","Active, not recruiting",Not Applicable,"Cantonal Hosptal, Baselland",NA,NA,NA,NA,NA,NA,Switzerland,0,5,Single high dose vitamin D|Placebo|Treatment as usual vitamin D,0
NCT04527081,8/31/2020,11/9/2020,Interventional,Study of COVID-19 DNA Vaccine (AG0302-COVID19),Completed,Phase 1/Phase 2,"AnGes, Inc.",NA,NA,NA,NA,NA,NA,Japan,0,6,AG0302-COVID19|AG0302-COVID19|AG0302-COVID19,1
NCT04525378,7/1/2020,9/30/2020,Interventional,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Phase 1,D'Or Institute for Research and Education,NA,NA,NA,NA,NA,NA,Brazil,0,1,Mesenchymal stromal cell-based therapy,0
NCT04526145,5/1/2021,12/1/2022,Interventional,OUR Stress/ Emotion Management for Black/African American Women With Hypertension,Recruiting,Not Applicable,Ohio State University,NA,NA,NA,NA,NA,NA,United States,0,3,Stress and emotion management,0
NCT04522466,4/3/2020,5/28/2020,Interventional,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Stop of the study by competent authority (ANSM),NA,NA,NA,NA,NA,France,0,1,Hydroxychloroquine (HCQ),0
NCT04527133,6/11/2020,8/11/2020,Interventional,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",Not Applicable,Aviron LLC,NA,NA,NA,NA,NA,NA,Russian Federation,0,0,Aprotinin,0
NCT04525742,7/5/2020,8/30/2020,Interventional,COVID-19 Pandemic and Parents of Disabled Children,Completed,Not Applicable,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,NA,NA,Turkey,0,1,Difficulties lived by disabled children's parents in the period of COVID-19 pandemic,0
NCT04525417,4/25/2020,9/25/2020,Interventional,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Completed,Not Applicable,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,NA,NA,NA,NA,NA,France,0,1,AAZ Covid-19 rapid test,0
NCT04526054,9/3/2020,9/3/2021,Interventional,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,Not Applicable,Hopital Foch,NA,NA,NA,NA,NA,NA,France,0,1,ENT exam|Olfactometry|Brain MRI,0
NCT04522986,8/21/2020,2/2/2021,Interventional,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,Phase 1,"Rohto Pharmaceutical Co., Ltd.",NA,NA,NA,NA,NA,NA,Japan,0,2,Mesenchymal stem cell,0
NCT04524663,12/19/2020,5/15/2021,Interventional,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,Completed,Phase 2,Stanford University,NA,NA,NA,NA,NA,NA,United States,0,6,Camostat Mesilate|Placebo|Standard of Care Treatment,0
NCT04522830,7/30/2020,2/28/2021,Interventional,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Completed,Phase 2,"Beech Tree Labs, Inc.",NA,NA,NA,NA,NA,NA,United States,0,9,BTL-TML-COVID|Placebo,0
NCT04522128,5/22/2020,9/1/2021,Interventional,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Completed,Not Applicable,University of Manchester,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,Behaviour Change Technique Intervention to Improve Quality of Life,0
NCT04523090,8/27/2020,12/31/2021,Interventional,Catalysing the Containment of COVID-19,Recruiting,Phase 2/Phase 3,University of Cape Town,NA,NA,NA,NA,NA,NA,South Africa,0,4,Nitazoxanide|Placebo,0
NCT04523181,10/8/2020,11/30/2021,Interventional,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Phase 2,Golden Biotechnology Corporation,NA,NA,NA,NA,NA,NA,United States|Argentina|Peru,0,8,Antroquinonol|Placebo,0
NCT04518969,5/3/2020,12/1/2020,Interventional,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,Not Applicable,Brugmann University Hospital,NA,NA,NA,NA,NA,NA,Belgium,0,0,CytoSorb,0
NCT04519320,5/18/2020,8/18/2021,Interventional,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,"Active, not recruiting",Not Applicable,Centre Hospitalier Universitaire de Besancon,NA,NA,NA,NA,NA,NA,France,0,2,Pulmonary function testing,0
NCT04519411,5/21/2020,12/31/2021,Interventional,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,Not Applicable,Mayo Clinic,NA,NA,NA,NA,NA,NA,United States,0,1,Transpulmonary pressure measurements,0
NCT04514627,7/13/2020,7/31/2021,Interventional,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,Not Applicable,Olive View-UCLA Education & Research Institute,NA,NA,NA,NA,NA,NA,United States,0,1,Auricular percutaneous neurostimulation,0
NCT04516954,8/1/2020,11/30/2020,Interventional,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Early Phase 1,Vinmec Research Institute of Stem Cell and Gene Technology,NA,NA,NA,NA,NA,NA,Vietnam,0,2,Convalescent COVID 19 Plasma,0
NCT04517123,9/1/2020,12/31/2021,Interventional,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,Not Applicable,Johns Hopkins University,NA,NA,NA,NA,NA,NA,United States,0,3,Prone Positioning,0
NCT04516837,8/31/2020,8/31/2021,Interventional,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Phase 2,Peking University People's Hospital,NA,NA,NA,NA,NA,NA,China,0,2,Eltrombopag|rhTPO,0
NCT04513158,8/14/2020,8/1/2021,Interventional,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Norton Healthcare,NA,NA,NA,NA,NA,NA,United States,0,2,Convalescent Plasma,0
NCT04508868,8/31/2020,12/23/2020,Interventional,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Terminated,Not Applicable,Uppsala University,Study terminated due to changes in government restrictions. Collected data to be presented as a pilot study.,NA,NA,NA,NA,NA,Sweden,0,2,Brief Behavioral Activation with Mental Imagery|Minimal Attention Control Intervention,0
NCT04511819,8/28/2020,3/31/2021,Interventional,Losmapimod Safety and Efficacy in COVID-19,Terminated,Phase 3,Fulcrum Therapeutics,Study terminated due to the rapidly evolving environment for the treatment of Covid-19 and ongoing challenges to identify and enroll qualified patients to participate.,NA,NA,NA,NA,NA,United States|Brazil|Mexico|Peru,0,19,Placebo oral tablet|Losmapimod oral tablet,0
NCT04512079,9/8/2020,12/31/2021,Interventional,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,NA,NA,NA,NA,NA,United States|Brazil|Colombia|India|Mexico,0,3,Enoxaparin|Apixaban,0
NCT04513470,8/1/2020,1/31/2021,Interventional,Allocetra-OTS in COVID-19,"Active, not recruiting",Phase 1,Hadassah Medical Organization,NA,NA,NA,NA,NA,NA,Israel,0,1,Allocetra-OTS,0
NCT04511949,7/12/2020,9/30/2020,Interventional,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,Not Applicable,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,NA,NA,NA,NA,NA,France,0,2,"COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)",0
NCT04511923,12/23/2020,12/31/2021,Interventional,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Recruiting,Phase 1/Phase 2,University College Hospital Galway,NA,NA,NA,NA,NA,NA,Ireland,0,2,Nebulised heparin,0
NCT04510662,8/31/2020,3/31/2021,Interventional,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Phase 2,Hospital Regional de Alta Especialidad de Zumpango,NA,NA,NA,NA,NA,NA,Mexico,0,0,Telmisartan,0
NCT04513184,7/14/2020,3/30/2021,Interventional,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Phase 2,Universidad Nacional Autonoma de Mexico,NA,NA,NA,NA,NA,NA,Mexico,0,3,IV Dexamethasone|Nasal Dexamethasone,0
NCT04519437,7/26/2020,10/25/2021,Interventional,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Phase 1,Regeneron Pharmaceuticals,NA,NA,NA,NA,NA,NA,United States,0,3,REGN10933+REGN10987|Placebo,0
NCT04519385,3/1/2020,7/1/2020,Interventional,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,Not Applicable,South Valley University,NA,NA,NA,NA,NA,NA,Egypt,0,1,Tocilizumab|Dexamethasone,0
NCT04517006,1/31/2021,4/4/2021,Interventional,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,Completed,Not Applicable,University of Toronto,NA,NA,NA,NA,NA,NA,Canada,0,4,Self-focused acts|Prosocial acts,0
NCT04517396,8/18/2020,12/31/2021,Interventional,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Phase 2,University of Pennsylvania,NA,NA,NA,NA,NA,NA,United States,0,8,Fenofibrate/fenofibric acid|Placebo|Usual care,0
NCT04516915,6/15/2020,5/31/2021,Interventional,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Phase 2,University Hospitals Coventry and Warwickshire NHS Trust,NA,NA,NA,NA,NA,NA,United Kingdom,0,1,IMU-838|Oseltamivir,0
NCT04514900,9/23/2020,3/8/2021,Interventional,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Completed,Not Applicable,University of South Carolina,NA,NA,NA,NA,NA,NA,United States,0,4,Video Chat +Personalized Feedback|Video Chat + Basic Feedback|Discussion Board for Social Support +Basic Feedback|Discussion Board for Social Support+Personalized Feedback,0
NCT04512027,9/15/2020,9/19/2020,Interventional,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,Not Applicable,Composite Interceptive Med Science,NA,NA,NA,NA,NA,NA,India,0,3,Standard of Care|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class,0
NCT04510493,10/23/2020,8/17/2021,Interventional,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Completed,Phase 3,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,NA,NA,Switzerland,0,5,Canakinumab|Placebo,0
NCT04511650,10/21/2020,2/26/2021,Interventional,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Terminated,Phase 2,Aerpio Therapeutics,"After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.",NA,NA,NA,NA,NA,United States,0,8,Razuprotafib Subcutaneous Solution|Placebo Subcutaneous Solution,0
NCT04508439,6/20/2020,8/30/2020,Interventional,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,Not Applicable,Hospital Regional de Alta especialidad de Ixtapaluca,NA,NA,NA,NA,NA,NA,Mexico,0,0,Enoxaparin,0
